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Irritable bowel syndrome (IBS) is a common functional bowel disorder characterised by 
abdominal pain or discomfort and altered bowel habit. It negatively influences quality of life 
and poses a considerable economic burden to patients, healthcare resources and society. 
Treatments are symptom-directed but the complex pathophysiology of the condition, and the 
heterogeneity and instability of presenting symptoms lead to treatment challenges. Many 
patients with IBS have attempted and/or seek information about dietary approaches to 
manage their symptoms.  
 
One issue that has limited obtaining robust research evidence for dietary advice interventions 
in IBS is the difficulty of implementing a suitable placebo control. Previous studies have utilised 
standard IBS dietary advice or habitual diet as the placebo comparator intervention, or have 
been feeding studies, all of which have their limitations. Therefore, a novel sham diet was 
designed, developed and evaluated for use as a placebo control in a dietary advice RCT.  
 
There is growing evidence for the clinical effectiveness of the low FODMAP diet in IBS, 
however a blinded, placebo-controlled, dietary advice RCT had never been performed. 
Furthermore, whether the acute effect of the low FODMAP diet on the GI microbiota could be 
prevented required investigation. Therefore a 2x2 factorial design blinded placebo-controlled 
RCT was conducted in 104 patients. More patients in the low FODMAP diet group reported a 
clinically important reduction in IBS-SSS score compared with the sham diet group (73% vs 
42%, p=0.005). There was also a lower abundance of stool Bifidobacteria in the low FODMAP 
diet group compared with sham (8.8 vs 9.0 log10 cells/g faeces, p=0.028). Probiotic co-
administration with VSL#3 ameliorated the effect of the low FODMAP diet on Bifidobacteria, 
and as a sole intervention increased Bifidobacteria abundance compared with placebo but did 
not have a convincing effect on GI symptoms. 
 
In conclusion, there is compelling evidence for the beneficial effect of the low FODMAP diet in 
a majority of patients with IBS. The ramifications of this diet both on the GI microbiota and on 
nutrient intake confirm the importance of FODMAP reintroduction to tolerance, and that the 
diet is dietitian-led. Probiotic ameliorated the effect of low FODMAP diet-induced microbiota 
aberration, however the degree of recovery in response to FODMAP reintroduction requires 
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1.1  Irritable bowel syndrome 
1.1.1 Introduction 
Functional bowel disorders (FBD) are characterised by chronic lower gastrointestinal (GI) 
symptoms in the absence of alarm features that suggest the presence of other disease 
(Longstreth et al., 2006, Gunnarsson and Simren, 2008). Symptom duration of at least 6 
months is necessary for diagnosis in order to distinguish FBD from transient GI symptoms. The 
Rome III diagnostic criteria for FBD are governed by the Rome Foundation, a not-for-profit 
expert panel devoted to the diagnosis and treatment of FBD. The following section will 
describe the diagnostic criteria, impact, pathogenesis and treatment of irritable bowel 
syndrome (IBS), one of the most prevalent FBD. 
 
1.1.2 Diagnosis and prevalence  
The diagnosis of IBS requires the presence of abdominal pain or discomfort together with an 
alteration in stool output (Figure 1.1) (Longstreth et al., 2006). Prior to a diagnosis of IBS, 
inflammatory markers and coeliac serology should be performed to rule out other causes for 
symptoms, and ‘red flag’ symptoms, such as rectal bleeding, should be investigated further 
(NICE, 2015).  
 
A clinical diagnosis of IBS has traditionally been one characterised by exclusion of other 
conditions. Alternatively, guidelines encourage that a positive diagnosis is made based on 
clinical history and the Rome III criteria. However, diagnosis of IBS is inherently difficult given 
the heterogeneity of the condition and symptom overlap with organic pathology, such as 
coeliac disease. Hence there has been recent research interest in the identification of 
diagnostic biomarkers for IBS. None in isolation perform better than symptom-based 
diagnostic criteria, however combined biomarkers, psychological markers and symptom 
criteria may present a future opportunity for rapid diagnosis (Sood et al., 2015). 
 
IBS is a common condition worldwide, contributing to 30% of general practitioner 
consultations related to GI complaints (Thompson et al., 2000) and up to 60% of referrals to 
gastroenterology outpatient clinics (Jones et al., 2000). It affects more females than males and 
is more prevalent in those under 40 years of age. A pooled global prevalence rate of 14% of 
females and 9% of males has been reported in a large systematic review and meta-analysis of 
55 studies conducted across America, Asia, Europe and Africa (Lovell and Ford, 2012).   
  Chapter 1: Introduction 
18 
 
Rome III NICE 
 
Recurrent abdominal pain or discomfort*at least 
3 days per month in the last 3 months associated 
with 2 or more of the following: 
(Criteria must be fulfilled for the last 3 months 
with symptom onset at least 6 months prior to 
diagnosis)  
 
1.  Improvement with defaecation 
2.  Onset associated with a change in 
  frequency of stool 
3.  Onset associated with a change in 
  form (appearance) of stool 
 
 
*Discomfort means an uncomfortable sensation 
not described as pain 
 
 
Abdominal pain or discomfort that is relieved by 
defaecation or associated with altered bowel 
frequency or stool form. This should be 




1. Altered stool passage (straining, urgency, 
incomplete evacuation) 
2. Abdominal bloating, distension, tension or 
hardness 
3. Symptoms made worse by eating 
4. Passage of mucus 
 
Supporting symptoms: Lethargy, nausea, backache 
and bladder symptoms 
 
Figure 1.1 Rome III (Longstreth et al., 2006) and NICE diagnostic criteria (NICE, 2015) for IBS 
 
The Rome III criteria specify four different IBS subtypes based on predominant stool form. 
Subtypes may differ in their pathophysiology, highlighting the importance of subtyping 
patients for targeting treatment. Subtyping is performed using the Bristol Stool Form Scale 
(BSFS) (Figure 1.2) (O'Donnell et al., 1990). Patients with diarrhoea-predominant IBS (IBS-D) 
and constipation-predominant (IBS-C) subtypes, as their names suggest, are characterised by 
the extremes of stool form. Patients with mixed subtype (IBS-M) have both diarrhoea and 
constipation, and patients with unsubtyped IBS (IBS-U) generally pass normal stools (Figure 
1.3) (Longstreth et al., 2006). IBS-D is generally reported as the most common subtype (40-
60% of all IBS) (Yao et al., 2012, Engsbro et al., 2012). Despite the utility of distinct subtype 
classifications, stool output in IBS is unstable. Indeed, at least 50% of patients with IBS switch 
subtype over a short time frame, and this occurs predominantly in those with IBS-D or IBS-C 
(Mearin et al., 2004, Engsbro et al., 2012).  
 
Although altered stool form and abdominal pain or discomfort are the hallmark features of IBS, 
other lower GI symptoms frequently co-exist, including bloating, flatulence, urgency and 
defaecation difficulties such as a sensation of incomplete evacuation. Indeed, UK clinical 
guidelines for IBS incorporate symptoms such as bloating and urgency as supportive of a 
diagnosis (Figure 1.1) (NICE, 2015). Other frequently reported comorbidities include upper GI 
symptoms, chronic pain syndromes (e.g. fibromyalgia), psychiatric conditions, somatisation 
and lethargy (Ladabaum et al., 2012, Whitehead et al., 2007). The high incidence of GI and






Figure 1.2 The Bristol Stool Form Scale categorises stool consistency into 7 types. Types 3,4,5 
are considered normal stool consistency. © 2000 Norgine Pharmaceticals Ltd. 
 
 
Figure 1.3 IBS subtypes based on stool form.  IBS-D, diarrhoea-predominant IBS; IBS-C, 
constipation-predominant IBS; IBS-M, mixed subtype IBS; IBS-U unsubtyped IBS 
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extra-intestinal conditions in IBS compared with healthy individuals is proposed to be due to 
hypervigilance and a lower threshold for medical consultation (Whitehead et al., 2007). 
 
1.1.3 Impact on health-related quality of life (HRQOL) 
Health-related quality of life (HRQOL) has been defined as quality of life that relates to health, 
rather than factors such as income or freedom that might also be considered important 
(Guyatt et al., 1993). Although there is no impact of IBS on mortality, the morbidity associated 
with its chronic nature and the high incidence of co-existing GI and extra-intestinal conditions 
contributes to a negative impact on HRQOL (Chang et al., 2010).  Specific concerns identified in 
a community survey of nearly 2,000 individuals with IBS from eight European countries were 
diet, concentration, sleep, coping with long journeys and their physical appearance (Hungin et 
al., 2003). Furthermore, patients with IBS spent more days in bed, missed more work days and 
spent more days seeing their doctor than individuals without the condition (Hungin et al., 
2003). 
 
Validated instruments for measuring HRQOL have been used to verify the negative impact of 
IBS on HRQOL. Patients with IBS report lower HRQOL scores for physical and mental domains 
compared with healthy controls according to a validated generic HRQOL questionnaire (SF-36) 
(Gralnek et al., 2000). Strikingly, lower subscores were also evident compared with patients 
with chronic disease such as diabetes, end stage renal disease and gastro-oesophageal reflux 
disease (Gralnek et al., 2000). Patients with IBS-D and IBS-M report worse HRQOL scores 
compared with IBS-C according to an IBS-specific HRQOL questionnaire (IBS-QOL), including 
lower subscores for food avoidance (Singh et al., 2015). Other determinants of lower HRQOL 
scores in IBS include symptom severity (more frequent diarrhoea, more severe abdominal 
pain), older age and psychological factors (depression,  neuroticism) (Koloski et al., 2012), 
highlighting the importance of both physical and psychological symptoms in determining 
HRQOL in IBS. 
 
1.1.4 Economic impact 
The economic cost of a disease/disorder can be categorised into three domains. Firstly, there 
are the costs incurred by the patient for medications and loss of earnings associated with the 
condition. There is no data on annual patient-incurred costs in IBS. Secondly, there are direct 
healthcare costs incurred due to medical consultations, investigations, and emergency care, 
which totals between £90 and £316 annually per patient in the UK (Canavan et al., 2014). The 
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national annual direct national healthcare cost totals £45-200 million in the UK and more than 
half of the national direct costs are related to non-GI complaints (Canavan et al., 2014), 
underlining the considerable comorbidity evident in patients with IBS. Finally, there are 
societal costs relating to absenteeism. There is little recent data in IBS but up to 50% of 
patients require time off work for their condition in Europe (Canavan et al., 2014), which likely 
has considerable downstream effects on productivity and costs to the workplace. Overall, it is 
acknowledged that IBS places a significant cost burden directly on the patient, to healthcare 
resources and society, emphasising the importance of efficient diagnosis and development of 
low cost treatment measures. 
 
1.1.5 Pathogenesis of IBS 
The pathogenesis of IBS is incompletely understood but is known to be multifactorial and 
complex in nature (Figure 1.4). Although there appears to be some genetic potential for the 
development of IBS (Villani et al., 2010), most work on the aetiology of the condition has 
concentrated on the contribution of the central nervous system, such as altered brain-gut 
signalling and psychological distress, and altered peripheral regulation of gut function (Hungin 
et al., 2015). The following sections will describe the evidence for the contribution of each of 
these factors to the pathogenesis of IBS. 
 
1.1.5.1 Central nervous system 
Central nervous system alterations have been proposed to contribute to the pathophysiology 
of IBS, especially in those with severe symptoms (Drossman et al., 2011).  Abnormalities in 
afferent processing and the activation of emotional arousal networks that modulate the 
afferent signals have been identified. There is also preliminary evidence for the presence of 
structural grey matter abnormalities in patients with IBS compared with healthy individuals, 
some of which are associated with  anxiety and depression (Tillisch and Labus, 2011).  
 
Along with these central alterations, accumulating evidence suggests that psychological 
stressors may have a direct role in the pathogenesis of IBS. For example, patients with IBS 
report a higher prevalence of early life trauma (e.g. physical, emotional or sexual abuse) than 
healthy controls, especially in females (Bradford et al., 2012). Furthermore, the two-fold higher 
prevalence of anxiety and depression in patients with IBS compared with healthy controls 





Figure 1.4 A summary of factors contributing to the pathogenesis of IBS 
 
(Ladabaum et al., 2012) confirms the strong association between psychological comorbidity 
and IBS, although a clear cause-effect relationship is yet to be established.   
 
Psychological distress may also play a secondary role in IBS. The presence of enhanced central 
activation when rectal distension is expected but not delivered compared with controls (Mayer 
et al., 2006) suggests hypervigilance exists in patients with IBS, which translates into a greater 
awareness of the presence of symptoms. This, combined with catastrophising (belief that the 
symptoms are due to serious disease), increases anxiety which subsequently worsens 
symptoms (Hungin et al., 2015). There is sufficient evidence to suggest that the central 
nervous system and psychological stress are directly and/or indirectly involved in the 
development of IBS, emphasising the importance of psychological therapy in at least a subset 
of patients. 
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1.1.5.2  Peripheral factors  
The bulk of research relating to the pathogenesis of IBS relates to peripheral alterations 
including altered colonic motility, increased intestinal permeability, low grade inflammation, 
visceral hypersensitivity and dysbiosis of the GI microbiota. 
 
1.1.5.2.1 Motility 
Abnormal motility has historically been considered an important factor in the pathogenesis of 
IBS. Exaggerated motility response to stimuli such as food and stress has been demonstrated in 
the small intestine and the colon in patients with IBS (Gunnarsson and Simren, 2009), which 
may contribute to urgency, diarrhoea and pain symptoms. Slower colonic transit time is 
evident in IBS-C compared with IBS-D and IBS-M, and gastric emptying is delayed in 76% of 
patients according to a recent study employing a wireless motility capsule device technique 
(DuPont et al., 2014), although the relationship between gastric emptying measured by this 
technique and actual emptying time of a meal is uncertain. Colonic transit time in IBS-D has 
also been shown to be reduced compared with controls and delayed in IBS-C in a study 
measuring transit by scintigraphy after adjusting for body mass index (Manabe et al., 2010). 
Only 30% of each subtype group were clinically diagnosed with abnormal transit, however, 
which suggests motility abnormality may only contribute to IBS pathophysiology in a subset of 
patients. Altered serotonin mucosal secretion and/or uptake of serotonin into enterocytes are 
likely to be important in motility abnormalities in IBS (Spiller, 2007), and recent evidence 
confirms the key role of the microbiota in modulating colonic motility, at least in animal 
models (Kashyap et al., 2013). 
 
1.1.5.2.2 Intestinal permeability and inflammation 
Increased intestinal permeability (i.e. increased absorptive capacity of the epithelial layer) and 
impaired tight junction protein expression may lead to local GI dysfunction in up to 50% of 
patients with IBS (Ohman et al., 2015).  It is proposed that this increased permeability leads to 
enhanced uptake of pathogenic bacteria or mediators of the commensal microbiota which 
leads to subsequent inflammatory changes (Ohman et al., 2015). Increased permeability has 
been associated with worse symptom profile (Zhou et al., 2009), however whether this 
alteration precedes the onset of IBS or occurs in response to the condition is unknown (Ohman 
et al., 2015).   
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There is accumulating evidence for the presence of low grade inflammation in some patients 
with IBS. Factors that support this theory include the increased risk of IBS following GI 
infection (post-infectious IBS, PI-IBS) (Marshall et al., 2010) and persistent increases in a range 
of mucosal inflammatory markers (Ohman and Simren, 2010). Increased blood concentrations 
of some (IL-6 and IL-8) but not all (activated T cells e.g. CD4+) inflammatory mediators, have 
also been demonstrated in IBS compared with healthy individuals (Matricon et al., 2012). The 
most consistent finding in this area is enhanced colonic infiltration of mucosal mast cells 
(Matricon et al., 2012), cells important for pathogen defence that may directly influence 
enteric sensory nerves (Barbara et al., 2004). This has also been demonstrated in the small 
intestine, but is most evident in the caecum and colon, with up to a 2-fold greater mast cell 
infiltration reported compared with controls (Matricon et al., 2012) and at levels which were 
comparable to samples of patients with ulcerative colitis in remission (Ahn et al., 2014).  
 
An association between mast cell infiltration and symptoms in IBS has been demonstrated. 
One study reported a majority of patients with IBS (34/44, 76%) exhibited raised numbers of 
mast cells in colonic mucosal samples compared with controls (Barbara et al., 2004). Mast cell 
concentration in close proximity to sensory neurons was positively correlated with severity 
and frequency of abdominal pain, suggesting a direct influence of mast cells on symptom 
generation.  Although this was not replicated in a recent large study in IBS-D (n=83) (Ahn et al., 
2014), it might be that mast cell activation is more clinically relevant than cell number per se 
(Theoharides, 2014). This was evident in the former study, with raised mucosal histamine and 
tryptase in IBS samples compared with controls, a finding that has been replicated in other 
work (Matricon et al., 2012). 
 
Taken together, it appears increased intestinal permeability and immune activation are 
important in a select subgroup of patients with IBS, however it is unclear whether these 
changes are a primary or secondary phenomenon. Many studies do not account for other 
factors that disrupt the mucosal barrier such as dietary exposure to food antigens (Fritscher-
Ravens et al., 2014) or stress (Piche et al., 2008), and studies often do not differentiate PI-IBS 
from other subtypes. Clarification is still required regarding the relationship between intestinal 
permeability and/or low grade inflammation in IBS with symptom generation and  the precise 
sites of the GI tract that are important in IBS.  
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1.1.5.2.3 Visceral hypersensitivity 
It is proposed there is a dysregulation in the bidirectional signalling between the brain and GI 
tract in IBS. The microbiome-brain-gut axis refers to the relationship between these systems in 
the pathophysiology of FBD and other disorders. One key aspect of this dysregulation, and a 
major pathophysiological feature of IBS, is visceral hypersensitivity. This refers to the 
intensification of signals to the brain induced by luminal, mechanical (e.g. distension) and 
chemical stimuli in the GI tract, which leads to augmented symptom experience in the patient 
with IBS.  
 
The most common test for measuring visceral hypersensitivity is rectal balloon distension. 
Forty years ago it was first demonstrated at least 50% of IBS patients have enhanced 
visceroperception on balloon inflation compared with only 6% of controls (Ritchie, 1973). Since 
then, studies demonstrate this is evident in IBS-D and IBS-C, is more common in females 
(Hungin et al., 2015), and is enhanced postprandially both in IBS and controls (Tornblom et al., 
2014). Prevalence data varies which is in part due to differences in the criteria used to define 
hypersensitivity (Ludidi et al., 2012). Interestingly, there is also evidence of widespread 
hypersensitivity in IBS in response to thermal, ischemic and cold pressor stimuli, which may be 
secondary to persistent altered central processing in response to chronic nociceptive input 
from the GI tract  (Zhou and Verne, 2011). Various rationales have been proposed for this 
enhanced sensitivity including altered TRVP1 expression, a receptor for noxious stimuli in 
rectal biopsies, aberrant central processing and the GI microbiota (Hungin et al., 2015). 
 
1.1.5.2.4 GI microbiota and byproducts 
The GI microbiota is becoming increasingly recognised as a key player in IBS. It may have direct 
influences at the mucosa and also via its luminal byproducts (e.g. gas, short chain fatty acids). 
Section 1.1.7 will focus in detail on the role of the GI microbiota in IBS.  
 
1.1.6 The GI microbiota 
The human GI tract harbors 1014 bacteria, 10 times more than the total number of cells in the 
human body and 150 times more genes than the human genome.  In addition to bacteria, the 
GI system also harbors viruses, protozoa and fungi which likely all contribute to the overall 
ecosystem but contribute to only 1% of the genomic content (Qin et al., 2010). Low pH and 
fast transit inhibit growth of bacteria in the upper GI tract and bacterial density and diversity 
increases distally from the stomach with a final microbial concentration of approximately 1011 
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cells/ml in the colon (Walter and Ley, 2011). The microbiota is a highly diverse, metabolically 
active community that exerts important influences on health and disease, and the host-
microbiota relationship has been described as a mutualistic ecosystem, as both benefits from 
the relationship (Backhed et al., 2005). Two distinct GI microbiota populations exist: that 
within the colonic lumen and that within the mucosa overlying the GI epithelium (Zoetendal et 
al., 2002).  
 
The luminal microbiota is likely a combination of nonadherent luminal bacteria and a mix of 
shed mucosal bacteria. There is significant variability in the composition of the luminal 
microbiota along the GI tract  (Walter and Ley, 2011), suggesting that diet and environmental 
conditions have a powerful impact on this compartment. Conversely, the mucosal microbiota 
composition from the ileum to the rectum is highly stable within an individual (Lepage et al., 
2005), suggesting a stronger host influence than environmental factors. Importantly, the 
mucosal microbiota are involved in ‘crosstalk’ at the mucosal border, between the lumen and 
the underlying tissue, where immune and enteroendocrine cells interact (Ohman et al., 2015).  
 
1.1.6.1 Composition, function and association with health and disease 
The composition of the microbiota has emerged as an important focus of research over recent 
decades in response to increasing understanding of its contribution to heath and disease. The 
two major phyla, Firmicutes and Bacteroidetes, comprise at least 90% of the known bacteria in 
the GI tract, and Actinobacteria contributes less than 10%. At the species level of taxonomy, 
the microbiota is characterised by a ‘long-tail’, with many species present in low abundance 
(Arumugam et al., 2011). Humans harbour approximately 160 bacterial species in total in the 
GI tract, 75 of which are found in up to 50% of individuals, indicating the presence of a ‘core’ 
microbiota (Qin et al., 2010). Despite the existence of a common core microbiota, large inter-
individual variation is possible including in the abundance of the core species (Qin et al., 2010). 
Furthermore, there is an absence of detrimental bacteria in the human GI tract in healthy 
individuals, suggesting a distinction between a healthy microbiome and that in disease (The 
Human Microbiome Project Consortium, 2012).  
 
A number of international groups have been established with the task of characterising and 
advancing our knowledge of the human microbiome, including MetaHIT (Metagenomics of the 
Human Intestinal Tract) in Europe and HMP (Human Microbiome Project) in the US. Early work 
from both consortiums suggested that healthy humans harbour one of three types of 
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microbiota clusters, termed ‘enterotypes’, driven by species composition (i.e. dominated by 
Bacteroides, Prevotella or Ruminoccous). It was postulated that each state may be 
prognostically and diagnostically predictive (Arumugam et al., 2011), however, the existence, 
and the number of distinct enterotype classifications has recently been questioned. In fact, it is 
postulated that these cluster classifications are driven more by environmental and host factors 
rather than inherent individual differences, and that interindividual microbiome differences 
are likely to be continuous rather than segregated. Furthermore, individual bacterial species 
may be more important for disease risk than enterotype classification (Knights et al., 2014). 
 
The GI microbiota fulfils a number of diverse beneficial physiological functions.  One key 
function is the breakdown of otherwise indigestible carbohydrates, leading to the production of 
short chain fatty acids (SCFA), which contribute to reduced colonic pH and inhibition of 
pathogens. Butyrate, one of the SCFA, has a number of important functions including provision 
of energy substrate to enterocytes and to some bacterial species, increasing expression of 
some epithelial tight junction proteins, and other immunomodulatory functions (Kannampalli 
et al., 2011). The GI microbiota also impacts on bile acid metabolism, synthesises a number of 
B vitamins and vitamin K, produces antimicrobial bacteriocins and is responsible for numerous 
other metabolic and immune functions. Although most of the recognised functions of the 
microbiota are beneficial, some of their metabolic outputs are harmful to the host e.g. the 
production of amines from protein catabolism that may react with nitrite can form 
carcinogenic nitrosamines (Montalto et al., 2009). 
 
The GI microbiome may contribute to overall human health and disease. For example, one 
study demonstrated greater microbiota richness and diversity in an elderly cohort (n=178) was 
correlated with better nutritional status and health (Claesson et al., 2012), and studies in 
children suggest that a less diverse microbiota is associated with higher risk of allergic disease 
(Storro et al., 2013). Furthermore, some disease states (e.g. IBS, inflammatory bowel disease 
(IBD), and Clostridium difficile-associated disease) are characterised by low bacterial diversity 
(Lozupone et al., 2012), and a low gene count (reduced ‘bacterial richness’) is associated with 
greater overall adiposity and insulin resistance (Le Chatelier et al., 2013). Cause-effect 
relationships are not yet clear, but data from animal microbiota transplantation models 
suggests some of these changes are not merely a consequence of disease (Turnbaugh et al., 
2006). 
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Together with the overall composition of the microbiota, specific bacteria are individually 
recognised for their health-promoting effects, some of which have been termed ‘keystone 
species’ (Scott et al., 2015). For example, Faecalibacterium prausnitzii, a member of the 
phylum Firmicutes, is one of the major commensal butyrate producers. It has been labelled as 
a biomarker of intestinal health in adults (Miquel et al., 2013) and is associated with 
maintenance of remission in IBD, although a specific role in IBS has not been identfiied. 
Bifidobacteria, a genus within the phylum Actinobacteria, has established beneficial effects on 
health. As well as fermenting carbohydrates and producing SCFA (acetic acid) and lactic acid, 
this group is immunomodulatory, may reduce induced colonic carcinogenesis in animals and 
has numerous other systemic effects including on blood cholesterol (Russell et al., 2011a). 
Conversely, a phylogenetic pattern of decreased F. prausnitzii, Bifidobacteria and Akkermansia 
spp. and increased Bacteroides is evident in low gene count individuals with an inflammatory 
phenotype (Le Chatelier et al., 2013), further supporting the potential importance of specific 
bacteria in disease pathogenesis. The absence of Bifidobacteria and enrichment of 
opportunistic bacteria from the phyla Proteobacteria and Spirochaetes in Hazda hunter-
gatherers in Tanzania, however, suggests the concept of a ‘healthy GI microbiota’ may not be 
straightforward, that its functionality is more important, and that both are dependent on diet, 
the physical environment and other lifestyle factors (Schnorr et al., 2014). 
 
1.1.6.2 Quantification 
Stool or mucosal samples are used to quantify and/or characterise the colonic GI microbiota. 
Most studies in IBS have evaluated stool samples due to the ease and non-invasive nature of 
sampling, although it is recognised that the luminal microbiota is distinct from the mucosal 
compartment in IBS (Carroll et al., 2010). Culture-independent methods of microbiota analysis 
have led to an increase in the identification of bacterial species in the GI tract (Zoetendal et al., 
2004) and enumeration of a majority of the GI microbiota (>70%) currently identified. Other 
recent advances in the study of the GI microbiota include the area of metagenomics, or the 
study of the overall microbiome (collective genomic material of the host microbiota). This has 
enabled characterisation of the functional capacity of the microbiota, which is essential for 
defining associations with disease, and is perhaps more meaningful than pure quantification. 
Metabolomic approaches, or techniques that study small molecule metabolites measurable in 
stool, urine and tissue produced by the microbiota and cells, have also been vital in 
contributing to our understanding of microbiota physiology and function. Specific GI 
microbiota quantification techniques are summarised in Chapter 2 (Table 2.3).  




1.1.6.3 Factors affecting the microbiota 
The GI microbiota community is shaped throughout life by a number of host-related and 
external factors. The human GI tract becomes colonised in utero. Early infant nutrition is known 
to be important modulator of microbiota composition and functioning, and may determine 
disease risk later life (Gritz et al., 2015). After infancy, children up to the age of four can be still 
clearly separated from adults based on their microbiota composition (Ringel-Kulka et al., 2013). 
Into adulthood, a more abundant and diverse microbiota community develops as the GI tract 
matures and through increased diet and environmental influence. Host factors such as gender, 
age (Claesson et al., 2012), ethnicity (Yatsunenko et al., 2012) and bodyweight (Ley et al., 
2006) impact on the composition of the microbiota, some of which may also be explained by 
comorbidity, diet or drug exposure.  
 
The GI microbiota of humans is relatively stable over time, however there are minor 
perturbations within this stable framework. The community is self-shaping as the microbiota 
‘assemble themselves according to available niches’ (Walter and Ley, 2011), and compete for 
their position within the community, determined largely by the adaptability of the organism 
phenotype, the physical environmental condition of the GI tract (e.g. gastric acid, motility, GI 
secretions) (Jalanka-Tuovinen et al., 2011), genetic factors and colonisation history (Walter and 
Ley, 2011). There is an overall resilience of the healthy microbiome with some temporal 
variability, which enables the system to return to an equilibrium after minor shifts (Relman, 
2012).  
 
Of all external influences, antibiotics have the most pervasive effect on the structure and 
composition of the GI microbiota. For example, pyrosequencing analysis demonstrates that 
ciprofloxacin administration leads to a dramatic reduction in richness and diversity and a 
reduction in abundance of a third of taxa within 3-4 days. The alteration, as well as the rapidity 
and degree of return varied between individuals in this small study of 3 individuals (Dethlefsen 
et al., 2008). Other medications that impact on the GI microbiota, but not understood to have 
as an extreme impact, include proton pump inhibitors and prokinetics that are commonly 
prescribed in IBS (Simren et al., 2013). These are frequently not accounted for in randomised 
controlled trials (RCTs) that evaluate the effect of interventions on the microbiota but should 
be a consideration to prevent confounding effects. 
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1.1.6.3.1 Dietary impact on the GI microbiota 
Two lines of evidence suggest that the GI microbiota is influenced by diet. Firstly, 
geographically distinct populations with vastly different habitual diets can be distinguished by 
their microbiome, and secondly, short term dietary interventions lead to clear alterations in 
microbiota composition.  
 
A number of studies demonstrate clear distinctions in microbiota communities between 
individuals differing by habitual, long term diet. It is proposed that the microbiota is shaped 
over time according to habitual diet in order to extract appropriate nutrition from the food 
substrate provided (Schnorr et al., 2014).  A recent study compared microbiota composition of 
African Americans (n=20) versus rural Africans (n=20) using DNA microarray. Dietary intakes 
differed in carbohydrate (47% of total energy vs 72%, respectively) and fibre content (14 g/d vs 
66 g/d) based on 3-day dietary recalls. Stool-associated microbiota differed at the genus level, 
with the African American samples dominated by Bacteroides compared with the Prevotella-
rich samples of the rural Africans (O'Keefe et al., 2015). This supports data from a previous 
study reporting profound differences in Prevotella-rich samples of African children compared 
with Italian children who followed a much lower fibre diet based on 3-day diet records (De 
Filippo et al., 2010).  Along with genus level differences, higher diversity and richness of the 
microbiota in agrarian versus Western style communities is a common finding (Yatsunenko et 
al., 2012, Schnorr et al., 2014, De Filippo et al., 2010). Indeed, other studies suggest that 
divergence in microbiota composition in community-dwelling elderly individuals versus those 
in long term care (Claesson et al., 2012) and athletes versus bodyweight-matched controls 
(Clarke et al., 2014) is due to differences in habitual dietary intake. Some of these comparative 
studies also report alterations in microbiota byproducts (e.g. SCFA) (De Filippo et al., 2010, 
O'Keefe et al., 2015), indicating habitual diet may not only modulate the microbiota but also its 
functionality. However, there is little acknowledgement and/or agreement on the role played 
by host-specific and environmental factors (e.g. genotype, morbidity, sanitation) in influencing 
host physiology in these cross sectional studies.  
 
Acute dietary interventions clearly have effects on the GI microbiota which most likely occur 
directly through altered substrate availability and/or indirectly through effects on transit time 
and pH. The addition of foodstuffs or nutrients such as cruciferous vegetable fibre (Li et al., 
2009), polyphenols (Queipo-Ortuno et al., 2012), wholegrain wheat (Windey et al., 2014) and 
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corn (Holscher et al., 2015) have variable effects on the composition of the microbiota, and the 
effect of oats and barley have been investigated in in vitro studies.  
 
Many studies examine the effect of manipulation of the whole diet on the GI microbiota, and 
in particular, the effect of extreme alteration to dietary carbohydrate or its contribution to 
energy intake (Table 1.1). Some studies reduce carbohydrate intake to as little 20 g/d (Duncan 
et al., 2007, Russell et al., 2011b, Brinkworth et al., 2009). Modification of the microbiota has 
also been reported in response to the gluten free diet (De Palma et al., 2009), which alters the 
dietary carbohydrate source and may unintentionally reduce carbohydrate intake. The most 
consistently reported changes in carbohydrate-reduced interventions include decreased 
abundance of the phylum Firmicutes, known to include many organisms capable of 
metabolising dietary plant polysaccharides, Bifidobacteria, and butyrate producers such as 
some Ruminococcaceae. Changes are rapid and can occur within 1-2 days (Wu et al., 2011, 
David et al., 2014). Studies evaluating the effect of short chain fermentable carbohydrate 
restriction on the GI microbiota are reviewed in Section 1.2.6.  
 
There is clear evidence that diet-induced alterations in the microbiota are individually variable 
(Walker et al., 2011, Li et al., 2009), and in fact are markedly more variable than that induced 
by the intervention itself (Walker et al., 2011). This is probably determined by baseline 
differences in the microbiota and the compensatory capacity of the entire microbiota 
community. Indeed, baseline concentration of Bifidobacteria is positively correlated with the 
bifidogenic response associated with fibre supplementation (Whelan et al., 2005). This may be 
just one aspect of a more extensive phenomenon but similar findings in other bacterial groups 
have not yet been reported.  
 
There are number of difficulties associated with researching the effect of dietary change on 
the microbiota. Firstly, there is the problem of collinearity, that is, changing one component of 
the diet leads to compensatory changes in other components e.g. a reduction in carbohydrate 
leads to increases in intake of protein and/or fat intake, which in itself might have specific 
effects on the microbiota. Secondly, dietary intake is not always precisely measured, which 
limits the confidence one can have that it is the intended dietary intervention per se that is 
effecting the microbiota alterations. Also, many studies include a maintenance diet pre-
intervention, which may alter baseline microbiota composition and mask true response to the 
intervention, and many studies are crossover in design which brings the risk of carryover      
  
Table 1.1 Summary of studies investigating the effect of carbohydrate modification on stool microbiota 
Reference Intervention Duration Participants Design Analysis 
method 
Impact on microbiota vs baseline Markers of 
fermentation vs. 
baseline 
(David et al., 
2014) 
Animal rich  (LC) 
vs plant rich(HC) 
5 d 10 healthy Randomised  
crossover 
Sequencing  Bacteroides LC 
Roseburia, R. bromii  LC 
Various alterations 
in SCFA  
(Fava et al., 
2013) 
HFLC vs HCLF 24 wk 88 at risk of 
metabolic 
syndrome 
RCT FISH total bacteria HF/LC 
Bifidobacteria, Bacteroides 
HC/LF 
F. prausnitzii HC/LF (low GI) 
No change in SCFA 
(Wu et al., 
2011) 
HFLF vs LFHF 10 d 10 healthy RCT Shotgun 
metagenomics  
Various taxa altered, individually 
variable responses 
Not measured 
(Walker et al., 
2011) 
Reduced energy  
HRS vs HNSP 






R. Bromii, % Roseburia  HRS 
% Ruminococcus HRS 
Not measured 
(Russell et al., 
2011b) 
HPLC vs HPMC 4 wk 17 obese men Randomised 
crossover 
FISH % Roseburia E. Rectale group 
HPLC,  % Bacteroides spp. HPLC 





HFLC vs HCLF 
8 wk 91 overweight 
and obese  
RCT Culture Bifidobacteria HF/LC 
 
SCFA, no change 
in pH HFLC 
(De Palma et al., 
2009) 





Bifidobacteria, F. prausnitzii 
Lactobacillus 
Not measured 
(Duncan et al., 
2007) 
Reduced energy 
HPLC HPMC  
4 wk 
 
19 obese men Randomised 
crossover 
FISH Roseburia  E. Rectale, 
Bifidobacteria,  total bacteria 
HPLC HPMC 
total SCFA HPMC, 
HPLC 
butyrate HPLC 
(Whelan et al., 
2005) 
Standard vs HF 
enteral formula 
14 d 10 healthy Randomised 
crossover 
FISH Clostridia, Bifidobacteria HF butyrate HF and 
standard 
LC, low carbohydrate; HC, high carbohydrate; HFLC, high fat low carbohydrate; HCLF, high carbohydrate low fat; FISH, fluorescence in situ hybridisation; HFLF, high 
fat low fibre; LFHF, low fat high fibre; HRS, high resistant starch; HNSP, high non starch polysaccharide; HPLC, high protein low carbohydrate; high protein 
moderate carbohydrate; HF high fibre 
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effects. Finally, all of these studies are in healthy or obese patients and outcomes may not be 
representative of potential effects of dietary modulation in patients with IBS. 
 
1.1.7 The GI microbiota in IBS 
There is evidence from both animal and human studies to support the key role of the GI 
microbiota in the development and persistence of the IBS phenotype.  
 
1.1.7.1 Proof of concept studies  
Germfree mouse models provide direct evidence that the GI microbiota induce local gut 
dysfunction whilst controlling for factors such as diet. An elegant study recently demonstrated 
this using faecal transplantation. Human faecal microbiota from healthy volunteers or 
individuals with IBS was transferred to germfree mice and colonic physiology and function 
measured. Microbiota alteration was demonstrable at four weeks and maintained at seven 
weeks, with stool samples of IBS microbiota recipients generally mirroring their donors’. 
Features of IBS were also evident in these mice compared with mice inoculated with healthy 
microbiota, including visceral hypersensitivity and 2-3-fold increased 24-hour hydrogen gas 
production at seven weeks (Crouzet et al., 2013). Behavioural changes have also been 
identified in transplanted mice, suggesting dysbiosis might be responsible for behavioural 
symptoms as well as colonic motor dysfunction in IBS (Collins, 2014).   
 
1.1.7.2 PI-IBS  
There is clear evidence that GI bacterial infection leads to an increased likelihood of persistent 
functional GI symptoms despite clearance of the pathogen. The Walkerton Healthy study, the 
largest and longest study of PI-IBS, prospectively followed a cohort of 3900 individuals affected 
by a water-borne bacterial outbreak. Incidence of IBS in those who had had experienced acute 
gastroenteritis was 28% at two years after the outbreak (Marshall et al., 2006), which 
continued to remain higher than controls at eight years (15% vs 5%, respectively, odds ratio 
(OR) 3.1) (Marshall et al., 2010). Psychological morbidity, female gender, and the severity of 
the initial infection were identified as predisposing factors for persisting PI-IBS. Similar findings 
have been reported for incidence of IBS at six months after ‘traveller’s diarrhoea’ (OR 3.51) in a 
recent systematic review and meta-analysis (Schwille-Kiuntke et al., 2015). Further work is 
required to evaluate the risk of IBS associated with individual pathogens, however these 
studies provide strong evidence that bacteria have a primary role in the onset of IBS in a 
subset of patients. Mechanisms underlying this process are unclear but may be via transient 
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alteration of the microbiota post infection, and ongoing dysbiosis in the presence of low grade 
mucosal inflammation (Collins, 2014). 
 
1.1.7.3 Intestinal permeability and inflammation 
A further line of evidence that supports the role of the microbiota in IBS pathogenesis relates 
to evidence of low grade immune activation in some patients. Dysbiosis is proposed to be one 
contributing factor for the enhanced expression of some toll-like receptors, degradation of 
epithelial tight junction proteins, increased intraepithelial permeability and dysregulation of 
the immune system and this is reviewed in detail elsewhere (Ohman et al., 2015). There is still 
much to understand about these observations in IBS, and in particular whether the role of the 
microbiota is aetiological or merely an epiphenomenon, and further studies that access the 
mucosa are required to enhance understanding of the microbiota neuroimmune ‘crosstalk’ at 
the mucosal border (Ohman et al., 2015).   
 
1.1.7.4 Dysbiosis 
A growing evidence base for dysbiosis in IBS suggests this might have a role in its pathogenesis. 
Differences in the luminal and mucosal GI microbiota of patients with IBS compared with 
controls have been reported at all levels of bacterial taxonomy using a range of qualitative and 
quantitative microbiological methods (Table 1.2 and Table 1.3) and recent evidence suggests 
stool-associated microbiota in IBS is less similar to healthy controls than mucosal microbiota 
(Rangel et al., 2015). In regards to stool microbiota, decreases in Bifidobacteria, Bacteroidetes, 
and F. prausnitzii, and increases in Firmicutes, and the ratio of Firmicutes to Bacteroidetes are 
commonly reported. Two of four studies also demonstrate a reduction in mucosal 
Bifidobacteria compared with controls (Kerckhoffs et al., 2009, Parkes et al., 2012). As well as 
alterations in specific microbial taxa, reduced diversity and temporal instability are reported in 
IBS patients compared with controls (Jeffery et al., 2012, Carroll et al., 2010, Sundin et al., 
2015, Matto et al., 2005), and individuals with functional GI symptoms exhibit a greater 
instability in the microbiota in response to dietary change (Manichanh et al., 2014).  
 
There is a divergence in stool microbiota composition depending on IBS phenotype. For 
example, one study has shown higher abundance of stool Lactobacilli in IBS-D compared with 
IBS-C patients (Malinen et al., 2005). Furthermore, the microbiota of patients with PI-IBS has 
been reported to resemble IBS-D (Jalanka-Tuovinen et al., 2014), or, conversely, has been 
reported to be distinct from non PI-IBS (Sundin et al., 2015).  Intriguingly, not all patients with 




Table 1.2 Studies assessing stool microbiota composition in IBS 
Reference Participants Method IBS vs controls 





Clostridium Clusters IV & XIVa  




Bacteroidetes, F. prausnitzii, 
Actinobacteria,  
Clostridium Cluster XIVa 





16S rRNA microarray 
 Bacteroidetes,  
R. Torques  
Clostridiales, methanogens 
(Jeffery et al., 2012) IBS n=37 
controls n=20 
pyrosequencing Firmicutes: Bacteroidetes  
Clustering of normal-like and 
dysbiotic  
(Carroll et al., 2012) IBS-D  n=23 





(Duboc et al., 2012) IBS-D n=14 
controls n=18 
qPCR Bifidobacteria 
E. coli  





16S rRNA microarray  
Firmicutes: Bacteroides  
Bacteroidetes , Bifidobacteria, 
Faecalibacterium spp. 




DGGE, qPCR  Lactobacillus 
Bifidobacteria 
(Tana et al., 2010) IBS n=26 
controls n=26 
Culture, qPCR Veillonella,  
Lactobacillus 
(Codling et al., 2010) IBS n=41 
controls n=33 
DGGE diversity 
(Carroll et al., 2010) IBS-D n=10 
controls n=10 
Culture, qPCR aerobic bacteria 
Lactobacillus 










(Kerckhoffs et al., 2009)  IBS n=41 
controls  n=26 
FISH, PCR  Bifidobacterium,  
 % B. catenulatum 
(Lyra et al., 2009) IBS n=20 
controls n=15 
qPCR R. torques,  
C. thermosuccinogenes  






of 16S rRNA genes, 
qPCR 
Collinsella aerofaciens  
C. cocleatum  
(Maukonen et al., 2006) IBS n=16 
controls n=16 
PCR-DGGE C. coccoides (IBS-C) 
Eubacterium rectale (IBS-C) 
(Malinen et al., 2005) IBS n=27 
controls n=22 
qPCR Clostridium coccoides,  
B. catenulatum, 
Lactobacillus (IBS-D vs IBS-C) 
(Si et al., 2004) IBS n=25 
controls n=25 
culture  Bifidobacteria 
 Enterobacteriaceae 
(Balsari et al., 1982)  IBS n=20 
controls n=20 
culture Coliforms, Lactobacillus, 
Bifidobacteria  
rRNA, ribosomal RNA ; qPCR, quantitative polymerase chain reaction; DGGE, denaturing gradient gel 
electrophoresis; FISH, fluorescence in situ hybridisation 
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Table 1.3 Studies assessing mucosal microbiota composition in IBS 
Reference Participants Method IBS vs controls 




 Clostridiales I 
(Parkes et al., 2012) IBS n= 47 
controls n=26 
FISH  total bacteriaBacteroides,  
E. rectale  C. coccoides cluster  
 Bifidobacteria (IBS-D vs IBS-C) 
(Carroll et al., 2010) IBS-D n=10 
controls n=10 
Culture, qPCR No difference 




B. catenulatum  
 
FISH, fluorescence in situ hybridisation; PCR, polymerase chain reaction  
 
IBS have an altered microbiota. Those patients presenting with more adverse psychological 
traits have been reported to harbour a ‘normal-like’ microbiota composition that clusters 
separately to other IBS patients (Jeffery et al., 2012).   
 
Moreover, there is recent evidence for the relationship of the microbiota with IBS symptoms. 
The most frequent finding is a negative relationship between stool Bifidobacteria 
concentration (Jalanka-Tuovinen et al., 2014, Rajilic-Stojanovic et al., 2011) and mucosal 
Bifidobacteria concentration (Parkes et al., 2012) and abdominal pain scores. Other findings 
include a positive relationship between abundance of Ruminococcus torques-like organisms 
(Jalanka-Tuovinen et al., 2014) with pain, a negative relationship between the abundance of 
Proteobacteria (Jeffery et al., 2012) with measures of pain, and a lower abundance of mucosal 
Bifidobacteria with greater stool frequency (Parkes et al., 2012). Alterations in microbiota 
composition in IBS have also been associated with depression. Specifically, a lower stool 
Firmicutes to Bacteroidetes ratio (Jeffery et al., 2012) and higher abundance of mucosal E. Coli 
(Parkes et al., 2012) is evident in those with higher anxiety and depression scores with IBS.  
 
The nature of the clinical phenotype-microbiota relationship and whether dysbiosis in IBS is a 
primary or secondary phenomenon are still unclear.  The association between dysbiosis and 
IBS symptoms is not consistent across studies; this may be due to variation in the IBS subtypes 
studied, differences in microbiota quantification techniques used, or in the degree of control 
over pre-study environmental factors that might influence the microbiota (e.g. antibiotics, 
diet). Precision of patient characterisation also varies significantly between studies, and given 
the heterogeneous nature of IBS, is an important consideration for future work in this area.   
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1.1.7.5 Microbiota byproducts 
Luminal bacterial metabolic byproducts may generate symptoms in IBS. The SCFA butyrate 
dose-dependently induces visceral hypersensitivity in mice (Bourdu et al., 2005) and, indeed, 
stool acetic and propionic acid concentrations are higher in IBS and have been associated with 
higher symptom scores (Tana et al., 2010). A recent study detected no difference in stool SCFA 
between patients with IBS and controls, although there was a lower colonic pH, suggesting 
greater colonic fermentation and SCFA production in patients with IBS  (Ringel-Kulka et al., 
2015). Interestingly, there was a negative correlation between SCFA and colonic transit time 
and a positive correlation between colonic pH and colonic transit time, suggesting an 
aetiological role for fermentation byproducts in determining motility and possibly symptoms in 
IBS (Ringel-Kulka et al., 2015).  In contrast, however, butyrate has been shown to dose 
dependently improve visceral hypersensitivity in healthy individuals (Vanhoutvin et al., 2009), 
and therefore the effects of SCFA on IBS symptoms require further clarification whilst 
controlling for diet.  
 
Fermentative breakdown of food substrates by the microbiota also generates hydrogen, 
carbon dioxide, methane and hydrogen sulphide gas, which are of significance in IBS. Intestinal 
hydrogen production from fermentation is the only source of hydrogen production in humans, 
rendering it a useful proxy for fermentation capacity. Endogenous fermentative gases are 
disposed of via 3 routes 1) absorption into the circulation, 2) disposal by gas-consuming 
bacteria (e.g. acetogenic bacteria convert carbon dioxide and hydrogen into acetic acid and 
water) and 3) elimination per rectum.  Animal work suggests microbiota from patients with IBS 
induces a marked two to three-fold increase in hydrogen production compared with controls 
(Crouzet et al., 2013). Conversely, diet-controlled (King et al., 1998) and diet-uncontrolled 
human studies (Tana et al., 2010) suggest individuals with IBS do not produce more hydrogen 
than controls although the rate of hydrogen production may be altered and influenced by diet 
(King et al., 1998), and may lead to lower total gas produced compared with a standard diet 
(Dear et al., 2005). Importantly, colonic gas volume correlates with peak symptom intensity in 
response to dietary challenge (Major et al., 2015b), suggesting a direct effect of fermentative 
gas on symptoms, and underlining the potential benefit of a reduction in dietary fermentable 
substrates.  
 
Gas transit may also be important in determining symptoms in IBS. An elegant scintigraphy 
study demonstrated the relevance of this by examining the colonic response to a one-hour gas 
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infusion in patients with IBS and bloating. Gas clearance from the proximal colon was impaired 
at 30 minutes compared with controls, and this was accompanied by exacerbation of GI 
symptoms (Hernando-Harder et al., 2010). 
 
There has been interest in investigating the association between the hydrogen-disposing 
bacterial groups and IBS. Some evidence for higher concentrations of methanogens in IBS-C 
exists, but the role of the microbiota in influencing gas volume in other IBS subtypes is unclear 
(Rajilic-Stojanovic et al., 2015). Intestinal gas homeostasis is complex and not completely 
understood, but is likely the product of many independent factors, including the gas disposal 
pathways and microbiota composition. Dietary substrate availability is clearly important and 
presents an opportunity for mediating symptom provocation.   
 
1.1.7.6 Microbiota-directed therapy 
Microbiota-directed interventions in IBS elicit improvements in GI symptoms in some studies, 
which provide further evidence of the role of the microbiota in IBS pathogenesis. The 
therapeutic role of these interventions in IBS is discussed in Section 1.3. 
 
1.1.8 Treatment options in IBS 
There are numerous pathophysiological mechanisms underlying the development of IBS and 
more research is required to confirm the contribution of each across IBS subtypes. 
Understanding the aetiology and the disease course of IBS is important in order to devise 
optimal treatment regimens. The following section summarises the current treatment options 
available for patients with IBS. 
 
1.1.8.1 Medical therapy 
The complex pathophysiology of IBS, symptom heterogeneity of presenting patients and 
instability of symptoms raises treatment challenges. Treatment is largely empirical and after 
lifestyle considerations (stress reduction, exercise, diet) have been addressed, medical 
treatment is targeted towards the predominant symptom with antispasmodics, anti-
diarrhoeals or  over-the-counter non gas producing laxatives (osmotic, bulking-forming or stool 
softeners) with an emphasis on self-management (NICE, 2015). There is little recent efficacy 
data of these first line treatment options in IBS. One systematic review and meta-analysis 
reported greater effectiveness of antispasmodics over placebo in IBS, although there was 
significant heterogeneity between studies, publication bias, greater adverse events reported 
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versus placebo, and a majority of the medications included were not available in the UK (Ford 
et al., 2008). Furthermore, studies included in the analysis recruited patients from all levels of 
medical care, which may mask true treatment effect in specific patient subgroups.  
 
If first line therapies have not been effective, low-dose antidepressants (tricyclic 
antidepressants or selective serotonin reuptake inhibitors) are effective in some patients. New 
agents with acceptable safety profiles are also available in secondary and tertiary care. For 
example, lubiprostone and linaclotide that increase colonic motility have demonstrated 
efficacy in patients with constipation, and serotonin antagonists (e.g ondansetron) may be 
effective in IBS-D. Psychological and behavioural interventions, including hypnotherapy, may 
also benefit some patients (NICE, 2015), however access to services offering these treatments 
may be limited. 
 
1.1.8.2 Antibiotic therapy 
It is plausible that if dysbiosis is a major aetiological factor in IBS, interventions that target the 
microbiota should be effective in some patients. One way of potentially restoring an abnormal 
microbiota is through antibiotic therapy. Rifaximin, a non-absorbable antibiotic that has 
received the most attention in the treatment of IBS, was recently the subject of a meta-
analysis. Therapeutic benefit was reported for adequate relief of global symptoms (OR 1.57),  
equivalent to a number needed to treat (NNT) of 10.2 (Menees et al., 2012), and it had effects 
on improving bloating compared with placebo (OR 1.55). Overall frequency of adverse events 
was similar between groups, including for diarrhoea, suggesting this may be an effective 
treatment for some IBS patients, although efficacy and safety profile beyond four months is 
still to be established. 
 
Antibiotics reduce overall GI microbiota load in the colon, and thereby reduce colonic gas 
production (Dear et al., 2005). Other effects are largely unknown, although a series of studies 
in animal models of IBS suggests rifaximin not only reduces bacterial content by up to 84%, but 
has specific effects at the level of the colonic mucosa, improving integrity and reducing 
inflammation, and normalising visceral hypersensitivity. Interestingly, a consistent finding in 
these studies is an increased abundance in ileal Lactobacilli in the animals receiving rifaximin, 
which is hypothesised to be responsible for the anti-inflammatory effect (Gao et al., 2014). 
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Overall, antibiotics appear to be an effective intervention in a proportion of patients. However, 
they may also increase the risk of developing GI symptoms (Maxwell et al., 2002). The paradox 
that antibiotics are used as a treatment but also are involved in the pathogenesis of functional 
GI symptoms is difficult to resolve, and the role of antibiotics in the pathogenesis of IBS may be 
related to a lower threshold for medical consultation (Whitehead et al., 2007), which leads to a 
greater likelihood of antibotic therapy in these patients. More data are required to understand 
the action of antibiotics in IBS, define predictors of response, clarify optimum dose, confirm 
durability of effectiveness, and assess long term safety.  
 
1.1.8.3 Diet  
Many patients believe that their IBS symptoms are related to diet. There is generally a lack of 
evidence regarding the underlying mechanisms by which food provokes symptoms in IBS, 
which has limited the development of validated diagnostic tests to identify specific food 
triggers. Furthermore, evidence for the effect of dietary intervention on IBS symptoms has 
historically been scarce. Data regarding manipulation of dietary fibre intake in IBS is 
inconsistent (Eswaran et al., 2013), uncontrolled trials of exclusion diets followed by 
reintroduction indicate individual foods (e.g. wheat) exacerbate symptoms (Nanda et al., 1989, 
Parker et al., 2008), but mechanisms by which they cause symptoms have not been identified.  
Furthermore, although associations between IBS symptoms and intake of caffeine, alcohol and 
fat have been reported in cross-sectional studies, no RCTs investigating the effect of their 
restriction have been performed. Nevertheless, interest in the dietary management of IBS 
continues to grow amongst clinicians and patients. In particular, a diet low in short chain 
fermentable carbohydrates (the low FODMAP diet) has gained significant attention. Dietary 
modification of the GI microbiota through probiotics or prebiotics present other potential 
approaches for the management of IBS. Each of these three strategies will be reviewed 
(Sections 1.2, 1.3). 
 
1.2 The low FODMAP diet 
1.2.1 Introduction 
Carbohydrates are an important component of the diet in humans and in UK adults they 
contribute to nearly half of total energy intake. They are a diverse group of substances 
characterised by a range of physical and physiological properties and have important roles in 
energy metabolism and colonic function. 
 
  Chapter 1: Introduction 
41 
 
Restriction of individual carbohydrates (e.g. lactose, fructose) has been considered for the 
management of GI symptoms for many years. Recently, broader restriction of several short 
chain fermentable carbohydrates has been of clinical and research interest. This diet has been 
termed a low ‘fermentable oligosaccharides, disaccharides, monosaccharides and polyols’ 
(FODMAP) diet. Section 1.2 will describe the individual components of this group of 
fermentable carbohydrates, evaluate the literature regarding the mechanisms underlying a 
low FODMAP diet and the available evidence regarding its clinical effectiveness in IBS, and 
discuss its impact on the GI microbiota and nutrient intake. 
 
1.2.2 Fermentable carbohydrates 
Some dietary carbohydrates such as glucose, sucrose and starch, are completely digested and 
absorbed in the small intestine. Carbohydrates known to be indigestible in humans include non 
starch polysaccharides (NSP), resistant starch, short chain carbohydrates and some polyols 
(Elia and Cummings, 2007). Up to 40 g of unabsorbed carbohydrate enters the colon per day in 
individuals consuming a Western diet (Scott et al., 2013). This then becomes available for 
bacterial fermentation either due to the absence, or reduced concentration, of suitable 
hydrolase enzymes for digestion, or in the case of some disaccharides and monosaccharides, 
due to incomplete absorption in the small intestine. The degree of carbohydrate digestibility is 
further influenced by the presence of disease (e.g. malabsorption disorders), interindividual 
variation, and in some cases, transit time and the dose consumed (Elia and Cummings, 2007). 
 
On entering the colon, carbohydrates with a high degree of polymerisation (DP>10) are 
fermented more slowly and produce less gas than their counterpart short chain carbohydrates 
(DP<10) (Hernot et al., 2009). Long chain polysaccharides contribute to a substantial 
proportion of indigestible dietary carbohydrate, and include plant cell wall NSP (e.g. cellulose, 
hemicelluloses and pectin), psyllium and resistant starch. Along with these long chain 
carbohydrates, smaller quantities of protein and fat also enter the colon from exogenous 
(dietary) and endogenous (e.g. red blood cells, sloughed epithelial cells) sources. Their effect 
on fermentation and metabolic byproducts is less well studied (Scott et al., 2013). The 
remaining chapter will review the short chain carbohydrates (i.e. fructans, galacto-
oligosaccharides, lactose, fructose and polyols) and review their dietary sources, digestibility 
and absorption, and physiological effects in the GI tract. 
 




Fructans, also termed ‘inulin-type fructans’ are a major dietary source of fermentable 
carbohydrates. They are either linear or branched fructose oligosaccharides that include inulin, 
oligofructose and fructo-oligosaccharides (FOS), and have a DP of 2-60. There is minimal 
digestion of fructans in the small intestine due to the lack of enzymes in the human GI tract 
able to hydrolyse the  (2-1) fructosyl-fructose glycosidic bonds. Up to 90% of fructans survive 
the small intestine undigested (Barrett et al., 2010, Hernot et al., 2009) and as a result of their 
unique properties in the colon they are classified as prebiotics (Section 1.3.1). 
 
Fructans are present as storage carbohydrates in plant products (Table 1.4). A majority of 
dietary fructans come from wheat, onion, garlic and leek, which are relatively low in fructans 
but consumed in large quantities (van Loo, 1995, Dunn et al., 2011). Commercial fructans 
derived from sucrose or chicory root are increasingly added to pre-prepared foods due to their 
textural and sensory properties and potential health benefits, including their low energy value. 
They are commercially added to low fat yoghurt, ice cream, breakfast cereals, protein 
powders, multivitamin and mineral products and probiotic supplements. Average fructan 
intake in healthy individuals is reported to be up to 4 g/d (Dunn et al., 2011) and slightly lower 
in patients with IBS at 2-3.5 g/d (Staudacher et al., 2012, Bohn et al., 2015).  
 
Table 1.4 FODMAP content of selected foods 











(van Loo, 1995) 
(Biesiekierski et al., 2011) 
(Whelan et al., 2011) 
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(Food Standards Agency, 2002) 
(Food Standards Agency, 2002) 
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(Yao et al., 2014) 
(Yao et al., 2014) 
(Yao et al., 2014) 
GOS, galacto-oligosaccharides 




As well as their prebiotic properties, fructans have other beneficial physiological effects. This 
includes bulking of stool through increasing stool biomass, and reducing the risk of colon 
cancer in animal models, which is proposed to be associated with increased butyrate 
production (Roberfroid, 2007). There is also evidence for beneficial effects systemically such as 
appetite regulation, lipid metabolism, and improved calcium bioavailability (Roberfroid, 2007). 
However, despite the beneficial effects on health, acute modest doses (7 g) may induce GI 
symptoms in IBS (Silk et al., 2009) and in healthy individuals (Bonnema et al., 2010), although 
isolated fructan restriction in IBS has not been evaluated. 
 
1.2.2.2 Galacto-oligosaccharides (GOS) 
Galacto-oligosaccharides (GOS) consist of galactose monomers (DP<10) with a terminal 
glucose unit, and include raffinose, stachyose and verbascose. Humans lack the α-
galactosidase enzyme, which results in the availability of GOS for colonic fermentation and its 
prebiotic effect (Section 1.3.1). Although overall food composition data for GOS is more sparse 
than for fructans, identified naturally occurring sources of GOS include human breast milk, 
pulses, legumes and some grains, nuts and seeds (Biesiekierski et al., 2011, Cummings and 
Stephen, 2007) (Table 1.4). GOS can also be commercially produced via -galactosidase 
enzymatic treatment of lactose, and is commonly added to infant formula, dairy products and 
beverages. Dietary intake data in healthy individuals is not available, however intake in 
individuals with IBS is low at 0.5-2 g/d (Staudacher et al., 2012, Bohn et al., 2015). 
 
Despite their prebiotic effect, studies in healthy individuals indicate relatively small doses of 
GOS induce GI symptoms. For example, acute ingestion of 80 g conventional soya flour (3 g 
GOS) elicits greater frequency of flatus compared with low stachyose and raffinose soya flour 
(0.5 g GOS) in healthy individuals (Suarez et al., 1999). Galactosidase enzyme supplementation 
reduces symptom score after high GOS test meals (7.5 g GOS) in healthy individuals compared 
with placebo, confirming this is a GOS-specific effect (Di Stefano et al., 2007), however isolated 
GOS restriction in IBS has not been investigated.  
 
1.2.2.3 Lactose 
Lactose is a disaccharide of glucose and galactose. Lactase hydrolysis of lactose into its 
constituent monosaccharides is required for absorption, and up to 70% of humans exhibit 
hypolactasia which results in lactose malabsorption (Lomer et al., 2008). The reported 
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prevalence of lactose malabsorption in IBS is variable, but three recent studies of patients with 
GI symptoms referred for hydrogen breath testing report a prevalence of 20-30%, which is not 
different to healthy individuals (Barrett et al., 2009, Wilder-Smith et al., 2013, Bate et al., 2010) 
although prevalence is much higher in Asian, African, and South American populations. 
Diagnosis of lactose malabsorption is not clinically meaningful unless lactose consumption 
exacerbates GI symptoms i.e. lactose intolerance.  
 
Lactose malabsorption can be measured in a variety of ways including measurement of breath 
hydrogen and methane in response to lactose challenge (lactose breath test), blood glucose 
concentration in response to a lactose challenge (lactose tolerance test), and evaluation of 
lactase activity in jejunal biopsy samples. There are a variety of limitations associated with 
these methods, including the time burden, lack of agreement on lactose dose for breath and 
tolerance tests, and the invasiveness of measuring lactase activity. There has been 
considerable debate regarding the usefulness of breath testing for the identification of 
tolerance to lactose in IBS. Presence of lactose malabsorption on breath testing is not 
representative of intolerance to lactose, likely due to interindividual differences in visceral 
hypersensitivity (Yang et al., 2013). Lack of agreement on breath test methodology and poor 
access to breath test facilities limits its use. Genotyping is useful as an objective diagnostic 
tool, whereas simple dietary restriction and rechallenge may be more accessible for most 
patients. 
 
Lactose is naturally present in mammalian milk (e.g. cow’s, goat’s and sheep’s), and products 
derived from it (e.g. yoghurt, ice cream, cheese) (Table 1.4). It is commercially added to baked 
goods as a browning agent or humectant (Lomer et al., 2008). Average intake of lactose is 
reported to be 12 g/d in the healthy population and 7-10 g/d in IBS (Staudacher et al., 2012, 
Bohn et al., 2015). A total dose of 12 g/d has been suggested as tolerable in those with lactose 
intolerance, meaning complete restriction is not required (Lomer et al., 2008).  Lactose-
reduced or hydrolysed lactose products (e.g. lactose free milk or yoghurt) are popular and 
convenient substitutes for standard lactose-containing products.  
 
Despite studies reporting that large doses of lactose solution (20-50 g) lead to GI symptoms in 
IBS (Wilder-Smith et al., 2013, Zhu et al., 2013) only a small number of RCTs and observational 
studies have been conducted investigating lactose restriction, with variable responses 
demonstrated. In one of the largest RCTs to date (n=122), lactose restriction was effective in 
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improving symptoms of only 40% of patients with IBS with confirmed lactose malabsorption on 
breath testing, despite those positive for lactose malabsorption experiencing greater 
symptoms during the test compared with those without lactose malabsorption (Parker et al., 
2001). Furthermore, of those who subsequently improved on a low lactose diet, double-blind 
placebo-controlled capsule challenge was positive in only 29%. Therefore, although lactose 
restriction may be helpful in a small proportion of patients with lactose intolerance, it may 
represent response to other aspects of the dietary restriction or to placebo effect, suggesting 
overall lactose restriction in isolation is relatively ineffective in IBS. 
 
1.2.2.4 Fructose 
Fructose is a 6-carbon monosaccharide that is dose-dependently and variably absorbed (Jones 
et al., 2011). Fructose absorption can occur through a number of routes of facilitated 
transport. The most widely researched are via the fructose-specific GLUT5 transporter and the 
GLUT2 transporter on the apical membrane of the intestinal epithelium, the latter involving a 
process of glucose-fructose co-transport. A third transporter (GLUT7) has also been identified, 
but is unlikely to be a major candidate due to its distal location in the ileum (Jones et al., 2011). 
There is considerable debate about the distribution and role of these transporters in fructose 
absorption. It is clear, however, that a fructose-glucose ratio of 1:1 dramatically improves 
fructose absorption (Truswell et al., 1988).   
 
Reported prevalence of fructose malabsorption, or the incomplete absorption of fructose, 
varies significantly between studies most likely due to variations in breath testing 
methodology. However, two large studies using identical challenge doses (35 g) and diagnostic 
criteria reported 25-55% of healthy people and a similar proportion of those with IBS present 
with fructose malabsorption (Barrett et al., 2009, Bate et al., 2010). Therefore, it appears 
evidence of fructose malabsorption without symptoms is a normal phenomenon, and, as is the 
case with lactose, it is only clinically relevant if symptoms are present during testing. 
 
Major dietary sources of fructose in the US include fruit, fruit products and products 
sweetened with high-fructose sweeteners (Marriott et al., 2009) (Table 1.4). Overall average 
daily fructose intake in the general US population has been reported as 41 g/d, (Marriott et al., 
2009). Although fructose intake in the healthy UK population has not been reported, much 
lower intakes have been reported in IBS patients in the UK and Europe (14-17 g/d) compared 
with the US (Staudacher et al., 2012, Bohn et al., 2015). It is clear that an acute 20-35 g 
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fructose load induce symptoms in some patients with IBS (Shepherd et al., 2008, Wilder-Smith 
et al., 2013), which is not always associated with evidence of malabsorption on breath testing 
(Wilder-Smith et al., 2013). The evidence for isolated dietary fructose restriction in IBS is 
unclear, as studies are observational and uncontrolled in nature (Ledochowski et al., 2000, 
Born et al., 2006).  
 
1.2.2.5 Polyols 
Polyols are sugar alcohols such as the monosaccharides sorbitol and mannitol. Their 
absorption is passive, variable between individuals and affected both by molecular size and 
organic disease (Fordtran et al., 1967, Elia and Cummings, 2007). The inability to absorb a 
complete 10 g dose of sorbitol has been reported in 60-70% of healthy individuals (Hyams, 
1983) and patients with IBS (Yao et al., 2014). There is greater absorption of mannitol than 
sorbitol in IBS, a finding that is hypothesised to be due to its differing hydroxyl position or to 
luminal factors affecting its water solubility and therefore absorption (Yao et al., 2014). Polyols 
are potential candidate prebiotics as they are available for fermentation, however evidence for 
their ability to selectively stimulate specific microbiota is limited. 
 
Fruit and vegetables are natural sources of sorbitol and mannitol, and sugar-free chewing gum 
is a significant source, containing at least 10 times the sorbitol per gram compared with many 
fruit and vegetables (Yao et al., 2014) (Table 1.4). Other polyols include the monosaccharides 
xylitol, erythritol, and the disaccharides isomalt and maltitol, many of which are commonly 
used as bulk sweetening agents in the food industry due to their sweetness, mouth feel, 
temperature stability and low calorific value. Polyol intakes are not well documented, but have 
been reported at 1 g/d in IBS (Staudacher et al., 2012, Bohn et al., 2015). 
 
Acute loads of sorbitol (10 g) or mannitol (10-17 g) in IBS clearly induce GI symptoms (Marciani 
et al., 2010, Yao et al., 2014). Furthermore, symptom improvement on sorbitol restriction has 
been demonstrated in 50-70% of patients with FBD (Fernandez-Banares et al., 2006, Goldstein 
et al., 2000, Born et al., 2006). However, a majority of these studies also restrict other 
carbohydrates (e.g. fructose, lactose), are observational in nature, and do not clearly define 
symptom response. Therefore whether isolated polyol restriction in IBS is effective is unclear.  
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1.2.3 Gl effects of FODMAPs 
There is considerable evidence that acute challenge with individual FODMAP carbohydrates 
induces GI symptoms in IBS, as described above. The dose-dependent and cumulative effect of 
FODMAPs been demonstrated using individual FODMAPs in solution (Rumessen and 
Gudmand-Hoyer, 1988, Shepherd et al., 2008), although only one study has tightly controlled 
for background diet by providing all food and fluid for the duration of the study (Shepherd et 
al., 2008). Increasing FODMAP intake through consumption of high FODMAP foods also leads 
to increased GI symptoms in individuals with excessive flatulence (Manichanh et al., 2014) and 
in patients with IBS (Ong et al., 2010) within a short period of time (2-3 days). The physiological 
effects of FODMAPs in the GI tract that are proposed to induce GI symptoms will now be 
described and are depicted in Figure 1.5 and a summary of relevant studies is presented in 
Table 1.5. 
 
1.2.3.1 Small intestinal water 
Certain FODMAPs increase small intestinal water. This has been demonstrated by ileostomy 
recovery and magnetic resonance imaging (MRI) studies. Indeed, one randomised single blind 
crossover feeding study in 10 patients with quiescent IBD showed effluent water increased by 
20% after a 4-day high FODMAP diet (112 g FODMAPs/d) compared with a diet with very low 
FODMAP content (6 g FODMAPs/d) (Barrett et al., 2010) (Table 1.5). An even greater effect on 
small intestinal water has been demonstrated in response to acute challenge using MRI. 
Healthy individuals were found to have a 10-fold higher small intestinal water volume 40 
minutes after consumption of a 17.5 g mannitol solution compared with an equimolar glucose 
solution (Marciani et al., 2010), and significant rises also occur after administration of 40 g 
fructose (Murray et al., 2014, Major et al., 2015b), which is partially resolved through 
contemporaneous ingestion of 40 g glucose (Murray et al., 2014). Inulin, conversely, has no 
effect on small intestinal water compared with glucose (Murray et al., 2014, Major et al., 
2015b), however further study is needed on the effect of smaller DP fructans that are more 
representative of those found in the diet.  
 
Increased small intestinal water volume, particularly in the context of visceral hypersensitivity 
in IBS, might provoke abdominal pain and bloating, and in the absence of adaptive colonic 
water absorption might result in diarrhoea. Indeed, the enhanced small intestinal water 
associated with intake of FODMAPs has recently been correlated with symptom exacerbation 
 




Figure 1.5 Mechanisms by which FODMAPs might induce symptoms in IBS. Unabsorbed 
fructose, polyols and lactose lead to water shifts in the ileum. Unabsorbed FODMAPs are 
fermented in the colon leading to luminal gas production. In the setting of visceral 
hypersensitivity and altered colonic functioning the resulting luminal distension leads to 
symptom exacerbation (Staudacher et al., 2014) 
 
  
Table 1.5 Studies investigating the effect of FODMAPs on small intestinal water and colonic fermentation 
Reference Study design Participants Intervention Outcome measures Findings 
Small intestinal water 
(Major et al., 2015b) Randomised, 
double blind 
crossover  
IBS n=29 40 g glucose solution (control) 
40 g fructose solution 
40 g inulin solution 
SBWC using MRI SBWC fructose vs glucose (p<0.005) 
Fructose correlation SBWC with symptoms (p<0.05) 
(Murray et al., 2014) Randomised, 
single blind, 
crossover 
Healthy n=16 40 g glucose solution (control) 
40 g fructose solution 
40 g inulin solution 
40 g fructose + 40g glucose 
solution 
SBWC using MRI  
 
SBWC  fructose vs glucose (mean difference 25 l/min; p<0.005) 
SBWC fructose + glucose (mean difference 16 l/min) vs fructose 
(not sig) 
SBWC inulin no effect vs glucose (p>0.7) 







4-day high FODMAP diet  
(112 g/d) 
4-day low FODMAP diet  
(6 g/d) 
Effluent weight 
Effluent water content 
effluent weight high vs low FODMAP diet (409 g vs 504 g; p=0.01) 
water content high vs low FODMAP diet (20% increase; p=0.013) 
(Marciani et al., 2010) Randomised, 
single blind, 
crossover  
Healthy n=11 17.5 g glucose solution (control) 
17.5 g mannitol solution  
 
SBWC using MRI  SBWC mannitol vs glucose at 40 minutes 
 (381 ml vs 47 ml; p<0.001) 
Fermentation 
(Major et al., 2015b) Randomised, 
double blind 
crossover  
IBS n=29 40 g glucose solution (control) 
40 g fructose solution 
40 g inulin solution 
Breath H2 samples over 
300 min 
Colonic volume using MRI 
colonic gas and volume inulin vs fructose, glucose (p<0.05) 
Inulin correlation colonic gas with symptoms (p<0.05) 
 
(Murray et al., 2014) Randomised, 
single blind, 
crossover 
Healthy n=16 40 g glucose solution (control) 
40 g fructose solution 
40 g inulin solution 
40 g fructose + 40g glucose 
solution 
Breath H2 samples over 
400min 
 
H2 inulin vs glucose (p<0.0001) and fructose (p<0.05) 
colonic gas inulin vs glucose (p<0.05)  
 





2-day high FODMAP diet (50 g/d) 
2-day low FODMAP diet (9 g/d) 
Breath H2 14 hours on 
day 2 
H2 production in high vs low FODMAP diet in both IBS (242 ppm vs 
62 ppm; p<0.001) and controls (181 ppm vs 43 ppm; p<0.001) 
SBWC, small bowel water content; MRI, magnetic resonance imaging; H2, hydrogen
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in patients with IBS (Major et al., 2015b), suggesting for the first time that there is a 
relationship between the increased small intestinal water and GI symptoms. Interestingly, 
small intestinal water content was higher even in those that were asymptomatic, signifying 
enhanced visceral hypersensitivity in the symptomatic group may have been central to 
provocation of symptoms. 
 
1.2.3.2 Fermentation  
The availability of short chain carbohydrates for colonic fermentation leads to increased 
hydrogen and methane production, resulting in luminal distension and pain in IBS (Table 1.5). 
The first study to demonstrate this was a controlled, crossover feeding study in patients with 
IBS (n=15) and healthy individuals (n=15). A high FODMAP diet (50 g/d) led to a marked 
increase in breath hydrogen production compared with a low FODMAP diet (<10 g/d) in 
patients with IBS and in healthy individuals (Ong et al., 2010). Furthermore, individual 
FODMAPs elicit distinct hydrogen responses. Hydrogen release occurs later, remains elevated 
for longer and is significantly greater after 40 g inulin compared with fructose in healthy 
individuals (Murray et al., 2014). Direct measurements of colonic gas volume using MRI also 
demonstrated substantially greater peak colonic volume after inulin versus fructose (265 vs 
142 volume/ml) (Major et al., 2015b). This is likely due to differences in transit time, which 
leads to variable availability for fermentation in the proximal colon, and variable fermentation 
rate between carbohydrates of different molecular geometry (Hernot et al., 2009). 
 
1.2.3.3 Motility, colonic volume and microbiota 
Some preliminary evidence suggests there are other means by which FODMAPs might induce 
symptoms. Firstly, some FODMAPs increase GI motility. Small intestinal transit time is 
increased following ingestion of 30 g of a fructose-sorbitol mixture in healthy individuals 
(Madsen et al., 2006), which further reduces availability of these substrates for absorption, 
increasing their exposure to bacteria for fermentation. Secondly, a short term low FODMAP 
diet appears to influence colonic volume measured on MRI. Colonic volume in healthy 
individuals increased 20% after one week on a low FODMAP diet, which is contrary to the 
expected reduction in volume that might occur secondary to reduced gas production (Major et 
al., 2015a). In fact, fasted expired hydrogen was reduced in this group suggesting that the 
increased colonic volume was independent of changes in gas and it was speculated that diet-
induced alterations in the microbiota were responsible. Further work is needed to confirm 
these findings in patients with IBS. 
  Chapter 1: Introduction 
51 
 
Given the effects of FODMAPs in the GI tract, it is plausible that dietary restriction of these 
carbohydrates might be effective in ameliorating IBS symptoms, particularly in patients with 
visceral hypersensitivity. Limiting luminal distension through reducing small intestinal water 
and colonic gas production would reduce sensory afferent input from the enteric system. 
Furthermore, the additive effect of these carbohydrates would suggest that collective 
restriction may improve symptoms more than restriction of one or two individual 
carbohydrates. 
 
1.2.4 Structure and delivery of the low FODMAP diet 
The low FODMAP diet is gaining widespread acceptance in primary, secondary and tertiary 
centres for the management of IBS. Data on clinical effectiveness of the low FODMAP diet is 
available only for dietitian-led advice and therefore it is unknown whether other methods of 
delivery (e.g. leaflet, advice from non-dietetic health professional) are as effective.  
 
Due to the complexity of the low FODMAP diet, the structure and delivery of advice is 
important for effectiveness and to ensure nutritional adequacy is achieved. Following careful 
assessment of medical, symptom and diet history, explanation is provided regarding the 
underlying mechanisms for the diet’s effectiveness. Specific individualised advice regarding 
low FODMAP fruit, vegetables, grains and dairy products is provided and is supported with 
complementary written information listing suitable and unsuitable foods. Advice regarding 
avoidance of added high FODMAP ingredients (e.g. inulin), food product label reading, eating 
out and maintaining a varied balanced diet is essential. Routine practice involves the 
restriction of FODMAPs for at least 4 weeks, which is followed by a systematic reintroduction 
phase if sufficient symptom response occurs. Each FODMAP carbohydrate is challenged in 
increasing doses to determine tolerance. Nutritional adequacy should be assessed throughout 
the entire process and addressed where necessary.  
 
1.2.5 Clinical effectiveness of the low FODMAP diet 
The following sections will review the evidence for the clinical effectiveness of the low 
FODMAP diet in relation to GI symptoms and HRQOL in IBS. 
 
1.2.5.1 GI symptoms 
The last decade has seen publication of numerous studies investigating the effect of a low 
FODMAP diet on IBS symptoms. Publication of two recent systematic reviews, albeit with 
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different conclusions, confirms the growing research interest in the area (Rao et al., 2015, 
Marsh et al., 2015). Many of the studies are limited due to their retrospective and/or 
uncontrolled observational nature, however some RCTs have been undertaken which report 
promising findings. 
 
The first retrospective study of the low FODMAP diet ever published undertook a case review 
of 62 IBS patients a median of 10 months after initial dietary consultation. Patients were 
advised to restrict fructans and fructose and some patients also received advice regarding 
avoidance of other FODMAPs. In total, 77% of patients reported improvement in symptoms, 
with an impressive majority of 85% of adherent patients reporting benefit (Shepherd and 
Gibson, 2006). Other prospective, uncontrolled studies support these findings especially for 
overall symptoms, pain, bloating and diarrhoea (Wilder-Smith et al., 2013, de Roest et al., 
2013).  
 
Our group evaluated the effect of dietitian-led low FODMAP dietary advice compared with 
standard dietary advice based on national guidelines (NICE, 2015) in a non-RCT of IBS patients 
(Staudacher et al., 2011). More patients (76%) reported satisfaction with symptom response 
compared with those receiving standard advice (54%) after 2-6 months (p<0.05), although 
follow up only included those patients who returned to clinic. Retrospective, uncontrolled and 
non RCTs are limited by obvious shortcomings associated with this type of research, including a 
lack of control of external factors that impact on symptom experience (e.g. drugs, diet), bias 
associated with non-random allocation and the inability to distinguish an effect of treatment 
over placebo. Furthermore, most studies of this nature do not measure dietary intake or 
compliance.  
 
Six RCTs have been undertaken investigating the effectiveness of a low FODMAP diet in adults 
with IBS (Table 1.6), of which three were unblinded. In these studies, patients randomised to 
low FODMAP dietary advice for 4-6 weeks reported improvements in a variety of GI symptoms 
based on various symptom scoring tools (Staudacher et al., 2012, Pedersen et al., 2014, Harvie 
et al., 2013).  Dietary intake was assessed in two of the three studies which confirmed a 
reduction in FODMAP intake, and only one reported no adverse alteration in other dietary 
components (e.g. fibre) that might bias symptom outcomes (Staudacher et al., 2012). There 
are inevitable problems associated with unblinded intervention studies in IBS as preconceived 
expectations about a treatment may prime patients to sense and record symptom outcomes 
  
Table 1.6 RCTs investigating the effectiveness of a low FODMAP diet in adults with IBS 
Reference Study design Participants Duration Adherence  Symptom scoring Findings 
Unblinded 






Rome III IBS 
LFD n=42 
LGG  n=41 
habitual diet n=40 
6 weeks No Web accessed IBS-SSS 8/42 (20%) low FODMAP withdrew due to difficulty of diet, 4/42 LGG 
withdrew  
IBS-SSS total score reduction low FODMAP (75 pts) compared with control 
(32 pts; p<0.01) but not compared with probiotic (32 pts, p=0.2) 
IBS-SSS score for all subscores low FODMAP vs baseline  
(Harvie et al., 2013) Randomised 
controlled trial 
(dietary advice) 
Rome III IBS 
waiting list n=27 
LFD n=23 
3 months FODMAP 
FFQ 
IBS-SSS reduction in IBS-SSS score low FODMAP (276 to 129 pts) compared with 
control (247 to 204 pts; p < 0.01) 
 IBS-SSS Δ in episodes pain low FODMAP compared with control (p < 0.01) 





Rome III IBS with 
bloating or diarrhoea 
habitual diet n=22 
LFD n=19 
4 weeks 7-day food 
diary 
AR question 
GI Symptom Rating 
Scale  
Bristol Stool Form Scale 
3/22 (14%) low FODMAP withdrew 
% patients reporting AR low FODMAP (68%) vs control (23%; p=0.005) 
% patients reporting improvement in bloating, borborygmi, urgency, overall 
symptoms low FODMAP vs control (p<0.05) 
% normal stool consistency low FODMAP vs control (24% vs 7%, p=0.02) 
Blinded 




Rome III IBS 
LFD n=38 
standard diet n=37 
4 weeks 4-day food 
diary 
IBS-SSS 
Stool frequency and 
consistency 
Responder: ≥ 50pt 
reduction total IBS-SSS 
4/38 (11%) low FODMAP diet withdrew, 3/37 (8%) standard diet withdrew  
total IBS-SSS score compared with baseline for low FODMAP diet (p<0.01) 
and standard diet (p<0.01) 
IBS-SSS subscores compared with baseline for pain frequency, severity of 
distension and life interference for both groups (p<0.01) 
50% responders low FODMAP diet, 46% responders standard diet (p=0.72) 
stool frequency low FODMAP diet vs baseline (1.9 vs 1.5/day, p<0.001) 
(Piacentino  et al., 





Rome III IBS n=75 
LFD-GF 









Satisfactory relief VAS 
improvement in intensity and frequency of abdominal bloating in LFD-GF 
and LFD vs habitual (p<0.001) 
No difference between groups for AR 
Satisfactory relief in LFD vs LFD-GF using VAS (p=0.044) 




Rome III IBS n=27 
Australian diet vs  
LFD 
21 days 7-day food 
diary 
100 mm VAS for 4 
symptoms and overall 
Stool frequency 
Stool water content 
overall GI symptoms low FODMAP diet (23 mm) vs typical Australian diet 
(45 mm; p<0.001). Similar outcomes for bloating, pain, stool dissatisfaction  
70% low FODMAP >10 mm reduction in overall GI symptoms 
Reduced stool frequency in IBS-D low FODMAP diet vs Australian diet 
LFD, Low FODMAP diet; LGG, L. rhamnosus GG; FFQ, food frequency questionnaire; IBS-SSS, IBS Severity Scoring System; AR, adequate relief; LFD-GF, low FODMAP diet and gluten free
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differently. This is a particular problem in IBS where outcomes are subjectively assessed and 
are highly sensitive to participant behaviour and where placebo effect is considerable (20-40%) 
(Elsenbruch and Enck, 2015). 
 
Blinded dietary intervention studies are notoriously difficult to perform. In low FODMAP 
studies to date, two methods have been employed to attempt to blind patients to the dietary 
intervention. One single blind crossover feeding study provided all food and fluid to patients 
for two 21-day feeding periods. Overall symptoms, pain, bloating and flatulence were 
significantly lower in response to low FODMAP feeding compared with patients were fed a 
typical Australian intake. Improvement in overall GI symptoms, demonstrated by at least a 10 
mm reduction on a visual analogue scale (VAS), was observed in 70% of patients, and 
symptoms were noted to improve in the first week of treatment (Halmos et al., 2014).  
 
An advantage of feeding studies is the ability to carefully control dietary intake and compliance 
to the intervention, however controlled feeding does not mimic the real-life challenges 
associated with free living individuals having to sustain a restricted diet. Furthermore, 
crossover studies carry with them questions regarding the minimum wash out period required 
between interventions, and the effect on patient perception on allocated treatments. Another 
specific issue in this study was the increase in symptoms in the control group, which may have 
been due to an increase in FODMAP intake compared with habitual diet, leading to an 
artificially greater symptom difference between the groups (Halmos et al., 2014). 
Nevertheless, this was the first placebo-controlled low FODMAP intervention trial and an 
important contribution to this area of research. 
 
The second blinded study (abstract only) compared the effect of a low FODMAP diet with and 
without gluten with controls following normal diet (n=75) (Piacentino  et al., 2015). The 
implementation of the diet was unclear, however it was double blind which suggested it was a 
controlled feeding study. Global response measured using a VAS was higher in patients 
consuming a standard low FODMAP diet compared with those consuming a combined low 
FODMAP-gluten free diet (p=0.044). This is the first evidence that low FODMAP advice alone is 
superior to a more restrictive approach. Interestingly, more patients continued the low 
FODMAP diet at the 16-month follow up (72%) compared with the low FODMAP-gluten free 
group (52%) further suggesting gluten avoidance in addition to the low FODMAP diet did not 
offer additional benefit. 




The third blinded study investigating the effect of the low FODMAP diet on symptoms in IBS 
was a recent large two-arm parallel design RCT conducted in Sweden (Bohn et al., 2015).  
Patients were randomised in a single blind fashion to either low FODMAP advice (n=38) or 
standard dietary advice (n=37) based on UK clinical guidelines (NICE, 2015) for 4 weeks. 
Symptom outcomes were measured using the IBS Severity Scoring System (IBS-SSS) and dietary 
compliance was evaluated by quantification of FODMAP intake based on 4-day food diaries. 
Clinical response, a 50-point reduction in IBS-SSS score, was demonstrated in both groups (50% 
low FODMAP vs 46% standard, p=0.72) and groups demonstrated comparable reduction in 
score compared with baseline. These results suggest that the low FODMAP diet may be no 
more effective than standard advice which contrasts with results of a large unrandomised 
controlled trial comparing the same two interventions (Staudacher et al., 2011).  
 
The lack of an effect of the low FODMAP diet above standard advice in this RCT could be 
explained in a number of ways.  Firstly, the RCT included all subtypes of IBS patients, and IBS-C 
comprised 25-35% of the entire cohort. Although published data are not available, patients 
with IBS-C may be less likely to respond to the low FODMAP diet, which in part might explain 
these findings. Secondly, this RCT was the first study to include IBS severity as an inclusion 
criterion, whereby patients required a score of at least 175 points (moderate severity) on the 
IBS-SSS. Therefore, this cohort may have been different to previous studies where baseline 
symptom severity was more variable. Thirdly, baseline FODMAP intake was lower than that 
reported in other work (Staudacher et al., 2012), although not all (Halmos et al., 2014), which 
decreased the absolute reduction in dietary FODMAP load that was possible. Clinical response 
to a low FODMAP diet is subject to the accuracy of the advice provided and the source of 
information used to formulate the low FODMAP diet was not specified in this study. Therefore 
the dietary advice may have been somewhat different to that implemented in previous 
studies. Finally, the standard advice provided in this and prior work was based on UK dietetic 
advice which involves avoidance of a number of foods (e.g. Brussels sprouts, sugar free gum), 
many of which are high in FODMAPs, which led to a significant reduction in the intake of 
fructose and a trend toward a reduced intake of GOS in the standard group in this study, which 
may have masked a true treatment effect in the low FODMAP group.  A strategy that avoids 
this problem would be the use of ‘sham’ dietary advice devised to maintain FODMAP and 
nutrient intake whilst remaining a convincing exclusion diet (see Chapter 3). Finally, the results 
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of this RCT may in fact have reflected a true lack of response in this cohort, and replication of 
these findings in future RCTs is required to verify whether this is the case. 
 
In summary, current evidence suggests up to 70% of patients with IBS report symptomatic 
benefit on a low FODMAP diet. Indeed, the first meta-analysis of low FODMAP RCTs reports 
effects on abdominal pain (OR 1.81), abdominal bloating (OR 1.75) and overall GI symptoms 
(OR 1.81) (Marsh et al., 2015). In line with these overall findings, national guidelines for the 
dietary management of IBS in the UK now advise consideration of a low FODMAP diet if basic 
diet and lifestyle measures have been unsuccessful in managing symptoms (NICE, 2015). 
However, until now, the impact of the low FODMAP diet on IBS symptoms has not been 
confirmed in a blinded placebo-controlled dietary advice RCT.  
 
1.2.5.2 HRQOL 
The effect of a low FODMAP diet on HRQOL in patients with IBS has been explored in a limited 
number of studies. Some studies demonstrate improvement in disease-specific HRQOL in 
patients with IBS after low FODMAP dietary advice (Ostgaard et al., 2012, Mazzawi et al., 2013) 
whilst others show no effect  (Pedersen et al., 2014). All studies that have measured HRQOL 
have, however, been hindered by lack of blinding, have been uncontrolled in nature or 
implement broad dietary changes rather than low FODMAP dietary advice alone. One 
unblinded RCT has evaluated HRQOL in response to low FODMAP intervention. Both IBS-SSS 
scores and IBS-QOL improved compared with controls at 3 months, although whether 
medication and other lifestyle factors that might impact on HRQOL were controlled was not 
specified (Harvie et al., 2013). It is known that HRQOL can improve in response to placebo 
(Eickhoff, 2008), and therefore a placebo-controlled RCT is required to confirm whether low 
FODMAP dietary advice does indeed impact on HRQOL. 
 
1.2.6 Impact of the low FODMAP diet on the GI microbiota 
Despite the beneficial clinical effects of a low FODMAP diet in IBS, some potentially 
unfavourable consequences may result from this type of dietary manipulation. In particular, 
implementation of the low FODMAP diet results in a considerable reduction in intake of 
prebiotic fructans and GOS (Staudacher et al., 2012, Bohn et al., 2015). This represents a 
considerable reduction in total carbohydrate substrate available for colonic fermentation. In 
line with data from other studies that impose significant dietary restriction, this is likely to 
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have repercussions on the composition and functioning of the GI microbiota. Four studies have 
investigated whether this is the case in patients with IBS. 
 
The first study, undertaken by our group, investigated the effect of a 4-week low FODMAP diet 
on stool microbiota in IBS patients with bloating or diarrhoea using fluorescence in situ 
hybridisation (FISH) (Staudacher et al., 2012). A reduction in total FODMAP intake of 50% led 
to a marked 6-fold reduction in the relative abundance of Bifidobacteria compared with 
controls who maintained FODMAP, macronutrient and fibre intake whilst following habitual 
diet. This microbiota alteration was inversely associated with baseline Bifidobacteria 
concentration, such that those with higher baseline concentration exhibited a greater 
reduction in abundance. This was a novel finding, although the reverse has previously been 
demonstrated with prebiotic supplementation (Whelan et al., 2005). There were no 
differences in total bacteria or other bacteria such as Lactobacillus or F. prausnitzii, or 
fermentation byproducts such as stool SCFA concentration or stool pH between groups.  
 
The second study investigated the effect of a 3-week low FODMAP diet on the gut microbiota 
using quantitative polymerase chain reaction (qPCR) and also demonstrated a reduction in 
absolute Bifidobacteria concentration (Halmos et al., 2014). This was accompanied by 
substantial reduction in total bacterial load of 47% compared with habitual diet, as well as 
reduction in absolute abundance of F. prausnitzii and Clostridium Cluster IV. Diversity of 
Clostridium Cluster XIV was greater after low FODMAP intervention compared with habitual 
diet, which was postulated to be due to species adaptation to altered substrate availability. 
This was a crossover study, and therefore the potential of carryover effects cannot be ruled 
out. Furthermore, microbiota data from the patients with IBS was pooled with a group of 
healthy controls (n=6), potentially concealing differences between the groups in terms of 
response to the dietary intervention.  
 
Two studies have recently investigated the effect of a low FODMAP diet on the GI microbiota 
in children. One uncontrolled study found no effect of a 1-week low FODMAP diet on overall 
diversity or abundance of specific bacterial groups based on 454 pyrosequencing (Chumpitazi 
et al., 2014). Another specifically assessed whether symptomatic response to two days of a low 
FODMAP diet, based on pain frequency, was predicted by microbiota at baseline or by diet-
induced changes to the microbiota (Chumpitazi et al., 2015). This was a crossover feeding 
study, and symptom response occurred in only 24% of patients. However, increased baseline 
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abundance of taxa such as Bacteroides, Ruminococcaceae and F. prausnizii, were associated 
with response, suggesting patients with a higher abundance of saccharolytic microbiota may 
benefit the most from a reduction in dietary fermentable substrates. No such association has 
been demonstrated in adult patients (Halmos et al., 2014), and more data are required in 
longer duration parallel-arm trials. 
 
Until now there has only been one parallel group RCT in adults investigating the effect of a low 
FODMAP diet on a limited number of bacterial groups. Clearly, there is still much to 
understand regarding the impact of this dietary approach on the GI microbiota. Importantly, it 
is not yet known whether the mucosal compartment is affected, or if there is a critical 
timepoint at which microbiota alterations might have functional consequences and whether 
these changes lead to short or long term health consequences. Further investigation into the 
relevance of microbiota composition in predicting symptom response to the low FODMAP diet 
is needed, and will require an agreed definition of ‘response’. Reintroduction of FODMAPs to 
tolerance may attenuate some of the diet-induced microbiota alterations, but this has never 
been explored. 
 
1.2.7 Impact of the low FODMAP diet on nutrient intake  
The clinical effectiveness of a dietary intervention must always be weighed against the impact 
it has on the ability of patients to maintain appropriate nutrient intake in the long term. The 
ramifications of an exclusion diet are, to a certain extent, dependent on the baseline diet of 
the patient group in question. A number of cross sectional studies have examined habitual 
dietary intake of individuals with IBS and report that patients meet nutrient requirements, 
including for calcium and folate (Bohn et al., 2013, Williams et al., 2011), and do not differ 
from healthy controls (Saito et al., 2005). With relation to intake of individual foods, there is 
some data to suggest that milk intake is lower in IBS versus healthy controls (Hayes et al., 
2014) although this is not a consistent finding (Saito et al., 2005). Therefore, from the evidence 
to date, it appears nutrient intake of patients with IBS meets nutrient recommendations and is 
not significantly different to healthy controls.  
 
Measurement of dietary intake in low FODMAP intervention trials is only sometimes 
undertaken to confirm dietary adherence to the intervention, and to ensure minimal 
modification of other important components such as fibre that might impact on symptoms. In 
relation to macronutrients, two dietary advice studies report that low FODMAP dietary advice 
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reduces total carbohydrate intake compared with habitual diet to 150-200 g/d (Staudacher et 
al., 2012, Bohn et al., 2015), which is reflective of carbohydrate intake in healthy individuals in 
the UK (Public Health England and Food Standards Agency, 2014). One study has reported a 
reduction in energy, protein and fat intake in patients following low FODMAP advice (Bohn et 
al., 2015), which may be of concern particularly if the diet is followed in the longer term. 
 
One RCT to date has examined micronutrient intake in patients following low FODMAP dietary 
advice (n=16) (Staudacher et al., 2012). Iron intake according to 7-day diet records was not 
different to controls following habitual diet, suggesting that iron-fortified wheat breakfast 
cereals and other iron-rich foods (e.g. pulses, nuts) were adequately substituted. However, a 
lower calcium intake was reported compared with controls (600 vs 730 mg/d, p=0.016), and 
although food group consumption was not reported, it is likely that this was due to restriction 
of high lactose foods (e.g. milk) with insufficient replacement of high calcium alternatives. 
Measurement error due to lack of low lactose food composition data in dietary analysis 
software may also be a contributing factor, as this could lead to underestimation of 
micronutrient intake. Finally, mean intake data may be skewed by low or high intakes, which 
would mask true average dietary intakes of a cohort, whereas data presented as the 
proportion of patients meeting nutrient requirements may be more meaningful. Nevertheless, 
further larger studies are required to confirm whether the intake of calcium and/or other 
micronutrients is compromised when patients with IBS follow a low FODMAP diet. 
 
1.2.8 Conclusion 
The low FODMAP diet is an emerging therapy that leads to symptom improvement in nearly 
three quarters of patients with IBS. Importantly, robust evidence is available for the 
mechanisms underlying its effectiveness. A blinded dietary advice RCT is required to measure 
its effect over placebo in a clinically relevant way, and its impact on HRQOL and nutrient intake 
requires further exploration. Furthermore, whether a simultaneous intervention could prevent 
the low FODMAP diet-induced GI microbiota alterations has never been investigated.  




1.3 Dietary approaches to modifying the microbiota  
1.3.1 Prebiotics 
A prebiotic is ‘a selectively fermented ingredient that results in specific changes in the 
composition and/or activity of the GI microbiota, thus conferring benefit(s) upon host health’ 
(Gibson et al., 2010). Beneficial effects of prebiotics include improved calcium absorption and 
bone health, enhanced lipid metabolism (Roberfroid et al., 2010), reduced risk of overweight 
(Perez-Cornago et al., 2015) and reduced risk of the development of colon cancer in animal 
models (Roberfroid et al., 2010). Furthermore, prebiotic supplementation, in contrast to the 
low FODMAP diet where some prebiotic substrates are restricted, may be useful in IBS where 
dysbiosis has a potential aetiologic role. The compounds identified as having the most 
evidence for prebiotic effects are the inulin-type fructans (FOS, inulin and oligofructose) and 
GOS, many of which are widely distributed throughout the diet predominantly in grains, 
vegetables and pulses. Food and commercial sources of prebiotics are described in Table 1.7.  
 
Table 1.7 The composition, source and structure of prebiotic carbohydrates 
Prebiotic Composition Commercial source Food source DP 
Inulin  (2-1) fructans Chicory root Wheat, garlic, 
onion, leek, bread 
11-65 
     Oligofructose (2-1) fructans Chicory root   10 







Lactose Beans and pulses 2-5 
Soya-oligosaccharides Raffinose and 
stachyose 
Soya bean whey Soya beans 3-4 
Xylo-oligsaccharides (1-4) linked xylose Xylan - 2-4 
Pyrodextrins Glucose-containing 
oligosaccharides 



















Total daily dietary intake of inulin and oligofructose in UK and Europe in healthy individuals is 4 
g/d and 10 g/d, respectively (Dunn et al., 2011, van Loo, 1995). Due to their indigestibility in 
  Chapter 1: Introduction 
61 
 
the human small intestine, prebiotics become available for colonic bacterial fermentation. 
Prebiotic carbohydrates with a smaller DP produce fermentation byproducts (SCFA, gas) at a 
higher rate than those with a larger DP (Hernot et al., 2009). The bifidogenic effect (the extent 
to which growth of Bifidobacteria is stimulated) of inulin and oligofructose is inversely 
associated with baseline Bifidobacteria concentration in vivo (Whelan et al., 2005). The 
magnitude of response appears to be highly variable and reverses within a week of cessation 
of supplementation (Davis et al., 2011), but prebiotic supplementation may be a therapeutic 
option for IBS, where dysbiosis, including reduced stool and mucosal Bifidobacteria 
concentration is a common feature.  
 
Prebiotic supplementation studies usually supplement background dietary prebiotic intake 
with an additional 5-20 g/d, essentially at least doubling prebiotic intake in most individuals. 
There are at least four RCTs investigating supplementation of prebiotics in adults with IBS or 
FBD. Two studies have found no effect of prebiotic supplementation of 6 g/d oligofructose for 
2 weeks (Hunter et al., 1999) or 20 g/d FOS for 12 weeks (Olesen and Gudmand-Hoyer, 2000) 
in IBS compared with placebo. In fact, symptoms were worse compared with placebo at four 
weeks in the latter study. In the third and largest study, 106 patients with new-onset, minor, 
functional bowel symptoms were randomised to receive 5 g/d oligofructose or placebo for six 
weeks (Paineau et al., 2008). Intensity and frequency of symptoms was reduced compared 
with placebo, however a major limitation of this study was the absence of an intention-to-treat 
analysis, which is significant as approximately half of the recruited sample were poorly 
compliant and excluded from the analysis.  
 
The most recent RCT of prebiotics in IBS recruited 60 patients to assess the effect of β-GOS on 
symptoms. It was the only study to assess the impact on the microbiota, confirming a 
bifidogenic effect in patients receiving either 3.5 g/d or 7 g/d for four weeks. The low dose 
group demonstrated improvement in a number of symptoms compared with baseline and 
placebo, and the high dose group also reported improvement in global score, although there 
was also a significant increase in bloating. This study is also limited due to the absence of an 
intention-to-treat analysis, and therefore did not account for the 16/60 patients who withdrew 
from the trial (Silk et al., 2009).  
 
Overall there is minimal evidence for the effectiveness of prebiotic supplementation for the 
management of IBS symptoms. Indeed none of the above studies were included in a recent 
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systematic review and meta-analysis of prebiotics in IBS (Ford et al., 2014b), and a withdrawal 
rate of 25-50% in the most recent studies might lead one to question the patient acceptability 
of prebiotic therapy in IBS. The dose at which luminal distension from increased fermentative 
gas production worsens symptoms needs evaluation. Furthermore, work is required to clarify 
whether there is a role for prebiotics in a subset of patients with IBS, and in particular whether 
there is a role for prebiotic carbohydrates that modulate the microbiota without substantially 
increasing colonic gas production.  
 
1.3.2 Probiotics 
Probiotics present another means of modulating the GI microbiota in IBS in order to improve 
GI symptoms. The following sections will describe the factors that are important in the 
selection of a probiotic, the mechanisms by which they might have an effect on GI function, 
and the evidence for the clinical effectiveness of probiotics in IBS. 
 
1.3.2.1 Definition 
Élie Metchnikoff first attributed health benefits to Lactobacilli in yoghurt in 1907. These 
benefits were thought to be mediated through alteration of the colonic microbiota. In 1965, 
the term probiotic was devised, meaning ‘for life’ in Greek.  Subsequent refining of the term 
has led to a precise definition that encompasses viability and a benefit to health. The current 
Food and Agriculture Organisation of the United Nations (FAO) and World Health Organisation 
(WHO) probiotic definition is ‘live microorganisms that, when administered in adequate 
amounts, confer a health benefit on the host’ (Hill et al., 2014).  
 
Probiotic benefit is proposed to occur as a result of adhesion, colonisation and action at the 
level of the colonic epithelium, although benefit can be conferred in the absence of adhesion 
and proliferation (Hill et al., 2014).  Formulation of a probiotic product involves isolation from 
the original source (e.g. food, human breast milk, faeces), enumeration and safety testing 
(Fontana et al., 2013). The most common probiotic organisms are Bifidobacteria, Lactobacilli or 
Saccharomyces boulardii and these are widely available over-the-counter in capsule, liquid or 
powdered form, or as addition to food, such as in yoghurt or fermented milk drink.  
 
1.3.2.2 Probiotics in health and disease 
Probiotic therapy has been the subject of intense preclinical and clinical research in health and 
a variety of disease states.  The role of probiotics as metabolic modulators in obesity, type 2 
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diabetes and the metabolic syndrome, and in the treatment and prevention of non-GI 
conditions such as acute respiratory infection, allergy, autoimmune disease and psychiatric 
disease is a major research focus. Considerable work has concentrated on the potential role of 
probiotics in disorders of the GI tract and currently there is evidence for their effectiveness in 
lactose malabsorption, antibiotic-associated diarrhoea (Scott et al., 2015), pouchitis and 
induction and maintenance of remission in ulcerative colitis (Shen, 2014). Although there has 
been considerable research on probiotics in IBS, a surprisingly large proportion of the 
published literature comprises reviews or commentaries rather than robust clinical trials of 
individual products.  
 
1.3.2.3 Viability of probiotics 
A key requirement of probiotics, according to the definition, is that the organisms are ‘live’ or 
viable. Non-viable bacteria that might have positive effects in vivo mediated through bacterial 
DNA or cell wall components (Rijkers et al., 2010) do not therefore fit within the current 
probiotic definition. A minimum dose of organisms is also not required under the current 
definition, although 1x109 colony forming units per serving is required in some countries for 
product labelling purposes (Hill et al., 2014).  
 
Probiotic viability can be assessed in vitro or in vivo. In vitro evaluation is performed by 
subjecting the organism(s) to adverse low pH conditions representative of the stomach (pH 
1.5-3.0) and bile salts that have antimicrobial effects (Fontana et al., 2013). Alternatively, 
enhanced stool recovery of the probiotic organism(s) after a period of oral supplementation is 
a measure of viability in vivo. Organism survival in vivo as a proportion of overall dose is 
relatively low (15-45%) (Del Piano et al., 2006).  
 
Probiotic survival through the GI tract is influenced by a number of host and product-specific 
factors. The major host-specific factors include genotype, age, diet and baseline microbiota 
composition. The contribution of each host-specific factor to determining probiotic viability is 
difficult to ascertain as they are inextricably linked. For example, diet shapes the microbiota, 
and ageing influences dietary intake and the microbiota. A number of probiotic-specific factors 
are important in influencing viability of the microorganisms in the product. These include the 
delivery matrix, the dose and the organism itself. For example, one problem with high dose 
probiotics is their susceptibility to suboptimal physical characteristics (e.g. dissolution) 
  Chapter 1: Introduction 
64 
 
compared with lower doses, which could impact on availability in the colon, and this requires 
consideration throughout product formulation and quality control (Whorwell et al., 2006).  
 
There are a number of probiotic products available in the UK with demonstrated viability 
(Table 1.8). VSL #3 is a high dose probiotic containing eight bacterial strains, including 
Bifidobacteria and Lactobacilli. It has been the most researched of all the UK available 
products, and its viability has been demonstrated. For example, supplementation with 900 
billion bacteria/day led to increased stool concentration of the strains B. infantis Y1 and B. 
breve Y8 and total Bifidobacteria in healthy individuals after three days in one small study 
(Brigidi et al., 2003). Furthermore, four weeks of supplementation at the same dose in patients 
with IBS has been shown to increase mucosal abundance of Bifidobacteria and Lactobacilli (Ng 
et al., 2013). Conversely, two studies have demonstrated a lack of effect of on stool microbiota 
after high dose supplementation in patients with IBS-C (Kim et al., 2015) and IBS-D (Michail 
and Kenche, 2011). These conflicting findings may be attributed to differing methodologies 
used to quantify the microbiota, inherent differences between IBS subtypes studied, or 
confounding factors such as baseline diet.  
 
Table 1.8 Probiotic products with demonstrated viability available in the United Kingdom 
Product Total dose Composition Reference for viability 
Alflorex 1 billion/capsule B. infantis 35624 (Charbonneau et al., 2013) 
    
Actimel 10 billion/100g L. casei DN 114 001 (Rochet et al., 2006) 
    
Activia 4 billion/125g B. actiregularis (Rochet et al., 2008) 
    








L. paracasei.  
L. delbrueckii subsp. 
bulgaricus 
(Brigidi et al., 2000, Brigidi et al., 
2001, Brigidi et al., 2003) 
    
Yakult 6.5 billion/65ml L. casei Shirota (Fujimoto et al., 2008) 
     
 
 
1.3.2.4 Adhesion and persistence 
Adhesion of a probiotic organism to the colonic mucosa promotes longer lasting residence in 
the colon and may also be essential for specific probiotic effects including pathogen exclusion 
and immunomodulation. Adhesion is a complex process and the cell components involved 
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have not been well examined. The duration of probiotic persistence in the colon on cessation 
of supplementation is also unclear. Stool recovery of the probiotic strains B. breve and B. 
infantis has been demonstrated up to six days following cessation of VSL#3 supplementation 
using culture methods (Brigidi et al., 2003). Furthermore, one recent study in IBS assessed 
stool microbiota composition throughout and following eight weeks of supplementation with 
B. infantis 35624 (Charbonneau et al., 2013). Peak concentration of the strain occurred at eight 
weeks and returned to baseline two weeks after discontinuation of the probiotic, with no 
differences between healthy individual and patients with IBS (Charbonneau et al., 2013). 
Therefore, overall it can be assumed that the duration of persistence is not influenced by the 
presence of IBS but may vary between probiotic products.  
 
1.3.2.5 Mechanisms of probiotic action in IBS 
Probiotics have various proposed modes of action in IBS.  One model has suggested probiotics 
act at three levels: the GI lumen, the colonic mucosa, and the nervous system (Figure 1.6) 
(Rijkers et al., 2010). The following section describes the various mechanisms of action by 
which probiotics might target IBS symptoms at these three levels. 
 
1.3.2.5.1 The lumen: Microbiota and microbiota byproducts 
Probiotics might improve IBS symptoms via direct augmentation or alteration of the 
commensal microbiota, which is known to be altered in a subset of patients with IBS (Section 
1.1.7.4). In effect, probiotic bacteria might replace a ‘missing part’ of the commensal 
microbiota, either in the small and/or large intestine, or stimulate a component of the existing 
commensal population (Scott et al., 2015). In doing so, functionality of the microbiota might be 
restored, leading to improvement of symptoms. This could occur through a variety of local 
pathways, such as competitive exclusion of other bacteria, the production of antibacterial 
bacteriocins or alteration in the fermentation capacity of the microbiota. The effect of 
probiotics probably extends further than modification of the commensal microbiota, as 
functional alterations have been identified using new genomic and metabolomic techniques in 
the absence of changes to microbiota composition (Scott et al., 2015).   








1.3.2.5.2 The lumen: GI transit 
Probiotics may exert an effect on GI transit, and thereby influence symptoms in IBS. For 
example, L. paracasei probiotic has been shown to attenuate hypercontractility induced by 
infection in a mouse model, although the same was not demonstrated for four other 
Lactobacillus and Bifidobacteria strains (Verdu et al., 2004). A recent meta-analysis of human 
studies reported an overall effect of probiotics on decreasing transit time (Miller and 
Ouwehand, 2013), although only two studies were in IBS, and both of these evaluated IBS-C 
patients. Furthermore, VSL#3 supplementation has been shown to increase transit time in IBS 
(Kim et al., 2005) but in another study it had no effect compared with placebo (Kim et al., 
2003). Therefore, the effect of probiotics on transit is variable, and may differ between IBS 
subtypes and probiotic products. Modulation of the microbiota and its metabolic output by 
probiotics (e.g. fermentation byproducts) may be important in mediating the effect on transit  
(Barbara et al., 2005, Ringel-Kulka et al., 2015), however this is difficult to demonstrate in 
isolation, as the microbiota, fermentation byproducts and GI transit are interdependent 
(Kashyap et al., 2013, Barbara et al., 2005, Ringel-Kulka et al., 2015).  
 
1.3.2.5.3 The mucosa: Intestinal permeability and inflammation 
It has been proposed that probiotics may improve IBS symptoms through attenuation of 
impaired intestinal permeability and the accompanying low grade immune activation. In vitro 
and animal studies have demonstrated probiotics influence tight junction protein expression 
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and increase the number of tight junction protein structures. For example, VSL#3 treatment 
for seven days leads to preservation of the expression of the tight junction proteins occludin 
and zonula occludins-1 (ZO-1) in colonic tissue of IBS rat models compared with placebo, which 
is associated with preservation of intestinal permeability (Dai et al., 2012). Most evidence of 
this nature is from animal infection models which may not be representative of epithelial 
dysfunction in non PI-IBS. 
 
Alteration in intestinal permeability in response to probiotic supplementation has been 
investigated in a small number of human studies. No difference in colonic intestinal 
permeability was found after four weeks of supplementation with a multispecies probiotic in 
one study of IBS-D patients. Small intestinal permeability was reduced compared with controls 
at four weeks, however, and this was accompanied by an improvement in global GI symptoms 
(Zeng et al., 2008). One further study investigated the effect of probiotics on inflammatory 
profile in IBS. Patients were randomised either to L. salivarius UCC4331 or B. infantis 35624 for 
eight weeks, and viability was confirmed by stool recovery (O'Mahony et al., 2005). Patients 
with IBS, who presented with a lower IL-10:IL-12 ratio at baseline, demonstrated changes to a 
level comparable with healthy controls at eight weeks. This was associated with an 
improvement in clinical symptoms, but both outcomes were only evident after B. infantis 
35624 and not with the Lactobacillus probiotic. These results suggest probiotics might improve 
symptoms through modulating inflammatory profile, and the effect appears to be product-
specific. More work is required to investigate the effect of probiotics on inflammation in IBS, 
and whether altered permeability is indeed an important mediator of these changes.  
 
1.3.2.5.4 The nervous system: Visceral hypersensitivity 
A number of animal studies suggest probiotics may reduce visceral hypersensitivity. For 
example, one study demonstrated that administration of B. lactis CNCM I-2494 dose-
dependently inhibited stress-induced visceral sensitivity in rats compared with saline (Agostini 
et al., 2012). Likewise, another study reported that seven days of VSL#3 supplementation led 
to lower abdominal reflex scores over a range of balloon distension pressures compared with 
placebo (Dai et al., 2012). In both studies, improved visceral hypersensitivity was associated 
with preservation of intestinal permeability.  
 
Human studies investigating the effect of probiotics on visceral hypersensitivity are limited. 
One 6-week RCT assessed the effect of a multispecies probiotic in patients with confirmed 
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visceral hypersensitivity based on rectal barostat measurements (Ludidi et al., 2014). The 
bacterial strains were chosen based on evidence supporting their impact on epithelial integrity 
and modulation of inflammatory markers, however rectal visceral hypersensitivity was not 
different between probiotic and placebo groups at six weeks. There was also no change in GI 
symptoms throughout progressive barostat pressures for either group. Conversely, a recent 
small study investigating VSL#3 demonstrated increased mean pressure thresholds for pain 
sensation in patients receiving VSL#3 compared with baseline, reflecting improvements in 
visceral hypersensitivity (Wong et al., 2015). There was no change for any other clinical 
parameters (e.g. first sensation of distension or urgency, pain tolerance) and mean scores 
compared with placebo were not reported. The positive effect of probiotics on visceral 
hypersensitivity from animal work has not robustly been replicated in humans, and more work 
is required to evaluate its effect in humans, and to determine whether improvements in 
visceral hypersensitivity, if any, are associated with reduced GI symptoms. 
 
1.3.2.5.5 The nervous system: The brain  
There has been recent growing interest in the role of probiotics on brain function. This may 
have implications in IBS as 1) there is impairment in the microbiome-brain-gut axis and 2) 
anxiety and depression are prevalent in IBS and may contribute to the pathogenesis of the 
condition.  
 
A number of animal models elegantly demonstrate the effect of probiotics on the brain, and 
specifically on behaviour and stress response. For example, anxiety and depressive behaviours 
are attenuated in stress-induced mice fed probiotic versus controls (Bravo et al., 2011, 
Desbonnet et al., 2010). There is also some limited evidence of probiotic influencing anxiety 
behaviours in humans. For example, administration of L. helveticus R0052 and B. longum 
R0175 for 30 days was associated with a reduction in overall hospital anxiety and depression 
scale score, and other measures of stress and anxiety in healthy individuals compared with 
placebo (Messaoudi et al., 2011).   
 
The first and only human study that has directly assessed brain function in response to 
probiotics was conducted in healthy female individuals (n=33) (Tillisch et al., 2013).  
Participants were allocated a milk drink containing Bifidobacteria and Lactobacillus species, 
dairy milk placebo or no intervention for four weeks. Intriguingly, lower activity was 
demonstrated in a number of brain regions in a negative attention task in the probiotic group 
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compared with controls. This included the periaqueductal gray, which is important in pain 
modulation (Behbehani, 1995). Whether this effect is evident in IBS and if IBS symptoms can 
be modulated via central mechanisms through probiotics has not been investigated. 
 
1.3.2.6 Benefits and limitations of animal studies  
Animal models are useful in reproducing some aspects of IBS for researching disease 
pathogenesis, underlying mechanisms and potential therapies. A number of models exist, 
including, ‘restraint stress’ which involves partial control of the animal’s movements by taping 
upper limbs to its body. Some studies use a neonatal maternal separation model, based on the 
notion that exposure to stress experience early in life leads to visceral hypersensitivity. Other 
models include the post-inflammatory technique which involves generating GI inflammation by 
induction of colitis, or the use of antibiotic therapy to induce microbiota perturbations.  
 
Much of the evidence for the mechanisms underlying probiotic effects in IBS stems from 
animal models and has not yet been extrapolated to humans in clinical trials. The complexity of 
the microbiota, dietary factors, stress response and coping mechanisms in humans are 
obviously distinct from animal models and they probably contribute to the disparity in animal 
versus human data in this area. Much further research is required for a complete 
understanding of the mechanisms of action of probiotics in patients with IBS.  
 
1.3.2.7 Clinical effectiveness of probiotics in IBS 
The abundance of studies investigating the mechanisms of action of probiotics, particularly in 
animals, is matched by a multitude of trials investigating their clinical effectiveness in patients 
with IBS. Indeed, eight systematic reviews and meta-analyses have been published in the last 
seven years. Systematic reviews and meta-analyses published in the last 5 years are detailed in 
Table 1.9. One recent meta-analysis is not included as it provided an analysis and summary 




Table 1.9 Systematic reviews and meta-analyses of probiotics in adults with IBS 














Dichotomous data:  
Persistence of symptoms after therapy 
 
Continuous data: 




Benefit over placebo  
56% probiotic vs 73% placebo RR 0.79 (0.70-0.89) 
 
 
Benefit over placebo SMD = -0.25 (-0.36,-0.14) 
Benefit over placebo SMD = -0.23 (-0.38, -0.07) 
No benefit over placebo SMD = -0.15 (-0.27, -0.03) 
No benefit over placebo SMD = -0.10 (-0.30, 0.10) 
(Hungin et al., 2013) SR 1313 11 RCTs Primary outcome: Global symptoms 
 
 
Primary outcome: Abdominal pain 
Primary outcome: Bloating 
Primary outcome: Flatulence  
Primary outcome: Transit/stool frequency 
5 of 9 studies found benefit over placebo 
2 of 4 studies found benefit over placebo in IBS-D 
 
4 of 6 studies found benefit over placebo 
1 of 3 studies found benefit over placebo 
0 of 3 studies found benefit over placebo  
0 of 2 studies found benefit over placebo 





1 of 2 studies found benefit of B. Lactis DN 173010 over 
placebo 
1 of 1 study found benefit of VSL#3 over placebo 
 
1 of 2 studies found benefit of VSL#3 over placebo 
SR, systematic review; MA, meta-analysis; RR, relative risk; SMD, standardised mean difference
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The most recent rigorous systematic review of probiotic RCTs in IBS reported a marginal 
benefit for probiotic therapy in IBS compared with placebo. For the global dichotomous 
outcome analysis, the NNT for all probiotics was seven (Ford et al., 2014b), which is similar to 
the treatment benefit attributed to soluble fibre supplementation (Moayyedi et al., 2014). This 
review was also the first to sub-analyse the effect of individual products on IBS symptoms, 
reporting benefit for L. plantarum DSM 9843, Escherichia and S. faecium but not 
Bifidobacteria-containing products, although there was only a small number trials available for 
subgroup analyses. Other reviews cite evidence for probiotics improving overall symptoms and 
abdominal pain and bloating in IBS, a lack of evidence for flatulence (Hungin et al., 2013) and 
weak evidence of effectiveness for specific products in defined patient subgroups i.e. B. lactis 
DN 173010  in IBS-C patients, VSL#3 in patients with IBS and bloating (McKenzie et al., 2012). 
 
The integration of data via systematic review and meta-analysis to estimate overall treatment 
effect is vital for the development of clinical guidelines, however debate exists as to whether 
meta-analyses are appropriate for probiotics in IBS (Whelan, 2014). Pooling data from studies 
that investigate a variety of probiotic organisms may obscure effects of certain strains or 
species. In fact, very few studies overlap with regards to probiotic composition, with the 
largest recent review including 35 RCTs that examined a total of 31 probiotic preparations 
(Ford et al., 2014b). Furthermore, significant heterogeneity exists between studies in relation 
to probiotic form, carrier product, duration of treatment and patient characteristics (e.g. IBS 
subtype, referral source). Control of concomitant IBS treatment and dietary intake, and 
measurement or reporting of adherence can vary widely (Ford et al., 2014b, Didari et al., 
2015). Finally, and critically, studies can differ markedly in ‘responder’ definition. For example, 
many trials define response as symptom relief at a minimum of 50% of timepoints, whereas 
others measure response based on the IBS-SSS, and others use non validated scales. 
 
Since the most recent meta-analysis described here, publication of probiotic RCTs in IBS 
continues at a rapid rate. At least 11 have been published in the last year, and approximately 
half of these showed a benefit for probiotic over placebo in IBS. There is fairly compelling data 
for a range of mechanisms in which probiotics impact on GI function via the microbiota, mostly 
from animal models, and this is accompanied by only moderate evidence for clinical 
effectiveness in IBS from human trials. RCTs investigating individual probiotic products in 
defined patient groups are needed to clarify their impact on specific GI symptoms as well as 
the optimum treatment regime to achieve benefit. 
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1.3.2.7.1 VSL #3 in IBS 
VSL#3 is a widely used multispecies probiotic containing Bifidobacteria (B. breve, B. longum, B. 
infantis) and Lactobacillus species (L. acidophilus, L. plantarum, L. paracasei, L. delbrueckii 
subsp. bulgaricus) and S. thermophilus. A total of six studies have examined the effect of VSL#3 
supplementation in IBS, including one in functional diarrhoea (Table 1.10). The first two 
studies were uncontrolled in nature and reported ‘clinical improvement’ in a majority of 
patients following a 10-day supplementation period (Brigidi et al., 2001) and reduced stool 
frequency in patients with IBS-D (Bazzocchi et al., 2002).  
 
Four VSL#3 supplementation RCTs have been conducted in IBS. Greater reduction in bloating 
(Kim et al., 2003) and lower flatulence scores (Kim et al., 2005) were reported after 4-8 weeks 
of varying doses of VSL#3 supplementation compared with placebo. One study demonstrated 
reduction in pain duration and distension severity compared with baseline in males, but no 
difference to placebo (Wong et al., 2015). Most RCTs evaluating VSL#3 in IBS have not 
measured stool outcomes and therefore this requires investigation in future studies. 
 
Three of the six VSL#3 supplementation trials reported improvement in at least one IBS 
symptom in the patients studied. However, this evidence is less convincing when the study 
design flaws are considered, such as continued inclusion of participants requiring antibiotics 
(Kim et al., 2005, Kim et al., 2003), multiple reported incidences of medication intake in one 
study that may have impacted on symptoms (Kim et al., 2003), and a protocol alteration mid-
study that reduced the intervention duration by half (Kim et al., 2005). Compliance was also 
infrequently reported. Finally, IBS symptoms were a primary endpoint in only one trial (Kim et 
al., 2005), and therefore the remaining studies may have been underpowered to detect 
symptom response.  
 
Therefore, there appears to be some limited evidence that VSL#3 improves symptoms of 
bloating, flatulence and abdominal pain in IBS.  However, the effect is not consistent across 
trials, and indeed no benefit was found for VSL#3 over placebo in a recent systematic review 
and meta-analysis (Ford et al., 2014b). Larger, more robust studies are required in 
homogenous IBS cohorts that use standardised outcome measures and evaluate compliance to 
confirm the place of VSL#3 in the management of IBS symptoms. 
  
Table 1.10 Studies of VSL#3 supplementation in IBS 
Reference Study design Participants Dose/d Duration 
Primary 
outcome 
Other outcomes Finding  







6 weeks Not stated Multiple symptoms (IBS-SSS) IBS-SSS total score at follow up 
vs baseline probiotic 193 to 132 
in males (p<0.05)  
IBS-SSS days of pain and 









8 weeks Not stated Multiple symptoms (GSRS) 
QOL (instrument not stated) 
No differences 















Bloating, flatulence, pain, 
urgency (100 mm VAS) 
Satisfactory relief bloating 
responders 46% probiotic vs 33% 
placebo (p=0.27) 
Flatulence placebo 39.5 mm vs 
probiotic  29.7 mm (p=0.01) 





8 weeks Transit time Weekly satisfactory relief  
(4 of 8 weeks = responder) 
Bowel function (consistency, 
frequency, ease of passage) 
Pain, bloating, flatulence, 
urgency (100 mm VAS) 
Satisfactory relief  33% probiotic 
38% placebo (p=1.00) 
Mean change in bloating 
probiotic -14 mm vs placebo -2 
mm (p=0.05) 
(Bazzocchi et al., 
2002) 





20 days Not stated n/a Reduction in mean stool 
frequency 7/d to 2/d (p<0.002) 





10 days Not stated Urgency, abdominal 
discomfort, stool frequency 
and consistency 
Clinical improvement in 9 of 10 
but data not reported 
IBS-SSS, IBS Severity Scoring System; GSRS, Gastrointestinal Symptom Rating Scale; QOL, quality of life; VAS, visual analogue scale
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1.3.2.8 Probiotic safety in IBS 
Probiotics generally have a sound overall safety profile. Some rare serious events (e.g. sepsis, 
metabolic complications) have been described in clinical trials in critically ill patients, and other 
trials report mild cases of abdominal pain, nausea, loose stools and flatulence (Doron and 
Snydman, 2015). A recent meta-analysis of probiotics in IBS reported an increased risk of 
adverse events compared with placebo (RR 1.21). The nature of the events was not detailed 
(Ford et al., 2014b), but it is plausible many were GI in nature. Clinical trials investigating new 
probiotic products must routinely collect safety data to confirm their safety profile for a variety 
of populations (Doron and Snydman, 2015). 
 
1.3.2.9 Guidelines for use of probiotics in IBS  
Clinical guidelines for the use of probiotics in IBS vary worldwide. The World Gastroenterology 
Organisation endorses probiotics as a primary intervention along with dietary and lifestyle 
considerations (World Health Organisation, 2009) whilst they do not feature in the Australian 
(Digestive Health Foundation, 2006) or US recommendations (Ford et al., 2014a). Meanwhile, a 
number of recommendations exist in the UK.  Secondary care guidelines advise probiotics as 
second line therapy for bloating after diet and medications have been tested (Spiller et al., 
2007), and dietetic guidelines advise their use as second line therapy (McKenzie et al., 2012). 
Specific guidelines for primary care advise probiotics as first line therapy alongside dietary and 
lifestyle advice for a period of 4 weeks at the dose recommended by the manufacturer (NICE 
2015).  
 
1.3.2.10 Patient acceptability and current clinical practice 
Probiotic use is highly prevalent in those with GI conditions (45-60%), and greater compared 
with those without a GI condition (28%) (Hung et al., 2015, Dossett et al., 2014). Individuals 
taking probiotics are more likely to be female, have higher educational status and are more 
likely to be dissatisfied with conventional treatment (Hung et al., 2015).  Probiotics are 
generally considered by gastroenterology patients as a ‘natural’ avenue of treatment (Hung et 
al., 2015, Mercer et al., 2012), but familiarity with probiotics is variable and often patients are 
sceptical about their usefulness and are left with unanswered questions about their role in 
managing their condition (Mercer et al., 2012). The frequency and pattern of physician-
prescribed probiotics in the UK is unknown as large cross-sectional surveys have not been 
performed. One US survey, however, has found that over 90% of the 56 gastroenterologists 
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surveyed reported recommending probiotics to patients, and in most cases this was for IBS 
(Williams et al., 2010).  
 
1.3.2.11 Probiotic as an adjunct therapy 
The aim of probiotic supplementation in IBS trials until now has been to investigate their 
independent effect on reducing GI symptoms. However, there is also an opportunity for the 
use of probiotic supplementation as adjunct therapy alongside dietary advice. The co-
administration of VSL#3, which has demonstrated bifidogenic effects in stool (Brigidi et al., 
2003) and mucosal samples (Ng et al., 2013), with dietary advice has never been investigated. 
Whether this is approach could prevent or at least ameliorate the impact of the low FODMAP 
diet on the GI microbiota requires investigation. This is especially interesting considering the 




Probiotic therapy is a safe and patient-acceptable intervention in IBS that has some 
effectiveness according to RCTs conducted to date. A limited number of viable products are 
available in the UK, although viability may not be required to induce a clinical effect. 
Mechanistic data from animal studies has not generally been replicated in human studies, 
which is likely due to inherent differences in microbiota, diet and stress and coping behaviours. 
The available evidence suggest effectiveness of probiotic products are strain specific and 
further robust RCTs are required to confirm the strains or combinations that are most effective 
for specific IBS symptoms. Their use as an adjunct therapy in IBS has not been evaluated. 
 
1.4 Limitations of dietary research in IBS 
The number of RCTs in this field of gastroenterology confirms the increasing interest in the 
management of IBS symptoms using dietary intervention. However, dietary research is 
inherently difficult and double-blind placebo-controlled trials, the gold standard method for 
evaluation of interventions, are almost impossible to conduct when altering whole diets. 
Furthermore, there is a lack of formal guidance for design and reporting of dietary studies, in 
contrast to pharmaceutical interventions for which multiple guidelines exist. 
 
Assessment of the effect of broad dietary changes (e.g. as for the low FODMAP diet), as 
opposed to modification of a specific nutrient or supplementation with a probiotic, is difficult 
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in IBS for a number of reasons. Firstly, the effect of collinearity applies meaning attributing 
effects to one component may be flawed (Freudenheim, 1999). For example, restriction of 
fructans from wheat inevitably leads to reduced gluten intake, which might in itself lead to 
symptom improvement. Secondly, baseline dietary intake and food beliefs might bias the GI 
response to dietary intervention. Many patients with IBS hold firm beliefs about food and this 
might negatively impact patient behaviour in a clinical trial setting (Kramer and Shapiro, 1984).  
 
Other difficulties in dietary research relate to selection bias, blinding and compliance. Complex 
psychological factors are associated with the desire to be involved in research, and dietary 
methods for managing symptoms are particularly attractive in IBS. Motivation and behaviours 
in volunteers may be different to those who do not volunteer for research, or decline 
involvement in research, and consequent selection bias may affect external validity (Kramer 
and Shapiro, 1984).  
 
Blinding is difficult in IBS trials as unblinding can occur in response to symptom improvement, 
and this can lead to a profound placebo effect which can overestimate true efficacy (Kramer 
and Shapiro, 1984). Probiotic supplementation studies can of course be placebo-controlled, 
and controlled feeding studies can be placebo-controlled and can help to limit unblinding in 
whole diet intervention studies, however they do not reflect ‘real life’ eating behaviour, and 
the problem of unblinding in response to symptom improvement remains. Nevertheless, 
measurement of potential bias related to unblinding can be performed by asking participants 
to guess their allocation (Yao et al., 2013).  
 
Participant compliance with altering their dietary intake is another difficulty in this area of 
research, and it is generally suboptimally reported, in part due to the difficulty in its accurate 
measurement. Biomarkers are not available for assessing compliance to whole diets, and 
therefore indirect measures of compliance are the method of choice (e.g. food diary, 
questionnaire). There will always be difficulties with conducting robust dietary intervention 
trials compared with pharmacological trials, and many of these are impossible to avoid. 
However, it is imperative that future dietary intervention trials continue to attempt to prevent 
unblinding and measure compliance where possible, and acknowledge the difficulties in doing 
so.  
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1.5 Conclusion and future research  
Individuals with IBS and other FBD have historically been difficult to treat by both medical and 
dietary means. The low FODMAP diet for the dietary management of IBS has been of major 
interest and has helped to successfully treat symptoms in a large proportion of patients. 
However, further work is needed to confirm the role of the low FODMAP diet, probiotic 
supplementation or a combination approach in patients with IBS. Whether the impact on stool 
Bifidobacteria in response to a low FODMAP diet is preventable by use of co-administered 
probiotic, and indeed if this has an additive effect on symptoms needs to be investigated. The 
low FODMAP diet is complex to follow and there has been limited work evaluating its effect on 
HRQOL, nutrient intake or on patient-centered outcomes such as acceptability of advice 
provided. Finally, the relative importance of host factors in determining response to the low 
FODMAP diet requires investigation. 
 
1.6 Aims of thesis 
1. To design a novel sham diet for use in a blinded placebo-controlled low FODMAP dietary 
advice RCT in patients with IBS (Chapter 3) 
2. To design and undertake a 2x2 factorial design RCT in patients with IBS to investigate: 
a. The effect of low FODMAP dietary advice on IBS symptoms, stool output and HRQOL 
(Chapter 4) 
b. The effect of low FODMAP dietary advice and probiotic supplementation on the GI 
microbiota and markers of fermentation (Chapter 6) 
















2 Design and methods of a 2x2 factorial design randomised controlled 
trial investigating the effect of low FODMAP dietary advice and 
probiotic supplementation in irritable bowel syndrome 
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2.1  Introduction 
Irritable bowel syndrome (IBS) is a highly prevalent chronic GI disorder (Lovell and Ford, 2012) 
that contributes to 30% of general practitioner consultations related to GI complaints 
(Thompson et al., 2000). The economic impact of IBS is considerable (Canavan et al., 2014), 
and is likely due to its prevalence, chronicity and possibly suboptimal treatment. Historically, 
the evidence for dietary management of IBS symptoms has been unconvincing. The low 
FODMAP diet, however, is a promising prospect for symptom management in over two thirds 
of patients (Staudacher et al., 2014).  
 
A number of limitations exist in RCTs that report evidence for the low FODMAP diet, some of 
which are inherently problematic in dietary intervention research, some of which were 
described in Section 1.2.5 and Section 1.4. For example, there is lack of blinding (Staudacher et 
al., 2012, Pedersen et al., 2014) and variable quality of control groups (habitual diet, 
alternative dietary advice), comparator dietary advice can overlap with low FODMAP advice 
(Bohn et al., 2015), and symptoms are evaluated as a secondary outcome (Staudacher et al., 
2012). Moreover, there has never been a direct comparison of the effect of low FODMAP 
dietary advice compared with placebo dietary advice on GI symptoms. There are two reasons 
why this is required. Firstly, dietary advice as an intervention more precisely reflects routine 
clinical practice compared with feeding studies, and therefore provides a better estimate of 
the effect size that could be reliably expected in a clinical situation. Secondly, there is a 
significant placebo effect in IBS (Elsenbruch and Enck, 2015). Therefore, the effect of low 
FODMAP dietary advice over placebo advice, rather than habitual diet or standard advice, is a 
more precise estimate of the independent effect of the low FODMAP diet on IBS symptoms, 
above and beyond aspects of the consultation, dietetic support and change in lifestyle per se.  
 
The effect of the low FODMAP diet on the GI microbiota is a critical area for further research. 
Preliminary studies demonstrate alterations in Bifidobacteria and other bacterial groups in 
response to 3-4 weeks of dietary restriction of FODMAPs. However, some of these findings 
may be limited by sample preparation (Halmos et al., 2015) or the quantification technique 
used (Staudacher et al., 2012), and further work employing robust methodology is required to 
broaden our understanding of the response of the microbiota to the low FODMAP diet. 
Whether any short term microbiota alterations can be prevented using an additional 
intervention, such as a probiotic, requires exploration. Various other important endpoints 
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require further examination, including the impact of the low FODMAP diet on aspects of 
HRQOL which has received limited exploration, and the effect on nutrient intake, and in 
particular micronutrient intake which has only been evaluated in one small study (Staudacher 
et al., 2012). 
 
Therefore, a placebo-controlled RCT was designed to address these research questions and 
build on previous literature. Where possible, a gold standard validated instrument was used 
for evaluating each endpoint. The following chapter describes the aims of the RCT, the 
hypothesis to be investigated, and the trial design, protocol, and methods of measurement 
used to evaluate the endpoints, according to the CONSORT guidelines for reporting RCTs 
(Moher et al., 2010). A rationale for the use of each method of measurement is provided. 
 
2.2 Aims of the RCT 
1. To investigate the effect of low FODMAP dietary advice on adequate relief of GI 
symptoms in patients with IBS (Chapter 4) 
2. To investigate the effect of low FODMAP dietary advice and probiotic supplementation 
on luminal Bifidobacteria concentration in patients with IBS (Chapter 6) 
 
Secondary objectives:  
To investigate the effect of:  
1. Low FODMAP dietary advice on IBS symptoms (incidence and severity of specific 
symptoms), stool output (stool consistency and frequency) and HRQOL (generic and 
IBS-specific) (Chapter 4) 
2. Low FODMAP dietary advice and probiotic supplementation on GI microbiota (total 
and individual microbiota concentration) (Chapter 6) 
3. Low FODMAP dietary advice and probiotic supplementation on markers of 
fermentation (stool SCFA and pH) (Chapter 6) 
4. Low FODMAP dietary advice on nutrient intake (macronutrients, micronutrients, 
FODMAPs)  (Chapter 5) 




This RCT was designed to test two hypotheses: 
1. H1: There is a difference in the proportion of patients reporting adequate relief of IBS 
symptoms between patients following low FODMAP dietary advice for four weeks 
compared with patients following placebo sham dietary advice 
2. H1: There is a difference in stool Bifidobacteria concentration between patients 
following low FODMAP dietary advice and taking a probiotic food supplement 
compared with patients following low FODMAP dietary advice alone 
 
2.3 The interventions, trial design and approvals 
2.3.1 Interventions 
Two interventions were employed in this RCT and each was matched with a placebo control.  
 
2.3.1.1 Diet 
The dietary intervention, the low FODMAP diet, requires avoidance of fructans, GOS, polyols, 
fructose and lactose, as described in Section 1.2.  The placebo control comparison was a sham 
diet, a novel exclusion diet developed for this RCT with demonstrated feasibility and dietary 
composition (Chapter 3). HS assessed baseline dietary intake and provided dietary advice to all 
patients in the RCT except for a small proportion of patients recruited at the second site. 
Dietary assessment was undertaken and dietary advice was provided for all patients over the 
same duration of time (approximately 20 minutes for assessment and 10 minutes for advice). 
Written dietary information was provided (Appendix 9.1) alongside verbal advice.  
 
2.3.1.2 Probiotic 
A number of probiotic products were considered for this RCT. Products available with 
established viability in the GI tract were B. lactis DN-173-010 (Activia), L. casei DN 114 001 
(Actimel), B. infantis 35624 (Align), L. casei Shirota (Yakult) or a Bifidobacteria and Lactobacillus 
multispecies product (VSL #3). A Bifidobacteria-containing product was required at the time of 
the design of the RCT as current evidence suggested the abundance of this genus was reduced 
in response to low FODMAP dietary advice (Staudacher et al., 2012). The probiotic that 
included Bifidobacteria (i.e. unlike Yakult), would not alter nutrient intake (i.e. not in yoghurt 
such as Activia) and was available in the UK (i.e. unlike Align which at the time was not 
available in the UK) was VSL#3.  
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VSL#3 is a probiotic multispecies preparation considered a food supplement within the 
definition of Directive 2002/46/EC of the European Parliament and of the Council of 10 June 
2002 on the approximation of the laws of the Member States relating to food supplements. 
The active product was supplied in 4.4 g sachets containing 450 billion live bacteria per sachet 
with maltose and silicon dioxide as inactive excipients. The sachets were gluten free and 
contained traces of lactose, but were suitable for a low FODMAP diet. The product contained 
the following eight bacterial species: 
 
 S. thermophilus 
 B.  breve, B. longum, B. infantis 
 L. acidophilus, L. plantarum, L. paracasei, L. delbrueckii subsp. bulgaricus 
 
The placebo was identical to the probiotic in appearance and taste, contained the same 
inactive excipients but no bacteria, and was administered in the same way as the active 
product. Probiotic and placebo sachets were provided by VSL Pharmaceuticals. Patients were 
supplied two boxes (Figure 2.1) each containing 30 probiotic/placebo sachets at the beginning 






2.3.2 Trial design 
Two trial design options are available for testing a two-fold hypothesis such as in this RCT. Two 
concurrent parallel arm trials could be conducted, with each testing one hypothesis. 
Alternatively, a factorial design trial could be conducted. A 2x2 factorial design is the simplest 
of factorial designs and enables investigation of two interventions individually and in 
combination. There are four groups, with one group receiving intervention A, one group 
Figure 2.1 Example blinded VSL#3 probiotic/placebo sachets and labelled product box 
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receiving intervention B, one group receiving both, and one group receiving neither (Table 
2.1).  
 
There are two advantages of a 2x2 factorial design study over a parallel arm alternative. Firstly, 
it promotes a more homogenous cohort as all recruited patients are randomised to the same 
trial. Secondly, it is more efficient, with a reduced sample size requirement of 70% of an 
equivalent parallel arm design trial (Mdege et al., 2014). These advantages are based on an 
assumption that there is a lack of interaction between the two interventions, or that the effect 
of each treatment is independent of the other. Here the analysis can be described as occurring 
‘at the margins’, and the effect of each treatment is assumed to be additive (McAlister et al., 
2003). The presence of an interaction implies that the effect of an intervention is dependent 
on the effect of another and therefore together they are either synergistic or antagonistic, and 
the analysis is performed ‘within the table’ (McAlister et al., 2003).   
 
Table 2.1 2x2 factorial design intervention matrix for the RCT 
  






















    
No (placebo) no nA No 
Yes (probiotic) nB nAB NB 
Margin No NA N 
 
 
A 2x2 factorial design was employed in this RCT with the a priori hypothesis that there would 
be no interaction between the interventions, due to the absence of published evidence to 
suggest this would be the case for symptom or microbiota endpoints. The anticipated additive 
outcomes of the interventions on the microbiota endpoint are described in Figure 2.2.  
 
The RCT was designed to measure outcomes in response to a 4-week intervention (Figure 2.3). 
Four weeks was considered a sufficient duration for evaluation of endpoints. It is known that 
diet-induced microbiota alterations can occur very rapidly, even within 2 days (David et al., 
2014), but trials assessing symptom response to a low FODMAP diet are usually of 3-4 weeks’ 
duration (Halmos et al., 2014, Staudacher et al., 2012, Bohn et al., 2015), and this is the 
minimum intervention duration recommended for IBS trials (Irvine et al., 2006). Furthermore, 
a 4-week intervention period allows measurement of outcomes at approximately the same




Figure 2.2 Estimated anticipated outcome of the interventions on Bifidobacteria 
concentration in the RCT. The parallel lines indicate the effect of the dietary intervention is 
independent of the effect of the probiotic 
 
stage of the menstrual cycle at both timepoints in females. This reduces the confounding 
effect of the menstrual cycle, which has been reported to influence symptoms in IBS 
(Heitkemper et al., 1995). 
 
2.3.3 Trial sites 
Patients were recruited from Gastroenterology and Dietetic Outpatient Clinics at Guy’s and St 
Thomas’ NHS Foundation Trust and St George’s Healthcare NHS Trust. The trial visits took 
place at King’s College London, School of Medicine, Diabetes and Nutritional Sciences Division, 
London, for Guy’s and St Thomas’ patients and at St George’s Hospital, London, for St George’s 
patients.  
 
2.3.4 Patient selection 
Patients were recruited from Gastroenterology and Dietetic Outpatient Clinics between 
January 2012 and November 2014. Patients were not recruited during December months to 
avoid poor compliance during the festive period and the confounding effects of alterations in 







Figure 2.3 RCT design 
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2.3.4.1 Inclusion criteria 
 Males and females aged 18-65 years with IBS-D, IBS-M or IBS-U according to Rome III 
criteria who do not have a major medical condition (e.g. diabetes, major active 
psychiatric condition), GI disease (e.g. IBD, coeliac disease) or history of GI resection. 
IBS-C patients were not included due to a lack of evidence for the effectiveness of the 
low FODMAP diet in this IBS subtype  
 Individuals able to provide informed consent 
 Individuals naïve to a low FODMAP diet 
 
2.3.4.2 Exclusion criteria  
 Abdominal pain or discomfort for less than 2 days in the screening week as 
recommended for trial eligibility screening (Longstreth et al., 2006) 
 Females who report to be pregnant or lactating, as this may impact on GI symptoms 
(Carlin and Alfirevic, 2008)   
 Consumption of antibiotics, prebiotics or probiotics (as supplemented to food 
products or as supplements) in the 4 weeks prior to, or during the RCT as this  
influences the microbiota 
 Use of lactulose or orlistat as they may lead to altered GI fermentation, and change to 
medications that might impact on GI function (e.g. biological therapy, cathartics) 
 Patients who have received bowel preparation for investigative procedures in the 
previous 4 weeks prior to or during the RCT as this influences the GI microbiota 
(Jalanka et al., 2015) 
 Patients who travelled to a developing country in the previous 2 weeks, as presence of 
GI infection may contribute to symptoms and/or influence the GI microbiota 
 Changes to IBS medication or dose in the 4 weeks prior to or during the RCT as this 
may affect IBS symptoms 
 Patients with additional specific dietary needs (e.g. iron deficiency, eating disorder, 
significant dietary restrictions such as gluten free/dairy free) as further dietary 
restriction may compromise nutritional status 
 Lactulose or glucose hydrogen breath test less than 2 weeks prior to screening or 
during the RCT as this could impact on symptoms, or lactose and/or fructose breath 
tests within the last 6 months or during the RCT, as this might stimulate interest in 
aspects of the low FODMAP diet and lead to unblinding 
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2.3.5 Sample size calculation 
The sample size calculation was based on co-primary endpoints of adequate relief of 
symptoms and stool Bifidobacteria concentration and it was assumed that there was no 
interaction between the main effects. Expected outcomes used for the calculations are 
presented in Table 2.2. The sample size calculation was performed by HS and Professor Kevin 
Whelan in consultation with Professor Janet Peacock (Professor of Medical Statistics) using 
simulation in the statistical software package ‘R’. The sample size calculation was based on 
previous data as follows: 
 
Hypothesis 1: The estimation of adequate relief of symptoms for the low FODMAP diet was 
based on the proportion of patients reporting adequate relief after low FODMAP advice from 
the only RCT available at the time (Staudacher et al., 2012). Combined global response data for 
placebo and probiotic supplementation from VSL#3 supplementation studies (Kim et al., 2005, 
Kim et al., 2003) was used for placebo and probiotic estimates. The estimated symptom 
response to sham diet was based on placebo response rate for global symptoms in the largest 
meta-analyses of IBS trials at the time (Pitz et al., 2005). It also represented the approximate 
midpoint of proportion of control patients reporting symptom relief following habitual diet in a 
previous unblinded controlled low FODMAP advice RCT (Staudacher et al., 2012) and controls 
reporting symptom relief in a comparison of low FODMAP advice with standard dietary 
intervention (Staudacher et al., 2011), and therefore was considered representative of 
symptom response to a placebo dietary intervention.   
 
Hypothesis 2: Expected stool Bifidobacteria concentration in response to a low FODMAP diet 
was available from one RCT published at the time, and sham and placebo groups were 
estimated to harbor Bifidobacteria concentration equivalent to controls from that study 
(Staudacher et al., 2012). Increased total Bifidobacteria concentration has been demonstrated 
after short term VSL#3 supplementation (Brigidi et al., 2003), which was summed with the 
placebo value to produce the expected mean Bifidobacteria concentration for the probiotic 
group. Expected standard deviations (SD) were estimated from previous data (Staudacher et 
al., 2012).  
 
Based on logistic regression and assuming a power of 80% and a 2-sided significance level of 
5%, the main effects of diet on adequate relief could be estimated with 88 patients. Based on 
previous work from our group (Staudacher et al., 2012), attrition of 12% was estimated,




Table 2.2 Expected outcomes for primary endpoints 
 
leading to an overall sample size of 100 allowing for attrition. The RCT required a sample size 
of 1572 patients to detect the effect of probiotic on adequate relief which was not feasible in 
the current time frame. Therefore the study was underpowered to detect the effect of the 
probiotic on adequate relief.  
 
Based on linear regression and assumed power 80% and overall 2-sided significance 5%, the 
main effects for the Bifidobacteria outcome could be estimated with 24 patients, or 28 
allowing for attrition. Therefore, the study was powered for both outcomes with an overall 
sample size of 100 allowing for attrition. 
 
2.3.6 Recruitment 
Patients were recruited at Guy’s and St Thomas’ NHS Foundation Trust by HS (n=96). A 
research assistant assisted with screening for 3 months midway through the 2-year 
recruitment period. HS and RN (a dietitian) recruited patients at St George’s Hospital (n=8). HS 
promoted awareness of the RCT to the referring clinicians (gastroenterologists, general 
practitioners) through presentations at team meetings and regular email contact. 
Gastroenterologists were requested to notify patients regarding the RCT in clinic, and a 
referrer ‘leaderboard’ within the Guy’s and St Thomas’ Gastroenterology department was set 
up by HS to promote ongoing participation of clinicians in referring patients to the RCT. 
 
2.3.7 Randomisation 
Block randomisation was used to allocate patients to one of the four treatment groups (Figure 
2.3). Randomisation was stratified by gender and the presence of IBS-D as microbiota 
composition may be different in this IBS subtype (Malinen et al., 2005). A random allocation 
sequence was prepared by researchers not involved in patient screening or recruitment 
Group 
Proportion of patients 
reporting adequate relief of GI 
symptoms (%) 
Bifidobacteria concentration 
Mean (SD)  
(log10 cells/g faeces) 
Sham diet 36 8.2 (0.6) 
Low FODMAP diet 68 7.4 (0.7) 
Placebo 35 8.2 (0.6) 
Probiotic 42 9.2 (0.7) 
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(Professor Kevin Whelan, Dr Miranda Lomer) using a random number generator (Microsoft 
Excel, 2010), and was stored securely in a location that was inaccessible to the clinic room 
used for trial visits. Allocation was by a 1:1 ratio with a block size of 8 to ensure even numbers 
of patients across the four groups throughout the study. The block size was blinded to HS and 
RN who recruited patients and conducted randomisation visits.  
 
2.3.8 Blinding 
Blinding of dietary interventions is rarely effective (Yao et al., 2013), hindering the ability to 
administer a successful blinded placebo diet. However, the fact that both the dietary and 
probiotic interventions were blinded to patients in this RCT may have mitigated some of these 
problems (as if one intervention became unblinded the patient was still blinded to the other). 
Nevertheless, it is suggested blinding success be measured and reported (Moher et al., 2010), 
but interpreted in the context that methodological issues of placebo and blinding are a 
particular challenge in dietary intervention studies. 
 
Patients were blinded to the low FODMAP/sham diet and probiotic/placebo allocation. The 
patient information sheet (Appendix 9.2) did not mention the term ‘low FODMAP’, instead 
referring to an intervention that ‘alters the carbohydrates in your diet‘, in order to prevent 
patients familiarising themselves with the diet. The researchers providing the advice (HS, RN) 
were specialist dietitians with expertise in the low FODMAP diet, and could not be blinded to 
the dietary allocation. Opaque envelopes labelled with sequential participant numbers 
concealed patients’ dietary allocation until all baseline data had been collected at the 
randomisation visit. 
 
The probiotic intervention was blinded to the patients and the researcher conducting the trial 
visits (HS, RN). Researchers who were not involved in patient recruitment or patient visits (Dr 
Miranda Lomer, Lee Martin) labeled batches of product prior to commencement of the RCT 
with participant numbers according to the randomisation sequence. Pre-labeled product was 
provided to patients at the end of the randomisation visit. Product boxes and sachets were 
identical in appearance and were identifiable only by participant number. Patients were 
unblinded to the dietary allocation at the end of Visit 2 and were notified regarding 
probiotic/placebo allocation after data analysis and unblinding. 
 




Clinical observational studies and case note reviews suggest proportions of patients that 
comply with dietary advice varies substantially (13-82%) (Glanz, 1980), and 76% of patients in 
dietary research report themselves to be compliant (Crumb-Johnson et al., 1993), although the 
definition of compliance and its method of measurement is inconsistent between studies. 
Compliance with dietary advice is difficult to measure in the absence of valid biomarkers, and 
there is no standardised tool for measuring dietary compliance to the low FODMAP diet. 
Therefore, compliance to dietary advice is usually measured by patient self-report. Previous 
studies have used measures of dietary compliance such as the proportion of days the patient 
reports adherence to the recommendations provided (Mitchell et al., 2011, Halmos et al., 
2014), frequency of consumption of unsuitable foods (Windhauser et al., 1999, Halmos et al., 
2014) and adherence based on pre-defined categories (Shepherd and Gibson, 2006). 
 
In this RCT, dietary compliance was measured using two methods.  It was objectively measured 
by post hoc assessment of FODMAP intake at the interim analysis (Section 3.4.2) and at final 
dietary analysis (Section 5.2.3). Self-reported compliance was also assessed at weekly 
telephone visits using four categories (‘in the last week I have followed the diet never/rarely 
(<25% of the time), sometimes (25-50% of the time), frequently (51-75% of the time) or always 
(76-100% of the time)) adapted from previous work (Shepherd and Gibson, 2006). A list of five 
unsuitable foods, based on the patient’s usual dietary intake, was used as a prompt at the 
weekly phone calls to increase accuracy of responses. For this RCT, noncompliance was 
defined by self-report because there is no objective threshold FODMAP intake value that 
defines a diet as ‘low FODMAP’.  Patients who reported following the diet <50% of the time on 
at least 2 of the 4 assessments were considered noncompliant to the dietary intervention.  
 
Measurement of compliance is remarkably infrequently reported in probiotic supplementation 
trials. Inspection of unused product is commonly used to measure compliance, where 
compliance is defined as consumption of at least 80% of product provided (Simren et al., 
2010). Evaluation of the microbiota in those patients allocated probiotic has also been used as 
a measure of compliance. Whether there is a compliance threshold below which microbiota 
and/or symptoms are unaffected by probiotic is unknown. Therefore, in this RCT compliance 
with the probiotic/placebo was considered intake of product on at least 80% of the trial 
duration in concordance with previous trials, by counting of unused sachets at Visit 2 and 
assessment of the compliance diary (Appendix 9.3). It was also deemed noncompliant if 
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compliance fell below 80% due to a recommended reduction in dose due to perceived side 
effects (Section 2.3.10).  
 
2.3.10 Adverse events and withdrawals 
Adverse events were recorded at each visit and at weekly telephone contacts. GI symptoms 
were only recorded as adverse events if they emerged or worsened relative to baseline. 
Duration, frequency and intensity of the adverse event, medication usage and possible 
relationship with probiotic/placebo were recorded. For each individual, multiple reports of 
adverse events were counted once and repetitions ignored. Where adverse events were 
thought to be due to the probiotic/placebo product, the patient was advised to split the dose 
(i.e. 1 sachet in the morning, 1 sachet in the evening). If after 3 days the symptoms continued, 
the patient was advised to reduce the dose to 1 sachet per day. In the case of a serious 
adverse event, it would have been reported to the Research Ethics Committee and the 
relevant Research and Development office. 
 
Patients were free to withdraw from the RCT at any time, according to standard ethics 
protocol. Patients who wished to discontinue participation in the RCT were classified as 
‘consent withdrawal’, or were identified as a ‘loss to follow up’ if the patient was 
uncontactable and subsequently did not complete the trial. Furthermore, patients were 
withdrawn if they failed to meet the eligibility criteria during the RCT (e.g. commenced 
antibiotic therapy).  
 
2.3.11 Ethics approval and Good Clinical Practice  
Ethical approval for this RCT was granted on 12 October, 2012 by the National Research Ethics 
Service Committee London Fulham (12/LO/1402). Research and Development approval was 
granted by King’s College London on 9 November, 2012 and by St George’s Healthcare NHS 
Trust on 10 January, 2013. The RCT was registered on the ISRCTN registry on 28 August, 2012 
(ISCRCTN02275221). The lead researcher completed Good Clinical Practice and Human Tissue 
Act and Consent Training prior to recruitment and processing of samples.  
 
The RCT was conducted in compliance with the principles of the Declaration of Helsinki (1996), 
and the principles of Good Clinical Practice. There were no major ethical risks associated with 
participation. The only potential burden for patients was the embarrassment associated with 
collecting stool samples, and the requirement for recording dietary and symptom information, 
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the latter of which is part of standard clinical practice. All patients who were allocated to the 
sham dietary intervention were provided with routine clinical dietary advice (including low 
FODMAP dietary advice) at the final visit it was clinically warranted, but this was only 
performed following all outcome data measurement and unblinding. There was no delay in 
standard clinical intervention for trial patients compared with equivalent patients on the 
routine clinic waiting list.  
 
The reasons for the research and the trial procedures were clearly explained and provided in a 
participant information sheet to eligible patients interested in participation (Appendix 9.2). 
Patients were given at least 24 hours to consider participation and ask further questions about 
the research. Written informed consent was obtained prior to any trial procedures (Appendix 
9.4). Patient details were anonymised by allocation of a screening number on screening and a 
participant number on randomisation. All personal data and research data were stored 
securely at King’s College London. Electronic data were password protected and hard copy 
data were stored securely in a locked filing cabinet. 
 
2.4 Trial protocol and procedures 
Standardised trial data documents were used at each stage of the recruitment and data 
collection process to ensure uniformity of practice and completeness of data collection.  
 
2.4.1 Screening 
Screening was conducted in two parts. Patients were identified as potentially suitable from 
outpatient clinics or referral letters. Medical notes were screened and if the patient appeared 
eligible, they were contacted by telephone. If the patient was interested in participating, they 
were screened against the inclusion and exclusion criteria and a brief diet history was taken to 
assess current dietary restrictions and to evaluate whether the patient was naïve to the low 
FODMAP diet. Once this had been completed, a participant information sheet was sent to the 
patient. After at least 24 hours, the patient was contacted and a consent visit was booked if 
they were interested in participating.  
 
At the consent visit, the trial procedures were clarified, the consent form was signed, a copy 
was filed at the research site and a copy was provided to the patient. A symptom, stool and 
diet record (Appendix 9.5) and stool collection kit were provided. The symptom record 
included a daily Gastrointestinal Symptom Rating Scale questionnaire (Section 2.5.1.3 ) and the 
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adequate relief question (Section 2.5.1.1) on day 7. The stool record required daily stool 
frequency and consistency recording using the BSFS (Section 2.5.1.4). Patients were advised on 
the method of stool collection, and the importance of the timing of stool collection at Visit 1 
(Section 2.4.2). The method of stool collection was described verbally and written information 
was provided (Appendix 9.6). Patients were advised that all smoking, dietary habits and 
medication were to be maintained during screening. Visit 1 was tentatively booked at a time of 
day that the patient was confident they could provide a stool sample, pending successful 
completion of the second stage of screening. 
 
The second stage of screening involved completion of the 7-day symptom, stool and diet 
record. This evaluated whether patients met symptom severity criteria (Section 2.3.4.2) and 
also served as baseline data for those who were subsequently eligible. Final eligibility was 
confirmed prior to Visit 1. 
 
2.4.2 Visit 1 
At Visit 1 the remaining baseline data were collected. The baseline symptom, stool and diet 
record was returned. Care was taken to ensure all symptom data were complete. Ambiguity in 
the diet records was clarified (Section 2.7.2). The order of data collection was kept consistent 
to minimise variability in response bias between patients. The following data were collected: 
 
 Current medications, past medical history, smoking history and duration of IBS symptoms 
 Anthropometry (height, weight, body mass index)  
 IBS-SSS questionnaire (Section 2.5.1.2, Appendix 9.7)  
 SF-36 and IBS-QOL questionnaires (Sections  2.5.2.1 and 2.5.2.2 and Appendices 9.8, 9.9) 
 
A fresh stool sample was collected during the visit, or no longer than one hour prior to Visit 1 
and immediately placed on ice. At the conclusion of baseline data collection, the 
randomisation envelope was opened, the patient was randomised to the low FODMAP/sham 
diet, dietary advice was delivered and the written dietary information provided. 
Probiotic/placebo product was allocated in coded boxes, with instructions on frequency and 
timing of administration. A probiotic/placebo compliance diary (Appendix 9.3) and a final 
symptom, stool and diet record was provided for completion in the week prior to Visit 2. 
Weekly monitoring phone calls and Visit 2 dates were booked and contact details for the 
research team were provided.  




2.4.3 Weekly monitoring 
Patients were contacted once a week during the intervention period by telephone. This served 
a number of purposes. Importantly, patients were prompted to adhere to the dietary advice 
and with taking the probiotic/placebo product. This was carried out after self-reported 
compliance to the diet, adverse events, medication usage and smoking habits were recorded. 
Finally, the call served as an opportunity for patients to ask questions about the diet. Brief 
clarification was provided where required. At the final weekly telephone contact (week 3), 
patients were reminded to commence recording in the symptom, stool and diet record, and to 
return the record and unused probiotic/placebo product sachets at Visit 2.  
 
2.4.4 Visit 2 
At Visit 2 all follow up data were collected. The follow up symptom, stool and diet record was 
collected. As per Visit 1, the order of data collection was kept consistent between patients. The 
data collected, in order, included: 
 
 Current medications and smoking history  
 Anthropometry (weight, body mass index)  
 IBS-SSS questionnaire   
 SF-36 and IBS-QOL questionnaires  
 Diet/probiotic acceptability questionnaire (Section 2.8, Appendix 9.10) 
 Unused placebo/probiotic product sachets were counted and compliance diary assessed 
 Success of blinding was measured by asking patients to guess their diet and 
probiotic/placebo product  group allocation 
 
A fresh stool sample was collected during the visit, or no longer than one hour prior to the visit 
and immediately placed on ice. Once all data had been collected, those patients requiring 
further dietary advice (e.g. low FODMAP advice for those in the sham diet group) were advised 
as appropriate and all patients were informed of the name of the probiotic product under 
investigation. 
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2.5 Methods of measurement and rationale: Clinical effectiveness 
2.5.1 Symptoms and stool output 
The symptom experience of patients with IBS is multi-dimensional and can be categorised into 
abdominal, defecatory and extraintestinal domains (Spiegel et al., 2010a). Measurement of 
symptom response in IBS should therefore span each of these domains. The three methods by 
which symptoms can be assessed in IBS is via clinical interview, provocation tests or subjective 
reporting. Clinical interview is time consuming and may underestimate symptom severity 
(McColl, 2004) and the usefulness and validity of provocation tests (e.g. rectal barostat) has 
been questioned (Mujagic et al., 2015). Subjective reporting is the most appropriate means of 
measuring symptom experience (McColl, 2004) and there are a number of validated 
questionnaires for measuring GI symptoms in IBS. Use of a questionnaire in isolation may be 
problematic as most are considered suboptimal (Trentacosti et al., 2010) and they are subject 
to recall bias.  Symptom diaries, however, are considered the gold standard method for data 
collection of this type, are less subject to recall bias (McColl, 2004), and allow for 
measurement of incidence and fluctuation of severity of symptoms over time.  
 
Electronic recording of symptoms is preferred over paper diaries, as it prevents retrospective 
recording (McColl, 2004). Indeed, an electronic diary fitted to a watch band was tested (PRO-
Diary Version 1.0.29) for this RCT. Cost (£800 for 2 units) and the restricted screen word count 
per question were limiting factors.  Furthermore, paper diaries are less burdensome for those 
patients who are less technologically capable. In light of the above, and to capture a broad 
dimension of symptom experience from abdominal, defecatory and extraintestinal domains, 
prospective diary recording and a validated IBS symptom questionnaire were chosen for this 
RCT. Face to face instruction was provided for completion of both, with telephone and email 
reminders where required to improve completion rate (McColl, 2004).  
 
2.5.1.1 Rationale for choice of method: Adequate relief 
The current gold standard for primary outcome assessment in treatment trials for IBS is the 
dichotomous response global symptom question, ‘do you have adequate relief of your IBS 
symptoms?’ (Irvine et al., 2006). Global symptom measures such as this have good 
correspondence with specific GI symptoms (Irvine et al., 2006). However, there are a number 
of limitations of this as an evaluation of symptom response. Firstly, a binary response doesn’t 
allow for detail regarding clinically important individual symptoms, which is better captured by 
a multi-item instrument. Secondly, it does not enable reporting of symptom exacerbation. 
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Thirdly, if there has been improvement, a quantification of the magnitude of the improvement 
is impossible. Fourthly, although it appears a simple question, it is demanding for patients to 
answer, as it requires synthesis of one response in relation to a multitude of individual 
symptoms (McColl, 2004), and the frame of reference for what is ‘adequate relief’ is probably 
variable between patients.  
 
Another proposed flaw of the adequate relief question is that is potentially confounded by 
baseline symptom severity. Specifically, it is reported to be biased towards patients with less 
severe IBS, who are more likely to have adequate relief in response to treatment, in the 
absence of improvement of other measures (Whitehead et al., 2006, Passos et al., 2009). 
There is some debate about this, however, and one subsequent study pooled data from a total 
of 9000 IBS patients from 12 RCTs and found no association between adequate relief and 
baseline severity (Spiegel et al., 2009). The adequate relief question is easy to administer, is 
clinically and statistically relevant in IBS drug trials, and has demonstrated content and 
criterion validity (Irvine et al., 2006). Many of its limitations can be addressed by 
administration of additional tools, and therefore this ‘gold standard’ measure was selected for 
use in this RCT and was administered on day seven of the symptom and stool recording period 
at baseline and follow up (Appendix 9.5). 
 
2.5.1.2 Rationale for choice of method: IBS Severity Scoring System (IBS-SSS) 
Multi-item tools that assess specific symptoms are of benefit where physiological processes 
are hypothesised to be associated with certain symptoms (Naliboff et al., 1999). The IBS-SSS is 
a 2-part questionnaire designed to assess individual symptoms over the previous 10 days. It 
has demonstrated concurrent validity, sensitivity and reliability (Francis et al., 1997). The first 
part of the questionnaire includes five VAS items evaluating abdominal pain frequency and 
intensity, abdominal distension, satisfaction with bowel habit, and quality of life (Appendix 
9.7). The second part collects information on bowel habit and site of pain, but is not scored 
and data generated here is usually not reported in the literature. 
 
Although VAS are limited by a lack of consistent meaning between individuals regarding a 
specific point on the scale (Wyrwich and Tardino, 2004), they provide continuous data which is 
simpler for analysis purposes, and have been shown to be validated for measurement of pain 
(Naliboff et al., 1999). Furthermore, with regard to the IBS-SSS, scoring allows categorisation of 
patients into mild (75-174), moderate (175-300) and severe (>300) cases, with a maximum 
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achievable severity score of 500 points, which is valuable in IBS where formal severity 
categories are not established (Drossman et al., 2011). Moreover, a minimal clinically 
important difference (MCID) of a 50-point reduction in score allows meaningful interpretation 
of score change over time (Francis et al., 1997).  
 
Although it has a number of merits, there are some limitations of the IBS-SSS. A major 
contribution to the total IBS-SSS score comes from questions regarding pain intensity and 
incidence. Although abdominal pain is a key feature of IBS, and its intensity and frequency 
should be captured, abdominal discomfort, flatulence and other symptoms, all perceived as 
important symptoms by patients (Spiegel et al., 2010b), are not measured in the IBS-SSS. Also, 
distinguishing abdominal pain from discomfort is difficult for patients (McColl, 2004), which 
provides opportunity for measurement error. Furthermore, the stool output question (‘how 
satisfied are you with your bowel habit?’) may not be sensitive to detect changes in specific 
symptoms such as urgency or change in stool consistency. Finally, characterising symptoms 
over a discrete period of time may be difficult for patients, and patients might recollect and 
report symptoms from over a broader period of time than required (Bellini et al., 2010).   
 
Overall, despite its limitations, the IBS-SSS has been regarded as an important tool for rating 
symptom severity in IBS and a recent comparative review of patient reported outcomes 
concluded that it is the preferred questionnaire for obtaining detailed information on 
symptoms in IBS (Bijkerk et al., 2003). It allows rating of response with a numerical score, 
classifies IBS severity and identifies those who achieve a MCID, all of which were considered of 
value for this RCT.  
 
2.5.1.3 Rationale for choice of method: Gastrointestinal Symptom Rating Scale (GSRS) 
The GSRS is a comprehensive symptom questionnaire initially developed and assessed for 
reliability in patients with IBS and peptic ulcer disease (Svedlund et al., 1988). GI symptoms 
and stool output are rated on a Likert scale, which initially included limited descriptors of 
severity, frequency, duration and impact on life. The scale has been validated in patients with 
gastroesophageal reflux disease (Revicki et al., 1998) and IBS (Wiklund et al., 2003).  
 
The benefits of this scale include the ability for it to be used prospectively and daily (Revicki et 
al., 1998), which is recommended for frequently occurring symptoms (Trentacosti et al., 2010) 
and minimises recall bias (Irvine et al., 2006). Although the most recent version excluded items 
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for belching and borborygmi, it assesses the most important IBS symptoms (Wiklund et al., 
2003). The GSRS was therefore used as the basis of the 7-day symptom record for this RCT. It 
was modified to include only items considered important in IBS. Items from the previous 
version (heartburn, acid reflux, nausea, borborygmi, belching) (Revicki et al., 1998) were added 
and items considered irrelevant or repetitive (two items relating to feeling full, visible swelling, 
relief of pain in response to bowel action) were removed. New items relating to tiredness and 
overall symptoms were also added, with a final scale consisting of 16 items (Appendix 9.5). 
Patients were asked to score the GSRS at the end of each day for seven days at baseline and at 
follow up, rather than the entire 4-week period to reduce patient burden (McColl, 2004). A 
minimum of three days was considered sufficient for data analysis if the record was not 
complete. The possible responses for each GI symptom were: 
 
0 = absent (‘I didn’t have this symptom’) 
1 = mild (‘I had it but it didn’t bother me much’) 
2 = moderate (‘it bothered me quite a bit’) 
3 = severe (‘it bothered me a great deal’)  
 
Summary data for each patient was then calculated: 
 
Incidence = Number of days the symptom was recorded as present during the 7-day 
recording period (i.e. scores 1-3)   
  
Severity = Average daily severity score (total 7-day severity score divided by 7) 
 
2.5.1.4 Rationale for choice of method: BSFS 
Stool frequency and form (consistency) are two important parameters in the measurement of 
stool output. Characterisation of stool output in community-dwelling individuals reveals there 
is normal variation in stool frequency in healthy individuals. A majority of individuals pass stool 
once in 24 hours (33% of women, 40% of males), but most range between a frequency of once 
every two days to twice a day (Heaton et al., 1992). Although this is not recent data it is the 
most comprehensive so far. Similarly, stool form is described as formed in a majority of 
healthy individuals, but up to 27% of females and 19% of males report hard stools (Heaton et 
al., 1992).  
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In IBS, altered stool output is required for diagnosis (Longstreth et al., 2006). Therefore, the 
assessment of both frequency and consistency is important in evaluating response to 
intervention. Stool frequency recorded prospectively in a daily diary is a better alternative to 
retrospective evaluation which can be subject to recall bias, particularly for those with 
diarrhoea or constipation (Lackner et al., 2014).  Evaluation of stool consistency should be 
performed using a diary comprising the BSFS (Longstreth et al., 2006), which is a written and 
pictorial scale and has been validated in IBS  (Figure 1.2) (O'Donnell et al., 1990).  
 
There is lack of agreement on what is constituted as ‘abnormal’ stool consistency, particularly 
for diarrhoea (Whelan et al., 2003), and therefore the BSFS adds to and is more objective than 
measures of stool output from the IBS-SSS and GSRS. According to the BSFS, stool is 
categorised on a 7-point scale based on cohesion of the stool surface. Types 1 and 2 stools on 
the BSFS are considered indicative of constipation and Types 6 and 7 of diarrhea (Longstreth et 
al., 2006). As for stool frequency, prospective evaluation of stool consistency is preferred, due 
to discordance between recall and diary recording (Coletta et al., 2010, Bellini et al., 2010). 
Therefore, patients in this RCT recorded their stool frequency and consistency using the BSFS 
for 7 days at baseline and follow up, and were encouraged to record their stool output 
throughout the day. 
 
2.5.2 HRQOL 
Health-related quality of life (HRQOL) is a measure of a patient’s experience of health and 
disease. It is an indication of disease impact (Guyatt et al., 1993), which is especially important 
in conditions marked by morbidity rather than mortality. Clinical response to a treatment may 
not necessarily correspond with a comparable response in emotional and physical functioning 
HRQOL endpoints between patients, and therefore HRQOL is in itself an important measurable 
outcome in clinical trials (Lea and Whorwell, 2001)  
 
HRQOL can be assessed by face-to-face interview or interviewer- or self-administered 
questionnaire. Face-to-face interview maximises response rate and leads to minimal missing 
data but requires an appropriately trained interviewer, whereas validated questionnaires are 
simple to use and require minimal resources. There has been substantial growth in the number 
of HRQOL questionnaires available in recent years (Garratt et al., 2002). One disadvantage of 
HRQOL questionnaires is that patients may misunderstand questions which increases the 
likelihood of missing data (Guyatt et al., 1993). Supervised completion of questionnaires can 
  Chapter 2: RCT design and methods 
100 
 
address both of these issues. Most validated HRQOL questionnaires consist of items that 
contribute to specific domains or scales (e.g. physical functioning, emotional functioning) and a 
total score. 
 
2.5.2.1 Rationale for choice of method: Short Form Health Survey 36 (SF-36) 
Generic HRQOL instruments capture a broad range of HRQOL issues relating to the effect of 
health status on functional capacity and emotional wellbeing. They can be applied to a variety 
of patient populations and are useful in a discriminative capacity, but are not especially 
responsive to change in treatment. There are a number of instruments available (e.g. SF-36, 
EuroQOL, SIP). The SF-36 is the most evaluated HRQOL questionnaire in health research 
(Garratt et al., 2002), is commonly utilised in the validation of other HRQOL measures, and was 
used as the generic HRQOL instrument in this RCT (Appendix 9.8). 
 
The SF-36 consists of 36 items that are either Likert-style response scale items or dichotomous 
scale questions. It includes more concepts than the original 20-item MOS short-from survey, 
which demonstrated floor effects (responses form a negatively skewed distribution; (Ware and 
Sherbourne, 1992) and is based on a response recall period of 4 weeks. Scoring involves 
transformation of each item to a 0-100 scale and calculation of scores for eight individual 
domains (physical functioning, role limitations because of physical health problems, bodily 
pain, social functioning, general mental health, role limitations because of emotional 
problems, vitality and general health perceptions), with a higher score representative of better 
HRQOL. 
 
2.5.2.2 Rationale for choice of method: IBS-QOL 
Disease-specific HRQOL instruments focus on aspects of the disease of interest and are more 
responsive to change in a defined cohort (Guyatt et al., 1993). There are a number of such 
instruments designed to measure IBS-specific HRQOL (e.g. IBS-QOL, DHSI, FDDQOL, IBS-
HRQOL). The IBS-QOL is a 34-item instrument with demonstrated reliability and validity in IBS 
(Patrick et al., 1998, Drossman et al., 2000). It is the most extensively psychometrically tested 
HRQOL instrument in IBS and recommended as the instrument of choice for this population  
(Bijkerk et al., 2003), and therefore was employed as the disease-specific HRQOL instrument 
for this RCT (Appendix 9.9). Each item utilises a 5-point Likert response scale, which is 
transformed to a 0-100 point scale and subscale scores are then calculated (dysphoria, 
interference with activity, body image, health worry, food avoidance, social reaction, sexual, 
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relationships). A total score can be calculated by summing the subscale scores. A score of 100 
denotes maximum HRQOL for subscales and the total score, and the MCID is a 14-point 
reduction in score (Drossman et al., 2007). As for the SF-36, the response recall duration is also 
four weeks.  
 
2.5.2.3 Questionnaire administration 
Patients completed the HRQOL questionnaires immediately following administration of the 
IBS-SSS questionnaire during the trial visits. The IBS-QOL was administered first and was 
followed by the SF-36 to reduce response bias. Patients were instructed to take their time and 
to ask questions if an item was unclear. Patients were reminded to use a recall period of four 
weeks while completing both questionnaires.  
 
2.6 Methods of measurement and rationale: Microbiota and markers of fermentation 
2.6.1 Sample collection 
The GI microbiota can be evaluated either using stool samples or colonic mucosal samples. It is 
acknowledged, however,  that these compartments vary in microbiota composition in IBS and 
in healthy controls (Rangel et al., 2015). Although mucosal samples may be more reflective of 
GI disease pathophysiology, they are difficult to obtain and bowel preparation prior to 
colonoscopy may alter the microbiota (Jalanka et al., 2015). Stool samples are limited by 
alterations in species composition that occur between collection and processing (Fraher et al., 
2012). However, historical evaluation of the microbiota in IBS has generally relied on stool 
samples, and due to the non-invasive nature of sampling, stool samples were collected to 
characterise the microbiota and evaluate markers of fermentation in this RCT.  
 
Sample collection and preparation in the RCT was standardised to reduce technical variability. 
Stool was collected by patients at Visit 1 and 2 using the stool collection kit provided. A whole 
stool was collected into a transparent bag placed over a disposable plate placed into the toilet 
bowl (Appendix 9.6). Patients were asked to refrain from urinating during voiding. The stool 
was collected either at the research site during the visit or no more than one hour prior to 
attending the research site for the scheduled visit. Patients who voided prior to the visit 
transported stool on ice in sample containers provided. Samples were immediately placed on 
ice at the research site until processing.  
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The stool sample was processed immediately after the research visit. Although DNA degrades 
at room temperature, the minimum time required before significant changes occur to the 
microbiota and/or the luminal environment (e.g. pH, SCFA) is unclear, but could range 
between 30 minutes and 14 days (Gorzelak et al., 2015, Lauber et al., 2010). In this RCT, time 
between storage on ice and freezer storage was limited to no more than 2 hours. The sample 
was double bagged and homogenised in a stomacher for 4 minutes (Steward Laboratory 
Blender Stomacher 400). This was required as differences in bacterial taxa are evident 
between the inner and outer stool microenvironments (Gorzelak et al., 2015). Multiple 
aliquots were taken for analysis of the microbiota, SCFA and pH and stored at -80°C.  
 
2.6.2 qPCR 
qPCR was used to measure the abundance of the stool microbiota in this RCT. This was 
performed by HS under the supervision of Professor Kevin Whelan, Dr Matthew Arno 
(Genomics Centre Manager, King’s College London) and Dr Petra Louis (Senior Research 
Fellow, University of Aberdeen). 
 
2.6.2.1 DNA extraction 
Extraction of DNA from stool samples is an essential step for both downstream analyses of the 
GI microbiota. The major steps involved in extraction are disruption and lysis of the bacterial 
cells usually chemically (by lysis buffer or enzymes) and/or mechanically (e.g. bead beating or 
sonication), removal of proteins, fat, carbohydrate, RNA and inhibitors (by addition of protease 
and detergents), and finally, the recovery of DNA  (Tan and Yiap, 2009). Commercial kits 
available to perform extraction utilise different techniques including organic extraction, 
‘salting out’ and silica-based methods. Limitations of extraction that might bias downstream 
outputs include insufficient lysis or incomplete removal of contaminants. These may occur as a 
result of an inefficient extraction method or impurity of the reagents (Tan and Yiap, 2009, 
Ariefdjohan et al., 2010). 
 
Studies comparing DNA extraction techniques have generally compared lysis efficiency and 
subsequent DNA yield and diversity between methods. Methods that utilise mechanical bead 
beating better maintain community structure of the human microbiota compared with 
enzymic lysis methods (Yuan 2012,). Specifically, the FastDNA™ SPIN kit for soil (MP 
Biomedicals Europe, Illkirch-Graffenstaden, France), which incorporates lysis of cells by bead-
beating, has demonstrated superior DNA yield compared with three other extraction kits 
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(Ariefdjohan et al., 2010). Therefore this kit was used to extract DNA for this RCT. This 
technique consists of mechanical lysis of bacterial cell walls followed by silica-based separation 
and purification of DNA using binders and centrifugation. All reagents were provided by the 
manufacturer. Sample preparation and DNA extraction was performed by HS as follows. 
 
2.6.2.1.1 Sample preparation and storage 
Immediately after the trial visit, a 3-5 g aliquot of fresh stool was weighed and diluted 1:3 in 
phosphate-buffered solution (PBS)/30% glycerol solution, which reduces DNA degradation and 
ice crystal formation (Squires and Hartsell, 1955). Glass beads were added and samples were 
vortexed for 2 minutes. Once completely homogenised, approximately 500 µl of the diluted 
sample was aliquoted into a lysing matrix E tube (LMT) (Figure 2.4) and the weight recorded. A 
preservation technique using RNA-later media was considered however this does not improve 
DNA yield in frozen samples (Gorzelak et al., 2015). The remaining diluted stool solution was 




Figure 2.4 Lysing matrix tube (2ml): Each contains 1.4mm ceramic spheres, 0.1mm silica 
spheres, and one 4mm glass bead used for mechanical bead-beating of the sample to lyse 
bacterial cells for DNA extraction 
 
2.6.2.1.2 DNA Extraction protocol 
Figure 2.5 presents an overall summary of the steps of DNA extraction. The detailed protocol is 
as follows: 
 
1. 122 µl mammalian tissue (MT) buffer was added to the LMT.  
2. A second buffer, 600 µl sodium phosphate buffer, was added to the LMT to wash the 
sample.  
3. The sample was homogenised in a FastPrep® instrument (MP Biomedicals, Sana Ana, 
CA) for 30 seconds at a speed setting of 6.5 m/s for 30 seconds.  
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4. The LMT was centrifuged at 14,000 x g for 10 minutes to pellet the debris. 
5. The supernatant was transferred to a 1.5 ml eppendorf tube for protein removal. 250 
µl protein precipitation solution was added and the sample was mixed by shaking the 
tube by hand 10 times.  
6. The sample was centrifuged at 14000 x g for 5 minutes to pellet the precipitate and 
the supernatant was transferred to a clean 15 ml falcon tube. 
7. 1ml of Binding Matrix Suspension was added and the tube was inverted by hand for 2 
minutes to allow binding of the DNA. The tube was left on a rack for 3 minutes at room 
temperature to allow settling of the silica matrix.  
8. A majority of the supernatant was discarded and the DNA-bound mix was resupsended 
in the remaining supernatant using a filter pipette. Approximately 600 µl of the 
mixture was centrifuged at 14,000 x g for 1 minute in a SPIN filter and catch tube 
system. Centrifugation allowed the DNA-bound matrix to be retained in the spin filter, 
while the liquid phase passed into the catch tube. 
9. The catch tube was emptied and blotted on tissue. The pellet was resuspended in 500 
l salt ethanol wash solution (SEWS-M) and centrifuged at 14,000 x g for 2 minutes to 
wash away impurities.  
10. The catch tube was emptied, replaced and the sample centrifuged a second time at 
14,000 x g for 2 minutes to dry the matrix of residual wash solution.  
11. The catch tube was discarded and a replaced with a new catch tube and the sample 
was air dried for 5 minutes under an extraction hood at room temperature.  
12. The matrix was resuspended in 180 µl of DNase, pyrogen-free water (DES) using a filter 
pipette tip and incubated for 5 minutes at 55°C in an oven (Shake ‘n’ Stack 
Hybridisation Oven, Thermo Scientific).  
13. The sample was centrifuged at 14,000 x g for 1 minute to transfer eluted DNA into the 
clean catch tube.  
14. The sample was transferred to a sterile eppendorf and centrifuged at 14,000 x g for 1 
minute. 
15.  DNA concentration was measured using a NanoDrop ND1000 instrument (Thermo 
Scientific, Waltham, MA, USA).  
16. The sample was briefly vortexed and given a pulse spin. 75-90 µl of the sample was 
aliquoted into a second eppendorf for storage at -20°C, whilst the remaining sample 
was stored at 4°C for qPCR. 
 




Figure 2.5 Summary of DNA extraction procedures using the FastDNA™ SPIN kit for soil. (MP 
Biomedicals Europe, Illkirch-Graffenstaden, France) 
 
2.6.2.2 Rationale for choice of method  
There are multiple methods for the quantification of microbiota from stool samples (Table 
2.3). Culture dependent techniques rely on a comprehensive understanding of the nutritional 
and growth requirements of the microorganisms of interest, and more than 30% of the total GI 
microbiota are not cultivable (Fraher et al., 2012). Therefore, culture-independent techniques 
have revolutionised understanding of the composition and functionality of the microbiota. 
These methods are based on detecting variance of small subunit ribosomal RNA (16Sr RNA) 
sequences, which are present in all living organisms, and allows assessment of qualitative and 
quantitative information on the species present (Fraher et al., 2012).  
 
qPCR is a technique used for quantification of the GI microbiota from phylum to strain level. It 
is a relatively rapid technique and is reported to be the most accurate culture-independent 
method to evaluate total microbiota concentrations in samples (Fraher et al., 2012). It is more 
sensitive than FISH and enables a higher throughput, but is less expensive than other methods 
such as next generation sequencing. Numerous steps in the technique introduces a risk of bias 
(Bustin et al., 2009), however this can be attenuated by reducing the number of personnel 
involved in the experimental methods. As such, in this RCT, HS performed all sample
  
Table 2.3 Summary of methods used to characterise the GI microbiota 
 
Method Description Advantages Disadvantages 
Culture Selective or differential media are used to isolate 
bacteria. Selective media stimulates growth of specific 
bacteria whereas differential media allow 
discrimination of closely related species 
 Cheap 
 Quantitative or qualitative 
 
 Labour intensive 
 Many species unculturable 
 Misses species that depend on other 
species for growth 
PCR (polymerase chain 
reaction) 
DNA is extracted from samples and 16S rRNA is 
amplified enzymatically throughout a heat cycling 
process that leads to DNA denaturation and synthesis 
 Qualitative  
 Highly sensitive 
 Not quantitative 





As above but amplification of 16S rRNA target is 
measured in real time. Fluorescence is proportional to 
the concentration of the target, and can be quantified 
via comparison with a standard curve 
 Quantitative  
 Most accurate technique for 
measurement of total bacteria 
 Highly sensitive 
 Numerous steps increase potential  for 
bias 
 Limited by primer design and choice 




PCR followed by band visualisation based on 
separation of 16S rRNA amplicons by application of 
electrophoretic current (DGGE) or restriction 
endonucleases (T-RFLP) 
 Cheap  
 Rapid  
 Can be quantitative if applied 
with other techniques  
 Semi-quantitative 
 Labour intensive 
 Bias associated with PCR 
 
Fluorescence in situ 
hybridisation (FISH) 
Fluorescently labelled oligonucleotide probes  
hybridise complementary 16S rRNA sequences, 
followed by quantification by flow cytometry or 
manual counting 
 Quantitative  
 No bias associated with PCR 
 
 Labour intensive  
 Identification of unknown species not 
possible 
 Relies on validated probes 
DNA micro-array Fluorescently labelled oligonucleotide probes 
hybridise to DNA on a solid surface and fluorescence is 
detected by a laser 









PCR amplification with fluorescent signal detection is 
followed by analysis of the exact nucleotide sequence 
of a DNA molecule which is compared to sequence 
databases. Includes Illumina® 
 High throughput 
 Low abundance bacteria 
detected 
 Measures of diversity possible 
 High start-up cost 
 Data analysis is complex and requires 
specialist bioinformatics experience 
 Bias associated with PCR 
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processing, preparation and qPCR experiments. Furthermore, in order to optimise the 
technical quality of the experiment, guidelines relating to conducting and interpreting qPCR 
experiments were strictly adhered to (Bustin et al., 2009). 
 
2.6.2.3 Principles of qPCR 
qPCR is a commonly applied technique for quantification of double-stranded DNA in a sample. 
Two oligonucleotide primers that complement the gene (the target DNA template sequence) 
of interest, deoxynucleotide solution (dNTP), a heat stable polymerase, magnesium ions, and a 
fluorescent reporter are required for the reaction. The following three stages occur during 
each PCR cycle: denaturation, annealing and extension. 
 
Application of high temperature (usually 95°C) denatures the DNA, and the double-stranded 
DNA melts into single strands (see Figure 2.6). The temperature and duration of application 
are dependent on the template sequence and the instrument used (Kubista et al., 2006). This 
is followed by subsequent lowering of temperature to approximately 5°C below the primer 
melting temperature (typically 40-75°C) to allow the primers to anneal to the sample DNA 
template. Application of the correct temperature in this phase is important to optimise 




 Figure 2.6  One PCR cycle involves denaturation, annealing and extension. One cycle leads to a 
doubling of amplicon (adapted from (Arizona State University, 2013) 
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The final stage involves increasing the temperature to optimise polymerase activity, which 
binds to the annealed primer-DNA complex, leading to synthesis of complementary DNA at a 
rate of up to 100 bases a second. This cycle is then repeated 40-50 times, resulting in 
amplification of DNA template (amplicons) of up to many millions of copies. The fluorescent 
reporter generates a fluorescent signal only when bound to double stranded DNA, and 
therefore there is a direct association between fluorescence and the number of amplicons  
formed (Kubista et al., 2006). 
 
2.6.2.4 Fluorescent reporters 
The process of multiple amplification cycles leading to an exponential increase in amplicon is 
utilised in both PCR and qPCR. However, the benefit of qPCR, or ‘real-time’ PCR, is the 
measurement of real-time amplicon accumulation according to the fluorescence generated. An 
effective fluorescent reporter has low background fluorescence, high fluorescence on binding 
to the target, and high specificity (Kubista et al., 2006). Two reporter systems are available for 
qPCR, SYBR green and the TaqMan probe (Smith and Osborn, 2009).  
 
SYBR green is relatively cheap, but its ability to generate a fluorescent signal when bound to all 
double-stranded DNA is a limitation as binding to nonspecific products and primer-dimers 
(Section 2.6.2.5) contributes to a signal. The TaqMan probe avoids this problem as it derives 
fluorescence only when the target sequence is amplified but is more expensive. SYBR green 
reporter was used in this experiment, as it has routinely been used in our laboratory. The SYBR 
Green Supermix (Biorad, Hercules CA) contained SYBR green dye, DNA polymerase, dNTP, 
magnesium chloride and passive reference dyes. The passive reference dye (ROX and 
fluorescein) normalises well to well differences in fluorescence variation due to non-PCR 




qPCR primers are single-strand oligonucleotide sequences specific for the 16Sr RNA target to 
be amplified. Specificity of primers is important, especially when SYBR green is used as the 
fluorescent reporter, in order to avoid production of nonspecific PCR products that contribute 
to the fluorescence signal (Smith and Osborn, 2009). Primer-dimer formation occurs where 
primers bind to each other due to complementary bases, which interferes with the PCR 
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reaction. To enable practical annealing temperatures and efficient amplification, primers 
should be 18-24 nucleotide bases long. 
 
Design of the qPCR experiment required initial selection of the specific primers that targeted 
the microbial groups or species of interest. For this RCT, a total of 12 primers were selected 
(see Table 2.4). Primers were chosen that targeted bacterial groups that have previously 
demonstrated to change in response to a low FODMAP intervention (e.g. Bifidobacteria, total 
bacteria, Clostridium cluster XIVa (Staudacher et al., 2012, Halmos et al., 2015). Others were 
chosen to target groups expected to increase in response to VSL#3 probiotic supplementation 
(Lactobacilli, B. longum, B. adolescentis). Finally, primers targeting some genus-level 
(Bacteroides, Prevotella, Roseburia spp.) and species-level bacteria (F. prausnitzii, Akkermansia 
muciniphila, Ruminococcus bromii) were chosen as they have been shown to alter in response 
to change in fibre and/or carbohydrate intake (Section 1.1.6.3.1), are considered potentially 
important for health and disease, or  are deemed  ‘keystone species’ (Scott et al., 2015).    
 
In this RCT, most primers had previously been validated in our laboratory. Two primer sets had 
not previously been validated (R. bromii, A. muciniphila) and appropriate efficiency validation 
was conducted. Three primer pairs that were designed and validated by collaborators (Rowett 
Institute of Nutrition and Health, University of Aberdeen) performed poorly in our laboratory, 
with poor overall amplification (B. breve, B. infantis) and poor efficiency (Clostridium Cluster 
IV). The latter assay was repeated and continued to perform poorly, and due to insufficient 
time to perform further validation experiments, data from these three assays were omitted. 
 
2.6.2.6 qPCR analysis 
2.6.2.6.1 Amplification curve 
DNA template in the original sample is quantified in a qPCR assay by plotting fluorescence 
against the cycle number. There are key aspects of the amplification cycle: baseline phase, 
exponential phase, cycle threshold and the linear phase (Figure 2.7). The baseline phase refers 
to the initial cycles of PCR where fluorescence is undetectable. PCR software enables 
conversion of baseline fluorescence of all samples to 0, also called ‘normalisation’. After 
baseline, amplification of the template should theoretically double in each cycle, leading to an 
exponential increase in fluorescence, termed the exponential phase.  Quantification during the 
assay occurs at the threshold, where the level of signal is considered significantly higher than 
baseline, termed the threshold cycle (Cq). This is early in the exponential phase where all the
  
Table 2.4 Characteristics of primers used in the RCT, including forward and reverse sequences, annealing temperature and standards used for each assay 
Target Primer name Sequence (5’-3’) 
Annealing 
temperature C°) 
Primer Reference Standard 
Universal 
UniF GTGSTGCAYGGYYGTCGTCA 






(Matsuki et al., 2002)  
(Bartosch et al., 2004) 






(Matsuki et al., 2002) 
(Wood et al., 1998) 
Prevotella copri 
DSM18205 BacPreRmod TTGAGTTTCACCGTTGCCGG 
Bifidobacteria  
BifF TCGCGTCYGGTGTGAAAG 
60 (Walker et al., 2011) B. adolescentis DSM 20083 
g-Bifid-R GGTGTTCTTCCCGATATCTACA 
      B. longum 
BlonF CAGTTGATCGCATGGTCTT 
60 (Malinen et al., 2005) B. longum DSM 20219 
BlonR TACCCGTCGAAGCCAC 
     B. adolescentis  
Bif164F GGGTGGTAATGCCGGATG 
60 (Ramirez-Farias et al., 2009) B. adolescentis DSM 20083 
BiADO-2 CGAAGGGCTTGCTCCCAGT 
Clostridium Cluster XIVa  
Erec482F CGGTACCTGACTAAGAAGC 
60 (Ramirez-Farias et al., 2009) R. hominis A2-183 
Erec870R AGTTTYATTCTTGCGAACG 
      Roseburia spp. & E. rectale  
RrecF GCGGTRCGGCAAGTCTGA 
63 (Walker et al., 2011) R. hominis A2-183 
Rrec630mR CCTCCGACACTCTAGTMCGAC 
      F.  prausnitzii  
FPR-2F GGAGGAAGAAGGTCTTCGG 
60 (Ramirez-Farias et al., 2009) F. prausnitzii A2-165 
Fprau645mR AATTCCGCCTACCTCTGCACT 
R.  bromii  
Rflbr730F GGCGGCYTRCTGGGCTTT 
60 (Salonen et al., 2014) R. bromii L2-63 
RbromR CAACTTTCCCCGAAGGGCACCTA 
A. muciniphila  
AM1 CAGCACGTGAAGGTGGGGAC 




60 (Malinen et al., 2005) L. reuteri DSM 20016 
Lab 0677 CACCGCTACACATGGAG 
 











Figure 2.7 Amplification plot for Roseburia standards (R. hominis A2-183): The fluorescence 
(ΔRn) is plotted against cycle number for five dilutions of standard (107/2µl to 103/2µl) and 
no-template controls (NTCs). The threshold cycle (Cq) is the cycle at which quantification 
takes place 
 
reagents are still in excess and amplification products will not compete with primer annealing 
(Smith and Osborn, 2009). There is an increase in Cq with reducing concentrations of starting 
template. The plateau phase occurs where the reaction is limited by insufficient polymerase, 
reporter or primer products or the PCR products interfere with annealing (Kubista et al., 2006) 
 
2.6.2.6.2 Standard curve 
For absolute quantification of the original DNA template, copy numbers can be determined 
from a standard curve (Figure 2.8). This curve is produced from amplification of the pure 
target (standards) at a range of concentrations (in triplicate) covering the expected 
concentrations in the sample (Taylor et al., 2010). The Cq of each standard dilution is plotted 
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against the known standard copies, and then abundance of the sample target in each qPCR 
plate well is determined by the software by comparison of the sample Cq to the standard curve 
(Smith and Osborn, 2009). The standard curve is also used to assess the reaction efficiency 
(Section 2.6.2.7.3). Using this method of quantification, the quality of the standard curve is 
critical for accuracy, and can be affected by accuracy of pipetting and stability of the diluted 
standards. In order to improve transparency of the data generated, reporting of a number of 
assay parameters is important according to the minimum information for publication of qPCR 




Figure 2.8 Standard curve for Prevotella assay (P. copri DSM 18205): A linear regression curve 
for Cq (termed Ct here) is plotted against known concentrations in the dilution series 
 
 
2.6.2.7 qPCR validation and optimisation 
2.6.2.7.1 Controls and limit of detection 
All qPCR assays included two no-template controls (NTC), molecular biology grade water 
(MBH20) and herring sperm DNA. These were treated identically to the samples by addition of 
all assay reagents except the DNA template. Fluorescence from the NTCs represented 
contamination or primer-dimers (Taylor et al., 2010). Sample fluorescence detected within 3.3 
cycles from the NTC was considered below the detection limit (Smith and Osborn, 2009). 
 




Specificity of the qPCR reaction refers to the degree to which fluorescence is generated from 
detection of the target template rather than nonspecific products. This should be evaluated at 
the end of each assay by assessment of the melt curve (dissociation curve) (Figure 2.9). This is 
constructed by heating of the double-stranded template until it dissociates and loses 
fluorescence (Smith and Osborn, 2009). Primer-dimer products are shorter than target 
amplicons and will melt earlier and are easily identifiable as separate peaks (Kubista et al., 
2006), whereas a sharp peak indicates amplification of one product, and good specificity of 
primer annealing. Where primers for genus-level bacteria were used (e.g. Bifidobacteria) a 
wider peak was expected due to detection of a wider range of species. A melt curve was 
generated and inspected for all assays. Where separate melt peaks were not clear, this was 




Figure 2.9 Dissociation curve for Roseburia assay for one 384-well PCR plate: The change in 
fluorescence is plotted against temperature.   
 
2.6.2.7.3 Efficiency, repeatability and sensitivity 
The efficiency of a reaction is an important indication of the success of the qPCR assay.  This 
represents the rate at which the polymerase converts the reagents to amplicon in the assay. A 
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two-fold increase in amplicons per cycle represents a 100% efficient reaction. Generally, 
acceptable efficiency ranges between 90-110%. Low efficiency of a reaction (<90%) can be due 
to contamination or suboptimal annealing temperatures whereas high efficiency (>110%) is 
usually due to primer-dimer formation or nonspecific amplicons (Taylor et al., 2010). Efficiency 
is calculated based on the slope of the exponential phase of the amplification curve (Efficiency 
= -1 + 10 (-1/slope)), whereby 100% efficiency is equivalent to a slope of -3.32. Efficiencies for the 
PCR experiments were calculated for this RCT and ranged between 86-102%.  
 
All samples were analysed in triplicate to reduce the effects of technical variability. Another 
standard procedure to assess variability is evaluation of the correlation coefficient (r2), or 
linearity, calculated from the standard curve. A low r2 represents significant differences in Cq 
between replicates and a recommended minimum is 98.0 (Taylor et al., 2010). Values for r2 
across the PCR experiments for this RCT were 99.0-99.8 indicating high repeatability.  
 
The sensitivity of a PCR reaction is a measure of the lowest number of template copies that 
could theoretically be detected in the assay. According to standard procedure, all samples that 
demonstrated fluorescence at a Cq≤3.3 cycles from the NTC Cq were considered below the 
detection limit due to inadequate fluorescence above background fluorescence from no-
template containing wells. 
 
2.6.2.8 qPCR protocol 
Preparation for each assay was carried out in a clean area of the laboratory using filter pipette 
tips and molecular biology grade reagents. Samples were recoded by a researcher not involved 
in the study in order that HS (who was not blinded to the diet allocation) was blinded to the 
samples. Prior to the assays the samples were manually diluted in MBH20 to a concentration of 
25 ng/µl. Samples were then transferred to clear 2.2 ml storage plates (Greiner Bio-one) at a 
volume of 100 µl per well. The samples were diluted with herring sperm DNA to a final 
concentration of 1.25 ng/µl by an automated pipetting system (Biomek FXP Laboratory 
Automation Workstation, Beckman Coulter, Brea, CA, USA) into three sets of two clear 96-well 
skirted PCR stock plates (Greiner Bio-one), of final volume 150 µl per well and sample locations 
were documented. Stock plates were stored at -20°C until required. For each assay, the 
following protocol was followed: 
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1. Standard dilutions series were prepared from 109 copies of 16S rRNA gene standards 
(Table 2.4). Five ten-fold dilutions were prepared using 5 µg/ml herring sperm DNA 
starting from 107 copies/2 µl). For lower abundance bacteria, dilutions were prepared 
starting from 106 copies/2 µl to ensure the standard curve covered the range of 
expected target abundances. For the universal assay, a set of 5-fold dilutions was 
prepared. Standard dilutions were discarded after 1 week and prepared again where 
required. 
2. Dried primers were diluted in MBH20 to 100 uM as per manufacturer’s instructions 
(Sigma-Aldrich) and stored at -20°C until required. For each assay, primers were 
further diluted to 10 uM in MBH20.  
3. The assay mix was prepared, by addition of SYBR green to the primers, ensuring there 
was sufficient for samples and NTCs in triplicate, allowing 20% extra volume for 
pipetting error.  
4. 6 µl assay mix was pipetted into clear 384 MicroAmp Optical 384-well reaction plates 
(Applied Biosystems) by the automated pipetting system, and then 4 µl of each sample 
was added in triplicate wells and mixed by the same system (Table 2.5). This quantity 
of DNA (total DNA concentration 5 ng) is considered sufficient to amplify high and low 
abundance targets. Two plates were required for each assay due to the number of 
samples in the experiment. Five standards and two NTCs were included in triplicate on 
each plate. Baseline and follow up samples for each patient were allocated to the 
same plate to minimise technical variability.  
5. Each qPCR plate was sealed using an optical adhesive cover and centrifuged (Platefuge 
Microplate Centrifuge, Benchmark Scientific). If the plate required storage prior to 
thermal cycling, it was covered with opaque foil and refrigerated at 4°C for no more 
than 2 hours.  
 
Table 2.5 Reagents added to each well of qPCR 384 well plate 
Reagent Volume per well 
SYBR green supermix 5 µl 
  
Forward primer (10µM) 0.5 µl 
  
Reverse primer (10µM) 0.5 µl 
  
Sample (1.25ng/ µl) 4 µl 
  
Total 10 µl 
  Chapter 2: RCT design and methods 
116 
 
2.6.2.9 Reaction conditions 
The thermal cycler used for all experiments was a 7900HT fast qPCR system (Applied 
Biosystems). Maintenance and calibration of the instrument had been performed annually. 
The reaction conditions were maintained as per usual practice in our laboratory (Table 2.6) 
and annealing temperatures were adjusted according to the assay (Table 2.4).  
 
Table 2.6 qPCR reaction conditions 
Step Number of cycles Temperature (°C) Duration 
1 Denaturation 1 95 3 minutes 











65 to 95 
10 seconds 
5 seconds 
*Annealing temperature varied between primer pairs 
 
2.6.2.10 Data analysis 
Data were analysed using SDS 2.4.1 (Applied Biosystems). Absolute quantification of copies of 
amplicons per well was calculated by comparison of the software-generated Cq of the target 
template with the standard curve. Triplicate data were checked and where amplification 
reproducibility was poor (i.e. where Cq SD≥0.3) mean copies per well was calculated based on 
data from two wells. Copies per well were then converted to log10 cells/g faeces accounting for 
the original sample weight, dilutions carried out during processing and the DNA concentration 
for each sample. Relative abundance of bacterial groups was calculated relative to total 
bacteria abundance for that sample. Scatterplots were used to perform final crosschecks. For 
example, the sum of species-level abundance (B. longum and B. adolescentis) was expected to 
be lower than their genus-level abundance (e.g. Bifidobacteria). Samples were only unblinded 
once data were finalised and locked. 
 
2.6.3 Markers of fermentation: Stool SCFA  
Carbohydrates are major substrates for fermentation in the colon. Therefore dietary 
modification that alters the carbohydrate type and/or volume entering the colon may lead to 
alteration in fermentation dynamics. Major byproducts of carbohydrate fermentation are 
SCFA, which have important influences on intraluminal and mucosal metabolism in the GI 
tract. SCFA were measured in this RCT in order to evaluate whether the interventions modified 
colonic fermentation. Gas liquid chromatography (GLC) is a quick, relatively inexpensive and 
commonly used technique for measurement of SCFA. Sample preparation was performed by 
  Chapter 2: RCT design and methods 
117 
 
HS, GLC was conducted by Robert Gray (Analytical Chemist, King’s College London) and was 
supervised by Professor Kevin Whelan.  
 
2.6.3.1 Rationale for choice of method  
Measurement of SCFA production in vivo can be performed directly or indirectly. One direct  
method of measurement is by calculation of the difference between carbohydrate entering the 
colon and the colonic organic matter and SCFA, although this is invasive and technically 
difficult to perform (Millet et al., 2010). Another method involves measuring the difference in 
SCFA between portal and venous blood, although this is biased as it is unable to account for 
uptake of SCFA by colonocytes (Millet et al., 2010).    
 
The indirect method of determining SCFA production is by measurement in stool.  A major 
disadvantage of this is that absolute net SCFA stool concentration is not representative of 
production. This is because SCFA production occurs predominantly in the caecum and 
ascending colon in humans and its concentration declines as the luminal contents transit 
distally, due to absorption of a majority of SCFA (>95%). Another disadvantage of this method 
is that stool SCFA is affected by variable stool volume (Cummings and Macfarlane, 1991). 
However, measurement of stool SCFA is relatively simple, and may be useful in detecting 
changes in excretion (Topping and Clifton, 2001), assuming stool volume does not change.  
 
GLC, high-performance liquid chromatography, ion exclusion chromatography and capillary 
electrophoresis are methods used to measure SCFA. GLC is quick, relatively inexpensive and is 
the most commonly used technique for measurement of SCFA.  This method is a separation 
technique in which samples are injected into a column oven. Various chemical constituents of 
the sample pass through the column with a carrier gas. The sample molecules elute from the 
column with different retention times depending on their chemical properties. A detector 
identifies the compounds present by measurement of retention time, and quantification is 
possible by measurement of the area under the peaks in the output. 
 
2.6.3.2 Sample preparation and storage 
A 3 to 5 g aliquot of fresh stool was stored at -80°C for SCFA analysis. 




2.6.3.3 SCFA extraction protocol 
1. The sample was defrosted on ice for one hour. 
2. The sample was weighed in a stomacher bag and the weight recorded. 
3. SCFA extraction buffer was added to create a 1/4 dilution. For 100 ml SCFA extraction 
buffer, 0.1 g mercury chloride (Sigma, UK) and 1 g phosphoric acid (Merck, Germany), 
added to inhibit fermentation, were mixed with 4.5 mg 2,2-dimethylbutyric acid 
(internal standard; Sigma, UK) and made up to 100 ml with distilled water. The internal 
standard is not produced by the GI microbiota during fermentation and elutes from 
the column within the same temperature as the SCFA under investigation. 
4. The double-bagged sample was homogenised in a stomacher (Steward Laboratory 
Blender stomacher 400) for 2 minutes. 
5. The slurry was centrifuged in a 15 ml falcon tube at 5000 g (Beckman J2-HS, USA) at 
4°C for at least 10 minutes.  
6. Approximately 1 ml of the supernatant was filtered through a sterile 0.2 μm filter into 
a Micro-vial Snap Ring Vial with integrated 0.2 ml glass micro insert and stored at -20°C 
until analysis. 
 
2.6.3.4 GLC protocol 
GLC was carried out using a 9890A series GLC system (Agilent Technologies, US) equipped with 
a flame ionisation detector and a 220 μm internal diameter, 25 m fused silica capillary column 
with a film thickness of 0.25 μm (ID-BP21, SGE, Australia). The carrier gas was nitrogen. The 
initial oven temperature was 80°C, and increased by 10°C/min up to 145°C, and then 
100°C/min up to 200°C to complete the elution. The injected sample volume was 0.2 μl, and 
1.2% formic acid cleaning solution (Merck, Germany) was injected between samples to 
minimise carry over from the previous sample.  
 
Calibration was undertaken using a blend of pure SCFA solutions at six different concentrations 
to produce calibration curves (area vs concentration). Concentrations of six SCFA (acetate, 
propionate, butyrate, valerate, isobutyrate and isovalerate) were obtained in duplicate and 
mean concentration calculated for each patient at each timepoint (µmol/g wet weight). 
Samples were reanalysed when reproducibility was suboptimal (variability >5%). Total SCFA 
concentration was calculated as the sum of the individual SCFA concentrations. The Agilent 
Chromatogram database (Agilent Technologies, US) was used to carry out data analysis. 
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2.6.4 Markers of fermentation: Stool pH 
Stool pH was measured in this RCT to measure GI fermentation. Sample preparation and 
measurement of stool pH was performed by HS with some assistance from Ann-Katherine Perz 
and Mary-Jo Searle (Laboratory Technicians, King’s College London). 
 
2.6.4.1 Rationale for choice of method 
Peak fermentation occurs in the caecum, which exhibits the lowest pH of the entire colon 
(Fallingborg et al., 1989). This is likely the best site for measuring changes in colonic 
fermentation and pH in response to dietary intervention but it is relatively inaccessible. As 
discussed above, most SCFA are absorbed in the colon, and measuring pH of the distal colon or 
stool may not accurately reflect change in pH related to altered fermentation that occurs in 
the proximal colon (Watson et al., 1972). Another limitation of measurement of distal colonic 
or stool pH is that it is also influenced by byproducts of protein metabolism (e.g. ammonia), 
which may then mask effects due to altered carbohydrate fermentation. Finally, stool pH 
decreases once stool is passed per rectum (Watson et al., 1972), and therefore pH varies 
depending on when it is measured. 
 
The wireless motility capsule, an oral indigestible data transmitter, can accurately measure pH 
in real time throughout the entire GI tract (Farmer et al., 2013). However, this type of 
assessment is somewhat invasive and not widely available, whereas measuring stool pH is non-
invasive, simple and inexpensive. Therefore, stool pH was measured in this RCT, along with 
stool SCFA to estimate alterations in fermentation. A standard solid phase probe was used to 
measure pH in undiluted samples at the end of the RCT due to laboratory space restrictions at 
the second site.  
 
2.6.4.2 Sample preparation and storage 
A 3 to 5 g aliquot of fresh stool was stored at -80°C for pH analysis. 
 
2.6.4.3 pH protocol 
1. The sample was defrosted on ice for 1 hour. 
2. A solids pH probe (InLab® Solids Pro, Mettler Toledo) was calibrated in buffered pH 
stock solution (Sigma, UK) daily prior to use. The probe tip was immersed in the 
sample to 1.5 cm depth until a pH value was detected and confirmed (FE20 Benchtop 
pH meter, Mettler Toledo). 




2.7 Methods of measurement and rationale: Nutrient intake 
Dietary intake was measured in this RCT in order to evaluate energy, nutrient and FODMAP 
intake. 
 
2.7.1 Rationale for choice of method: Unweighed diet record 
Dietary intake can be measured using recall (e.g. food frequency questionnaire (FFQ), 24-hour 
recall) or prospective methods (e.g. diet records). All are limited in accuracy due to reporting 
error, the tendency for individuals to alter their dietary intake whilst being monitored, the 
systematic and random error associated with coding of diet records, and the limitations 
associated with food composition tables (Bingham, 1987). FFQ and dietary recall are 
commonly used in large scale epidemiological studies. A FFQ that quantifies nutrient and 
FODMAP intake has been validated, but overestimates nutrient intake (Barrett and Gibson, 
2010). Conversely, the 24-hour recall technique is limited by difficulties with conceptualisation 
of portion sizes, risk of under-reporting, and inability to capture day-to-day variability in intake 
(Ma et al., 2009).  
 
Weighed diet records are considered the gold standard for estimating dietary intake in 
controlled intervention trials, however this is burdensome for the patient. Unweighed diet 
records are less burdensome and correlate well with biological markers of food intake (e.g. 24 
hour urine nitrogen and potassium) (Bingham et al., 1995). They also have excellent agreement 
with 16-day weighed food diaries compared with recall methods (Bingham et al., 1994) and 
inclusion of portion size photographs improves accuracy  (Bingham et al., 1994).  
 
Seven days of dietary intake data are required for a   10% precision for energy intake 
(Bingham, 1987). This period of time also ensures each record represents intake from both 
weekdays and the weekend. Therefore, a 7-day unweighed diet record was considered the 
most rigorous method for estimating nutrient intake in this RCT. The record developed for this 
RCT (Appendix 9.5) was based on the National Diet and Nutrition Survey (NDNS) diary which 
includes food photographs for estimating food portions. The validity of new ways of capturing 
dietary intake (e.g. personal digital assistant, mobile phone) has not yet been confirmed (Illner 
et al., 2012) and therefore  conventional paper-based methods were preferred.  
 




Comprehensive advice was provided to patients at the Screening Visit and Visit 1 regarding 
completion of the diet records. In order to improve accuracy of records the following advice 
was provided verbally and in written form (Appendix 9.11): 
 
1. Record all food and drink intake regularly throughout the day whilst at home or away 
from home, to minimise missing data  
2. Provide as much information as possible for every food, including brand and type (e.g. 
Hovis granary bread, medium slice) 
3. Estimate portions using household measures (e.g. teaspoon, tablespoon, cup), or from 
the 30 food photograph codes provided, or from food packaging 
4. For home cooked recipes, record details of all ingredients, individual ingredients 
weights (specifying dry or cooked weight) and cooking methods 
5. Record as much detail as possible for meals when eaten away from home (e.g. method 
of cooking, details of ingredients, portion sizes) 
6. Record intake of vitamin or mineral supplements 
 
An example diet record was presented to the patient to confirm the level of detail required. 
Completed food diaries were reviewed in detail at the trial visits to ensure data were 
sufficiently detailed and complete. A minimum of three days was considered sufficient for data 
analysis if the record was not complete. 
 
2.7.3 Data input  
Analysis of diet records was performed by manual input of data into specialist software. A 
number of software programs were assessed for use in this RCT. All software packages 
considered comprised food and drink composition data from McCance and Widdowson’s 
Nutrient databank (6th edition) and other minor sources, and therefore choice of software was 
instead based on ease of operation, ability to create new foods and recipes, and ease of 
exporting data. Dietplan 6 P3 (Forestfield Software, Horsham, UK) was considered the best 
choice for the purposes of this RCT.  
 
Food and drink data from diet records were entered into Dietplan by matching items with 
appropriate foods in the software database. Data were entered by dietitian coders (HS, FR, 
ZB), two of which were blinded (FR, ZB). HS was experienced in dietary input and developed a 
  Chapter 2: RCT design and methods 
122 
 
dietary data protocol for the RCT, which incorporated standard portion weights for common 
foods. To maximize inter-rater reliability, FR and ZB were comprehensively trained according 
to the data input protocol, regular meetings were held to resolve queries and to agree on 
methods of coding, and each patient’s baseline and follow up record was inputted by one 
coder. Where data were ambiguous or missing, standard procedures were employed to 
minimise variability between coders. For example, where a portion size was missing, a 
previously recorded portion was used, or an average was estimated using standard guidance 
(Food Standards Agency, 1994). Inter-rater agreement was also assessed after input of a total 
of 21 records (Section 2.7.5). 
 
Where possible, foods were matched with sufficiently representative foods already existing in 
the database. In the case that a food did not have an appropriate match in the database, a new 
food was created by adapting an existing database item and adjusting the nutrient content 
according to food label information. Where a new food contained a high FODMAP ingredient, 
this was specified in the new food name (e.g. ‘cheese and onion crisps’ or ‘apple crumble’) to 
alert coders in subsequent FODMAP analysis (Section 2.7.6). Similarly, due to lack of 
composition data for alternative foods in most software databases, wheat free (e.g. wheat free 
bread) and lactose free products (e.g. lactose free milk) were created as new foods using 
available composition data from packaging. A total of 296 new foods were created. 
 
Cold composite foods were entered as individual ingredients (e.g. ham sandwich = ham + 
bread + spread), and hot composite foods were entered as a new recipe unless existing 
composite foods in the database were considered sufficiently representative. Weight losses on 
cooking were taken from standard guidelines (Food Standards Agency, 2002). A total of 180 
new recipes were created. New foods and recipes were added to a local database that was 
created and shared between coders to avoid duplication.  
 
2.7.4 Data cleaning  
Energy, macronutrient and micronutrient intake was calculated for each patient at both 
timepoints. Energy intakes were examined and data were checked against the original diet 
records for portion size errors and corrected as appropriate where energy intake fell outside 
the 2.5-97.5th percentile range for gender-matched combined 2008/2009 and 2011/2012 
NDNS data (1058-3315 kcal for males, 769-2587 kcal for females). The complete dataset was 
also sorted in descending order for portion size, protein, fat, NSP, iron, vitamin C and sodium 
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to check for excessive intakes that might represent input error, and where required, records 
were examined for errors and corrected.  
 
2.7.5 Inter-rater agreement 
Inter-rater reliability is a measure of the agreement between raters on a specified measure 
and is important in research where multiple independent coders are involved in data 
interpretation and input. Inter-rater agreement was assessed for energy and fibre intake 
between the three coders (HS, FR, ZB). A total of 21 diet records were randomly selected for 
entry in triplicate (7 baseline, 7 sham and 7 low FODMAP diet records). In response to the 
analysis, obvious input errors were identified and corrected. Systematic errors due to 
differences in coding were identified, categorised and the data input protocol was updated as 
required. 
 
Inter-rater agreement for dietary record coders was assessed in a number of ways. Intraclass 
correlations and examination of Bland Altman plots are the most common methods utilised for 
measuring agreement in nutrition research (Zaki et al., 2012). Both were performed as each in 
isolation do not provide sufficient information for assessment of inter-rater reliability (Rankin 
and Stokes, 1998). Sufficient clinically important range of agreement for the Bland Altman plot 
was decided at a mean difference ± 1.96 SD (Bland and Altman, 2007).  
 
2.7.6 FODMAP intake analysis 
Direct analysis of the FODMAP composition of foods is performed by high performance liquid 
chromatography (HPLC) and enzymatic kits. A comprehensive FODMAP composition database 
has been produced by collaborators in Monash University based on published composition 
data from direct FODMAP analysis (Biesiekierski et al., 2011, Muir et al., 2007, Muir et al., 
2009, Yao et al., 2014) and is incorporated into Foodworks Version 7 (Xyris Software, 
Australia). Dietary intake data from Dietplan for this RCT was imported into Foodworks for 
FODMAP analysis by collaborators at Monash University, Melbourne, Australia. This process 
was supervised by Dr Jane Muir (Head of Translational Nutrition Science, Monash University, 
Melbourne, Australia). Due to food term differences between UK Dietplan software and the 
Australian Foodworks software, dietary intake data from diet records required extensive 
formatting before being suitable for import into Foodworks. The formatting was performed by 
HS and SC (a research dietitian) and was performed as follows: 
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1. Dietplan data were extracted for each patient and exported to Excel. This included the 
participant number, the list of foods consumed and the weight of each food 
consumed. 
2. An aggregate list was compiled for foods and fluids consumed throughout the RCT for 
very patient (23674 foods and fluids). 
3. All individual carbohydrate-containing foods (with names unique to Dietplan) were 
converted to food terms unique to the Foodworks database. For example, Dietplan 
term ‘apples, eating, average, raw’ was converted to Foodworks term ‘apple, green, 
FODMAP’. Where a cooked food could only be matched with a raw food Foodworks 
term, a proportionate weight was allocated (e.g. 85% of the raw vegetable weight) to 
account for water gain from cooking. 
4. Recipes were created for Dietplan composite foods and individual food components 
were labeled with Foodworks food terms. 
5. Finalised food lists were then imported into Foodworks for FODMAP composition 
analysis. 
 
2.8 Methods of measurement and rationale: Acceptability 
Patient-reported acceptability of treatment is an important determinant of compliance to an 
intervention and of its feasibility in the clinical setting. Acceptability is rarely measured in 
dietary studies, but it can be relatively simply evaluated using semi-structured interviews or 
questionnaires. Semi-structured interview requires trained interviewers and are time 
consuming. Acceptability questionnaires assessing whole diets or supplements assess factors 
such as palatability, cost, ease of use, perceived health or adverse effects, and the likelihood of 
future application using Likert scales (Lindsay et al., 2014, Barnard et al., 2004, Young et al., 
2010). There are no validated acceptability questionnaires for the low FODMAP diet or for 
probiotic intervention. Therefore, a short 18-item acceptability questionnaire was purpose-
designed for this RCT (Appendix 9.10). It assessed various aspects of acceptability of the 
interventions that were considered important for future clinical application and research. 
Responses were scored on Likert and dichotomous scales and items included: 
 
Dietary acceptability: 
 Ease of meal preparation and eating out 
 Time spent shopping and cooking 
 Palatability  








 Perceived adverse effects 
 Knowledge of the definition of a probiotic 
 Future use 
 
2.9 Statistical analysis 
Data handling and statistical analysis was conducted by HS with advice from Robert Grant 
(Senior Lecturer in Medical Statistics, St Georges University of London) and the Statistical 
Consultancy Service at King’s College London. Statistical analysis was conducted according to 
the published guidelines (ICH, 1998). Advice regarding the statistical plan and expert opinion 
regarding statistical analysis was provided at annual RCT meetings by a clinical trial advisor, Dr 
James Lindsay (Consultant Gastroenterologist, Bart’s Health NHS Trust). All statistical analysis 
was performed using IBM SPSS Statistics for Windows Version 22.0. Unblinding of the 
treatments occurred after analysis of the primary endpoints.  
 
Prior to statistical analysis, all continuous data were examined for normality using histograms. 
If possible, non-normally distributed data were transformed, or non-parametric analysis was 
conducted.  For demographic data and some nutrient intake data, continuous variables were 
compared using dependent t-tests and independent t-tests or Wilcoxon signed-rank and 
Mann-Whitney U tests for non-normally distributed data. Categorical variables were compared 
using the Chi-squared test. 
 
Linear regression was performed to evaluate the effect of diet and product on continuous 
variables (microbiota, stool SCFA and pH, IBS-SSS, GSRS symptom severity, stool output, 
HRQOL). Logistic regression was performed to evaluate the effect of diet and product on 
categorical variables (adequate relief, proportion meeting MCID for IBS-SSS, IBS-QOL). 
Negative binomial regression was performed to evaluate the effect of diet and product on 
incidence of GI symptoms (GSRS). Adjusted regression models were performed to account for 
differences between groups at baseline and bootstrapping of confidence intervals (95%) was 
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computed due to non normal data. Interaction terms were added into regression models to 
check for interactions between the two independent variables (diet, product).  
 
Where more than two groups were compared (e.g. subgroup analysis), the Chi-squared test 
was used for categorical variables, and Kruskal-Wallis tests were used for non-normally 
distributed continuous data and one-way analysis of variance (ANOVA) were used for normally 
distributed continuous data with Tukey’s post hoc tests where the assumption of homogeneity 
of variances was met. Welch tests with Games-Howell post hoc tests were performed where 
homogeneity of variance was not met. Pearson’s product-moment correlation was run to 
assess the relationship between baseline Bifidobacteria concentration and change in 
Bifidobacteria concentration. Nutrient intake data were compared between diet groups using 
analysis of covariance (ANCOVA), adjusting for baseline intake, where assumptions of 
normality, independence of covariate and treatment effect and homogeneity of regression 
slopes were met. Proportion of patients meeting dietary reference values (DRVs) was 
compared within groups using the McNemar’s test. Multiple logistic regression was run to 
evaluate predictors of clinical response.  
 
Data are presented as summary data e.g. mean (SD) or number (%) with estimates and 95% 
confidence intervals (CI) and a 2-sided p value. Differences were considered significant where 
p≤0.05. 
 
2.9.1 Analysis sets 
The primary analysis was based on the intention to treat (ITT) dataset, which comprised all 
randomised patients including withdrawals and non-compliers. The ITT analysis is conservative 
as it avoids optimistic estimates of efficacy by accepting that deviations from the protocol and 
poor compliance are realistic in clinical practice (Gupta, 2011). Sensitivity analyses are 
important to evaluate the credibility of the primary findings (Thabane et al., 2013). Sensitivity 
analyses on the per protocol (PP) dataset was performed for the primary endpoints. The PP 
dataset was comprised of data only from the subset of patients who did not violate the 
protocol, were compliant with the interventions and completed the trial. This analysis set 
helps to estimate the efficacy of the interventions in those who received the intervention for 
the intended duration, but may be biased as adherence may be related to the treatment or the 
condition itself (ICH, 1998).  
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2.9.2 Missing and ambiguous data 
Every effort was made to minimise missing data. Questionnaires completed at the research 
site were checked immediately to ensure no data points were missing. Missing data points for 
7-day symptom and stool records were considered ‘missing completely at random’, which are 
less likely to bias outcomes (Sterne et al., 2009). Missing data for withdrawn patients is 
inevitable in RCTs. In order to perform an ITT analysis, imputation was required to create a 
complete ITT dataset. 
 
There is no universally accepted method for handling missing data. Moreover, a trial is 
regarded as valid if the methods for dealing with missing data are ‘sensible’ and are defined a 
priori (ICH, 1998). Single imputation methods include imputing the last observation or 
imputing the mean of the observed values. Both of these methods are straightforward to 
implement but can lead to underestimation of SD. Alternatively, multiple imputation creates 
an imputed dataset by combining results from multiple created datasets using regression. 
However, it is computationally complex and has its own statistical pitfalls, described elsewhere 
(Sterne et al., 2009). It was decided a priori that multiple imputation would be used for missing 
data if there was >10% data points missing. Ignoring missing data from withdrawn patients, 
the missing data in this RCT were limited to the GSRS and were minimal (<2% of all data 
points). Therefore, it was decided that multiple imputation was not warranted and a last 
observation carried forward method was employed. 













3 Design, development and evaluation of the sham diet 




The gold standard method for investigating the effectiveness of a drug or nutrient (e.g. 
supplement) intervention is the double blind, placebo-controlled RCT. This presents a problem 
in dietary research firstly due to the difficulty of blinding whole diets, and secondly due to the 
challenge of employing an appropriate placebo control. Feeding studies are a potential 
solution to both of these problems as the intervention diet can be created as almost 
indistinguishable to the control diet, and with extreme effort both the patient and the 
investigator can be blinded to both diets.  However, feeding studies are burdensome for the 
participant and the researcher in terms of time and monetary costs and have limited external 
validity as in routine clinical practice patients are not fed a therapeutic diet in a controlled 
environment. In the clinical setting dietary alteration is an outcome of transmission of advice 
from the practitioner, which is implemented by the patient, and is influenced by numerous 
factors relating to food beliefs, motivation and other aspects of behaviour change. Therefore, 
a clinical trial where dietary advice is given to free-living patients is more representative of 
what is achievable in the clinical setting and therefore the results will have far greater external 
validity. 
 
Three suitable options exist for control interventions in IBS dietary advice trials. The first two 
are healthy eating advice or dietary advice based on accepted national guidelines (NICE, 2015), 
and the latter has been implemented in a recent RCT (Bohn et al., 2015). However, both 
present difficulties for a number of reasons. Advice cannot be applied homogenously to 
patients due to variability in baseline dietary intake. Blinding is difficult as both strategies are 
widely recognised. Furthermore, neither healthy eating nor national guideline dietary advice fit 
the criteria of a placebo, as both are active interventions that might influence GI symptoms. 
The third option for a control intervention is a formulated diet that includes dietary advice to 
modify food intake but that does not alter nutrients or the specific food component (e.g. 
FODMAPs) being investigated, also known as a ‘sham diet’.  
 
A sham diet holds a number of advantages as a placebo in IBS dietary intervention studies. It 
can be tailored to appear as an exclusion diet, and therefore offers potential as a convincing 
placebo comparison to the low FODMAP diet. It has been recommended that the number of 
foods removed in a sham exclusion diet be comparable to the intervention diet (Yao et al., 
2013), however detailed guidance for development and implementation of sham diets in IBS 
and indeed other disease states is scarce.  




Despite sham dietary advice being a gold standard in dietary research, there are only a limited 
number of studies that have used it as a placebo control for dietary advice hypothesised to 
improve physical symptoms. These studies included patients with IBS (Atkinson et al., 2004), 
anal fissure (Carroccio et al., 2013) and non-GI conditions including migraine (Mitchell et al., 
2011) and bulimia nervosa (Dalvit-McPhillips, 1984). In these studies, the foods restricted in 
the sham group were either chosen based on prior experience of the foods being well 
tolerated in that patient population (Carroccio et al., 2013) or according to patients‘ baseline 
diet (Dalvit-McPhillips, 1984). Generally, little information was provided on the design of the 
sham diet, and no studies reported the success of blinding, which is important where 
outcomes are based on subjective measures. 
 
Sham dietary advice as a placebo control comparison to low FODMAP dietary advice has never 
been used and would need to fulfil a number of criteria. It would need to: 1) be a convincing 
exclusion diet, 2) be feasible to follow, 3) restrict an equivalent number of foods compared 
with the low FODMAP diet, 4) modify dietary carbohydrate sources, as for ethical purposes 
patients have to be informed that the active intervention diet involves altering carbohydrate 
intake, and 5) have no impact on nutrient or FODMAP intake, particularly fibre intake, which 
may impact on symptoms (Moayyedi et al., 2014) and stool microbiota (David et al., 2014). 
There are no established sham exclusion diets that fit the requirements described above. 
 
3.2 Aim of this chapter 
The aim of this chapter is to describe the design, development and evaluation of a novel sham 
diet for use in a low FODMAP dietary advice RCT in patients with IBS.   
 
The chapter is divided into 2 parts and is set out as follows: 
 
1. Methods for the design, development and evaluation of the sham diet, which included a 
pilot study and an interim analysis (Section 3.3) 
2. Results of the interim analysis (Section 3.4) 
 





3.3.1 Design of the diet 
The sham diet was developed by HS in conjunction with Prof Kevin Whelan and Dr Miranda 
Lomer. Foods to be included in the sham diet were selected using the following method:  
 
1. Preliminary suitable and unsuitable low FODMAP diet food lists were used as a starting 
point for creation of suitable and unsuitable food lists for the sham diet. Food groups 
were addressed individually and breads and cereals were considered first as this group 
contributes the most to fructan intake (Dunn et al., 2011). For the sham diet, 
foods/products were allocated to suitable and unsuitable lists based upon the need to 
create some restriction, whilst neither increasing nor decreasing fructan and fibre 
intake. For example, wheat products were allocated to the suitable list, and cereal 
grains less commonly consumed in the UK (e.g. millet, rye) and products manufactured 
from these grains (e.g. bread, pasta, breakfast cereal) were allocated as unsuitable. 
2.  Fruit, vegetables and pulses contribute significantly to FODMAP intake (Muir et al., 
2009, Yao et al., 2014, Biesiekierski et al., 2011), and therefore these foods required 
careful consideration regarding their suitability in the sham diet. High FODMAP foods 
regularly consumed in the UK diet (e.g. apple, pear, pulses) were allocated to the 
suitable list in order to maintain FODMAP intake. Foods were also assigned to the 
suitable list if restriction would impact intake of other high FODMAP foods. For 
example, tomato is often consumed in dishes that contain high FODMAP vegetables 
(e.g. onion and garlic) and therefore this was assigned to the suitable list. Conversely, 
approximately 50% of the fruits and vegetables considered suitable on the low 
FODMAP diet were assigned to the unsuitable list, and preference was given to those 
fruits and vegetables less likely to affect intake of other foods. 
3. Dairy and dairy alternative products were allocated to the suitable list, to ensure 
lactose intake was maintained. Meat and meat alternatives and fat sources were 
broadly allocated to the suitable list, except for where an unsuitable food was included 
in a meat-containing mixed meal. For example, a meat-containing ready meal 
containing chives would be considered unsuitable as chives were allocated to the 
unsuitable list. 
4. The habitual dietary intake of individuals with IBS from a previous study (Staudacher et 
al., 2012) was examined. The top 10% of foods consumed, by energy and carbohydrate 
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content and total weight, were transferred to the suitable list in order to promote 
maintenance of nutrient intake.  
5. The number of unsuitable foods on the sham diet was confirmed as approximately 
equivalent to that of the low FODMAP diet. 
 
3.3.2 Design of the dietary resource 
Access to written dietary resources has been associated with greater likelihood of response to 
low FODMAP dietary advice (Gearry et al., 2009). Therefore, a written resource was designed 
for both the low FODMAP diet and sham diet groups (Appendix 9.1). The content was limited 
to suitable and unsuitable food lists, and pictures and other potentially persuasive sections 
(e.g. mechanisms of action of the low FODMAP diet) that are usually included in clinical 
resources were not included to maintain blinding and to minimise and equalise the placebo 
effect across groups. General format, length of the resource and wording on generic 
information (e.g. advice on caffeine, alcohol intake) was identical.   
 
3.3.3 Development  
The diet was reviewed by members of the research team (one senior academic dietitian, one 
non gastroenterology research/clinical dietitian and one clinical gastroenterology dietitian) 
and one independent researcher. There was a consensus that the diet was not difficult 
enough, which might increase the risk of unblinding. To address this, it was recommended that 
two additional staple carbohydrate foods be allocated to the unsuitable list. Based on previous 
dietary intake data, potato, oats and rice were the three most commonly consumed non-
wheat carbohydrate sources. Therefore, to increase the difficulty of the diet, oats and rice 
were allocated to the unsuitable list, but potatoes were not. 
 
3.3.4 Evaluation  
After review and subsequent amendment of the sham diet, it was evaluated both in a pilot 
study in healthy individuals and then in an interim analysis of the RCT.  
 
3.3.4.1 Pilot study 
The pilot study aimed to assess the feasibility of the sham diet, its success as a convincing 
exclusion diet and its nutrient and FODMAP content. An uncontrolled blinded pilot study was 
performed in healthy individuals (n=7). Individuals were advised that the diet was a test diet, 
but were not aware of the purpose of the diet. Individuals completed a 3-day diet record at 
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baseline that covered a period of one weekend day and two weekdays and were advised to 
continue their habitual diet during this period. Following the baseline period, individuals were 
advised on following the sham diet, and were provided the written resource. Individuals 
followed the sham diet for three days whilst completing a second 3-day diet record. At the end 
of the pilot study, a purpose-designed acceptability questionnaire was completed to provide 
feedback on feasibility and credibility of the diet. This provided information on convenience, 
cost, degree of change to the diet, quality of the resource, and a blinding question (i.e. ‘how 
surprised would you be if I now told you this was a “make believe” diet’).  
 
Energy and nutrient intake was analysed using Dietplan 6 P3 (Forestfield Software, Horsham, 
UK) and FODMAP intake was analysed by collaborators at Monash University, Melbourne, 
Australia using Foodworks Version 7 (Xyris Software, Australia). This process was supervised by 
Dr Jane Muir (Head of Translational Nutrition Science, Monash University, Melbourne, 
Australia). Data for FODMAP analysis was formatted by HS prior to analysis, as described in 
Section 2.7.6. 
 
Demographic and dietary data are presented in Appendix 9.12. There were no differences in 
macronutrient or FODMAP intake between baseline and sham diet. There was higher intake of 
NSP during the sham diet compared with baseline (17.3 g/d vs 13.4 g/d, p=0.043). On 
examination of individual intakes, there was a large increase in NSP intake for four individuals 
on the sham diet compared with baseline (mean 6 g/d), which was due to large portions of 
isolated high fibre foods (e.g. All bran, legumes and nuts).  
 
Regarding acceptability of the diet (data not shown), difficulty of meal preparation, flavour of 
meals, and money and time spent food shopping were no different for the sham diet 
compared with baseline. Finding suitable foods when eating out was a little more difficult and 
most individuals reported making many changes to their diet, indicating it led to substantial 
changes in dietary choice. When individuals were verbally questioned regarding how they 
would feel when told that the diet was a ‘make believe’ diet, most individuals expected it a 
little (3/7) or were neutral or surprised (2/7). 
 
These results confirmed that the sham diet was not substantially different from baseline for 
energy, macronutrient and FODMAP intake, was feasible to follow, and was convincing as an 
exclusion diet. However, the increased NSP intake on the sham diet compared with baseline 
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was a concern due to its potential effect on IBS symptoms (Moayyedi et al., 2014). This may 
have represented a true increase in NSP intake. Conversely, the intervention also came at least 
one week after the baseline recording period which may have led to an order effect. 
Furthermore, a 7-day sham intervention may have more precisely captured true NSP intake, as 
7-day diet records are preferable for measuring intake than 3-day diet records (Bingham, 
1987). 
 
A number of actions were taken to minimise changes in NSP intake for patients randomised to 
sham dietary advice in the RCT. Firstly, attention to fibre intake was emphasised by addition of 
a fibre counter to the both sham and low FODMAP resources. This would serve as a reminder 
to the dietitians (HS, RN) to attempt to maintain fibre intake in those allocated to sham dietary 
advice and to tailor advice accordingly (e.g. emphasise continuation of a low or high fibre 
wheat breakfast cereal, depending upon habitual dietary intake). Secondly, weekly phone calls 
to patients in the sham diet group were used to screen for unusually high fibre intakes. Lastly, 
due to the uncertainty about the effect of the sham diet on NSP intake, an interim analysis was 
planned after 20 patients had been recruited to the RCT. 
 
3.3.4.2 Interim analysis 
An a priori interim analysis of dietary intake was performed after 20 patients had been 
randomised to the RCT to confirm whether nutrient and FODMAP content of the sham diet 
was maintained compared with baseline (habitual diet). Seven-day diet records were analysed 
for nutrient and FODMAP content at baseline and follow up using Dietplan 6 P3 (Forestfield 
Software, Horsham, UK) and Foodworks Version 7 (Xyris Software, Australia), respectively. 
Data for FODMAP analysis was prepared as described in Section 2.7.6. The interim analysis was 
conducted by HS who was blinded to the dietary allocation (i.e. whether diet records for the 
analysis were allocated to sham diet or low FODMAP diet) throughout the data input and 
analysis process (ICH, 1998). In addition to analysis of dietary intake, success of blinding was 
measured by asking patients to guess their dietary treatment group allocation. 
 
3.3.4.3 Statistical analysis of the interim analysis 
Non parametric tests were used as data did not meet the assumptions for ANCOVA due to 
non-normality and inequality of variances. Wilcoxon signed-ranks tests were used to compare 
dietary intake within groups and Mann-Whitney U tests were used to compare dietary intake 
between sham diet and low FODMAP diet groups at each timepoint and for change in intake.  




3.4 Results of the interim analysis 
A total of 20 patients were included in the analysis (11 sham diet, 9 low FODMAP diet).  
 
3.4.1 Nutrient intake  
There was no difference in nutrient intake between sham diet and low FODMAP diet groups at 
baseline (Table 3.1). Similarly, there were no differences in energy, NSP or macronutrient 
intake at follow up compared with baseline within each group, except for carbohydrate and 
starch in the low FODMAP group, which were lower at follow up compared with baseline.  
 
3.4.2 FODMAP intake  
There were no differences in FODMAP intake at baseline between groups, except for fructans, 
which was lower in the sham group compared with the low FODMAP group (p=0.028). There 
were no differences in total or individual FODMAP intake in the sham group at follow up 
compared with baseline, however there was a lower total FODMAP, fructans, sorbitol and 
mannitol intake in the low FODMAP group at follow up compared with baseline (p<0.05), and 




A majority of the patients in the interim analysis who received sham dietary advice guessed 
their allocation correctly (9/11, 82%). One patient guessed they had been allocated to the low 
FODMAP group and one was unsure. 
  
Table 3.1  Energy, nutrient and FODMAP intake from food and fluid in the interim analysis of patients with IBS participating in a 2x2 factorial design RCT 
of  low FODMAP dietary advice and probiotic supplementation (n=20) 
 Sham diet (n=11) Low FODMAP diet (n=9) 
Baseline Sham 
vs low FODMAP 
Follow up Sham 
vs low FODMAP 
Change between baseline and follow up 
 Baseline Follow up p
#
 Baseline Follow up p
#
 p* p* Sham diet Low FODMAP diet P* 
Energy (kcal/d) 1819 (424) 1772 (695) 0.782 2020 (618) 1775 (358) 0.074 0.450 0.990 -47 (521) -245 (376) 0.257 
Protein (g/d) 69 (16) 68 (23) 0.721 72 (20) 73 (15) 0.721 0.597 0.564 -1 (15) 1 (13) 0.940 
Fat (g/d) 79 (19) 80 (37) 0.959 82 (24) 74 (15) 0.386 0.821 0.671 1 (31) -8 (26) 0.545 
Carbohydrate (g/d) 199 (64) 189  (74) 0.616 217 (55) 183 (56) 0.017 0.326 0.843 -10 (62) -34 (32) 0.364 
Starch (g/d) 99 (42) 94  (41) 0.260 125 (35) 103 (40) 0.047 0.151 0.603 -5 (32) -22 (32) 0.257 
Sugars (g/d) 87 (31) 87 (37) 0.959 84 (30) 74 (23) 0.203 0.821 0.338 0 (38) -10 (26) 0.597 
NSP (g/d) 10.5 (5.3) 11.2 (5.6) 0.610 13.0 (3.9) 11.9 (4.3) 0.953 0.326 0.628 0.7 (2.2) -1.1 (3.9) 0.705 
FODMAPs 
Total FODMAPs (g/d) 15.6 (8.7) 14.1 (8.1) 0.878 12.4 (4.0) 6.7 (5.3) 0.037 0.579 0.011 -1.5 (6.3) -5.7 (5.7) 0.089 
     Fructans (g/d) 4.1 (1.3) 4.1 (2.0) 0.508 6.3 (2.4) 2.2 (2.2) 0.009 0.028 0.023 0 (1.3) -4.1 (3.0) 0.002 
     GOS (g/d) 0.7 (0.4) 0.9 ( 0.5) 0.386 1.1 (0.8) 1.0 (0.8) 0.445 0.165 1.000 0.2 (0.7) -0.1 (0.8) 0.280 
     Lactose (g/d) 8.7 (8.6) 6.1 (5.3) 0.333 3.3 (3.8) 2.7 (3.1) 0.878 0.131 0.059 -2.6 (6.4) -0.6 (4.5) 0.545 
     Total fructose (g/d) 14.1 (6.8) 16.4 (10.1) 0.515 12.0 (5.7) 11.7 (3.3) 0.575 0406 0.364 2.3 (7.9) -0.3 (5.2) 0.762 
     Excess fructose (g/d) 1.0 (0.9) 1.6 (1.4) 0.126 0.8 (0.6) 0.6 (0.4) 0.646 0.650 0.199 0.6 (0.9) -0.2 (0.6) 0.161 
     Sorbitol (g/d) 0.6 (0.5) 1.3 ( 1.7) 0.415 0.4 (0.3) 0.1 (0.1) 0.047 0.705 0.031 0.7 (1.6) -0.3 (0.3) 0.059 
     Mannitol (g/d) 0.4 (0.3) 0.2 (0.2) 0.059 0.4 (0.4) 0.2 (0.1) 0.047 0.821 0.384 -0.2 (0.3) -0.2 (0.4) 0.496 
Values are mean (SD) *Total FODMAPs are calculated as the sum of individual carbohydrates including excess fructose (not total fructose). 
#
 Wilcoxon signed-ranked test *Mann-Whitney U test 




Evaluation of this novel sham diet confirmed its suitability for use in the RCT.  The interim 
analysis confirmed maintenance of energy, NSP, macronutrient and FODMAP intake in 11 
patients following sham dietary advice compared with baseline. This is reassuring given the 
initial pilot study in healthy individuals suggested the sham diet increased NSP intake, which 
was of potential concern considering fibre can modify IBS symptoms.  
 
Acceptability outcomes from the pilot study demonstrated the sham diet was feasible to 
follow but did lead to some difficulties, for example, with eating out. This suggests the sham 
diet achieved its role as an exclusion diet for the purposes of this RCT. However, some 
individuals from the pilot study reported being unsurprised when told the diet was ‘make 
believe’, calling into question whether the diet was convincing as a placebo. Furthermore, 
most patients in the interim analysis guessed their allocation correctly. It is plausible, however, 
that patients allocated to the sham diet in the RCT might guess treatment allocation based on 
whether they experienced symptom response, as it was clear the intervention diet aimed to 
reduce IBS symptoms. Therefore, it is difficult to determine whether lack of symptom 
response, rather than poor design of the sham diet, was the reason why some patients 
guessed their allocation.  
 
There were some nutrient intake findings in the low FODMAP diet group that are of interest 
from the interim analysis.  The reduction in carbohydrate and starch intake at follow up 
compared with baseline is not surprising given the substantial change to carbohydrate sources 
in the diet and is in keeping with previous data (Staudacher et al., 2012, Bohn et al., 2015). 
Furthermore, the interim analysis confirmed that low FODMAP dietary advice in the absence 
of verbal or written explanation of the mechanisms underlying the approach was still effective 
in reducing FODMAP intake. A significant reduction in intake of all individual FODMAPs was not 
evident, and this may have been due to the small number of patients included in the analysis, 
which may have also been the reason for the difference in baseline intake of fructans. 
However, recruitment of more patients was not feasible due to time constraints. 





Evaluation of dietary intake and acceptability data confirmed the suitability of this novel sham 
diet for a dietary intervention RCT in patients with IBS. Suboptimal blinding was a potential 
concern as this can lead to bias in studies with subjective outcome endpoints (e.g. GI 
symptoms). An interim analysis of GI symptom outcomes was not performed, and therefore 
whether suspicion of allocation was actually related to symptom response could not be 
verified. Furthermore, the effect of expectation bias in this RCT may be attenuated as patients 
were also blinded to the second intervention (i.e. probiotic/placebo product). The preservation 
of energy, nutrient and FODMAP intake over time in patients receiving sham dietary advice 
confirms the suitability of this diet as a placebo control when investigating the effect of dietary 
intervention (i.e. low FODMAP diet, probiotic) on the GI microbiota. 












4 The effect of low FODMAP dietary advice and probiotic 
supplementation on clinical outcomes in irritable bowel syndrome 




The clinical effectiveness of a low FODMAP diet has not been evaluated in a placebo-controlled 
dietary advice study in IBS. It has been shown to lead to adequate control of symptoms in 68% 
of patients with IBS when provided as dietary advice compared with 23% of those following 
habitual diet (Staudacher et al., 2012). Other work has suggested low FODMAP dietary advice 
provides no significant benefit over other standard dietary advice for IBS (Bohn et al., 2015), 
but its benefit over placebo dietary advice study has not been tested. In the clinical situation, 
the placebo effect can be harnessed for the benefit of the patient, however in research it leads 
to difficulty to identify interventions that hold therapeutic gain. This is especially important in 
IBS, where placebo effect is higher than for other GI disease (e.g. IBD), and has been reported 
to be 20-40% (Elsenbruch and Enck, 2015). Furthermore, placebo effect might not just 
influence GI symptoms but also HRQOL outcomes (Eickhoff, 2008). 
 
There is some limited evidence for the benefit of VSL#3 probiotic on IBS symptoms. Three of 
four supplementation RCTs that have been conducted report response in at least one IBS 
symptom. These studies are limited in design and methodology (Kim et al., 2003, Kim et al., 
2005, Wong et al., 2015), may be underpowered to detect differences in symptom response,  
and compliance in these studies is infrequently reported. Therefore the benefit of VSL#3 for 
symptoms of IBS requires clarification. 
 
Abdominal pain is frequently utilised as a primary endpoint in clinical trials of drugs for IBS, 
however, a spectrum of lower GI symptoms including bloating, flatulence and urgency, and 
fatigue are endorsed by patients as being important to them (Spiegel et al., 2010a). Symptoms 
can range from being mild and infrequent to severe and continuous. Instruments for 
measuring individual GI symptoms can be global or specific and can measure dimensions of 
frequency and/or intensity of symptom experience (Naliboff et al., 1999).   
 
Patient-reported outcomes such as HRQOL and acceptability are important adjunct endpoints 
when measuring success of a therapeutic intervention. This is especially pertinent in IBS where 
a biomarker for clinical symptom severity is not yet established. Measurement of HRQOL is 
important as patients respond differently to disease based on a number of factors (e.g. coping, 
social support, psychological comorbidity) (Wong and Drossman, 2010). Furthermore, it can be 
considered a net effect of the benefits and harms of a treatment, and useful for the planning 
of clinical services. The effect of low FODMAP dietary intervention on HRQOL has never been 
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assessed in a blinded RCT, and its effect in unblinded studies is equivocal (Pedersen et al., 
2014, Harvie et al., 2013). The effect of VSL#3 on HRQOL has not been comprehensively 
evaluated. One study reported greater HRQOL to some but not all components of an 
unvalidated questionnaire (Michail and Kenche, 2011), whilst another demonstrated no 
difference between VSL#3 and placebo for the quality of life IBS-SSS subscore (Wong et al., 
2015). Furthermore, there are no studies assessing the acceptability of VSL#3 in IBS, or 
assessing acceptability of the low FODMAP diet, other than in a retrospective study of patients 
with IBD (Gearry et al., 2009). Therefore HRQOL and acceptability of these interventions 
requires evaluation. 
 
4.1.1 Aim of this chapter 
The aim of this chapter is to report the results for clinical outcomes from the 2x2 factorial 
design RCT investigating the effect of low FODMAP dietary advice and probiotic 
supplementation in patients with IBS. Clinical outcomes were measured using the adequate 
relief question (co-primary endpoint; Section 2.5.1.1), IBS-SSS (Section 2.5.1.2), GSRS (Section 
2.5.1.3), BSFS (Section 2.5.1.4), SF-36 (Section 2.5.2.1) and the IBS-QOL (Section 2.5.2.2). 
 
The hypothesis was that there is a difference in the proportion of patients reporting adequate 
relief of IBS symptoms between patients following low FODMAP dietary advice for four weeks 
compared with patients following placebo sham dietary advice (Section 2.2). 
 
This chapter is divided into four parts, and addresses the results as follows: 
1. Patient recruitment and progress, characteristics, compliance and blinding (Section 4.2) 
2. GI symptoms and stool output (Section 4.4) 
3. Health-related quality of life (HRQOL) (Section 4.5) 
4. Acceptability of the interventions (Section 4.6) 
 
4.2 Patient recruitment and progress, characteristics, compliance and blinding 
4.2.1 Patient recruitment and progress 
Patients were screened between January 2012 and October 2014. Figure 4.1 presents the 
CONSORT diagram of the trial. Of the 162 potential participants who were screened, 43 were 
excluded due to meeting the exclusion criteria. Of the 119 who entered the second screening 
period (7-day symptom and dietary recording period) five failed to meet the severity criteria, 
five withdrew and five were lost to follow up. A total of 104 patients were recruited to the RCT 
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who make up the ITT population. Of these, 95 patients finished the study and nine were 
withdrawn. The patients who withdrew did so due to family reasons (n=1), loss to follow up 
(n=1), commencing antibiotics (n=6) and major protocol violation (n=1, following an extreme 
alternative diet instead of the allocated sham diet). Of the 95 that completed the study, all 
were compliant with the diet, and eight did not meet the compliance criteria for the product 
(probiotic/placebo) intervention, which left 87 patients in the PP analysis. The sample size 
target (n=100) was achieved and the final patient completed the last study visit in December 
2014. 
 
Figure 4.1 Consort diagram for the 2x2 factorial design RCT of low FODMAP dietary advice 
and probiotic supplementation 
 
4.2.2 Baseline patient demographic and clinical characteristics 
Baseline characteristics are presented in Table 4.1 There was no difference between either 
sham or low FODMAP diet groups or placebo and probiotic groups for any baseline variables. 
Most patients were white (83%) and female (67%). Most patients had IBS-D (66%) with a mean 
(SD) symptom duration of 6 years (8 years). Most patients did not take medications for their 
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symptoms. Of the 104 patients randomised, 96 were recruited from Guy’s and St Thomas’ NHS 
Foundation Trust and eight were recruited from St George’s Healthcare NHS Trust. 
 
Table 4.1 Baseline demographic and clinical characteristics for patients with IBS participating 













Age yrs  34 (12) 37 (12) 0.270 34 (12) 37 (12) 0.292 
Female n (%) 35 (66) 35 (69) 0.836 35 (69) 35 (66) 1.000 
Symptom duration mths  62 (77) 87 (111) 0.222 61 (69) 87 (115) 0.713 
IBS subtype        
    IBS-D n (%) 34 (64) 35 (69)  
0.672 
34 (67) 35 (66)  
0.482     IBS-M n (%) 12 (23) 12 (23) 10 (19) 14 (26) 
    IBS-U n (%) 7 (13) 4 (8) 7 (14) 4 (8) 
Current medications       
    Antidiarrheal n (%) 2 (4) 3 (6) 1.000 2 (4) 3 (6) 1.000 
    Analgesic n (%) 0 (0) 4 (8) 0.054 3 (6) 1 (2) 0.358 
    Antispasmodic n (%) 6 (11) 5 (10) 1.000 8 (16) 3 (6) 0.119 
Ethnicity white n (%) 44 (83) 42 (82) 1.000 41 (80) 45 (85) 0.610 
Smoker n (%) 3 (6) 5 (10) 0.148 1 (2) 7 (13) 0.060 
Vegetarian n (%) 1 (2) 1 (2) 1.000 0 (0) 2(4) 0.495 
Weight kg  73 (19) 69 (13) 0.232 70 (14) 72 (18) 0.612 
BMI kg/m
2
  25 (5) 24 (4) 0.902 25 (5) 25 (5) 0.607 
Values are mean (SD) unless stated 
 
4.2.3 Compliance  
Compliance to the dietary advice is reported in Section 5.2.3. Overall mean compliance to the 
product (probiotic or placebo) was 93% i.e. all patients took the recommended number of 
sachets on 93% of the days they took part in the RCT. There were eight patients (5 placebo, 3 
probiotic) who were compliant fewer than 80% of days and this was not different between 
groups (p=0.470).  
 
4.2.4 Blinding 
The success of blinding was measured by asking patients to guess their allocation to the diet 
and product groups at the end of the RCT. For the dietary allocation, 34/48 (71%) of the sham 
diet group and 33/47 (70%) of the low FODMAP diet group guessed their allocation correctly 
while 10/48 (21%) of the sham diet group and 10/47 (21%) of the low FODMAP diet group 
were not sure of their allocation. For the product allocation, 9/45 (20%) of the placebo group 
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and 14/50 (28%) of the probiotic group guessed their allocation correctly and 18/45 (40%) of 
the placebo group and 21/50 (42%) of the probiotic group were unsure. There was no 
difference in responses between placebo and probiotic (p=0.514). 
 
4.3 Results: Adverse events  
Overall, the total number of adverse events reported was small. Six patients reported 
worsened IBS or upper GI symptoms throughout the duration of the RCT (4 sham diet, 2 low 
FODMAP diet; 4 placebo, 2 probiotic) and this was not different between the diet or product 
intervention groups (p>0.05). Other adverse events not thought to be related to the diet or 
product interventions were reported in 38% of patients (e.g. headache, cold, toothache) and 
this was not different between diet or product intervention groups (p>0.05) 
 
4.4 Results: GI and stool output 
For all outcomes, there was no interaction between the diet and product interventions and 
therefore the main effects for the dietary intervention and the probiotic intervention are 
presented individually. The primary analysis based on the ITT dataset is presented. A further 
analysis based on the PP population is presented for the primary outcome.   
 
4.4.1 Adequate relief 
Logistic regression was performed to assess the effect of diet and product in predicting the 
likelihood of adequate relief of IBS symptoms. The logistic regression model was statistically 
significant χ(3)=8.979 (p=0.030). The model explained 11% of the variance in adequate relief 
and correctly classified 63% of cases. Sensitivity was 43%, specificity was 80%, positive 
predictive value was 62% and negative predictive value was 61%. Of the predictor variables 
after adjusting for baseline differences (model 2), probiotic was statistically significant (Table 
4.2). At follow up, patients in the probiotic group had a 2.41 (95% CI 1.06, 5.52; p=0.037) 
greater odds of reporting adequate relief of symptoms compared with placebo. This difference 
was no longer evident for the analysis of the PP population (OR 1.96, 95% CI 0.81, 4.74; 
p=0.136). There was a trend for an effect of low FODMAP diet, with patients having a 2.18 
(95% CI 0.98, 4.89; p=0.058) greater odds of reporting adequate relief compared with sham 
diet, and the findings were similar for the PP population (OR 2.37, 95% CI 0.98, 5.69; p=0.054). 
There was also no difference when intervention combinations were compared (Table 4.3). 
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Table 4.2 Adequate relief at follow up for patients with IBS participating in a 2x2 factorial 
design RCT of low FODMAP dietary advice and probiotic supplementation 
Adequate relief n (%) 
Model 1 Model 2 
OR (95% CI) p OR (95% CI) p 
Intention to treat analysis, n=104     
Sham diet 
20/53 (38) 
low FODMAP diet 
29/51 (57) 





2.19 (0.99, 4.88) 0.054 2.41 (1.06, 5.52) 0.037 
Per protocol analysis, n=87     
Sham diet 
17/44 (39) 
low FODMAP diet 
26/43 (61) 





1.95 (0.81, 4.67) 0.136 1.96 (0.81, 4.74) 0.136 
OR odds ratio; CI confidence interval; Model 1 Crude analysis; Model 2 Baseline adjusted  
 
Table 4.3 Adequate relief for the intervention combinations at follow up for patients with 
IBS participating in a 2x2 factorial design RCT of low FODMAP dietary advice and probiotic 
supplementation 
 Intention to treat n=104 Per protocol n=87 
 AR n (%) p
#
 AR n (%) p
#
 




Sham diet + probiotic  13/26 (50) 11/22 (50) 
low FODMAP diet + placebo  12/24 (50) 10/18 (56) 






Table 4.4 presents the IBS-SSS outcomes at follow up for the ITT population after adjusting for 
baseline. Bootstrapped CI were computed due to non-normal data. A linear regression 
established that a low FODMAP diet could statistically significantly predict total IBS-SSS scores 
at follow up, F(3,83)=21.34 (p<0.001). The low FODMAP diet accounted for 42% of the 
explained variability in the total IBS-SSS score. Figure 4.2 presents a comparison of baseline 
and follow up scores for total IBS-SSS score for the two dietary interventions. The low FODMAP 
diet could also predict all IBS-SSS subscores except for pain severity. When the PP population 
was evaluated, the low FODMAP diet was also able to predict the days of pain subscore (data 
not shown, p=0.034).  
. 
  
Table 4.4 IBS-SSS at follow up for the intention to treat population (n=104) of patients with IBS participating in a 2x2 factorial design RCT of low 



















Table 4.5 Outcomes for patients achieving the minimal clinical important difference in IBS-SSS score for the intention to treat population (n=104) of 
patients with IBS participating in a 2x2 factorial design RCT of low FODMAP dietary advice and probiotic supplementation 
 




Low FODMAP diet 
(n=51) 





OR (95% CI) p 
Achieving MCID n (%) 22 (42) 37 (73) 3.42 (1.45, 8.07) 0.005 27 (53) 32 (60) 1.49 (0.63, 3.52) 0.363 
MCID, minimal clinically important difference; OR; odds ratio; CI, confidence interval 
















IBS-SSS total (pts) 224 (89) 173 (95) -66.3 (-94.0, -34.4) 0.001 207 (98) 192 (93) -4.8 (-34.3, 24.4) 0.721 
Pain severity 40 (23) 33 (24) -8.3 (-17.5, 0.04) 0.062 38 (24) 35 (24) -0.7 (-9.1, 8.1) 0.892 
Days of pain (days) 44 (29) 30 (27) -16.2 (-24.6, -8.0) 0.001 39 (28) 35 (30) -1.7 (-10.2, 7.6) 0.690 
Distension severity 40 (24) 29 (25) -14.3 (-22.2, -6.3) 0.002 34 (24) 35 (26) 1.1 (-7.2, 9.6) 0.766 
Satisfaction with bowels 53 (17) 42 (23) -13.8 (-20.8, -7.0) 0.002 49 (22) 46 (20) -2.8 (-10.2, 4.0) 0.459 
Affecting life 47 (21) 40 (20) -8.8 (-16.1, -1.7) 0.022 46 (21) 41 (20) -3.3 (-9.8, 3.4) 0.322 
Change in IBS-SSS (pts) -44 (72) -117 (86) -66.3 (97.4, -35.0) 0.001 -78 (96) -82 (78) -4.8 (-34.3, 28.0) 0.750 
All units are (mm) unless stated. Values are raw mean (SD) with estimated mean difference and 95% confidence interval 
 







There was no effect of product on total IBS-SSS score, any subscores, or change in IBS-SSS 
score. When examining the proportion of patients meeting the MCID for the IBS-SSS (50 point 
reduction in total IBS-SSS score), the logistic regression model was statistically significant 
χ(3)=19.286 (p<0.001) after adjusting for baseline differences. The model explained 23% of the 
variance in MCID and correctly classified 69% of cases. Sensitivity was 76%, specificity was 
60%, positive predictive value was 71% and negative predictive value was 66%. Patients in the 
low FODMAP diet group had a 3.42 (95% CI 1.45, 8.07; p=0.005) greater odds of achieving the 
MCID compared with the sham group, whilst there was no significant effect of the probiotic 
compared with placebo (OR 1.49, 95% CI 0.63, 3.52; p=0.363) (Table 4.5). Mean IBS-SSS scores 
at baseline and follow up for the diet and product interventions are presented in Appendix 
9.13. 
 
When intervention combination groups were compared, the change in IBS-SSS score was 
higher for the low FODMAP groups compared with the sham groups (p<0.001), and there was 
a difference between groups for the proportion meeting the MCID (sham diet + placebo 37% 
vs sham diet + probiotic 46% vs low FODMAP diet + placebo 71% vs low FODMAP diet + 
Figure 4.2 Comparison of total IBS-SSS total scores between the dietary interventions for 
the intention to treat population (n=104) of patients with IBS participating in a 2x2 factorial 
design RCT of low FODMAP dietary advice and probiotic supplementation 
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probiotic 74%; p=0.013). Comparisons between intervention combination groups for IBS-SSS 
outcomes is presented in Appendix 9.14 
 
4.4.3 GSRS 
Incidence and severity of 15 symptoms and overall symptoms at follow up after adjusting for 
baseline values for the ITT population are presented in Table 4.6 and Table 4.7. The incidence 
(number of days symptoms present over 7 days) of borborygmi (p=0.005), bloating (p=0.011), 
flatulence (p=0.023), urgency (p=0.010) and sensation of incomplete evacuation (p=0.003) 
were lower for the low FODMAP diet group compared with the sham diet group. When the PP 
population was evaluated these differences were still evident, as well as a lower incidence of 
overall symptoms for low FODMAP diet compared with sham diet (1.6 vs 2.3 days; p=0.028). 
There was no difference in incidence of individual symptoms or overall symptoms for probiotic 
compared with placebo. 
 
Bootstrapped confidence intervals were computed for GSRS severity outcomes due to non-
normal data. There was a lower severity of abdominal pain (p=0.010), borborygmi (p=0.003), 
bloating (p=0.001), belching (p=0.031), flatulence (p=0.001), urgency (p=0.001), sensation of 
incomplete evacuation (p=0.039) and overall symptoms (p=0.020) for the low FODMAP group 
compared with the sham diet group and a lower severity of flatulence for the probiotic group 
compared with placebo (p=0.033). When the PP population was evaluated (data not shown) 
these differences were still evident, and there was also a lower severity of tiredness for the 
low FODMAP diet group compared with the sham diet group (1.3 vs 1.5, p=0.018). GSRS 
incidence and severity values for baseline and follow up for the diet and product interventions 
are presented in Appendix 9.15. 
 
4.4.4 Stool output 
Outcomes for stool consistency, stool frequency and the proportion of stools of normal 
consistency (Types 3,4,5 on the BSFS) at follow up after adjusting for baseline differences for 
the ITT population are presented in Table 4.8. Bootstrapped confidence intervals were 
computed due to non-normal data. A linear regression established that low FODMAP dietary 
advice could statistically significantly predict stool consistency at follow up, F(3,100)=11.364 
(p<0.001). The low FODMAP diet accounted for 23% of the explained variability in stool 
consistency. Figure 4.3 presents mean stool consistency for the two dietary interventions at 
  
Table 4.6 Gastrointestinal Symptom Rating Scale symptom incidence at follow up for the intention to treat population (n=104) of patients with IBS 
participating in a 2x2 factorial design RCT of low FODMAP dietary advice and probiotic supplementation 
 
















Abdominal pain 2.1 (2.0) 1.5 (1.9) 0.67 (0.40, 1.11) 0.119 1.9 (2.1) 1.7 (2.0) 0.98 (0.59, 1.61) 0.943 
Heartburn 0.2 (0.6) 0.4 (1.1) 1.25 (0.52, 3.03) 0.607 0.2 (0.6) 0.4 (1.1) 1.59 (0.66, 3.85) 0.302 
Acid reflux 0.3 (0.7) 0.4 (0.9) 1.47 (0.63, 3.45) 0.677 0.3 (0.6) 0.4 (0.9) 2.08 (0.85, 5.00) 0.107 
Nausea 0.6 (1.4) 0.3 (0.9) 0.42 (0.18, 1.01) 0.054 0.6 (1.6) 0.3 (0.6) 1.03 (0.43, 2.44) 0.950 
Borborygmi 1.9 (2.2) 1.0 (1.9) 0.43 (0.24, 0.77) 0.005 1.6 (2.2) 1.4 (2.1) 1.32 (0.74, 2.38) 0.350 
Bloating 2.2 (2.3) 1.5 (2.0) 0.50 (0.29, 0.85) 0.011 1.9 (2.2) 1.8 (2.2) 0.85 (0.50, 1.43) 0.545 
Belching 1.9 (1.8) 0.6 (1.4) 0.68 (0.36, 1.27) 0.226 0.9 (1.8) 0.8 (1.6) 0.67 (0.35, 1.27) 0.180 
Flatulence 2.7 (2.4) 1.5 (2.0) 0.56 (0.33, 0.93) 0.023 2.6 (2.4) 1.7  (2.0) 0.73 (0.44, 1.20) 0.220 
Constipation 0.3 (0.7) 0.4 (1.2) 1.37 (0.60, 3.13) 0.459 0.3 (1.0) 0.4 (0.9) 1.22 (0.53, 2.78) 0.644 
Diarrhoea 0.5 (1.2) 0.5 (1.5) 0.79 (0.36, 1.75) 0.562 0.7 (1.5) 0.4 (1.1) 0.69 (0.32, 1.54) 0.367 
Loose stool 1.3 (1.8) 1.1 (1.9) 1.00 (0.57, 1.75) 0.999 1.4 (2.1) 1.1 (1.6) 0.94 (0.54, 1.67) 0.843 
Hard stool 0.2 (0.6) 0.3 (0.7) 1.15 (0.46, 2.86) 0.769 0.1 (0.4) 0.4 (0.8) 2.70 (0.97, 2.27) 0.057 
Urgency 1.6 (1.8) 1.2 (1.9) 0.47 (0.26, 0.83) 0.010 1.5(2.0) 1.4 (1.8) 1.32 (0.76, 2.27) 0.325 
Incomplete evacuation 1.7 (2.2) 0.7 (1.4) 0.41 (0.23, 0.74) 0.003 1.3 (2.1) 1.2 (1.8) 1.04 (0.59, 1.85) 0.877 
Tiredness 2.8 (2.4) 2.0 (2.5) 0.72 (0.44, 1.16) 0.181 2.6 (2.6) 2.2 (2.3) 0.83 (0.51, 1.33) 0.431 
Overall symptoms 2.3 (2.5) 1.6 (1.9) 0.66 (0.40, 1.10) 0.109 2.3 (2.5) 1.7 (2.0) 0.68 (0.41, 1.12) 0.127 
Values are mean (SD) of the number of days on which the symptoms were present in seven days; Exp (β) rate ratio and 95% confidence intervals
  
Table 4.7 Gastrointestinal Symptom Rating Scale symptom severity at follow up for the intention to treat population (n=104) of patients with IBS 
participating in a 2x2 factorial design RCT of low FODMAP dietary advice and probiotic supplementation 
 
















Abdominal pain 1.1 (0.6) 0.9 (0.7) -0.26 (-0.43, -0.06) 0.010 1.0 (0.7) 0.9 (0.6) -0.03 (-0.24, 0.17) 0.753 
Heartburn 0.2 (0.3) 0.2 (0.5) 0.01 (-0.10, 0.13) 0.872 0.2 (0.3) 0.2 (0.5) 0.10 (-0.02, 0.21) 0.128 
Acid reflux 0.2 (0.5) 0.2 (0.4) 0.03 (-0.06, 0.13) 0.515 0.2 (0.3) 0.2 (0.4) 0.05 (-0.04, 0.14) 0.276 
Nausea 0.3 (0.5) 0.3 (0.4) -0.04 (-0.16, 0.09) 0.535 0.3 (0.6) 0.2 (0.3) -0.09 (-0.23, 0.04) 0.191 
Borborygmi 1.0 (0.7) 0.7 (0.6) -0.34 (-0.51,-0.15) 0.003 0.9 (0.7) 0.8 (0.7) 0.01 (-0.17, 0.18) 0.913 
Bloating 1.1 (0.7) 0.8 (0.7) -0.35 (-0.52, -0.17) 0.001 1.0 (0.7) 1.0 (0.7) -0.03 (-0.20, 0.15) 0.780 
Belching 0.6 (0.7) 0.5 (0.6) -0.18 (-0.33, -0.02) 0.031 0.6 (0.7) 0.5 (0.6) -0.12 (-0.29, 0.05) 0.084 
Flatulence 1.3 (0.7) 0.9 (0.6) -0.36 (-0.55, -0.17) 0.001 1.2 (0.7) 1.0 (0.6) -0.20 (-0.37, -0.01) 0.033 
Constipation 0.3 (0.4) 0.2 (0.4) 0.05 (-0.10, 0.18) 0.559 0.2 (0.4) 0.3 (0.4) 0.06 (-0.08 , 0.19) 0.452 
Diarrhoea 0.3 (0.5) 0.2 (0.5) -0.07 (-0.20, 0.05) 0.257 0.3 (0.5) 0.2 (0.4) -0.04 (-0.16, 0.08) 0.505 
Loose stool 0.7 (0.7) 0.5 (0.6) -0.18 (-0.37, 0.02) 0.080 0.7 (0.7) 0.5 (0.6) -0.06 (-0.25, 0.12) 0.542 
Hard stool 0.2 (0.2) 0.2 (0.3) 0.18 (-0.03, 0.13) 0.166 0.2 (0.2) 0.2 (0.3) 0.07 (-0.04, 0.16) 0.203 
Urgency 0.7 (0.6) 0.6 (0.7) -0.35 (-0.53, -0.16) 0.001 0.7 (0.7) 0.6 (0.6) 0.05 (-0.13, 0.24) 0.610 
Incomplete evacuation 0.7 (0.7) 0.5 (0.6) -0.21(-0.40, -0.02) 0.039 0.7 (0.7) 0.6 (0.6) -0.04 (-0.22, 0.15) 0.674 
Tiredness 1.3 (0.7) 1.0 (0.8) -0.22 (-0.45, 0.01) 0.067 1.2 (0.8) 1.0 (0.8) -0.09 (-0.32, 0.11) 0.393 
Overall symptoms 1.2 (0.6) 1.0 (0.6) -0.22 (-0.39, -0.04) 0.020 1.2 (0.6) 1.0 (0.6) -0.17 (-0.34, 0.01) 0.066 
Values are mean (SD) severity rated daily over seven days on a scale of 0 (absent), 1 (mild), 2 (moderate), 3 (severe), estimated mean differences and  
95% confidence intervals
  
Table 4.8 Stool output at follow up for the intention to treat population (n=104) of patients with IBS participating in a 2x2 factorial design RCT of low 
FODMAP dietary advice and probiotic supplementation 
         
Stool consistency 4.3 (1.1) 3.9 (1.0) -0.50 (-0.83, -0.15) 0.008 4.2 (1.0) 4.0 (1.1) -0.11 (-0.44, 0.22) 0.544 
Stool frequency 12.9 (7.4) 14.0 (8.5) -0.18 (-1.96, 1.69) 0.843 13.8 (8.3) 13.1 (7.6) -1.41 (-3.18, 0.40) 0.136 
Stool normal consistency (%) 61 (30) 67 (26) 6.23 (-3.62, 15.57) 0.200 64 (30) 64 (26) -1.91 (-11.19, 7.54) 0.689 
Values are mean (SD) with estimated mean differences and 95% confidence intervals 
Stool consistency, mean Bristol Stool Form Scale type over the 7-day period;  
Stool frequency, mean number of stools over the 7-day period;  
Stools normal consistency, proportion of stools of types 3-5 over the 7-day period 
 

























baseline and follow up, as well as raw data for each individual, to show variations depending 
upon tendency towards hard or loose stools.  
 
There was no effect of the low FODMAP diet on stool frequency or proportion of normal 
stools, or for probiotic on any stool outcomes. Mean stool output data for baseline and follow 
up for the diet and product interventions are presented in Appendix 9.16. There were no 
differences for stool outcomes between diet or product interventions when the PP dataset 
were analysed. Neither were there any differences for stool outcomes between intervention 
combinations (see Appendix 9.17). 
 
4.5 Results: HRQOL  
4.5.1 Generic HRQOL 
Quality of life scores for the 8 scales of the SF-36 are presented in Table 4.9. Bootstrapped 
confidence intervals were computed due to non-normal data and outcomes were adjusted for 
baseline. There was an effect of the low FODMAP diet on SF-36 scores. A linear regression 
established that the low FODMAP diet could predict two SF-36 subscales at follow up. ‘Role 
limitations due to physical health’ was significantly predicted by the low FODMAP diet 
F(3,100)=25.001 (p<0.001), accounting for 41% of the explained variability. ‘Energy/fatigue’ 
scale was also significantly predicted by the low FODMAP diet F(3,100)=41.238 (p<0.001), 
Figure 4.3 Mean stool consistency (black line) at baseline and follow up for patients with 
IBS in the sham diet group (n=53) and the low FODMAP diet group (n=51) participating in a 
2x2 factorial design RCT of low FODMAP dietary advice and probiotic supplementation 
  
Table 4.9 HRQOL at follow up for the intention to treat population (n=104) of patients with IBS participating in a 2x2 factorial design RCT of low FODMAP 
dietary advice and probiotic supplementation 
Values are mean (SD), estimated mean differences and 95% confidence intervals 

















SF-36         
Physical functioning 87.3 (22.3) 86.3 (21.3) 2.5 (-2.2, 7.7) 0.357 88.9 (19.2) 84.7 (23.8) -3.0 (-8.6, 1.6) 0.278 
Role limitations due to physical health 55.2 (39.6) 70.6 (39.3) 13.0 (1.6, 24.1) 0.033 62.8 (39.8) 62.7 (40.6) -5.8 (-17.4, 7.0) 0.330 
Role limitations due to emotional problems 65.4 (37.5) 64.1 (43.1) -3.4 (-15.9, 8.5) 0.598 71.2 (38.3) 58.5 (41.3) -6.8 (-20.2, 6.4) 0.330 
Energy/fatigue 42.6 (19.9) 52.1 (23.3) 7.5 (1.6, 13.3) 0.016 43.9 (19.7) 50.4 (23.8) 2.3 (-3.6, 8.1) 0.427 
Emotional wellbeing 63.3 (17.3) 68.7 (17.8) 4.6 (-0.2, 10.0) 0.082 66.0 (17.8) 65.8  (17.7) 0.04 (-5.1, 4.9) 0.991 
Social functioning 77.8 (20.7) 73.3 (27.3) -3.3 (-10.4, 4.2) 0.398 76.0 (25.0) 75.2 (23.6) -1.3 (-8.7, 6.1) 0.731 
Pain 65.1 (20.4) 63.5 (27.0) 3.2 (-3.5, 9.8) 0.349 61.0 (23.7) 67.5 (23.6) 2.6 (-4.8, 10.0) 0.460 
General Health 56.2 (19.7) 57.5 (22.4) 3.1 (-0.9, 7.1) 0.141 55.8 (20.7) 57.8 (21.4) 2.6 (-1.9, 7.0) 0.235 
IBS-QOL         
Overall 70.6 (18.1) 72.4 (19.7) 4.8 (0.02, 9.5) 0.057 68.6 (20.7) 74.3 (16.6) 0.5 (-4.0, 6.0) 0.849 
Dysphoria 72.2 (20.5) 71.9 (24.7) 1.7 (-5.0, 8.2) 0.640 69.6 (24.7) 74.4 (20.3) 0.3 (-5.9, 7.4) 0.937 
Interference with activity 71.2 (20.6) 72.9 (24.2) 4.9 (-1.4, 10.9) 0.120 68.9 (23.3) 75.0 (21.1) 1.4 (-4.1, 7.0) 0.640 
Body Image 64.2 (22.7) 73.2 (22.7) 11.0 (5.5, 16.5) 0.001 64.8 (24.2) 72.2 (21.5) -0.5 (-6.1, 4.2) 0.847 
Healthy worry 71.1 (20.8) 73.0 (20.0) 2.5 (-3.7, 8.2) 0.383 69.6 (23.3) 74.4 (17.0) 2.8 (-2.7, 8.5) 0.336 
Food avoidance 57.9 (29.2) 51.1 (26.7) -0.9 (-9.2, 6.6) 0.823 53.6 (28.8) 55.5 (27.5) -1.5 (-9.1, 5.8) 0.683 
Social reaction 71.7 (22.2) 77.5 (22.4) 7.4 (1.2, 13.7) 0.026 71.2 (23.3) 77.7 (21.1) 1.0 (-5.8, 7.6) 0.769 
Sexual 76.2 (28.6) 79.7 (24.7) 4.7 (-1.6, 11.2) 0.163 73.3 (29.3) 82.3 (23.4) 5.2 (-1.2, 12.7) 0.150 
Relationships 80.5 (19.9) 81.2 (18.8) 5.4 (0.6, 10.6) 0.041 77.5 (20.1) 84.1 (18.1) 2.0 (-3.0, 6.8) 0.451 
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accounting for 54% of the explained variability. There were no differences in outcomes when 
the PP population were analysed, however, there was also an effect of the low FODMAP diet 
on increasing the ‘general health’ scale score compared with sham diet (p=0.05). Mean 
baseline and follow up SF-36 scores for the diet and product intervention groups are presented 
in Appendix 9.18. There was no effect for probiotic on any SF-36 scales. There were no 
differences between intervention combinations for SF-36 scales (Appendix 9.19).  
 
4.5.2 IBS-specific HRQOL 
Quality of life scores for the 8 subscales and total score for the IBS-QOL are presented in Table 
4.9. Bootstrapped confidence intervals were computed due to non-normal data and outcomes 
were adjusted for baseline. A linear regression established that the low FODMAP diet could 
predict three IBS-QOL subscales at follow up. The low FODMAP diet significantly predicted 
‘body image’ (F(3,100)=46.990, p<0.001, accounting for 59% of the explained variability); 
‘social reaction’ (F(3,100)=32.915, p<0.001, accounting for 50% of the explained variability) 
and ‘relationships’ (F(3,100)=36.919, p<0.001, accounting for 53% of the explained variability).  
 
When the PP population was examined, there was no difference in outcomes compared with 
the ITT dataset, however there was an additional effect of the low FODMAP diet on increasing 
overall score compared with sham diet (p=0.036). Mean baseline and follow up IBS-QOL scores 
for the diet and product intervention groups are presented in Appendix 9.18. There was no 
difference in IBS-QOL scores between combination intervention groups (Appendix 9.19). 
Probiotic did not show any effect compared with placebo, in either the ITT or PP analysis. 
 
Table 4.10 presents the outcomes for patients that achieved the MCID for IBS-QOL (increase of 
14 points) after adjusting for baseline. Logistic regression was performed to assess the effect 
of diet and product in predicting the likelihood of achieving the MCID for the IBS-QOL. The 
logistic regression model was statistically significant χ(3)=22.755 (p<0.001), explaining 27% of 
the variance and correctly classifying 66% of patients. Sensitivity was 45%, specificity was 80%. 
The positive predictive value was 58% and the negative predictive value was 75%. The low 
FODMAP diet was a significant predictor variable, with patients receiving low FODMAP dietary 
advice having a 2.81 (95% CI 1.15, 6.88, p=0.023) greater odds of achieving the MCID 
compared with those receiving sham dietary advice. Probiotic did not show any effect 
compared with placebo. There was no difference between groups when intervention 
combinations were compared (Appendix 9.19). 
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Table 4.10 Outcomes for patients achieving the minimal clinically important difference in 
IBS-QOL score for the intention to treat population (n=104) of patients with IBS participating 
in a 2x2 factorial design RCT of low FODMAP dietary advice and probiotic supplementation 


















MCID n (%) 
14 (26) 26 (51) 
2.81 
(1.15,6.88) 




OR, odds ratio; CI, confidence intervals 
 
 
4.6 Results: Acceptability 
Acceptability outcomes for the diet interventions are presented in Table 4.11.  A greater 
proportion of patients reported negative (‘no’) rather than positive (‘yes’) responses to diet 
acceptability, and therefore acceptability questions are presented in the negative context. For 
most questions, more patients receiving low FODMAP advice found the diet less acceptable 
than patients receiving sham dietary advice. Regarding the acceptability of being involved in 
the research overall, over half of the patients reported the benefits of involvement 
outweighed the burden of following the diet (60% sham diet vs 73% low FODMAP diet, 
p=0.217). 
Table 4.11 Proportion of patients with IBS reporting negative responses to diet acceptability 
questions (compared with usual diet) who completed a 2x2 factorial design RCT of low 
FODMAP dietary advice and probiotic supplementation  (n=95) 














Meal preparation was difficult  28 (58) 43 (91) <0.001 
Time spent shopping for food was longer 22 (46) 40 (85) <0.001 
Time spent preparing and cooking meals and snacks was longer 11 (23) 34 (72) <0.001 
Finding suitable food choices when eating out was difficult 38 (79) 45 (96) 0.027 
The flavour of the meals and snacks was unappealing 8 (17) 37 (78) <0.001 
Grocery shopping and eating was more expensive 4 (8) 40 (85) <0.001 
Diet was inconvenient 34 (71) 42 (89) 0.039 
Diet was troublesome/difficult 34 (71) 43 (91) 0.017 
Made many changes to diet 28 (58) 44 (94) <0.001 
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A summary of results relating to acceptability of the probiotic are presented in Table 4.12. 
Most patients reported willingness to trial a probiotic in the future (84%). Regarding questions 
that assessed patient understanding of probiotics, most patients reported they believed they 
understood the definition of a probiotic prior to the RCT (65%) and most classified a probiotic 
as a complementary/alternative medicine (53%) rather than standard treatment (21%) or 
neither complementary medicine or standard treatment (26%). The full acceptability results 
are presented in Appendix 9.20. 
 
Table 4.12  Proportion of patients reporting responses to product acceptability questions 
who completed a 2x2 factorial design RCT of low FODMAP dietary advice and probiotic 
supplementation  (n=95) 





4.7 Discussion and conclusion 
4.7.1 GI symptoms and stool output 
The aim of this chapter was report the effect of low FODMAP dietary advice and probiotic on 
clinical outcomes in IBS. The hypothesis that there is a difference between the proportion of 
patients reporting adequate relief of symptoms between following low FODMAP dietary advice 
and patients following sham dietary advice can only be tentatively accepted, as there was only 
a trend towards statistical significance (p=0.057).  
 
The lack of statistically significant difference between dietary intervention groups for the 
adequate relief endpoint and the disparity with previous data could be explained in a number 
of ways. Firstly, the proportion of patients achieving adequate relief (57%) was lower than that 
reported in the only other low FODMAP dietary advice RCT that reported a dichotomous 
symptom endpoint (68%) (Staudacher et al., 2012). The previous study was essentially 
unblinded which may have artificially enhanced the response rate in those receiving low 
FODMAP dietary advice. Secondly, in the current RCT, low FODMAP dietary advice was 
delivered without explanation of how the diet affects GI physiology, which may be important 









Taking the sachets daily for 4 weeks was easy 40 (89) 39 (77) 0.169 
I experienced a side effect from probiotic/placebo sachet 8 (17) 9 (19) 1.000 
I would take a probiotic in the future 41 (92) 38 (76) 0.076 
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formal evaluation. There may have been a greater response rate if this had been included as 
part of the education process. Finally, although the adequate relief endpoint is currently 
considered the gold standard for measuring response in IBS trials (Irvine et al., 2006) and has 
been used as the primary endpoint in series of trials for IBS drugs such as alosetron and 
tegaserod, its multiple limitations have received significant attention in the literature 
(described in Section 2.5.1.1).  
 
One recent analysis of pooled linaclotide data in IBS-C showed that a large proportion of non-
responders to the dichotomous endpoint in these trials in fact reported some improvement in 
important clinical symptoms (63% reported improvement abdominal pain and 52% in 
complete spontaneous bowel movements) (Lacy et al., 2014), which adds to the uncertainty of 
adequate relief as an appropriate endpoint in IBS. Similar contradictions were found in a 
recent study of the low FODMAP diet in IBS patients (n=75) where no difference was evident 
between low FODMAP diet and controls using a dichotomous global symptom endpoint 
whereas global symptoms scored using VAS were significantly lower after low FODMAP diet 
(Piacentino  et al., 2015). This was also so in the current study in that low FODMAP dietary 
advice resulted in significant symptom improvement when measured using both the IBS-SSS 
and the GSRS that did not translate into greater numbers with adequate relief of symptoms. 
Although adequate relief was chosen as the primary endpoint for the current RCT its 
usefulness as a primary endpoint in future research requires clarification (see Chapter 7).  
 
Adequate relief was reported in more patients receiving probiotic than those receiving placebo 
in this RCT. Although this was clearly a statistically significant finding, this RCT was not 
powered to detect differences for the probiotic intervention. Furthermore, there was a 
disparity between the outcome for the ITT population and the PP population, suggesting there 
was a lack of an effect when only those compliant and completed patients in the RCT were 
considered.  Another reason that one should interpret the effect of probiotic on adequate 
relief with caution is that previous studies of VSL#3 have reported lower response rates using 
dichotomous endpoints (33%-46%) (Kim et al., 2003, Kim et al., 2005) than found here. 
Perhaps more importantly, the outcome for adequate relief in this RCT distinctly deviates from 
findings of the IBS-SSS and GSRS instruments. There was a lack of effect of probiotic on IBS-SSS 
scores, incidence of symptoms according to the GSRS, severity of symptoms according to the 
GSRS (except for flatulence severity), and for any stool outcomes. Therefore, taken together, 
although there appears to be an effect of probiotic on adequate relief here, the global 
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symptom response rate appears to be substantially higher than previous studies and is at odds 
with multiple other symptom findings. Therefore the results require replication in a suitably 
powered study before a definitive conclusion can be made about the effect of VSL#3 on global 
or individual IBS symptoms. 
 
In stark contrast to the findings for adequate relief, there were wide-ranging significant effects 
of low FODMAP dietary advice on individual symptoms according to other validated 
instruments including the IBS-SSS. Three studies have so far measured the effect of low 
FODMAP dietary advice using the IBS-SSS, all reporting reduction in score (75-130 points), with 
a difference from baseline (Bohn et al., 2015) and lower scores compared with controls (Harvie 
et al., 2013, Pedersen et al., 2014). The change in IBS-SSS score demonstrated by the low 
FODMAP group in this RCT is consistent with previous data and is almost twice that recently 
reported for a multistrain probiotic preparation (Sisson et al., 2014).  
 
Although the improvement across almost all IBS-SSS subscores in this RCT has not been 
evident in all previous studies, it is interesting that two of the three previous studies also fail to 
demonstrate improvement in pain severity subscore (Bohn et al., 2015, Harvie et al., 2013). 
The reason for this is unclear, especially considering that in the current RCT pain severity 
according to the GSRS fell in the low FODMAP diet group. This discrepancy may be due to 
differences in the range of possible answers between the two instruments i.e. four response 
options for the GSRS on a Likert scale versus many possible responses for the IBS-SSS on a VAS.  
 
The proportion of patients in the low FODMAP group that met the MCID for the IBS-SSS in this 
RCT is impressive (73%). Unfortunately, comparison with other studies is limited as many fail 
to report this endpoint. One probiotic study has recently reported 45% of patients met the 
MCID (Sisson et al., 2014), but there is no previous data available either for patients receiving 
low FODMAP dietary advice or VSL#3 supplementation. Nevertheless, it is likely that this 
outcome is very representative of the proportion of patients responding to low FODMAP 
dietary advice as it is comparable to reported overall response rate from previous trials 
(Staudacher et al., 2014).  
 
Patients in the low FODMAP diet group demonstrated improvement in the severity of 
individual symptoms of bloating, pain and flatulence. The beneficial effect of a low FODMAP 
diet on these symptoms has been shown in previous RCTs using the GSRS (Staudacher et al., 
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2012), VAS (Halmos et al., 2014) and IBS-SSS subscores (Bohn et al., 2015). Indeed, a recent 
systematic review reported that pain and bloating were the most responsive symptoms to low 
FODMAP dietary intervention (Marsh et al., 2015). This is unsurprising as FODMAP challenge 
clearly increases colonic fermentation (Ong et al., 2010, Murray et al., 2014) and colonic 
volume (Major et al., 2015b), and therefore restriction should reduce luminal distension and 
sensory afferent input induced by gas, thereby improving this cluster of symptoms.  
 
Other symptoms that are probably induced by luminal distension from increased gas 
production are belching and borborygmi, which both improved in response to low FODMAP 
advice. These symptoms are less frequently measured in clinical trials, although borborygmi 
was measured in one study and was responsive to low FODMAP dietary advice (Staudacher et 
al., 2012). Both cause significant social distress to some patients and should routinely be 
measured in IBS trials.  
 
The probiotic intervention had an effect on improving flatulence severity compared with 
placebo in this RCT, in the absence effect on other GI symptoms. This supports data from a 
previous study where improved flatulence scores were evident after the same dose of VSL#3 
after 4 weeks but no effect on bloating or pain (Kim et al., 2005). One other VSL#3 
supplementation study in IBS measured flatulence and found no effect of probiotic compared 
with placebo (Kim et al., 2003), although half the daily dose (450 billion bacteria) was used 
compared with the other studies. Overall, it appears likely that VSL#3 has an impact on 
flatulence in IBS, although these results require replication in an adequately powered study.  
 
Diet or product interventions had no impact on symptoms of nausea, heartburn or acid reflux 
in this RCT. Gastroesophageal reflux disease commonly co-exists with IBS (Whitehead et al., 
2007), although the reported incidence and severity of these symptoms at baseline in this RCT 
was relatively low overall. Tiredness was also unchanged in response to low FODMAP dietary 
advice. The cause of tiredness is clearly multifactorial and probably varies from one patient to 
the next. Taking into account that the underlying pathophysiology of upper GI and systemic 
symptoms is distinct from lower GI symptoms in IBS, it is not unexpected that low FODMAP 
dietary advice did not improve this cluster of symptoms. 
 
Various symptoms relating to stool evacuation and stool output were measured in this study, 
including urgency and diarrhoea. There was a beneficial effect of low FODMAP dietary advice 
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on incidence and severity of urgency in this RCT, which supports results from one previous 
study that measured this symptom (Staudacher et al., 2012). Urgency is a pervasive problem 
and can have a major impact on the ability of patients to undertake day-to-day activities, but is 
unfortunately an infrequently evaluated outcome. The improvement in urgency can be 
explained by the well-established effect of FODMAPs on increasing ileal water (Barrett et al., 
2010, Marciani et al., 2010, Murray et al., 2014, Major et al., 2015b). To this effect, it is 
surprising that there was a lack of improvement in diarrhoea and/or loose stool symptoms 
after low FODMAP dietary advice according to the GSRS. Although reduced ileal water is 
associated with improved perception of stool consistency, at least in ileostomy patients 
(Barrett et al., 2010), no RCTs until now have in fact demonstrated a positive impact of a low 
FODMAP diet on reported diarrhoea in IBS patients.   
 
The reduction in incidence and severity of the sensation of incomplete evacuation in patients 
after low FODMAP dietary advice is somewhat surprising and has not been shown previously. 
This may be related to evacuation of a firmer stool, leading to a more defined start and end of 
each stool, or even to reduction in visceral hypersensitivity, which was not measured here. 
Further work is required to characterise the burden of this symptom in non-constipated 
patients with IBS, and to measure treatment response. In contrast, there was no effect of low 
FODMAP dietary advice on improving constipation or hard stools in this RCT. This can be 
explained by the abovementioned effect of FODMAPs on increasing ileal water, and therefore 
FODMAP restriction is unlikely to soften hard stool, and may in fact lead to the reverse. 
However, constipation scores here and in one other RCT that measured it (Staudacher et al., 
2012) did not worsen. Furthermore, stool water does not significantly change in any IBS 
subtype in response to low FODMAP feeding, although this has only been shown in a small 
subgroup analysis (Halmos et al., 2014). The effect of a low FODMAP diet on stool water, 
constipation, and indeed for overall symptoms in patients with IBS-C requires further 
investigation. 
 
Despite no clear effect of low FODMAP dietary advice on diarrhoea or loose stool (measured 
using the GSRS), a reduction in stool consistency according to the BSFS was apparent, although 
frequency and proportion of normal stools did not change. Other studies have reported that 
the low FODMAP diet had an effect on increasing the proportion of normal stools (Staudacher 
et al., 2012), reducing stool frequency compared with baseline (Bohn et al., 2015) and reducing 
stool frequency in IBS-D compared with a control diet (Halmos et al., 2014). The reason for the 
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lack of effect of low FODMAP dietary advice on stool frequency and proportion of normal 
stools in this RCT is unclear. Different outcomes between studies may be due to a number of 
reasons including variation in trial methodologies, nuances in the low FODMAP dietary advice 
provided, differences in IBS subtypes included and/or varying IBS severity inclusion criteria 
cutoffs.  
 
The effect of the interventions on stool output was also measured in this RCT by the 
‘satisfaction with bowel habit’ IBS-SSS subscore.  This question could theoretically encompass 
any combination of factors related to bowel habit, including stool consistency, frequency, 
urgency and completeness of evacuation. Patients in the low FODMAP diet group 
demonstrated an improved subscore compared with those in the sham diet group, in 
agreement with previous studies (Pedersen et al., 2014, Halmos et al., 2014). This IBS-SSS 
subscore outcome contrasts with the lack of effect on GSRS scores for diarrhoea and loose 
stool in this RCT. This might be due to variable attitudes and definitions for the terminology of 
some of these symptoms, which has been shown to be the case for diarrhoea in non IBS 
patients (Majid et al., 2012). Overall, it can be concluded that the low FODMAP diet improves 
overall satisfaction with bowel habits in addition to specific symptoms of urgency, and 
sensation of incomplete evacuation. 
 
The absence of an interaction between the diet and product interventions for each clinical 
outcome in this factorial design study infers that the individual effect of each intervention is 
statistically additive. However, significant effects were not evident between groups when 
intervention combinations were compared for adequate relief and stool output. Examination 
of change in IBS-SSS score amongst intervention combinations, in fact, confirmed that low 
FODMAP dietary advice appeared to be driving most of the differences between intervention 
combination groups. A parallel trial design planned a priori to investigate the clinical effects of 
a combination low FODMAP diet-probiotic intervention is required to confirm whether the two 
can indeed be considered additive for clinical outcomes in IBS.  
 
4.7.2 HRQOL 
HRQOL determines health seeking behaviour in patients with IBS (Williams et al., 2006), which 
emphasises the importance of its measurement and identification of treatments that improve 
HRQOL in this patient group. It is known patients with IBS report poor HRQOL, and even score 
lower on some HRQOL measures than patients with other chronic disease e.g. end stage renal 
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disease (Gralnek et al., 2000). Furthermore, measures of HRQOL, rather than GI symptoms 
alone, may better describe the overall impact of treatment and the shift in illness experience 
in patients with IBS. This is because HRQOL in IBS is primarily predicted by extraintestinal 
symptoms such as fatigue and feelings of nervousness, tension and hopelessness rather than 
physical symptoms (Spiegel et al., 2004). Also, theoretically, the impact of a treatment could 
be considered a net result of its effect on the condition in question and any disadvantages 
associated with treatment (e.g. cost, side effects). Accordingly, although low FODMAP dietary 
advice improved IBS symptoms, the burdens associated with following the diet (as 
demonstrated by the acceptability data), could influence its ability to positively influence 
HRQOL. 
 
According to the SF-36 outcomes in this RCT, low FODMAP advice led to significant 
improvement in some components of generic HRQOL. Specifically, there was an improvement 
in ‘role limitations due to physical health’ and ‘energy/fatigue’. These outcomes suggest low 
FODMAP dietary advice led to improvement in the ability to complete work and daily activities 
in the context of physical health and reduced feelings of fatigue, tiredness and lack of energy. 
The general health scale score was higher for the low FODMAP group compared with sham but 
this difference did not reach statistical significance, although it was significant on analysis of 
the PP population.  
 
Disease-specific measures of quality of life are more responsive to treatment effects than 
generic measures (Guyatt et al., 1993) and are recommended for evaluating changes in HRQOL 
in IBS (Bijkerk et al., 2003). This RCT demonstrates that the low FODMAP diet induces 
significant measurable improvements in IBS-specific HRQOL. These results are in agreement 
with the improved IBS-SSS subscore for patients in the low FODMAP group relating to quality 
of life. Indeed, there was a 2.81 higher odds of achieving the MCID for the IBS-QOL in the low 
FODMAP diet group compared with the sham diet group, and there were significantly higher 
scores for three specific subscales. Two of these subscales were associated with impact of IBS 
on relationships with other individuals (‘social reaction’, ‘relationships’). The third subscale, 
‘body image’, included questions relating to ‘feeling fat’ and being limited with clothing choice. 
Increased score for this subscale is likely due to parallel improvements in physical GI symptoms 
e.g. bloating. Food avoidance was the subscale that was scored the lowest across all groups at 
baseline, suggesting that patients associate dietary factors with their condition. There was no 
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effect of dietary intervention on the food avoidance subscale, which is unsurprising as 
participation in the RCT required restriction of the types of foods to be consumed.  
 
The findings for IBS-specific HRQOL in this study replicate data from other low FODMAP 
studies.  For example, a previous unblinded RCT has shown a similar absolute improvement in 
mean total IBS-QOL score from baseline (approximately 15 points) in patients after 3 months 
(Harvie et al., 2013), and improvements in IBS-QOL scores are evident in patients in other less 
robustly designed studies (Mazzawi et al., 2013, Ostgaard et al., 2012, Pedersen et al., 2014). 
Although many large intervention trials in IBS fail to measure HRQOL which prevents 
comprehensive comparisons of the effect of low FODMAP dietary advice with other 
approaches, similar absolute improvement in IBS-QOL score have been shown for 
antispasmodic medications  (Clave et al., 2011, Hou et al., 2014) and cognitive behavioural 
therapy (Labus et al., 2013). The HRQOL results from this RCT suggest low FODMAP dietary 
advice can be considered a therapy that, although complex and requiring considerable effort 
on behalf of the patient, improves HRQOL to at least an equivalent degree to other effective 
therapeutic approaches.  
 
This is the first study to assess the effect of VSL#3 supplementation on HRQOL using robust 
validated HRQOL instruments. There was no change in any components of either the generic 
or IBS-specific HRQOL instruments in patients receiving probiotic compared with those 
receiving placebo. One study has reported improvement in some aspects of HRQOL in 
response to VSL#3 supplementation but this was using an unvalidated questionnaire (Michail 
and Kenche, 2011). The lack of an effect of VSL#3 on HRQOL is unsurprising considering there 
was no impact on IBS-SSS scores, most GSRS scores and stool outcomes. A trial adequately 
powered for symptom response is required to confirm whether there is an effect of VSL#3 
supplementation on HRQOL in IBS patients.  
 
4.7.3 Acceptability 
The acceptability data in this study are useful for two reasons. Firstly, they present information 
about the overall benefit of the interventions from a patient perspective. This type of data is 
infrequently measured in nutritional intervention studies (Jackson et al., 2005) but is 
imperative for planning and development of clinical services. Furthermore, acceptability 
influences the likelihood of adherence (Berkow et al., 2010), and therefore is an important 
endpoint for any trials measuring the effect of dietary intervention on disease outcomes. 




Overall, a large proportion of patients in the low FODMAP diet group reported the diet was 
difficult to follow and that many changes were required in order to implement the advice 
provided. Many patients reported difficulties with practical aspects of the diet, such as time 
spent preparing meals, eating out, and the cost associated with alternative products. These 
issues are commonly identified issues in clinical practice, and some have been reported 
previously in IBD patients following low FODMAP dietary advice (Gearry et al., 2009). With 
regard to the probiotic intervention, acceptability responses were generally positive, with 
most patients reporting that the probiotic was easy to take and that they were willing to take a 
probiotic in the future.  
 
In the unblinded clinical situation difficulties with practical dietary issues (e.g. cooking while on 
the low FODMAP diet, perceived probiotic side effects) are more easily addressed as time can 
be spent providing practical solutions for difficulties or barriers specific to each patient. 
Qualitative studies are required to delve into these issues further in order to improve our 
understanding of the burdens associated with dietary change, particularly in relation to the 
low FODMAP diet, and to determine whether strategies currently aimed to help minimise 
patient burden actually do so.  
 
The second benefit of acceptability data in this RCT is that it helps establish the suitability of 
the placebo interventions. For example, it is reassuring that responses were equivalent 
between groups for most product acceptability questions, implying that those that did not 
receive active intervention had a comparable overall experience to those that received the 
active product. With regard to the diet acceptability questions, there is a suggestion that 
aspects of the sham diet could be fine-tuned. There is inherent difficulty in developing a 
dietary intervention that imposes a significant practical burden on patients whilst causing 
minimal change in nutrient intake, however these results highlight potential areas of the sham 
diet that could be addressed in the future, for example, restriction of additional foods that 
would impact on palatability and time spent on food preparation.  
 
4.7.4 Strengths and limitations 
This is the first placebo-controlled RCT investigating the impact of low FODMAP dietary advice 
on a wide range of IBS symptoms and stool output using a battery of validated symptom 
measurement instruments. It is likely that application of multiple assessment instruments 
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better captures the change in symptom experience of patients and also counters potential 
differences in patient definitions of key symptoms (e.g. diarrhoea). It is also the largest ever 
RCT investigating the clinical impact of the low FODMAP diet, and the largest to investigate the 
effect of low FODMAP dietary advice and VSL#3 on generic and disease-specific HRQOL and 
patient acceptability outcomes. The demographic characteristics of patients recruited to this 
RCT were representative of the wider population, being predominantly female, mostly IBS-D 
and of relatively young age (Lovell and Ford, 2012) and therefore the outcomes presented 
here are considered generalisable to the wider IBS population. 
 
Until now, the only other placebo-controlled blinded RCT investigating the effect of the low 
FODMAP diet on clinical outcomes provided all food and fluid to patients (Halmos et al., 2015)  
which arguably hold less external validity than the current RCT. Furthermore, RCTs that have 
provided patients with low FODMAP dietary advice have either been unblinded (Staudacher et 
al., 2012, Harvie et al., 2013, Pedersen et al., 2014) or have not been placebo-controlled (Bohn 
et al., 2015). Therefore, the outcomes presented from this blinded placebo-controlled RCT 
could be considered among the most robust to date. 
 
Compliance to the interventions in this RCT was very good according to subjective and 
objective measures of compliance. This not only increases confidence that outcomes of the 
RCT are due to the interventions rather than external factors, but also confirms that the 
interventions can be undertaken by patients. Furthermore, outcomes for the ITT and PP 
populations were generally concordant, which further strengthens confidence in the results 
(Thabane et al., 2013), and suggests the methodology broadly reproduced aspects of clinical 
practice. Of the randomised patients, withdrawals totaled 9% of the total recruited sample, 
which is under the recommended proposed  cut off of 20% (Irvine et al., 2006). 
 
This is the first RCT to measure the success of blinding patients to a low FODMAP dietary 
advice intervention. Although 70% of patients correctly guessed their allocation, this was still 
fewer than that reported previously in a crossover low FODMAP feeding study (83%) (Halmos 
et al., 2014). It is acknowledged that successful blinding is rarely achieved in dietary 
intervention studies, and therefore whether a better outcome than this is possible is 
uncertain. The product was allocated in a double blind fashion in this RCT, and most patients 
were unable to guess their allocation (72%), which is better than that reported in another 
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probiotic RCT (Whorwell et al., 2006), and also confirms the effectiveness of the placebo as a 
placebo product. 
 
There are also strengths of this RCT that relate to HRQOL and acceptability. This was the first 
blinded RCT investigating HRQOL in response to low FODMAP dietary advice through the 
application of commonly used validated HRQOL instruments. This allowed for comparison with 
previous low FODMAP studies and other non-dietary IBS interventions. Baseline SF-36 and IBS-
QOL scores in this RCT were similar to that previously reported in large studies of primary and 
secondary care patients with IBS (Gralnek et al., 2000, Sisson et al., 2014, Clave et al., 2011) 
suggesting the impact of low FODMAP dietary advice on HRQOL are generalisable to the wider 
population with IBS.  
 
There were a number of limitations of the RCT specific to the clinical outcomes presented in 
this chapter. Firstly, relating to the blinding of patients, the probiotic intervention was 
allocated in a double-blind fashion however it was impossible to double blind the dietary 
advice. Therefore, dietary advice was provided in a single blind fashion, with the same 
conviction and level of detail provided to each group. However, it cannot be guaranteed that 
there were subtle unconscious differences in the way the advice was presented, which may 
have led to experimenter bias and contributed to patients becoming suspicious of their 
allocation. Furthermore, patients, where required, were asked to avoid online searches for 
dietary treatments for their symptoms to promote continued naivety to the low FODMAP diet. 
Whether patients complied with this advice is unknown.  
 
Blinding is essentially an attempt to spread expectancy evenly across groups (Colagiuri, 2010). 
Any unblinding in this RCT may have also occurred in patients who received active treatment 
and experienced symptom improvement. This is acknowledged as a problem inherent in any 
trial with physical symptom endpoints and is difficult to address. The application of two 
blinded interventions in this RCT may have mitigated expectation bias (as if one intervention 
becomes unblinded the patient is still blinded to the other), however this is impossible to 
verify. Overall, it is accepted that methodological issues such as blinding and placebo are a 
particular challenge in dietary intervention studies and may never be fully remedied. 
 
Four other limitations relate to methodological aspects of the RCT. Firstly, there are two issues 
related to recruitment. Due to time constraints sufficient patients (n=1572) could not be 
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recruited to power the RCT for detecting differences for adequate relief between probiotic and 
placebo groups. Furthermore, recruitment across two sites could be considered a disadvantage 
in this RCT. This relates to the provision of the dietary advice itself, which ideally should be 
delivered to all recruited patients by the same dietitian. There may have been some variability 
in researcher bias in this RCT due to two dietitians conducting the study visits and providing 
the dietary advice. However this was likely to be minimal as only eight patients were recruited 
at the second site, and the second dietitian was trained and observed to optimise consistency 
in the way trial visits were conducted to help limit this bias as much as possible. 
 
Secondly, patients recruited for this RCT were a homogenous group of secondary care patients 
and within a specified age range. Patients with IBS-C and with major comorbidity were 
excluded. Symptoms at baseline were of moderate severity according to the IBS-SSS, of low to 
moderate severity according to the GSRS, and HRQOL scores were comparable to IBS patients 
from primary and secondary care. Therefore, although these symptom, HRQOL and 
acceptability outcomes are likely applicable to most IBS patients, whether they are 
generalisable to patients in primary care,  IBS-C patients, those with significant comorbidity, or 
those experiencing symptoms at the mild or severe extremes of symptom severity cannot be 
confirmed. 
 
Thirdly, the dietary advice provided in this RCT was not completely representative of the style 
of delivery in the clinical situation. Specifically, in order to prevent unblinding, advice to the 
low FODMAP diet group did not include an explanation of the physiological basis of the low 
FODMAP diet. This may have underestimated the true effect of the diet that might be possible 
in real life practice. Alternatively, in clinical practice patients do not usually undertake as 
intensive evaluation, are not telephoned weekly and do not provide stool samples and 
therefore the effect of merely participating in a study may have overestimated the true effect 
of the diet compared with real life practice. 
 
Finally, there were limitations related to the measurement of the clinical endpoints. There is 
an inherent difficulty in measuring GI symptoms in IBS due to the lack of available biomarkers 
for symptom severity. Limitations of these instruments have been discussed in detail 
elsewhere (Section 2.5 and Section 4.7.1). Until more objective measures of IBS symptoms are 
accepted, large blinded RCTs that use robust validated methods of measuring patient reported 
outcomes are essential. The problem of reactivity, where participation in research leads to 
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behaviour change (i.e. the Hawthorne effect), is also relevant when considering the 
measurement of clinical endpoints. For example, involvement in the trial could lead to 
increased attention to other lifestyle factors which might impact on experience or perception 
of IBS symptoms and clinical outcomes (Kramer and Shapiro, 1984). However, this effect 
should be even across groups in a large enough trial, and therefore should not have influenced 
outcomes of this RCT. 
 
4.7.5 Significance of results 
Clinical benefit of low FODMAP dietary advice on IBS symptoms over and above placebo has 
never been investigated. This placebo-controlled RCT provides evidence that low FODMAP 
dietary advice leads to improvement in overall and specific GI symptoms in patients with non-
constipation predominant IBS. Specifically, 73% of patients report a global clinical response 
based on the IBS-SSS, and 57% report response based on the adequate relief question, 
although the potential limitations of the latter endpoint are acknowledged. At a conservative 
estimate, this corresponds to a 2-3 greater odds of symptomatic response to low FODMAP 
dietary advice compared with placebo, which is at least equivalent to some pharmaceutical 
treatments (e.g. some antispasmodics, antidepressants) (Enck et al., 2010). With regards to 
specific symptoms, it is likely that patients with bloating, borborygmi, flatulence and 
dissatisfaction with bowel habit (specifically urgency and sensation of incomplete evacuation) 
will benefit from this intervention. Although the diet may be onerous with regards to cost, 
palatability and the extra time required, clinical response is paralleled with improvements in a 
number of HRQOL outcomes. This confirms that reductions in physical symptoms as a result of 
the low FODMAP diet translate into improvement at a broader biopsychosocial level.  In 
contrast, the effect of VSL#3 on symptoms and HRQOL in IBS is equivocal. There was clear 
disagreement between global measures of response (adequate relief vs IBS-SSS) for patients 
receiving probiotic in this RCT and a wide-ranging lack of response for other clinical variables 
measured. Although any potential benefit of this probiotic can be considered additive when 
used as a parallel treatment with low FODMAP dietary advice, its benefit as a sole therapy is 








This RCT has demonstrated that dietitian-led low FODMAP dietary advice provides a 
therapeutic effect for a wide range of IBS symptoms in a majority of patients compared with 
placebo, which is known to be a powerful phenomenon in IBS. Furthermore, symptom 
improvement is associated with increased HRQOL scores, confirming there is a beneficial 
impact on patient-perceived health despite the burdensome nature of the diet.  This is a key 
finding considering that treatment of IBS is often suboptimal and less than 40% of patients in 
report satisfaction with treatment (Drossman et al., 2009). Whether the improved HRQOL in 
response to low FODMAP dietary advice translates into reduced healthcare utilisation or wider 
economic implications (e.g. reduced absenteeism, reduced requirement for medication) is 
unknown and requires evaluation.  
 
Reduced ileal water and colonic fermentation are the likely mechanisms by which the low 
FODMAP diet improves GI symptoms. Further work is required to broaden our understanding 
of the effects of the diet on stool consistency and other aspects of stool output, and indeed its 
overall effectiveness in IBS-C. In addition to the effects on clinical parameters, the low 
FODMAP diet may lead to consequences such as altered nutrient intake, changes in the GI 
microbiota and other aspects of the colonic environment. These will be addressed in Chapters 
5 and 6. 












5 The effect of low FODMAP dietary advice on nutrient and FODMAP 
intake in irritable bowel syndrome 




Dietary management of IBS with the low FODMAP diet may be effective in a large proportion 
of patients with IBS. In Chapter 4 it was demonstrated that 57% of patients reported adequate 
relief of GI symptoms and 73% of patients achieved the MCID for IBS-SSS, however one 
potential shortcoming of many exclusion diets is the risk of nutritional inadequacy, and this is 
especially so if the excluded foods are nutrient-rich. A gluten free diet, for example, leads to a 
reduction in carbohydrate, fibre and a number of B vitamins in females, and a reduction in iron 
intake in males and females compared with the pre-diagnosis diet (Shepherd and Gibson, 
2013). Likewise, lower micronutrient intake (calcium, iron, folate) has been reported in those 
with atopic dermatitis following an exclusion diet compared with controls (Kim et al., 2013), 
and patients with multiple food allergies have a lower intake of protein and a number of 
micronutrients (including B vitamins) when compared with patients requiring only single food 
exclusion (Kim et al., 2013). Although research in other disease groups is helpful in estimating 
the potential risk associated with an exclusion diet in IBS, nutrient intake data may be 
confounded by the effect of the disorder itself, and of course the risk is specific to the features 
of the diet in question. 
 
The effect of short term exclusion of high FODMAP foods on nutrient intake has been 
investigated in two dietary advice RCTs (Bohn et al., 2015, Staudacher et al., 2012). Only one of 
these included an evaluation of micronutrient intake (iron, calcium). In a small sample of 
patients with IBS, there was a lower calcium intake in those following low FODMAP advice 
compared with controls consuming their habitual diet (603 mg vs 730 mg, p=0.016)  
(Staudacher et al., 2012). This is a preliminary finding and more extensive evaluation is 
required in a larger cohort. In addition, this finding was a comparison between the low 
FODMAP diet and usual diet and therefore it is unclear whether this was the result of any 
dietary exclusion or specific to the low FODMAP diet. Furthermore, whether micronutrient 
intake of patients with IBS on a low FODMAP diet are comparable with the general UK 
population and meet UK dietary reference values (DRVs) has not been reported. 




5.1.1 Aim of this chapter 
The aim of this chapter is to report the results of a RCT to investigate the effect of low 
FODMAP dietary advice on nutrient and FODMAP intake in patients with IBS. The chapter will 
be divided into three parts: 
 
1. Inter-rater agreement between diet record coders (Section 5.2.1) 
2. Habitual nutrient intake of patients with IBS (Section 5.2.2) 
3. Compliance with the dietary interventions (Section 5.2.3) 
4. Nutrient intake results for the low FODMAP group and sham diet group from the RCT of 
low FODMAP dietary advice (Section 5.2.4) 
5. Bodyweight (Section 5.2.5) 
 
5.2 Results  
Diet records were coded and entered into dietary composition software by HS and two 
additional dietitian coders. A total of 199 7-day diet records were entered by three coders. HS 
entered 20 diet records and the remainder were coded by the two other coders. Inter-rater 
agreement was evaluated as described in Section 2.7.5. 
 
5.2.1 Inter-rater agreement 
Inter-rater agreement was evaluated for energy and NSP for the first 21 diet records available 
(7 baseline, 7 sham diet, 7 low FODMAP diet), and therefore these were coded in triplicate.  
Bland-Altman plots were examined (see Figure 5.1 for energy and Appendix 9.21 for NSP). 
  
Most differences between coders were within the limits of agreement of mean difference ± 
1.96 SD. The mean differences for daily energy and NSP intake are presented in Table 5.1 and 
were <50 kcal/d for energy and <1 g/d for NSP. Intraclass correlation coefficients were greater 
than 0.9 indicating excellent reliability between coders. A total of nine outliers (where mean 
difference > 1.96 SD) were identified and it was noted that these outliers were due to various 
discrepancies which were categorised. These were attributed to: patient error (unclear portion 
size or food description), coder error (portion size error, omission, food code error), database 
error. The database error was due to duplication of an existing database food with a newly 
created identical food that was different in NSP content. These errors were corrected prior to 
final nutrient intake analysis presented in the following sections. 







Figure 5.1 Bland Altman plots for energy intake from 21 diet records (7 baseline, 7 sham 
diet, 7 low FODMAP diet) to assess inter-agreement between three diet record coders. 
Records were from patients with IBS participating in a 2x2 factorial design RCT of the low 
FODMAP dietary advice and probiotic supplementation 
Mean -1.96 SD 
Mean +1.96 SD 
Mean 
Mean 
Mean -1.96 SD 
Mean +1.96 SD 
Mean 
Mean -1.96 SD 
Mean +1.96 SD 
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Table 5.1 Mean difference and intraclass correlation coefficients between three coders for 
energy and NSP for 21 diet records (7 baseline, 7 sham diet, 7 low FODMAP diet) to assess 
inter-agreement. Diet records were from patients with IBS participating in a 2x2 factorial 
design RCT of low FODMAP dietary advice and probiotic supplementation 
Coders 











HS and Coder 1 -33 (-68, 2) 0.990 -0.2 (-0.9, 0.4) 0.982 
Coder 1 & Coder 2 -8 (-38,22) 0.994 -0.3 (-1.1, 0.4) 0.980 
HS & Coder 2 -41 (-86, 4) 0.984 -0.1 (-0.8, 0.6) 0.978 
Values are mean difference and 95% confidence intervals. NSP, non starch polysaccharides 
 
5.2.2 Habitual nutrient intake of patients with IBS  
Habitual diet of all patients in the RCT was assessed by comparing nutrient intake at baseline 
with gender-specific nutrient DRVs (Department of Health, 2004) and national population 
intakes in age and gender-matched individuals in the UK (Public Health England and Food 
Standards Agency, 2014) (Appendix 9.22). Nutrient intake at baseline on average met 
requirements for most nutrients, and was similar to that of national population intakes. Mean 
daily intake of calcium for males (909 mg/d) and females (790 mg/d) was higher than the 
reference nutrient intake (RNI, 700 mg/d). In males (n=34), intake of iron (12.4 mg/d) was 
higher than the RNI (8.7 mg/d), whereas in 19-49 year old females (n=70), iron intake (11.0 
mg/d) was lower than the RNI (14.8 mg/d) and in females intake of potassium (2759 mg/d) 
was lower than the RNI (3500 mg/d).  
 
5.2.3 Compliance with the dietary interventions 
Self-reported compliance to the dietary interventions measured at weekly telephone visits was 
very good. All patients were classified as compliant to the dietary advice, where 
noncompliance was defined as following the diet <50% of the time on at least 2 of the 4 
assessments. Most patients reported following the diet at the highest rating of compliance 
(‘followed the diet >75% of the time’) at each week. There was no difference in compliance 
between groups (Table 5.2).  




Table 5.2 Proportion of patients with IBS who completed the 2x2 factorial design RCT of low 
FODMAP dietary advice and probiotic supplementation and reported the highest rating of 
compliance ('I followed the diet more than 75% of the time') (n=95) 
 Sham diet  
n=48 





Week 1  n (%) 46 (96) 44 (94) 0.884 
Week 2  n (%) 45 (93) 43 (92) 0.784 
Week 3  n (%) 43 (90) 43 (92) 0.668 




Total and individual FODMAP intake from diet records was evaluated (Table 5.3). In the low 
FODMAP diet group, there was a lower intake of total and individual FODMAPs at follow up 
compared with baseline (p<0.05), except for total and excess fructose (p>0.05). FODMAP 
intake was compared between diet groups at follow up after adjusting for baseline differences. 
There was a significantly lower intake of total FODMAPs in the low FODMAP diet group 
compared with the sham diet group (9.9 g/d vs 17.4 g/d, p<0.001) and lower intake of 
fructans, sorbitol, lactose (all p<0.001) and mannitol (p=0.041), but no difference between 
groups for GOS (0.8 g/d vs 0.9 g/d, p=0.080) or excess fructose (1.9 g/d vs 1.4 g/d, p=0.821). 
 
5.2.4 Nutrient intake results from the RCT of low FODMAP dietary advice 
Energy, macronutrient, NSP and micronutrient intake from food and fluid were evaluated at 
baseline and follow up in the RCT. Fifteen micronutrients considered potentially at risk on 
restriction of FODMAPs were included in the analysis (potassium, calcium, magnesium, 
phosphorous, iron, zinc, beta-carotene, B vitamins and vitamin C).  
 
A total of 27 (26%) patients reported intake of a vitamin or mineral supplement (31% sham 
diet, 21% low FODMAP diet) at baseline. Multivitamin and mineral supplements were the most 
commonly reported (13% of all patients), followed by vitamin C (7%), iron (6%) and calcium 
(3%). Two patients were strict lacto-ovo vegetarians (1 sham, 1 low FODMAP). Results are 
presented for the ITT population for nutrient contribution from food and fluid only, the most 
conservative estimate of dietary intake of the cohort. 
  
 
Table 5.3 Total and individual FODMAP intake for the intention to treat population of patients with IBS participating in a 2x2 factorial design RCT of low 















Baseline Follow up p
#
 Baseline Follow up p
#
 Sham diet low FODMAP diet 
           
Total FODMAPs (g/d)* 17.6 (8.8) 17.4 (10.5) 0.527 18.3 (8.7)  9.9 (6.4) <0.001 <0.001 -0.2 (7.8) -8.4 (9.1) <0.001 
     Fructans (g/d)
 
5.0 (2.6) 5.0 (2.9) 0.403 5.0 (2.0) 2.5 (1.9) <0.001 <0.001 -0.1 (2.9) -2.5 (2.8) <0.001 
     GOS (g/d) 0.9 (0.5) 0.9 (0.5) 0.730 0.8 (0.5) 0.8 (0.6) 0.018 0.080 -0.01 (0.6) -0.1 (0.6) 0.490 
     Lactose (g/d) 9.0 (7.8) 8.9 (9.1) 0.843 9.4 (7.7) 4.3 (4.3) <0.001 <0.001 -0.1 (6.2) -5.2 (7.7) <0.001 
     Total fructose (g/d) 14.3 (7.7) 15.5 (8.7) 0.314 13.4 (6.3) 12.7 (5.9) 0.347 0.112 1.3 (6.2) -0.8 (7.0) 0.121 
     Excess fructose (g/d)
 
1.4 (1.2) 1.4 (1.4)  0.286 2.0 (2.0) 1.9 (2.8) 0.134 0.821 -0.1 (0.4) -0.2 (7.8) 0.614 
     Sorbitol (g/d) 1.0 (1.0) 1.0 (1.0) 0.688 0.7 (0.8) 0.3 (0.5) <0.001 <0.001 0.04 (1.1) -0.4 (0.8) 0.031 
     Mannitol (g/d) 0.4 (0.3) 0.3 (0.3) 0.051 0.4 (0.4) 0.1 (0.2) <0.001 0.041 -0.06 (0.4) -0.2 (0.4) 0.025 
Values are mean (SD). Data were log transformed  
*Total FODMAPs are calculated as the sum of individual carbohydrates including excess fructose (not total fructose) 
#
 Dependent samples t-test baseline vs follow up within groups 
##
ANCOVA follow between groups adjusted for baseline 
###
Independent samples t-test 




5.2.4.1 Nutrient intake in the low FODMAP group  
The impact of low FODMAP dietary advice on nutrient intake was assessed by comparing 
nutrient intake at follow up in the low FODMAP diet group with baseline (habitual diet) (Table 
5.4). There were no differences in energy, protein, fat or NSP intake between baseline and 
follow up in the low FODMAP group. Daily NSP intake for patients in the low FODMAP diet 






In the low FODMAP diet group, there was a lower intake of total carbohydrate at follow up 
compared with baseline (198 g/d vs 213 g/d, p=0.020) and for starch (110 g/d vs 122 g/d, 
p=0.004). There was no difference in intake of micronutrients at follow up except for iron 
which was lower compared with baseline (10.3 mg vs 11.3 mg, p=0.009), and for beta-carotene 
and vitamin B6 which were higher compared with baseline. 
 
Figure 5.2 Mean daily NSP intake for individual patients at baseline and follow up in the 
low FODMAP group (n=51) from the 2x2 factorial design RCT of low FODMAP dietary 
advice and probiotic supplementation No significant differences in NSP intakes were 
detected (13.0 g/d vs 12.8 g/d; p=0.578) 
  
Table 5.4 Total energy and nutrient intake from food and fluid for the intention to treat population of patients with IBS participating in a 2x2 factorial 
design RCT of low FODMAP dietary advice and probiotic supplementation (n=104) 
   
Sham diet 
n=53 










Baseline Follow up p
#
 Baseline Follow up p
#
 Sham diet low FODMAP diet 
Energy, macronutrients, NSP 
Energy (kcal/d) 2042 (504) 1891 (599) 0.013 1957 (525) 1861 (465) 0.079 0.517 -139 (395) -78 (312) 0.386 
Protein (g/d) 80 (20) 75 (21) 0.041 77 (25) 78 (22) 0.772 0.100 -5 (16) 1 (14) 0.306 
Fat (g/d) 85 (24) 80 (28) 0.114 81 (24) 78 (25) 0.298 0.787 -5 (21) -3 (19) 0.652 
Carbohydrate (g/d)
 
229 (62) 206 (62) <0.001 213 (58) 198 (58) 0.020 0.678 -23 (45) -15 (45) 0.380 
 Starch (g/d) 128 (40) 115 (39) 0.001 122 (35) 110 (39) 0.004 0.916 -13 (28) -12 (30) 0.850 
 Sugars (g/d) 90 (33) 84 (33) 0.134 82 (29) 75 (30) 0.058 0.457 -6 (27) -6 (23) 0.893 
 NSP (g/d) 14.5 (5.9) 13.3 (5.1) 0.038 13.0 (4.2) 12.8 (4.8) 0.771 0.578 -1.2 (4.1) -0.2 (4.6) 0.223 
Micronutrients 
Potassium (mg/d) 3026 (945) 2851 (873) 0.059 2915 (871) 3006 (745) 0.231 0.029 -175 (661) 92 (539) 0.026 
Calcium (mg/d)
 
860 (347) 803 (292) 0.159 797 (275) 773 (316) 0.346 0.769 -57 (288) -23 (176) 0.480 
Magnesium (mg/d) 290 (110) 267 (89) 0.002 275 (91) 272 (78) 0.707 0.045 -32 (71) -3 (53) 0.019 
Phosphorous (mg/d) 1311  (368) 1206 (342) 0.005 1240 (385) 1227 (343) 0.707 0.112 -106 (262) -13 (241) 0.063 
Iron (mg/d)
 
11.9 (3.7) 11.4 (4.0) 0.208 11.3 (3.1) 10.3 (2.5) 0.009 0.157 -0.5 (2.8) -1.0 (2.6)   0.338 
Zinc (mg/d) 9.0 (2.8) 8.1 (2.6) 0.004 8.5 (2.7) 8.6 (2.7) 0.779 0.072 -0.9 (2.1) 0.1 (2.9) 0.044 
Beta-carotene (µg/d) 3800 (3081) 3878 (2655) 0.834 3777 (2795) 5027 (3632) 0.025 0.044 78 (2701) 1250 (3848) 0.074 
Values are mean (SD). 
#
 Dependent samples t-test baseline vs follow up within groups 
##
ANCOVA follow between groups adjusted for baseline 
###
Independent samples t-
test change between groups
  
 
Table 5.4 (cont) Total energy and nutrient intake from food and fluid for the intention to treat population of patients with IBS participating in a 2x2 
















Baseline Follow up P
#
 Baseline Follow up P
#
 Sham diet  low FODMAP diet 
Thiamin (mg/d) 1.5 (0.5) 1.4 (0.4) 0.027 1.4 (0.4) 1.3 (0.4) 0.460 0.604 -0.1 (0.3) 0 (0.4) 0.351 
Riboflavin (mg/d) 1.6 (0.7) 1.5 (0.6) 0.100 1.5 (0.6) 1.5 (0.5) 0.194 0.879 -0.1 (0.4) -0.1 (0.5) 0.906 
Niacin (mg/d) 20.6 (7.6) 19.7 (7.5) 0.283 21.0 (8.5) 21.7 (8.7) 0.383 0.120 -0.9 (5.9) 0.6 (4.8) 0.167 
Vitamin B6 (mg/d) 2.0 (0.7) 1.9 (0.6) 0.272 1.9 (0.7) 2.1 (0.6) 0.036 0.016 -0.1 (0.5) 0.1 (0.5) 0.023 
Vitamin B12  (µg/d) 5.2 (2.5) 4.7 (2.3) 0.115 5.3 (3.8) 6.1 (2.6) 0.064 0.001 -0.5 (2.4) 0.9 (3.2) 0.018 
Folate (µg/d) 226 (90) 230 (92) 0.640 234 (93) 235 (83) 0.920 0.980 3 (56) 1 (69) 0.840 
Pantothenic acid (mg/d)
 
4.9 (1.8) 4.5 (1.5) 0.043 4.7 (1.7) 4.8 (1.9) 0.718 0.091 -0.4 (1.5) 0.1 (1.3) 0.073 
Biotin (µg/d)
 
35 (17) 31 (18) 0.014 35 (18) 35 (17) 0.820 0.079 -3.6 (10.4) 0.5 (15) 0.112 
Vitamin C (mg/d)
 
93 (51) 91 (48) 0.758 95 (55) 109 (58) 0.053 0.039 -2 (37) 14 (52) 0.073 
Values are mean (SD). 
#
 Dependent samples t-test baseline vs follow up within groups, 
##
ANCOVA follow between groups adjusted for baseline 
###
Independent samples t-
test change between groups 
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In order to evaluate the nutritional adequacy of the low FODMAP diet, intake of 
macronutrients and micronutrients in the low FODMAP group at follow up were compared 
with gender-specific DRVs and intake in age and gender-matched individuals in the UK 
(Appendix 9.22). Broadly, mean nutrient intakes met or exceeded the DRVs for most nutrients 
and intakes were broadly similar to that of UK individuals. For females (n=35), mean daily 
intake of potassium (2876 mg/d) was lower than the RNI (3500 mg/d) and in 19-49 year olds 
iron intake (10.7 mg/d) was lower than the RNI  (14.8 mg/d).   
 
Nutrient intake of patients in the low FODMAP diet group was also examined by comparing the 
proportion of patients meeting the NSP individual minimum intake (the NSP equivalent for 
RNI, which will now be referred to as RNI) and RNI for micronutrients (for which an RNI is 
available) at follow up compared with baseline (Figure 5.3). The proportion of patients 
meeting the RNI was significantly lower at follow up compared with baseline for calcium (49% 
vs 65%, p=0.039) and for iron, although the latter did not reach statistical significance (43% vs 
49%, p=0.375). There were no significant differences in gender-specific comparisons with the 
DRVs (Appendix 9.23).  
 
 
Figure 5.3 Proportion of patients meeting RNI at baseline and at follow up in the low 
FODMAP diet group (n=51) in a 2x2 factorial design RCT of low FODMAP dietary advice and 
probiotic supplementation * p<0.05 McNemar’s test  
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5.2.4.2 Nutrient intake in the low FODMAP diet group compared with the sham diet group 
Nutrient intake was compared between the low FODMAP group and the sham diet group at 
follow up (Table 5.4). There were no significant differences between the two diet groups for 
energy or macronutrient intake after adjusting for baseline differences. Neither were there any 
differences in micronutrient intake between the two diet groups at follow up except for a 
higher intake of potassium, magnesium, beta-carotene, some B vitamins and vitamin C in the 
low FODMAP diet group.  
 
5.2.4.3 Nutrient and FODMAP intake in the sham diet group 
The impact of sham dietary advice on nutrient intake was assessed by comparing intake at 
follow up with baseline (habitual diet) in the sham diet group (Table 5.4). There was a lower 
intake of energy at follow up compared with baseline (1891 kcal/d vs 2042 kcal/d, p=0.013), as 
well as for carbohydrate (206 g/d vs 229 g/d, p<0.001), starch (115 g/d vs 128 g/d, p=0.001), 
protein (75 g/d vs 80 g/d, p=0.041) and NSP (13.3 g vs 14.5 g/d p=0.038). There were also 
lower intakes of magnesium, phosphorous, zinc, pantothenic acid and biotin. Proportions of 
patients meeting the RNI for NSP was not different at follow up compared with baseline (66% 
vs 60%, p=0.549). Total and individual FODMAP intake did not change (Table 5.3).  
 
5.2.5 Bodyweight 
In the sham diet group, bodyweight at follow up was not significantly different to baseline 
(72.5 kg vs 72.7 kg, p=0.259). In the low FODMAP diet group, bodyweight was lower at follow 
up compared with baseline (68.7 kg vs 69.1 kg, p=0.026), however there was no difference in 
bodyweight change between the sham diet and low FODMAP diet groups (-0.2 kg vs -0.4 kg, p 
=0.480). 
 
5.3 Discussion and Conclusion 
The aim of this chapter was to investigate the effect of low FODMAP dietary advice on nutrient 
intake in patients with IBS. A 7-day unweighed diet record was used to measure dietary intake 
in this RCT, and is the most accurate method of evaluating dietary intake other than the gold 
standard weighed diet record (Bingham et al., 1995). The diet records in this RCT also included 
portion size photographs to assist patients with portion size estimation (Bingham et al., 1994). 
Three coders entered the diet record data for analysis and inter-rater agreement analysis 
suggested excellent agreement between coders. Hence, these results are a robust and 
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accurate representation of the diet and nutrient intake of a large cohort of patients with IBS 
recruited from secondary care.  
 
5.3.1 Habitual nutrient intake of patients with IBS 
This study demonstrates that nutrient intake of patients with IBS consuming their habitual diet 
generally meets national recommendations. Iron intake in females of 19-49 years of age was 
lower than the RNI, however, this is also evident in the wider UK female population (Public 
Health England and Food Standards Agency, 2014). Potassium intake in females was also lower 
than the RNI. This might be attributable to a lower overall intake of fruit and vegetables (which 
are good sources of potassium) among individuals with IBS, however the intake of potassium 
reported here was higher than the UK general population. Therefore these data suggest there 
is no evidence of IBS-specific nutrient inadequacy when patients follow their habitual diet. The 
current data supports previous work in UK community patients with IBS (n=104) which showed 
that habitual intake met the RNIs for macronutrients and a small number of evaluated 
micronutrients (Williams et al., 2011). The same has been reported for secondary care patients 
with IBS in Sweden (n=187) in which intake was evaluated using 4-day diet records and all 14 
micronutrients analysed met the Nordic dietary intake recommendations (Bohn et al., 2013). 
 
Habitual nutrient intake of patients in this study was broadly similar to gender-matched 
individuals from the UK population (Public Health England and Food Standards Agency, 2014). 
This supports previous data from our group that has demonstrated nutrient intake of UK 
secondary care patients with IBS was similar to healthy controls (McCoubrey et al., 2008). 
Intake of calcium and iron in that study was lower in patients compared with controls, 
however, which might be related to differences in dietary assessment methodology. Indeed, 
FFQs, have been shown to underestimate calcium intake, and were used to evaluate intake in 
that study (Bingham et al., 1994).  
 
This is the largest UK study to evaluate habitual dietary intake in IBS using diet records, 
including assessment of the intake of a large range of micronutrients. Mean nutrient intakes 
generally met RNIs and reflected nutrient intake of the general UK population. This is a 
valuable contribution to the existing literature as previous studies have been limited by their 
use of FFQ (McCoubrey et al., 2008, Williams et al., 2011), which can over or under-estimate 
intake of some nutrients (Bingham et al., 1994), or use unvalidated questionnaires to assess 
dietary intake (Hayes et al., 2014). Furthermore, many studies do not provide sufficient detail 
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on the specific dietary data collection method, food composition databases used or dietary 
coding protocols.  
 
It is acknowledged that external validity of this study may be limited somewhat due to the 
likelihood of some responder bias (i.e. those that were recruited to the RCT may be more 
attentive to their diet). Furthermore, this group of patients had been referred to secondary 
care and therefore their dietary intake may not be representative of community patients with 
IBS, although it could be hypothesised that secondary care patients are likely to have more 
restricted diets. Overall, these results are reassuring considering up to 92% of secondary care 
patients with IBS change their dietary intake in an attempt to alleviate their symptoms and less 
than 15% do so with formal dietetic advice (Hayes et al., 2014). 
 
5.3.2 The effect of low FODMAP dietary advice on nutrient intake 
According to subjective and objective compliance measures, patients in the low FODMAP 
group adhered well to the dietary advice in this RCT. Subjective compliance was better than 
that reported previously for patients following the low FODMAP diet using a similar 4-point 
subjective scoring system (Shepherd and Gibson, 2006), although this is expected as the 
current study was of much shorter duration (4 weeks vs 14 months) and it is recognised that 
self-reported compliance reduces over time spent following a diet (Berkow et al., 2010).  
 
Total FODMAP intake reduced by approximately half in the low FODMAP group in this RCT, and 
absolute intake at follow up was approximately half of the total FODMAP intake reported by 
patients in the sham diet group. This magnitude of difference is similar to that in patients 
following low FODMAP dietary advice compared with a control group consuming habitual diet 
in a previous RCT (Staudacher et al., 2012). However, the reduction in FODMAP intake 
identified here is smaller compared with a recent Swedish dietary advice study where 4-day d 
records reported a quartering of FODMAP intake compared with baseline (4 g/d vs 17 g/d) 
(Bohn et al., 2015). This disparity in FODMAP intake is somewhat expected due to differences 
in habitual FODMAP intake secondary to cultural differences, likely variability in the dietary 
advice provided, and differences in food composition tables used to analyse dietary intake.  
 
There was a significant difference between low FODMAP diet and sham diet groups in the 
intake of total and most individual FODMAPs at follow up after adjustment for baseline 
differences. This confirms the effectiveness of low FODMAP advice in reducing FODMAP intake 
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in this RCT. There was no difference between low FODMAP diet and sham diet groups for GOS 
intake at follow up, although the low FODMAP diet group did demonstrate a reduction from 
baseline whilst intake in the sham group remained stable. Both groups had relatively low 
intake of GOS at baseline when compared with previous data (Staudacher et al., 2012), which 
may have contributed to the lack of difference at follow up. There was a lack of difference 
between groups at follow up for intake of excess fructose, and this has been evident in other 
work (Bohn et al., 2015). Fructose in excess of glucose at a sitting, rather than the total excess 
fructose over a day, is more important for determining whether fructose is incompletely 
absorbed. Therefore the results for excess fructose here are not of concern.  
 
Adherence to the low FODMAP diet requires a reduction in the intake of energy dense foods 
(e.g. milk, cereals, pulses, nuts). This RCT provides evidence that intake of protein and fat in 
patients following low FODMAP dietary advice is not different to habitual dietary intake. One 
potential risk of a low FODMAP diet is a reduction in energy intake due to inadequate 
substitution of high FODMAP foods, which was evident in a recent Swedish study, where daily 
energy intake reduced by more than 400 kcal in patients following low FODMAP dietary advice 
compared with baseline (Bohn et al., 2015). It was not reported whether this resulted in any 
change in bodyweight. In the current RCT, there was a small reduction in energy intake 
(approximately 100 kcal/d) in the low FODMAP diet group which was accompanied by a 
reduction in mean bodyweight of 0.4 kg over the duration of the 4-week intervention. Total 
energy intake was not statistically different to baseline, similar to a previous UK dietary advice 
RCT (Staudacher et al., 2012), and suggests that patients were generally able to substitute 
sufficient alternative foods into the diet, under the instruction of a skilled dietitian, to maintain 
energy intake. Whether bodyweight is maintained after four weeks, during the reintroduction 
of FODMAPs and in the longer term requires investigation. 
 
Intake of carbohydrate and starch reduced in the low FODMAP diet group compared with 
baseline, in line with previous research (Staudacher et al., 2012). A gluten free diet leads to a 
reduced intake of polysaccharide carbohydrates (De Palma et al., 2009) and the low FODMAP 
diet similarly involves a restriction of wheat and gluten-containing products. Some patients 
may not choose to include wheat free alternative breads and cereals due to poor palatability 
and/or higher cost, which might have contributed to these findings. Nevertheless, intake of 
carbohydrates at follow up in the low FODMAP group in this study (198 g) still represented a 
much higher intake than that used in a low carbohydrate intervention in IBS (20 g) (Austin et 
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al., 2009) and the difference compared with baseline could be considered nutritionally 
insignificant, and unlikely to impact on microbiota outcomes.  
 
Fibre can improve or worsen IBS symptoms (Eswaran et al., 2013) and also has effects on the 
microbiota and markers of fermentation (Whelan et al., 2005). Therefore, in order to 
investigate the independent effect of restricting fermentable carbohydrates in IBS, it was 
essential that overall fibre intake was maintained in the low FODMAP diet group. Despite 
alterations in the intake of total FODMAPs, total carbohydrate and starch, NSP intake was 
maintained in the low FODMAP diet group. This was evident both when evaluating mean daily 
intake as well as the proportion of patients meeting the RNI. Previous low FODMAP dietary 
advice studies have either shown maintenance of fibre intake (Staudacher et al., 2012) or a 
reduction (Bohn et al., 2015), whilst feeding studies attempt to maintain fibre intake by 
addition of fibre supplements to low FODMAP meals (Barrett et al., 2010, Ong et al., 2010). 
Whether changes occurred to the intake of soluble or insoluble fibre fractions cannot be ruled 
out, as the current dietary analysis software did not allow for their evaluation, however it is 
unlikely that there were dramatic differences in the context of an overall preservation of total 
NSP intake. 
 
This is the most comprehensive evaluation of micronutrient intake in patients following low 
FODMAP dietary advice. Other low FODMAP dietary advice studies have either only evaluated 
macronutrient intake (Bohn et al., 2015) or measured intake of a limited number of 
micronutrients (e.g. iron, calcium) (Staudacher et al., 2012). Intake of all micronutrients except 
for iron was maintained from baseline in the low FODMAP diet group. Although the difference 
at follow up was not different to the sham group after adjusting for baseline, this may still 
represent a nutritional concern, and a trend for a reduced iron intake in patients following the 
low FODMAP diet has been demonstrated previously (Staudacher et al., 2012).  
 
A reduction in iron intake could plausibly occur due to substitution of iron-fortified wheat 
breakfast cereals (iron content 7-13 mg/100g) with low iron non-wheat products such as oats 
(0.5 mg/100g), or a reduction in the intake of pulses (2-3 mg/100g). However, examination of 
the proportion of patients achieving the RNI for iron may be more indicative of meaningful 
changes in dietary iron intake as mean daily intakes can be skewed by a small number of 
individuals with extreme values. The proportion of patients in the low FODMAP diet group 
meeting the RNI for iron was not different at follow up compared with baseline, and this was 
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also the case when gender-specific groups were examined. Finally, although there was an 
overall reduction in iron intake amongst patients in the low FODMAP diet group, a small 
reduction was also evident in the sham diet group. Therefore, it could be the change in iron 
intake in both groups was due to transient dietary change in response to being observed, and 
may not represent an effect specifically related to following a low FODMAP diet. 
 
Calcium is one micronutrient that has been considered at potential risk of deficiency in 
patients following a low FODMAP diet, and has previously been shown to be reduced 
compared with controls following their habitual diet (Staudacher et al., 2012). Intake of 
calcium for the low FODMAP diet group (773 mg/d) was not significantly lower than habitual 
diet (797 mg/d) in this RCT, and was higher than previous data (603 mg/d) (Staudacher et al., 
2012) and on average exceeded the RNI (700 mg/d). However on examination, calcium was the 
only micronutrient for which there was a significantly lower proportion of patients meeting the 
RNI at follow up compared with baseline, which is equivalent to 8/51 patients failing to meet 
the RNI after low FODMAP advice although they met the RNI while following their habitual 
diet.  
 
The likeliest explanation for the effect of low FODMAP dietary advice on calcium intake is an 
inadequate substitution of high lactose calcium-rich foods with low lactose calcium-rich 
alternatives (e.g. lactose free milk products or calcium-fortified plant milks). It could also be 
due to natural variation in dietary intake (Bingham, 1987), however the likelihood of this being 
the case is small, particularly given the large sample size. Another potential important 
contributor to this finding is measurement error resulting from the lack of nutrient 
composition data for novel lactose free products. Where possible, such novel foods were 
registered as new foods on the analysis database and their calcium content added, where 
available. Calcium is essential for a number of physiological functions including nerve 
conduction and hormone secretion, and inadequate intake may be related to osteoporosis, 
cardiovascular disease and other chronic conditions (Peterlik and Cross, 2009).  If there is a 
true reduction in calcium intake when patients follow the low FODMAP diet, this may have 
long term ramifications, especially if the diet is followed strictly for extended periods of time.  
 
This RCT demonstrates that patients following a low FODMAP diet broadly maintain nutrient 
intake despite being advised to restrict intake of many nutrient-rich food items across a 
number of food groups. Furthermore, where RNIs were not met, they also failed to be met 
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whilst patients were consuming their habitual diet. This suggests that advice from a specialist 
dietitian regarding a low FODMAP diet does not broadly compromise nutrient intake and that 
the low FODMAP diet could potentially be used without nutritional concern. However, these 
results confirm that there is risk of patients failing to meet the RNI for calcium and this 
requires specific attention in the clinical consultation.  
 
5.3.3 The suitability of the sham diet 
An important outcome of this study was the nutrient intake of patients following sham dietary 
advice. Compliance data for the sham diet indicates patients followed the diet as well as those 
patients in the low FODMAP diet group. Objective measurement of compliance was difficult, as 
there was no specific measurable food component that could be used to evaluate this. 
Arguably, in this situation, the fact that patients perceived they were following a ‘special’ diet 
was more important than compliance to the diet itself.  
 
The aim of the sham diet was to modify dietary carbohydrate sources and restrict an 
equivalent number of foods compared with the low FODMAP diet but to have no impact on 
nutrient or FODMAP intake. A reduction in energy, carbohydrate, protein and NSP was evident 
in the sham diet group compared with baseline. However, when comparing intake at follow up 
with the low FODMAP diet group, and when comparing the change in nutrient intake between 
groups, there were no differences. Importantly, the proportion of patients achieving the RNI 
for NSP at baseline compared with follow up did not change. Fibre can worsen or improve 
symptoms, and therefore it was vital that fibre intake was preserved during the sham diet for it 
to be considered a ‘placebo diet’. There were some differences in micronutrient intake in the 
sham diet group, however this is unlikely to have any impact on nutritional status in the short 
term or on clinical or microbiological outcomes in the RCT.  
 
Another key aim of the sham diet was that it did not alter FODMAP intake. Total and individual 
FODMAP intake clearly was maintained in the sham diet group, and was comparable to 
previous data from patients with IBS following habitual intake (Staudacher et al., 2012, Bohn et 
al., 2015). There was a trend for a reduced intake of mannitol in the sham group, which may 
have been due to a reduced intake of high mannitol vegetables, however this is unlikely to 
have had any effect on clinical outcomes. 
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Overall, the results of the dietary intake analysis of patients in the sham group have 
demonstrated that the sham diet developed for this RCT was entirely suitable as a placebo 
comparator for low FODMAP dietary advice in terms of its nutritional composition. Alteration 
in intake of energy, some macronutrients and micronutrients was evident, however the 
change in intake of these nutrients between groups was not significantly different for most 
nutrients, and would not have had any bearing on clinical or microbiological outcomes.   
 
5.3.4 Strengths and limitations 
This is the largest study that has prospectively assessed habitual dietary intake of UK patients 
with IBS and the most comprehensive dietary evaluation of patients following low FODMAP 
dietary advice. It is also the first to assess the effect of low FODMAP dietary advice on dietary 
intake in the context of a placebo-controlled study and the first to evaluate the effect of a 
novel sham diet on dietary intake in IBS.  
 
When individuals are asked to record food and fluid intake there is risk of them altering their 
intake in order to simplify the process or to impress the researcher (Bingham, 1987). 
Comparison of low FODMAP dietary advice with a placebo dietary advice intervention 
somewhat accounts for this response bias and might allow for a more precise estimate of 
important alterations in nutrient intake that might occur external to the research setting. It is 
acknowledged that assessment of dietary intake is subject to error, however it was 
endeavoured to minimise this where possible. The assessment methodology (7-day diet 
record) chosen is a robust method for measuring dietary intake whilst minimising patient 
burden. Significant effort was made to ensure all diet records were checked and clarified with 
each patient, and verification of inter-rater agreement between coders maximised the 
accuracy of coding.  
 
The study has some limitations that need to be acknowledged. This study included patients 
between ages 18-65 years, without significant co-morbidity or significant existing dietary 
restrictions, and only non IBS-C subtypes were included. Therefore whether these outcomes 
can be extrapolated to other patient groups is unclear. There was also likely to be a degree of 
response bias leading to inclusion of patients with a keen interest in dietary approaches to 
managing their symptoms, which may have underestimated the true effect of the low 
FODMAP diet on nutrient intake.  
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Furthermore, this study examined dietary intake in the fourth week following low FODMAP 
dietary advice. Nutrient intake in patients following low FODMAP advice for extended periods 
has not been prospectively investigated. Hypothetically, calcium intake could improve over 
time as patients adjust and adapt to their new dietary regime or are able to reintroduce some 
lactose into the diet. The converse could be also be true, that calcium intake might reduce as 
patients become less enthusiastic about incorporating variety into the diet. Finally, it must be 
acknowledged that there is limited availability of alternative food composition data. This may 
have led to inaccuracy and/or underestimation of nutrient intake, which adds to the inherent 
difficulties of measuring dietary intake using food tables. 
  
5.3.5 Significance of the results 
This study has confirmed that low FODMAP dietary advice leads to a clear reduction in 
FODMAP intake but does not significantly alter energy or nutrient intake in patients with IBS-D, 
IBS-M and IBS-U, other than for calcium in some patients. This is important for clinical practice 
as many patients will follow the low FODMAP diet for at least four weeks. The low FODMAP 
diet led to a minor reduction in bodyweight over the 4-week period, although the change in 
bodyweight was not different to that which occurred in the sham diet group, and therefore 
this is unlikely a clinical concern for most patients, but emphasises the importance of 
monitoring anthropometric outcomes in routine clinical care. NSP intake in the low FODMAP 
diet group was maintained and therefore any clinical or luminal alterations that occur in 
patients in this RCT in response to a low FODMAP diet can confidently be attributed to the 
restriction of FODMAPs rather than changes to NSP intake.  
 
The sham diet designed for use as a placebo comparator intervention in this study proved to 
be successful in altering food intake without altering macronutrient or total FODMAP intake 
compared with the low FODMAP diet group. Some differences were evident for micronutrient 
intake, which is unsurprising given the difficulty in designing such a diet, and this is unlikely to 
have any impact on other outcomes of this RCT. Furthermore, this is a valuable resource that 
can be utilised in future studies that examine clinical response to dietary intervention in IBS. 
 
Finally, this study has confirmed that habitual dietary intake of patients with IBS is generally 
nutritionally replete. Mean dietary intake of the nutrients that failed to meet gender-specific 
RNIs (e.g. iron) were also evident in the general population. Whether the same is the case for 
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primary care patients, patients with IBS-C or those with multiple comorbidities is not known 
and requires further investigation.  
 
5.3.6 Conclusion 
This RCT has confirmed that comprehensive low FODMAP dietary counselling from an 
experienced dietitian leads to a reduction in FODMAP intake but does not lead to nutritional 
implications in secondary care patients with IBS after four weeks, other than for calcium. 
These results are reassuring considering this dietary intervention requires avoidance of 
multiple foods across a number of food groups and exclusion diets have been shown to lead to 
nutritional inadequacy (Kim et al., 2013). It is recommended dietitians place strong emphasis 
on the inclusion of high calcium foods when advising patients to follow a low FODMAP diet. 
Whether the results from this study are valid for less compliant patients, patients that are self-























6 The effect of low FODMAP dietary advice and probiotic 
supplementation on the gastrointestinal microbiota and markers of 
fermentation in irritable bowel syndrome 




The importance of the GI microbiota in health and disease has become a growing focus of 
scientific research. Dysbiosis is proposed as one likely contributor to the pathophysiology of 
IBS. Commonly reported alterations include reduced stool Bifidobacteria and Bacteroidetes 
concentration and lower diversity compared with healthy individuals (Section 1.1.7.4).  
 
Independent of disease-associated dysbiosis, other external factors have important impact on 
modulating the abundance and taxonomic composition of the microbiota. For example, 
habitual dietary intake modulates GI microbiota composition, and acute dietary change can 
directly influence the microbiota within a short period of time (1-3 days) (Wu et al., 2011, 
Walker et al., 2011, David et al., 2014). Much of the research that has assessed the effect of 
carbohydrate-modified interventions on the composition of the microbiota has been 
conducted in the overweight or obese consuming very low levels of carbohydrate intake (<25 
g/d) (Duncan et al., 2007, Russell et al., 2011b, Brinkworth et al., 2009). The effect of 
carbohydrate-modified dietary intervention on the GI microbiota in IBS has not been 
extensively studied. 
 
A low FODMAP diet reduces the abundance of GI Bifidobacteria in adults with IBS (Halmos et 
al., 2015, Staudacher et al., 2012). It may also have effects on other bacterial groups such as F. 
prausnitzii, overall microbiota abundance and luminal fermentation byproducts (Halmos et al., 
2015) although this has not been consistently demonstrated (Staudacher et al., 2012). Having 
lower microbial richness (Tap et al., 2015) or GI symptoms (Manichanh et al., 2014) is 
associated with increased susceptibility to diet-induced alteration in the microbiota. Therefore, 
the impact of dietary manipulation on the microbiota in patients with IBS may be more 
pronounced than in healthy individuals, which is of further concern as this patient group 
already exhibit dysbiosis (Section 1.1.7.4). The nature and extent of microbiota modulation 
and its byproducts in response to a low FODMAP diet, and potential approaches to preventing 
it, requires further evaluation. 
 
The Bifidobacteria-lowering effect of the low FODMAP diet is a concern. Firstly, this genus has 
a number of beneficial impacts on the host including pathogen exclusion and 
immunomodulatory effects (Lee and O'Sullivan, 2010). Secondly, there is growing evidence for 
the inverse relationship of lower luminal Bifidobacteria with clinical symptoms in IBS (Jalanka-
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Tuovinen et al., 2011, Rajilic-Stojanovic et al., 2011). Therefore, maintenance of Bifidobacteria 
may be important for long term GI health and for optimising symptoms in IBS.  
 
Probiotic supplementation can modify the GI microbiota and some products have 
demonstrated beneficial effect for IBS (Ford et al., 2014b), although which individual species 
and strains are most effective is unclear. Until now, there has been no study of the use of a low 
FODMAP diet and probiotic co-administration. A large parallel design study is required to 
confirm the extent and nature of the effect of the low FODMAP diet on the GI microbiota and 
SCFA, and to evaluate whether these acute alterations can be prevented by probiotic 
supplementation.  
 
6.1.1 Aim of this chapter 
The aim of this chapter is to report the results for the GI microbiota, SCFA and pH from the 2x2 
factorial design RCT investigating the effect of low FODMAP dietary advice and probiotic 
supplementation in patients with IBS.  
 
The GI microbiota was measured using qPCR (Section 2.6.2), SCFA were measured using GLC 
(Section 2.6.3), and stool pH was measured using a pH electrode (Section 2.6.4). 
 
The hypothesis was that there is a difference in stool Bifidobacteria concentration between 
patients following low FODMAP dietary advice and taking a probiotic supplement compared 
with patients following low FODMAP dietary advice alone (low FODMAP diet + placebo) 
(Section 2.2). 
 
The chapter is divided into the following two parts: 
1. GI microbiota (Section 6.2.1) 
2. Stool SCFA and pH (Section 6.2.2) 




For all outcomes in this chapter, there was no interaction between the diet and product 
interventions and therefore the main effects for these are presented individually, and are 
adjusted for baseline values. The primary analysis based on the ITT dataset is presented. The 
analysis for absolute and relative abundance of the microbiota based on the PP population is 
presented in Appendix 9.24.   
 
6.2.1 GI microbiota 
Absolute abundance of total bacteria (universal) and 11 bacterial groups are presented in 
Table 6.1. Linear regression established that diet could predict absolute abundance of four 
bacterial groups at follow up. Absolute Bifidobacteria abundance could be significantly 
predicted F(3,96)=30.709 (p<0.001) by both diet and by product, and they accounted for 47% 
of the explained variability. Lower absolute abundance was evident in the low FODMAP diet 
group compared with sham diet (p=0.028) and there was higher abundance for probiotic 
compared with placebo (p=0.021).  
 
Diet could predict concentrations of Bacteroides spp. F(3,98)=39.017 (p<0.001), accounting for 
53% of the explained variability, with higher abundance in the low FODMAP diet group 
compared with the sham diet group (p=0.040). Roseburia spp. & Eubacterium rectale was also 
predicted by diet F(3,89)=40.585 (p<0.001), accounting for 54% of the explained variability, 
with lower abundance in the low FODMAP diet group compared with sham (p=0.034). There 
were no differences for absolute abundance of any other bacteria measured, including for F. 
prausnitzii. 
 
Results for the relative abundances of the microbiota are presented in Table 6.2. Linear 
regression established that diet could predict relative abundance of Bacteroides spp. F(3,98)= 
38.24 (p<0.001), with a higher proportion in the low FODMAP diet group compared with sham 
(p=0.001). Total Bifidobacteria F(3,96)=20.11 (p<0.001), B. longum F(3,89)=10.60 (p<0.001) and 
B. adolescentis F(3,55)=18.012 (p<0.001) were all predicted by diet and were lower in the low 
FODMAP diet group compared with sham (p<0.05). All outcomes remained when the per 
protocol population were examined except that the absolute abundance of Bacteroides spp. 
became nonsignificant for diet. 
  
 
Table 6.1 Absolute abundance of microbiota (log10 cells/g faeces) at follow up for the intention to treat population of patients with IBS participating in a 
2x2 factorial design RCT of low FODMAP dietary advice and probiotic supplementation (n=104) 
 
















Universal 10.9 (0.4) 10.9 (0.3) -0.04 (-0.17, 0.07) 0.511 10.9 (0.3) 10.9 (0.4) -0.02 (-0.13, 0.09) 0.741 
Bacteroides spp. 10.0 (0.6) 10.1 (0.7) 0.187 (0.02, 0.35) 0.040 10.2 (0.5) 10.1 (0.8) -0.16 (-0.31, 0.01) 0.077 
Prevotella spp. 7.8 (1.9) 7.1 (1.7) -0.23 (-0.56, 0.08) 0.176 7.5 (1.8) 7.4 (1.9) -0.01 (-0.29, 0.29) 0.953 
Bifidobacteria 9.0 (1.1) 8.8 (0.7) -0.32 (-0.60, -0.03) 0.028 8.7 (1.1) 9.1 (0.7) 0.31 (0.03, 0.56) 0.021 
     B. longum 8.5 (0.9) 8.0 (0.8) -0.60 (-0.82, -0.35) 0.001 8.3 (1.0) 8.2 (0.9) -0.23 (-0.47, -0.01) 0.058 
     B. adolescentis 8.2 (1.1) 7.6 (1.0) -0.39 (-0.80, -0.01) 0.066 7.8 (1.1) 8.0 (1.1) -0.16 (-0.57, 0.24) 0.457 
Clostridium Cluster XIVa 10.1 (0.8) 10.2 (0.6) 0.04 (-0.21, 0.27) 0.752 10.1 (0.7) 10.2 (0.7) 0.07 ( -0.16, 0.31) 0.597 
     Roseburia spp. & E. rectale 9.8 (0.5) 9.4 (0.8) -0.19 (-0.38, -0.21) 0.034 9.5 (0.8) 9.6 (0.6) 0.01 (-0.18, 0.20) 0.932 
     F. prausnitzii 9.7 (0.6) 9.5 (0.8) -0.09 (-0.31, 0.15) 0.469 9.6 (0.8) 9.7 (0.6) 0.09 (-0.19, 0.34) 0.538 
R. Bromii 8.7 (0.7) 8.5 (0.9) -0.05 (0.27, 0.18) 0.672 8.6 (0.8) 8.6 (0.8) -0.07 (-0.30, 0.17) 0.546 
A. muciniphila 7.9 (1.1) 7.9 (1.0) -0.42 (-0.90, 0.03) 0.074 7.9 (1.0) 7.8 (1.1) -0.20 (-0.59, 0.19) 0.353 
Lactobacilli 7.6 (0.9) 7.6 (0.9) 0.18 (-0.33, 0.68) 0.533 7.5 (1.0) 7.6 (0.9) 0.10 (-0.43, 0.66) 0.680 
Values are mean (SD), estimated mean difference and 95% confidence intervals 
  
 
Table 6.2 Relative abundance of microbiota (% of total) at follow up for the intention to treat population of patients with IBS participating in a 2x2 
factorial design RCT of low FODMAP dietary advice and probiotic supplementation (n=104) 
 
















Bacteroides spp.  20 (15) 30 (17) 8.94 (4.67, 13.43) 0.001 26 (16) 23 (17) -3.81 (-8.33, 0.29) 0.088 
Prevotella spp. 8 (16) 5 (12) -2.52 (-8.67, 3.78) 0.433 6 (12) 7 (16) 4.66 (-0.090, 10.31) 0.145 
Bifidobacteria  4 (5) 2 (2) -2.21 (-3.36, -1.19) 0.003 3 (5) 3 (3) 0.11 (-1.15, 1.20) 0.867 
      B. longum  1 (2) <1 (1) -0.93 (-1.56, -0,39) 0.014 1 (2) 1 (1) -0.35 (-0.93, 0.18) 0.258 
      B. adolescentis  1 (1) <1 (1) -0.52 (-0.84. -0.22) 0.018 <1 (1) 1 (1) 0.03 (-0.25, 0.36) 0.852 
Clostridium Cluster XIVa  24 (17) 25(13) 0.92 (-4.35, 6.51) 0.744 22 (16) 26 (15) 4.83 (-0.18, 9.52) 0.062 
      Roseburia spp. & E. rectale  9 (8) 7 (8) -0.59 (-3.30, 2.16) 0.687 7 (6) 9 (9) 1.70 (-1.21, 4.50) 0.241 
      F. prausnitzii  9 (9) 9 (10) 0.07 (-3.86, 3.66) 0.974 9 (9) 10 (9) 0.55 (-2.94, 4.38) 0.760 
R. Bromii 1 (1) 1 (1) 0.36 (-0.01, 0.72) 0.073 1 (1) 1 (1) -0.33 (-0.71, 0.06) 0.110 
A.muciniphila  <1 (<1) <1 (1) 0.10 (-0.28, 0.62) 0.722 <1 (1) <1 (<1) -0.42 (-0.94, 0.03) 0.254 
Lactobacilli  <1 (1) <1 (<1) -0.02 (-0.35, -0.18) 0.914 <1 (1) <1 (<1) -0.13 (-0.53, 0.12) 0.522 
Values are mean (SD), estimated mean difference and 95% confidence intervals
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Absolute abundances of microbiota were compared between combination intervention groups 
(Appendix 9.25). Bifidobacteria abundance was highest in the sham diet + probiotic group and 
lowest in the low FODMAP diet + placebo group, and this difference was statistically significant 
on between groups comparisons (9.2 vs 8.6 log10 cells/g; p=0.020). Bifidobacteria 
concentration was not different between low FODMAP diet + probiotic (8.9 log10 cells/g) and 
the sham diet + placebo group (8.8 log10 cells/g) but was higher for the low FODMAP diet + 
probiotic group (8.9 log10 cells/g) compared with the low FODMAP diet + placebo group (8.6 
log10 cells/g), although this did not reach statistical significance. 
 
Baseline absolute abundance of Bifidobacteria was compared with change in Bifidobacteria 
abundance for the per protocol population with detectable Bifidobacteria concentration at 
both timepoints (Figure 6.1). There was a significant negative correlation between baseline 
Bifidobacteria abundance and change in Bifidobacteria abundance for those receiving low 
FODMAP dietary advice with placebo or probiotic and for patients receiving sham dietary 
advice and probiotic (p<0.001) (i.e. those with high baseline Bifidobacteria had a greater 
reduction in Bifidobacteria), but not for patients receiving sham dietary advice and placebo 
(p=0.059). 
 
6.2.2 Stool SCFA and pH 
Stool SCFA concentrations and pH are presented in Table 6.3 and the full dataset is presented 
in Appendix 9.26. Linear regression analysis demonstrated that diet could predict acetate 
concentration F(3,100)=7.39 (p<.001), accounting for 16% of the explained variability. Acetate 
was lower in the low FODMAP diet group compared with sham (p=0.029). There was no effect 
of diet or product on total SCFA, any other SCFA or stool pH, although a trend for lower total 
SCFA was evident in the low FODMAP group compared with sham diet (p=0.061). The PP 
analysis revealed no other differences.  
 
When assessing the effect of combination interventions, there was a consistent pattern of a 
higher concentration of total SCFA, acetate, butyrate and propionate in the low FODMAP + 
probiotic group compared with the low FODMAP diet + placebo group, but lower 
concentrations compared with the sham diet + probiotic group, although there were no 
statistically significant differences (Appendix 9.27 ). 
 





Figure 6.1 Baseline stool Bifidobacteria abundance compared with change in Bifidobacteria 
abundance for the per protocol population of patients with IBS participating in a 2x2 
factorial design RCT of low FODMAP dietary advice and probiotic supplementation A:  low 
FODMAP diet (n=42); B: sham diet (n=42). Values in green represent patients randomised to 
probiotic and values in blue represent patients randomised to placebo  
  
Table 6.3 Stool SCFA concentration (µmol/g faeces) and stool pH at follow up for the intention to treat population of patients with IBS participating in a 
2x2 factorial design RCT of low FODMAP dietary advice and probiotic supplementation (n=104) 
 















(95% CI) p 
Total SCFA  124.0 (69.4) 98.6 (43.7) -22.2 (-46.9, -4.0) 0.061 108.6 (42.8) 113.1 (71.9) 10.1 (-9.4, 33.2) 0.374 
   Acetate  73.1 (37.1) 58.2 (25.9) -14.5 (-27.3, -3.2) 0.029 64.8 (27.4) 66.8 (43.6) 5.3 (-5.0, 17.2) 0.351 
   Butyrate  21.5 (15.8) 15.7 (9.5) -3.3 (-7.3, 0.3) 0.120 17.9 (10.1) 19.4 (15.9) 2.7 (-1.4, 7.2) 0.274 
   Propionate  20.9 (16.2) 18.0 (9.7) -2.7 (-7.8, 1.5) 0.322 18.9 (8.3) 20.1 (17.0) 2.1 (-2.3, 7.4) 0.439 
   Valerate  2.4 (1.5) 2.0 (1.3) -0.4 (-0.8, 0.1) 0.126 2.2 (1.2) 2.2 (1.6) 0.1 (-0.4, 0.5) 0.880 
   Isobutyrate 2.7 (1.8) 2.6 (1.4) -0.3 (-0.7, 0.2) 0.302 2.7 (1.7) 2.6 (1.6) -0.1 (-0.5, 0.4) 0.844 
   Isovalerate  2.2 (1.4) 2.0 (1.1) -0.1 (-0.9, 0.3) 0.449 2.2 (1.2) 2.1 (1.4) -0.1 (-0.8, 0.5) 0.647 
pH 6.7 (0.5) 6.8 (0.5) -0.03 (-0.20, 0.14) 0.181 6.8 (0.5) 6.8 (0.5) 0.7 (0.47, 0.85) 0.737 
Values are mean (SD), estimated mean difference and 95% confidence intervals
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6.3 Discussion and Conclusion 
6.3.1 GI microbiota 
This 2x2 factorial design RCT confirmed that low FODMAP dietary advice leads to distinct 
alterations in the composition of the stool microbiota in patients with IBS. This included a 
reduction in the absolute and relative abundance of the genus Bifidobacteria and the species 
B. longum, and a reduction in the relative abundance of B. adolescentis. At the genus level, the 
relative abundance of Bifidobacteria across all timepoints (2-4%) was in line with previous data 
using qPCR on stool samples in IBS (Kerckhoffs et al., 2009), and the alterations in 
Bifidobacteria induced by low FODMAP dietary advice supports data from previous work using 
both FISH (Staudacher et al., 2012) and qPCR (Halmos et al., 2015). Moreover, this is the first 
time that low FODMAP diet-induced species-specific reductions in Bifidobacteria have been 
reported. 
 
The reduction in Bifidobacteria abundance in the low FODMAP group is most likely explained 
by the reduced intake of prebiotic fructans and GOS. Compared with patients in the sham diet 
group, patients in the low FODMAP diet group had lower daily intake of fructans (5 g vs 2.5 g, 
p<0.001) and a trend for lower intake of GOS (0.8 g vs 0.9 g, p=0.080), which is in line with 
previous low FODMAP dietary advice studies (Staudacher et al., 2012, Bohn et al., 2015). These 
prebiotic carbohydrates are known to enhance abundance of luminal Bifidobacteria when 
supplemented for four weeks even in small doses (2.5-3.5 g/d) in healthy volunteers (Bouhnik 
et al., 2007) and in patients with IBS (Silk et al., 2009). This RCT indicates that the reverse is 
true when a similar absolute quantity is removed from the diet.  
 
The difference in Bifidobacteria abundance in the low FODMAP diet group compared with the 
sham diet group in this RCT (0.2 log10 cells/g faeces) was less substantial than found previously 
(0.8 log10 cells/g faeces) (Staudacher et al., 2012). This could be due to methodological 
differences in microbiota quantification (qPCR vs FISH) but also to differences in the nature of 
the control groups. Unlike the previous study, the control group in the current study was 
required to alter their dietary intake (albeit with an aim to maintain nutrient and FODMAP 
intake) which may have led to a change in Bifidobacteria abundance and therefore reduced 
the degree of difference between the two groups.  
 
The change in Bifidobacteria concentration was negatively correlated with baseline abundance 
for most patients in this RCT. Specifically, those that received low FODMAP dietary advice who 
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harboured higher initial baseline Bifidobacteria (and thus the greatest potential for reduction) 
demonstrated a greater reduction, and the nature of the association was not different in those 
who also received probiotic. Likewise, those who received probiotic supplementation alone 
(probiotic + sham diet) with initial low Bifidobacteria abundance demonstrated the greatest 
increase in abundance. This inverse association has previously been shown with FODMAP 
restriction (Staudacher et al., 2012) and with prebiotic supplementation (Whelan et al., 2005) 
but never in response to probiotic supplementation. Interestingly, there appeared to be a 
threshold at a baseline Bifidobacteria concentration of 9.0-9.5 log10 cells/g at which probiotic 
supplementation had no further effect on increasing Bifidobacteria abundance. Whether this is 
a real phenomenon and whether it occurs with other probiotics in healthy individuals or in IBS 
requires confirmation.  
 
Although the restriction of the prebiotic fructans and GOS likely had the strongest influence on 
reducing Bifidobacteria in the low FODMAP diet group, restriction of other dietary constituents 
may also have contributed to this finding. Wheat (Windey et al., 2014), wholegrain products 
(Costabile et al., 2008), a range of fruits and nuts and possibly phenolic compounds (Parkar et 
al., 2013) are bifidogenic and/or impact on other bacterial groups (Graf et al., 2015) and a 
gluten free diet leads to a reduction in Bifidobacteria and B. longum (De Palma et al., 2009). 
Carbohydrate restriction also leads to reduction in the stool Bifidobacteria (Brinkworth et al., 
2009, Duncan et al., 2007) although previous studies severely restrict intake to much lower 
daily intakes than in this RCT. Nevertheless, although prebiotic restriction likely had a strong 
influence on the Bifidobacteria abundance for the low FODMAP group here and in previous 
work, it cannot be ruled out that inevitable alteration in consumption of other dietary 
constituents also contributed. 
 
It was not unexpected that absolute abundance of luminal Bifidobacteria was higher after four 
weeks in the probiotic group compared with placebo. VSL#3 is a high dose Bifidobacteria-
containing probiotic and its viability in stool has previously been confirmed (Brigidi et al., 
2003). There was no effect of probiotic on concentrations of B. longum and B. adolescentis 
compared with placebo in this RCT. This is surprising considering that VSL#3 contains both of 
species. This suggests there were significant shifts in other Bifidobacteria species, such as B. 
longum and B. breve, not measured here due to poor qPCR amplification. The absence of an 
enhanced Lactobacillus concentration in response to the probiotic is also unexpected 
considering VSL#3 also contains four Lactobacillus species. On examination of the data, 
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however, there was an increased concentration of Lactobacillus in the placebo group at follow 
up which may have contributed to the nonsignificant finding between groups. There was a 
lower proportion of patients with Lactobacillus below the detection limit in the probiotic group 
(9%) vs placebo group (53%; p<0.001) (Appendix 9.28) indicating that more patients harboured 
detectable levels of Lactobacillus in the probiotic group compared with placebo. 
 
When combination interventions were compared, low FODMAP dietary advice with probiotic 
co-administration (low FODMAP diet + probiotic) led to conservation of total Bifidobacteria, 
evidenced by no difference in abundance compared with the sham diet and placebo group, 
and the mean absolute abundance was higher compared with the low FODMAP and placebo 
group, although the latter did not reach statistical significance. Strictly speaking, the 
hypothesis that there is a difference in the luminal Bifidobacteria concentration between 
patients following a low FODMAP diet with probiotic compared with patients following a low 
FODMAP diet alone cannot be accepted. However, these results suggest that the 
Bifidobacteria-lowering effect of a low FODMAP diet is somewhat ameliorated by VSL#3, and 
co-administration leads to Bifidobacteria abundance that is at least equivalent with patients 
who receive neither intervention, which is in agreement with the anticipated outcome 
presented in Chapter 1 (Figure 2.2). 
 
Absolute abundance of Roseburia spp. and E. rectale, a subgroup of Clostridium Cluster XIVa, 
was lower in the low FODMAP diet group compared with the sham diet group in this RCT. The 
relative abundance of these organisms are similar to that found in other work in obese and 
healthy individuals (Duncan et al., 2007). These saccharolytic species are able to degrade a 
wide range of carbohydrates, especially starch (Flint et al., 2012). Total carbohydrate and 
starch intake were marginally reduced in both low FODMAP diet and sham diet groups, 
suggesting that the reduction in Roseburia spp. & E. rectale abundance in the low FODMAP 
group may be secondary to reduced colonic availability of short-chain fermentable 
carbohydrates rather than total carbohydrate or starch. Reduced Roseburia spp. may also at 
least in part be explained by reduced acetate availability, as this SCFA is known to be a 
requirement for growth of this group (Duncan et al 2004). 
 
The Roseburia spp. finding here is in line with other work that has shown reduction in 
abundance of this group on extreme restriction of total carbohydrate (Russell et al., 2011b, 
Duncan et al., 2007), and in the absence of changes in the larger Clostridium Cluster XIVa to 
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which it belongs (Duncan et al., 2007). Comparative work also reports a positive association of 
Roseburia in vegetarians but negative association in omnivores (De Filippis et al., 2015), 
suggesting that modest differences in carbohydrate intake may be enough to alter abundance 
of this group. Surprisingly, a low FODMAP feeding study failed to demonstrate differences in 
Roseburia compared with habitual diet (Halmos et al., 2015). This may be due to the previously 
mentioned methodological limitations of the study (e.g. pooling of samples), the smaller 
sample studied, and the addition of psyllium and resistant starch to the low FODMAP diet (that 
does not occur in routine clinical practice), supplementation of which have been shown to 
increase the abundance of this group (Walker et al., 2011).  
 
Although the low FODMAP diet group demonstrated a reduction in the abundance of 
Roseburia spp., a bacterial group that are major butyrate producers, there was no alteration in 
total stool butyrate concentration compared with sham diet. Carbohydrate restriction has 
previously shown to lead to a 30-70% reduction in stool Roseburia spp. and E. rectale 
abundance which was positively associated with stool butyrate concentration (Duncan et al., 
2007). The absence of a change in stool butyrate is reassuring, and suggests there was 
sufficient flux through butyrate-producing pathways from other organisms such as F. 
prausnitzii, which has been correlated with relative stool butyrate concentration in healthy 
individuals consuming a normal diet (Benus et al., 2010). However, the reliance on stool 
measures of SCFA is limited and will be discussed. 
 
There was a higher abundance of Bacteroides spp. at four weeks in the low FODMAP group 
compared with sham diet in this RCT. However, on closer inspection, there were within-group 
reductions in absolute and relative Bacteroides abundance in both diet groups from baseline 
values (Appendix 9.29). Therefore this finding suggests there was a less marked decline in 
Bacteroides spp. abundance in the low FODMAP diet group compared with that found for the 
sham diet group. The decline in Bacteroides in both groups together with the finding that both 
groups demonstrated a reduction in carbohydrate intake at follow up compared with baseline 
fits with the previously reported findings of a positive association of Bacteroides abundance 
with carbohydrate intake (Fava et al., 2013, Russell et al., 2011b). Bacteroides spp. have 
diverse saccharolytic capabilities (Flint et al., 2012) and differences in intake of major 
carbohydrate sources between groups (e.g. rice, oats in low FODMAP vs wheat in sham) may 
have led to the different magnitude of response in Bacteroides between groups. 
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There was no difference in total bacteria or F. prausnitzii between the low FODMAP diet group 
and the sham diet group which supports previous work comparing low FODMAP advice to 
habitual diet (Staudacher et al., 2012) but is in contrast with a feeding study suggesting 
FODMAP restriction leads to a reduction in F. prausnitzii compared with habitual diet (Halmos 
et al., 2015). This discrepancy is likely due to the differences in study design. The feeding study 
reduced FODMAP intake dramatically, which is more likely to impart extensive and widespread 
alterations in the microbiota compared with the current RCT in which free living patients 
consume self-selected foods and fluids based on dietary advice, as occurs in clinical practice. 
The preservation of F. prausnitzii in response to low FODMAP dietary advice in this RCT is 
reassuring given its role as a ‘keystone species’, its major contribution to commensal butyrate 
production and the proposal that it could be a biomarker of intestinal health in adults (Miquel 
et al., 2013).  
 
Other important organisms that may have relevance for health were unaltered by low 
FODMAP dietary advice. These include the mucin degrader A. muciniphila and the butyrate 
producer R. bromii which have been shown to be diet-sensitive, specifically to polyphenols and 
resistant starch, respectively (Anhe et al., 2015, Walker et al., 2011). Therefore, it could be 
proposed that a significant reduction in FODMAP intake, which reduces prebiotic intake, leads 
to a reduced abundance of Bifidobacteria and Roseburia spp., but other diet-sensitive 
microorganisms appeared to be preserved due to sufficient intake of other dietary 
components (e.g. resistant starch, polyphenols), though intakes of these components were not 
measured here. 
 
6.3.2 Stool SCFA and pH 
This is the first report that a low FODMAP diet leads to lower stool acetate concentration 
compared with controls. This alteration occurred in the absence of significant differences in 
total SCFA or other individual SCFA, although there was a trend for a lower total SCFA 
concentration in the low FODMAP diet group compared with sham (p=0.061). Two studies 
have examined the effect of the low FODMAP diet on stool SCFA and found no impact of the 
low FODMAP diet, both were smaller studies that may not have been sufficiently powered to 
detect differences (Staudacher et al., 2012, Halmos et al., 2015) and one also pooled samples 
from healthy subjects and IBS which may have masked differences in patients (Halmos et al., 
2015).  
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The reason for this alteration in stool acetate concentration is unclear and likely multi-
dimensional. The most plausible explanation is a reduction in the abundance of the acetate-
producing Bifidobacteria. It could also be due to reduced abundance of other microorganisms 
that generate acetate (Ruminococcus spp. and Clostridium spp.), increased colonic absorption 
of acetate or prolonged colonic transit time. Butyrate-producers (especially F. prausnizii and 
Roseburia spp. & E. rectale) also utilise acetate in cross feeding reactions (Duncan et al., 2004), 
and therefore increased utilisation through this pathway may have also contributed.  
 
Although novel in terms of a low FODMAP diet, the reduced stool acetate concentration is not 
a new finding when considering studies that alter total dietary carbohydrate intake. For 
example, carbohydrate restriction leads to reduction in stool acetate in obese individuals over 
3-8 weeks (Brinkworth et al., 2009, Russell et al., 2011b, Salonen et al., 2014) and a similar 
effect has been demonstrated in healthy individuals after five days of a fibre-free high protein 
diet (David et al., 2014). Furthermore, individuals following agrarian diets or plant-based diets 
have higher stool acetate concentration compared with controls (De Filippo et al., 2010, De 
Filippis et al., 2015).  
 
The effect of VSL#3 probiotic on stool SCFA in IBS has never been examined, and there is a lack 
of data regarding the in vivo effect of other Bifidobacteria-containing probiotics on stool SCFA 
concentration in IBS. Intriguingly, low FODMAP dietary advice with probiotic co-administration 
(low FODMAP diet + probiotic) in this RCT appeared to somewhat ameliorate the reduction in 
total SCFA, butyrate, acetate and propionate (Appendix 9.27), although this was not 
statistically significant. This is also interesting considering that there were no independent 
effects of VSL#3 on stool SCFA concentrations compared with placebo despite its bifidogenic 
effect.  It is difficult to explain the reason for the absence of a higher stool SCFA concentration 
in response to VSL#3, but it may be due to shifts in SCFA pathways in the colon at times of 
greater SCFA availability, such as increased colonic absorption.  
 
It is unknown whether a lower stool acetate concentration has any effect on GI function. 
Colonic SCFA absorption stimulates sodium-dependent water absorption and therefore it may 
have led to altered water availability in the colon and possibly altered stool consistency. 
Furthermore, whether acetate concentration per se is specifically associated with other 
parameters of colonic or overall health in IBS is unknown. It is reassuring that butyrate, known 
for its protective effect on the colonic mucosa, did not reduce significantly in response to low 
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FODMAP dietary advice. This may be explained by an unaltered abundance of predominant 
butyrate producers from Clostridium Cluster XIVa, such as F. prausnitzii (Benus et al., 2010), 
despite a reduction in Roseburia spp. which is positively correlated with stool butyrate 
concentration (Duncan et al., 2007). The numerous important effects of butyrate in the colon 
are recognised and well described, but the relevance of a change in stool acetate is less clear. 
Stool concentration in cancer patients is lower versus controls and it has been demonstrated 
to induce apoptosis of cancer cells in vitro, although less so than butyrate (Topping and Clifton, 
2001). 
 
Stool pH in this RCT was unaltered in response to low FODMAP dietary advice or the probiotic 
intervention. This is largely unsurprising as stool pH is influenced by concentrations of multiple 
metabolites, not just byproducts of carbohydrate fermentation. For example, protein 
fermentation by-products (phenols, amines and ammonia) and organic acid by-products of 
hexose and pentose metabolism (lactate and succinate) also contribute to pH of the lumen 
(Cummings and Macfarlane, 1991). Furthermore, a majority of carbohydrate fermentation and 
SCFA production occurs in the caecum, which are then absorbed in the distal colon (Cummings 
and Macfarlane, 1991), meaning stool pH is limited as a marker for colonic pH.  
 
One study has reported increased stool pH after low FODMAP feeding compared with habitual 
diet in healthy individuals and IBS patients (Halmos et al., 2015). Stool collection, handling and 
storage was conducted by participants over a period of five days which may have led to 
variability and potentially suboptimal sample handling, although this is more likely to have led 
to increased fermentation and artificially reduced pH of samples, and is likely to have occurred 
across all samples. Another explanation might be that the stringent FODMAP restriction 
compared with this RCT led to reduced SCFA production and therefore a higher pH, however 
no differences were evident in SCFA concentration compared with habitual diet. Stool pH 
across all groups and timepoints in that study was higher than in this RCT and compared with 
previously reported data from healthy individuals (Fallingborg et al., 1989), and therefore 
methodological differences between studies may have contributed to the variability in 
findings. 
 
Further work is required to characterise the changes in fermentation dynamics in the colon in 
response to the low FODMAP diet and whether alterations in microbiota by-products, such as 
SCFA, and their subsequent impact on luminal pH have an impact on GI health. 
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6.4 Strengths and limitations 
There are a number of strengths of this RCT in relation to the findings presented here. Firstly, 
the application of the intervention through advice from a specialist dietitian and the duration 
of the intervention closely reflected clinical practice. Therefore the observed effects on the 
microbiota may closely represent expected outcomes in clinical practice, in contrast to feeding 
studies where dietary intake is more tightly controlled. A robust technique was used to 
characterise the microbiota in this RCT, and aspects of microbiota functionality was measured 
through evaluation of stool SCFA and pH.  
 
There are also some limitations of the current RCT with relation to the evaluation of the 
microbiota. Firstly, the use of the sham diet in this study, although imperative for placebo-
controlled comparison of symptom response, may have had a bearing on comparisons 
between groups for the microbiota outcomes. The sham diet required a change to food intake 
which likely had at least a subtle impact on the GI microbiota in some patients. A diet that 
maintained habitual intake would have been the optimal comparison for evaluation of 
microbiota response to the low FODMAP diet, however this could not have been classified as a 
placebo control and would impact on conclusions regarding the clinical effectiveness reported 
in Chapter 4.  
 
GI microbiota composition was evaluated using qPCR, which is a relatively rapid technique, and 
an accurate culture independent method for quantifying microbiota. However, it is limited by 
the number of assays that are practically feasible to include in the experiment. Therefore, 
there may have been alterations in abundances of other genera and species that were not 
evident with the primers used here. Furthermore, measures of diversity, that are possible with 
metagenomic sequencing but not with qPCR, were not evaluated here. This requires 
evaluation, as microbiota diversity is increasingly recognised as an important marker for health 
(Lozupone et al., 2012).  
 
Another limitation relates to the measurement of fermentation byproducts. SCFA 
concentration is likely associated with stool volume (Cummings and Macfarlane, 1991), and 
stool volume was not measured in this study. Therefore, a change in stool volume in response 
to the interventions may have biased these outcomes. Furthermore, SCFA measured in stool is 
the net product of the dynamic process of both SCFA production and absorption, the latter of 
which is affected by colonic transit time (Cummings and Macfarlane, 1991). Precise 
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measurement of in vivo local SCFA production and luminal pH throughout the colon is difficult 
due to the inaccessibility of the caecum and proximal colon where the majority carbohydrate 
fermentation takes place (Cummings and Macfarlane, 1991).  
 
Estimation of local fermentation rates throughout the colon would be possible using a wireless 
motility capsule device to measure pH. Measurement of transit time is also possible with this 
device, which is associated with alteration in microbiota composition and function (Kashyap et 
al., 2013). There are also numerous methods of estimating protein fermentation (Yao 2015), 
which, if maintained throughout a low FODMAP diet, might allow more precise judgements 
about the contribution of carbohydrate fermentation alteration to stool pH. Metabolomic 
techniques also present a possible solution for measuring the functional response of the 
microbiota to diet.  
 
Another shortcoming of this RCT relates to the explanation for the diet-induced alterations in 
the microbiota. Although the aim of the low FODMAP diet was to simply restrict fermentable 
carbohydrates, there may have been unmeasured alterations in dietary diversity or other 
dietary components that contribute significantly to colonic fermentation (e.g. resistant starch) 
and/or to microbiota composition (e.g. polyphenols, pectin). This problem of collinearity is, 
however, almost unavoidable in studies that manipulate whole diets and especially in dietary 
advice studies where patients have freedom of dietary choice for an extended period of time. 
Therefore, without a complete composition analysis of all foods and fluids consumed, which is 
not feasible in a dietary advice study, the dietary influences responsible for the change in the 
microbiota in the low FODMAP group cannot be confirmed. 
 
6.5 Significance of the findings 
This is the largest evaluation of the effect of low FODMAP dietary advice on the GI microbiota 
in patients with IBS, and the first to investigate whether the diet-induced effect on the 
microbiota can be prevented by an adjunct therapy. The findings confirm the Bifidobacteria-
lowering effect of the low FODMAP diet, which has been shown previously in smaller RCTs 
(Staudacher et al., 2012, Halmos et al., 2015), and is proposed to be largely due to a reduced 
intake of prebiotic fructans and GOS. There was also a bifidogenic effect of VSL#3, as 
demonstrated previously (Brigidi et al., 2000, Brigidi et al., 2001, Brigidi et al., 2003). Novel 
findings are also presented, including evidence that the low FODMAP diet reduces 
Bifidobacteria species (B. longum and B. adolescentis) and Roseburia spp. & E. rectale, as well 
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as stool acetate concentration. Additionally, the co-administration of probiotic ameliorated the 
diet-induced effect on the Bifidobacteria. The implications of these findings for clinical practice 
are presented in Chapter 7.  
 
These findings were evident in a homogenous cohort of patients with IBS-D, IBS-M and IBS-U 
whose habitual dietary intake is broadly similar to the general UK population. Therefore it is 
assumed the findings here are representative of the effect of the low FODMAP diet in the 
majority of patients with IBS who comply with low FODMAP dietary advice. Whether the 
findings can be applied to patients who may have vastly different microbiota composition (e.g. 
patients who currently take a probiotic, have comorbidity, are obese, or the young or elderly) 
or who are less compliant with dietary advice compared with patients in this RCT, is unknown.  
 
6.6 Conclusion 
This RCT confirms that low FODMAP dietary advice leads to alteration in the abundance of a 
number of bacterial groups, and on their metabolic byproducts. Probiotic co-administration 
ameliorates the diet-induced effect on Bifidobacteria abundance, which may be important due 
to its established benefits on host function (Lee and O'Sullivan, 2010), and that Bifidobacteria 
is associated with clinical symptoms in IBS. It remains to be determined whether the 
disturbance induced by the low FODMAP diet is extreme enough to lead to persistent 
alteration over time. Furthermore, the effect of FODMAP reintroduction on the GI microbiota 
and its byproducts requires evaluation. 













7 Final discussion 




7.1  Summary of findings 
Irritable bowel syndrome is a common GI disorder that has a marked impact on HRQOL 
(Gralnek et al., 2000). The heterogeneity of the condition and an incomplete understanding of 
its pathophysiology have contributed to the lack of uniformly successful treatment 
approaches. Moreover, many patients and their healthcare providers consider diet has a key 
role in managing symptoms (Hungin et al., 2014, Halpert et al., 2007). This is supported by the 
growing body of evidence confirming the effectiveness of dietary intervention in managing IBS 
symptoms, although it is acknowledged that gold standard placebo-controlled dietary 
intervention RCTs are difficult to conduct. 
 
The aim of Chapter 3 was to describe the design, development and evaluation of a novel sham 
diet for use as a placebo comparator in a 2x2 factorial design dietary advice RCT investigating 
the effect of low FODMAP dietary advice and probiotic supplementation in patients with IBS. 
The main aims of the sham diet were to alter carbohydrate sources but maintain FODMAP and 
nutrient intake, whilst being feasible to follow and convincing as an exclusion diet. Outcomes 
of a pilot study and an interim analysis of FODMAP and nutrient intake from the RCT 
confirmed the suitability of the sham diet for use as a placebo control in this study.  
 
The aim of Chapter 4 was to report the results for the clinical outcomes of the low FODMAP 
dietary advice RCT. Convincing evidence was presented that low FODMP dietary advice has a 
beneficial impact on symptom and HRQOL scores compared with placebo sham dietary advice. 
Low FODMAP dietary advice was effective even though it was provided without a description 
of the underlying physiological effects of FODMAPs in the GI tract. The acceptability data 
presented in this chapter, however, indicated a large proportion of patients reported difficulty 
with practical aspects of the low FODMAP diet. Acceptability may be higher in clinical practice 
where extra supportive material and time is dedicated to the education process.  
 
Data from this RCT, also presented in Chapter 4, suggests that the effect of VSL#3 on GI 
symptoms is equivocal, although it is acknowledged there was insufficient power to detect 
differences for probiotic over placebo. There was no interaction between the two 
interventions (low FODMAP diet and probiotic), and therefore statistically speaking, the effect 
of low FODMAP dietary advice and VSL#3 on GI symptoms is considered additive. On subgroup 
analysis of the intervention combination groups for IBS-SSS outcomes there were no difference 




when low FODMAP dietary advice was provided alone compared with when it was co-
administered with the probiotic (i.e. low FODMAP diet + placebo vs low FODMAP diet + 
probiotic), and therefore it remains to be confirmed whether low FODMAP dietary advice with 
probiotic is more effective for improving symptoms than low FODMAP dietary advice alone. 
 
Clearly, the clinical response to low FODMAP dietary advice and to probiotic based on 
adequate relief in this RCT is in stark contrast to outcomes from the IBS-SSS, GSRS and HRQOL 
instruments. Recently, the same discrepancy was noted in 75 patients with IBS randomised to 
either a low FODMAP-low gluten diet or a low FODMAP-normal gluten diet (Piacentino  et al., 
2015). When compared with controls consuming a normal diet, there was no difference 
between groups using a dichotomous endpoint, but clear differences were evident when 
global symptoms were rated using a VAS. The authors concluded that a VAS better 
discriminated treatment outcome compared with a dichotomous response question.  
 
This incongruous relationship was explored further by grouping patients from the current RCT 
according to the presence or absence of adequate relief (Table 7.1). Clear differences in IBS-
SSS total score and subscores were evident between the groups. This confirms that a positive 
response to the adequate relief question in this RCT was generally accompanied by a lower 
mean IBS-SSS score.  
 
Table 7.1 IBS-SSS scores at follow up grouped by adequate relief response for patients that 
completed a 2x2 factorial design RCT of low FODMAP dietary advice and probiotic 
supplementation (n=95) 
 Adequate relief 
(n=48) 





IBS-SSS score (pts) 140.5 (81.6) 249.6 (76.3) <0.001 
     Severity of pain  26.3 (27.4) 46.0 (27.7) <0.001 
     Days of pain (days) 23.5 (20.7) 47.1 (20.1) <0.001 
     Distension severity 24.5 (21.3) 44.4 (25.6) <0.001 
     Satisfaction with bowels 28.8 (16.8) 55.5 (14.8) <0.001 
     Affecting life 37.4 (19.9) 56.7 (17.3) <0.001 
Change in IBS-SSS  (pts) -124.0 (87.0) -50.7 (72.2) <0.001 
Achieved IBS-SSS MCID n (%) 39 (81) 20 (43) <0.001 
All units are (mm) unless stated. Values are mean (SD). 
# 
Mann-Whitney U tests for continuous variables 
and Chi-squared test for categorical variable 




When patients were grouped according to baseline IBS-SSS severity, however, the nature of 
the discrepancy between adequate relief and IBS-SSS outcomes became clear (Figure 7.1). 
Patients with severe IBS symptoms at baseline (according to the IBS-SSS) demonstrated the 
greatest reduction in IBS-SSS score (mean -116 points) compared with those with moderate (-
76 points) and mild symptoms (-16 points). However, those with severe symptoms reported 
adequate relief the least (34%) compared with those with moderate (62%) or mild symptoms 
(40%). This suggests that for many patients with severe symptoms who experienced a large 
reduction in IBS-SSS score, of even more than 2-fold the MCID, this level of clinical response is 




Figure 7.1 Change in IBS-SSS score and proportion of patients reporting adequate relief at 
follow up for patients with mild, moderate or severe symptoms at baseline. Patients 
included completed a 2x2 factorial design RCT of low FODMAP dietary advice and probiotic 
supplementation (n=95; severity categories based on IBS-SSS: mild 75-174 pts, moderate 
175-300 pts, severe 301-500 pts)  
 




A similar pattern of findings has been reported in a large cohort of primary and secondary care 
patients with IBS treated with standard medical care. A lower proportion of patients with 
severe IBS symptoms reported adequate relief after the six month intervention compared with 
those with mild or moderate symptoms, whereas patients with severe symptoms exhibited the 
greatest change in IBS-SSS score at 6 months (Whitehead et al., 2006). In contrast, this same 
discrepancy was not detected in a large pooled analysis of 12 RCTs (Spiegel et al., 2009), 
however in this study adequate relief response was compared with a 50% improvement 
endpoint, a different endpoint to IBS-SSS change, which was used in the current exploratory 
analysis. Overall, it can be concluded that clinical response based on the adequate relief 
dichotomous endpoint may underestimate the effectiveness of an intervention, particularly in 
patients with severe symptoms. Indeed, when considering these data and the disadvantages of 
the adequate relief question that have already been discussed (Section 2.5 and Section 4.7.1), 
use of this dichotomous outcome as a primary endpoint to discriminate clinical responders 
from non-responders is deemed questionable. 
 
The aim of Chapter 5 was to report the results of low FODMAP dietary advice on nutrient 
intake of patients in the RCT. The results supported data from the interim analysis presented in 
Chapter 3, demonstrating that FODMAP intake remained stable in the sham diet group and 
reduced in the low FODMAP diet group. There were some minor alterations to nutrient intake 
in the sham diet group compared with the low FODMAP diet group but this was for 
micronutrients (e.g. potassium, magnesium) that should not have confounded microbiology or 
symptom outcomes. NSP intake in the low FODMAP diet group did not change, confirming that 
altered NSP intake was not responsible for the improvement in GI symptoms in response to 
low FODMAP dietary advice. Furthermore, nutrient intake in patients prior to and following 
the low FODMAP diet was broadly similar to the UK population. The finding that the 
proportion of patients that achieved the RNI for calcium was lower after low FODMAP dietary 
advice is in line with previous work (Staudacher et al., 2012) and highlights the importance of 
patients consuming low lactose, high calcium alternative foods while on the low FODMAP diet.   
 
Over two thirds of the sham diet group (71%) guessed their allocation to the sham diet, which 
may have been due to a lack of symptom improvement in this group. The symptom response 
rate, or placebo effect, in the sham diet group was 38% for adequate relief and 42% for those 
achieving the MCID for IBS-SSS, figures in line with overall placebo response rates reported for 




IBS (20-40%) (Elsenbruch and Enck, 2015), suggesting that suspicion of allocation appeared not 
to heavily impact on placebo response rate in the sham diet group.  
 
The aim of Chapter 6 was to report the results for the GI microbiota and markers of 
fermentation from the RCT. qPCR findings showed low FODMAP dietary advice led to a 
reduction in the abundance of stool Bifidobacteria, which confirms previous data (Staudacher 
et al., 2012, Halmos et al., 2015), and also demonstrated that the degree of reduction was 
negatively correlated with baseline concentration. This is the first data to show that there is a 
reduced abundance of B. longum, B. adolescentis and Roseburia spp. & E. rectale in response 
to low FODMAP dietary advice, which was likely due to decreased availability of fermentable 
carbohydrate substrate for these saccharolytic organisms, and an outcome that may not have 
previously been demonstrated due to smaller sample sizes. For the first time, it was 
demonstrated that low FODMAP dietary advice led to reduced stool acetate concentration, a 
byproduct of carbohydrate fermentation which has been previously shown to reduce in 
response to decreased carbohydrate intake (David et al., 2014).  
 
It could be argued that the low FODMAP diet-induced effect on the microbiota may have been 
underestimated in this RCT due to the reduced intake of carbohydrate, starch and NSP in the 
sham diet group. This may have had an unintended effect on the microbiota in response to the 
sham diet, thereby masking broader alterations in the microbiota in the low FODMAP diet 
group that were not evident from the current data. The ideal method to test this would be to 
compare the microbiota composition of patients following low FODMAP advice with patients 
consuming habitual diet, although this would not suffice as a placebo control group for 
investigating symptom endpoints. Considering that the absolute change in carbohydrate and 
starch intake was not different between the low FODMAP and sham diet groups, it could be 
argued that microbiota findings here are representative of what occurs in response to 
FODMAP restriction per se and not to an alteration in other dietary components such as total 
carbohydrate or starch. 
 
Probiotic supplementation with VSL#3 generally led to changes in the microbiota that had 
been anticipated prior to the RCT (Figure 2.2). Enhanced Bifidobacteria abundance was 
apparent in the probiotic group compared with placebo. Interestingly, there was no difference 
in Lactobacillus abundance between groups. However, there was a significantly lower 




proportion of patients in the probiotic group with Lactobacillus numbers below the detection 
limit, indicating that probiotic supplementation had led to colonisation in the GI tract.   
 
As was the case for symptom analysis, the lack of an interaction between diet and product 
interventions for the microbiota analysis suggests that their impact is additive and not 
synergistic or antagonistic. This effect is evident when Bifidobacteria abundance for 
combination intervention groups was compared. However, it may be that the response in all 
patients is not simply additive in nature. As suggested by the inverse correlation between 
baseline Bifidobacteria and Bifidobacteria change in response to dietary intervention (Figure 
6.1), there is likely substantial inter-individual variability in the microbiota alteration in 
response to low FODMAP diet and probiotic co-administration. Sufficiently powered studies 
are required to clarify the extent and nature of individual microbiota responses to combined 
low FODMAP diet and microbiota-targeted treatments (e.g. probiotic or prebiotics). 
 
7.2 Predictors of symptom response to low FODMAP dietary advice 
Identifying determinants of response to a disease intervention is important for timely 
treatment of the condition. This is particularly so for the heterogeneous disorder of IBS for 
which there is an extensive array of medical, cognitive and/or dietary management strategies 
available.  
 
Adherence is a factor associated with greater symptom response to the low FODMAP diet in 
patients with IBS (Shepherd and Gibson, 2006). Demographic and clinical variables may also be 
potential markers of response. For example, one study compared responders (n=19) versus 
non-responders (n=19) to low FODMAP dietary advice (Bohn et al., 2015) and found a higher 
proportion of females and older age in responders compared with non-responders (Bohn et 
al., 2015). In contrast, one small study (n=8) in children failed to demonstrate any differences 
in gender, BMI, ethnicity or clinical parameters (14-hour hydrogen or methane production, 
pain frequency, stool frequency or transit time) between responders and non-responders, 
although this is likely to have been inadequately powered to detect such differences 
(Chumpitazi et al., 2014).  
 
Dietary composition may be an important baseline factor in predicting response to the low 
FODMAP diet. Overall nutrient composition was not different between responders and non-




responders in one study (Chumpitazi et al., 2015), however a lower baseline dietary intake of 
FODMAPs was identified in responders compared with non-responders in a recent study in 
adults (Bohn et al., 2015). This might suggest that patients who previously self-restricted high 
FODMAP foods (perhaps due to a perception that they provoke symptoms) are more likely to 
achieve benefit (Bohn et al., 2015). Overall, however, there is limited consistent evidence that 
suggests demographic, clinical or dietary factors predict response to the low FODMAP diet in 
patients with IBS. 
 
There are several limitations of the studies investigating predictors of response to low 
FODMAP restriction. Firstly, limitations relate to aspects of study design. The crossover nature 
of studies (Halmos et al., 2015, Chumpitazi et al., 2015) are potentially problematic, as they 
hold risk of carryover effects, particularly where interventions are separated by less than a 
week (Chumpitazi et al., 2015). This is particularly important for symptom endpoints, as 
carryover in the second arm could influence whether ‘response’ was achieved or not. Also, two 
of the three studies were feeding studies (Halmos et al., 2015, Chumpitazi et al., 2015) which 
may not have been representative of a low FODMAP diet that is achievable in the clinical 
setting and therefore the findings may not reflect outcomes in patients following a self-
selected low FODMAP diet.   
 
Another limitation of the studies relates to methodological aspects. Firstly, two of the three 
studies were in children (Chumpitazi et al., 2015, Chumpitazi et al., 2014) and whether any 
potential predictors of response in children are also applicable to adults is unknown. 
Furthermore, the duration of the dietary intervention (two days to three weeks) would have 
had a major impact on the likelihood of response, and indeed an unusually low response rate 
was reported in two of the studies (response rates 8/33 and 4/8) where the duration of the 
dietary intervention was two days (Chumpitazi et al., 2015) and one week, respectively 
(Chumpitazi et al., 2014). Finally, and importantly, the definition of a ‘responder’ to the low 
FODMAP diet varies between studies. Responder definitions have included ≥50% reduced pain 
frequency in children (Chumpitazi et al., 2014, Chumpitazi et al., 2015), a score lower 
compared with control intervention (> 20 mm below those receiving a control diet) (Halmos et 
al., 2015), or reaching the MCID for the IBS-SSS (Bohn et al., 2015). Therefore, a parallel study 
in a large cohort using appropriate response criteria is required to clarify whether response is 
determined by baseline variables. 




Multiple logistic regression analysis was undertaken to predict response in the low FODMAP 
diet group for this RCT based on demographic, clinical severity and dietary variables that 
previous studies and physiological plausibility indicate may be important in determining 
response (Table 7.2). Controlling for the other variables, the only variable that predicted 
achieving the MCID for IBS-SSS (50-point reduction in score) was change in FODMAP intake. 
For every one gram reduction in FODMAP intake at follow up compared with baseline, there 
was a 1.14 odds (95% CI 1.01, 1.29) of achieving the MCID for IBS-SSS score. Variables that did 
not predict response were age (p=0.390), duration of symptoms (p=0.327), baseline IBS 
severity (p=0.365) and baseline FODMAP intake (p=0.390). 
 
Table 7.2 Multiple logistic regression analysis assessing predictors for meeting the MCID for 
IBS-SSS score in patients allocated to the low FODMAP diet group (n=51)  in a 2x2 factorial 
design RCT of low FODMAP dietary advice and probiotic supplementation (responders n=37)  
 
Variable OR 95% CI p 
Age (yrs) 1.03 0.97, 1.09 0.390 
Duration of symptoms (mths) 1.00 0.99, 1.00 0.327 
IBS-SSS  at baseline (pts) 1.00 0.99, 1.01 0.365 
Total FODMAP intake at baseline(g) 0.95 0.85, 1.07 0.390 
Change in FODMAP intake (g) 1.14 1.01, 1.29 0.033 
OR, odds ratio; CI, confidence interval 
 
This is the largest evaluation of predictors of response to low FODMAP dietary advice (37 
responders) using an established response definition based on the validated IBS-SSS, as used in 
previous responder analysis (Bohn et al., 2015). The results suggest that certain demographic 
and clinical factors are not important determinants of response to low FODMAP dietary advice. 
Furthermore, patients with a low baseline FODMAP intake will have a likelihood of response to 
low FODMAP dietary advice that is equivalent to patients with a high baseline intake. This is in 
contrast to previous work (Bohn et al., 2015), which may be due to a much larger sample in the 
current analysis (37/51 responders vs 19/38 responders in previous study). That change in 
FODMAP intake is predictive of response is somewhat expected, and reassuring, and provides 
further evidence that it is FODMAP restriction that is responsible for the effectiveness of the 
low FODMAP diet, rather than other unintended unmeasured dietary alteration. 
 




7.3 Implications for clinical practice 
The results of this RCT provide compelling evidence that low FODMAP dietary advice is 
effective for improving GI symptoms and HRQOL in patients with IBS (57% of patients based on 
the adequate relief question and 73% based on the MCID for IBS-SSS). It might be interpreted 
that low FODMAP dietary advice with co-administered VSL#3 is superior to low FODMAP 
dietary advice alone when considering its effect on Bifidobacteria abundance. However, the 
microbiota is a resilient ecosystem, and has ability to recover after perturbation (Relman, 
2012), and it remains to be determined whether the disturbance induced by the low FODMAP 
diet alone is extreme enough to lead to persistent alteration over time. It is also vital that the 
effect of graded FODMAP reintroduction on the GI microbiota and its byproducts is 
investigated, not only as this is part of routine clinical practice, but also as there is considerable 
cost associated with probiotic co-administration (currently £90/patient for a 4-week course of 
VSL#3). In summary, the implications for clinical practice from this work are as follows: 
 
1) Low FODMAP dietary advice should remain a primary dietary strategy for managing 
IBS symptoms if first line dietary and lifestyle intervention is ineffective (McKenzie et 
al., 2012). It is recommended that current guidelines advising the consideration of low 
FODMAP dietary advice in patients with IBS and bloating (McKenzie et al., 2012) be 
revised to include all patients with IBS-D, IBS-M or IBS-U.  
2) The effect of VSL#3 alone for specific GI symptoms is equivocal, despite its impact on 
increasing stool Bifidobacteria abundance, and there is insufficient evidence to 
recommend its routine use in patients with IBS-D, IBS-M and IBS-U. 
3) In terms of symptom benefit, there is currently insufficient evidence to recommend 
that low FODMAP diet-VSL#3 combination therapy be used in routine practice in 
preference to the low FODMAP diet alone.  
4) Although the long term effects on the microbiota were not investigated here, the 
acute effects of the low FODMAP diet on the microbiota suggest that reintroduction of 
FODMAPs to tolerance should be undertaken, with specific emphasis on prebiotic 
fructans and GOS. 
5) Low FODMAP dietary advice should be provided by a registered dietitian. Advice 
should be individualised, and in view of the impact on calcium intake, emphasis should 
be placed on inclusion of low lactose calcium-rich alternatives, or a calcium 




supplement should be considered if intake of sufficient dietary calcium is not 
achievable. 
 
7.4 Recommendations for future research 
A number of key areas for further research emerge based on the current findings. The RCT 
evidence for the clinical response to the low FODMAP diet is growing, particularly for patients 
in secondary care, however its effect on clinical outcome and dietary intakes in dietitian-led, 
general practitioner-led and self-taught patients in the community setting requires further 
study. The effect of low FODMAP dietary advice in IBS-C is also unclear. The use of a sham diet, 
such as that developed here, is recommended as a feasible and effective placebo comparator 
for placebo-controlled RCTs investigating the impact of the low FODMAP dietary on symptom 
response. 
 
With the growing evidence of the role of the GI microbiota in health and disease, more 
research is required evaluating the effect of the low FODMAP diet on the composition and 
community structure of the GI microbiota. The timepoint at which the microbiota alterations 
occur, the impact of long term FODMAP restriction and the ramifications of these changes (if 
any) on colonic health require investigation. Whether the mucosal microbiota is altered, 
particularly as mucosal abnormalities are already evident in IBS compared with healthy 
controls (Section 1.1.7.4), requires investigation. It is vital that prospective studies addressing 
these research questions attempt to control for confounding factors that were not measured 
here, such as stress (Bailey et al., 2011) and GI transit (Kashyap et al., 2013), and emerging 
dietary modulators of the microbiota (e.g. polyphenols), although it is acknowledged that the 
latter is more feasible in feeding studies than dietary advice studies.  
 
It is understood that there are profound inter-individual differences in the microbiota response 
to dietary change (Duncan et al., 2007), and this has not been evaluated in patients following a 
low FODMAP diet. An appreciation of the specificity of the effect on the microbiota between 
individuals, and whether this is in fact predictive of symptom response may help to form the 
basis of personalised dietary interventions in the future.  
 
In addition to the host-specific factors that might determine the nature of the diet-induced 
response of the microbiota, the composition of the low FODMAP diet itself is probably 




important. The individual fermentable carbohydrates restricted as part of a low FODMAP diet 
differ in digestibility and prebiotic potential and therefore each FODMAP probably has unique 
influences on microbiota composition. It is already known, for example, that GOS are more 
selectively bifidogenic than fructans, which have broader effects on the microbiota ecosystem 
(Bindels et al., 2015). The independent and combined effects of FODMAPs on the microbiota 
require further study and this may modify future application of the diet, particularly in patients 
with mild symptoms who do not require complete restriction and for which the impact on the 
microbiota should be minimised.  
 
It is important that future research on the microbiota in this area is not purely focused on the 
low FODMAP diet-driven changes in its composition, but also on the effect of its metabolism 
and function. This is particularly important as functionality of the microbiota might be more 
strongly influenced by dietary change than the composition of the microbiota itself (Salonen et 
al., 2014). The measurement of bacterial metabolites known to be important in colonic health 
(e.g. SCFA, phenolic compounds) and disease (e.g. N-nitroso compounds, ammonia), some of 
which have previously been associated with carbohydrate intake (Russell et al., 2011b), will be 
important in the evaluation of whether the removal of fermentable substrates is potentially 
damaging to long term health. Indeed, these insights may lead to the development of targeted 
interventions that improve IBS symptoms but optimise colonic health (e.g. low FODMAP diet 
combined with added fibre/prebiotic/probiotic).  
 
Finally, a number of recommendations arise in relation to measuring symptom response in IBS. 
Consideration of the primary clinical endpoint in this work (adequate relief of symptoms) in 
isolation would have led to a vastly different interpretation of the clinical effect of the 
interventions. There are obvious limitations of the use of this dichotomous endpoint alone as 
discussed in Section 2.5.1, Section 4.7.1 and Section 7.1. It is recommended that where future 
studies use dichotomous endpoints that the following should be applied: 1) combination 
endpoints e.g. adequate relief question and proportion of patients meeting the MCID for IBS-
SSS; or 2) the US Food and Drug Administration subtype-specific recommendations, although 
these are limited to IBS-C and IBS-D (FDA, 2012).  
 




7.5 Conclusion of this doctoral thesis 
The low FODMAP diet is becoming an increasingly widespread approach for the management 
of GI symptoms in patients with IBS. This thesis has presented evidence from a large blinded 
placebo-controlled RCT that the low FODMAP diet has beneficial clinical impact in up to 73% of 
patients with IBS-D, IBS-M and IBS-U, and specifically for symptoms such as bloating, 
borborygmi, flatulence and dissatisfaction with bowel habit (specifically urgency and sensation 
of incomplete evacuation), which also translates into improved HRQOL outcomes. Dietary 
intake is not compromised in patients following low FODMAP dietary advice, although this 
study confirms calcium is an at-risk nutrient that requires emphasis in the clinical consultation. 
The impact of a 4-week low FODMAP diet on the GI microbiota can be ameliorated by co-
administration of a probiotic, and this is potentially advantageous in a condition characterised 
by dysbiosis, although the impact of FODMAP reintroduction requires evaluation before 
combined low FODMAP diet-probiotic therapy is recommended as routine practice.
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9.1 Written dietary resource sample pages  





Sham diet resource  
 
   
  Chapter 9: Appendices 
 
 
Chief Investigator: Dr Kevin Whelan  




9.2 Participant information sheet  
Participant Information Sheet 
The impact of dietary interventions for irritable bowel syndrome on luminal 
microbiota, symptoms, nutrient intake and quality of life: 
a randomised controlled trial 
 
We would like to invite you to take part in a research study conducted by King‟s College 
London and Guy‟s and St Thomas‟ Hospital to assess the effect of dietary interventions in 
irritable bowel syndrome (IBS). Before you decide we would like you to understand why 
the research is being done and what it would involve for you. We will go through this 
information sheet and answer any questions you have. 
 
What is the purpose of the study? 
The purpose of this 5-week study is to investigate the effect of dietary interventions on the 
bacteria in your bowel. One diet intervention that alters some carbohydrates in your diet 
(e.g. the types of fruits and vegetables) might be effective for symptoms such as bloating, 
abdominal pain and flatulence for many people with IBS.  
 
There are certain bacteria in your bowel e.g. bifidobacteria. Recent research has shown 
that the diet intervention described above can impact on the concentration of bifidobacteria 
in your bowel.  
 
Probiotics are friendly bacteria added to foods that can increase bifidobacteria in the 
bowel. This study will investigate the effect of the dietary intervention with a probiotic food 
supplement on: 
 
 Bacteria in the bowel and products of bacterial fermentation 
 Gut behaviour (e.g. wind, bloating) 
 Stool frequency and consistency 
 Dietary intake 
 Quality of life 
 
Who are we recruiting? 
We are looking for approximately 106 men and women between 18 and 65 years of age 
who have IBS but without constipation as the predominant symptom. People who have 
other gut conditions or who have diabetes, psychiatric or other chronic diseases will not be 
eligible to take part. People who have recently taken certain medications (e.g. prebiotics, 





Do I have to take part? 
It is up to you to decide whether to take part in the study. We will describe the study 
and go through this information sheet with you. If you agree to take part, we will then 
ask you to sign a consent form. You are free to withdraw at any time, without giving a 
reason. 
 
What will happen to me if I take part? 
The study will last for five weeks, and you will attend two or three visits at King‟s 
College London throughout the study to provide samples and have measurements 
taken. Each visit should last no more than 1 hour. Further details about each visit can 
be found in this information sheet. 
 
What will I have to do? 
Screening visit: 
If you are interested in taking part we will fully explain all study procedures and check 
that you are eligible. The consent form will need to be signed prior to the start of the 
study and this may involve an additional visit to the study site. Once the consent form is 
signed, we need to check your symptoms are severe enough and so we will need you 
to record information about your gut symptoms and your bowel habits each day for 7 
days, and also record all you eat and drink for 7 days. These diaries should take no 
more than a total of 1 hour to complete spread over the 7 days and if you take part this 
will form the baseline data for the study. 
 
Visit 1 and 2: 
At the end of the 7-day baseline period you will attend King‟s College London for Visit 1 
and four weeks later you will attend Visit 2. 
 
At these visits: 
 We will review your symptom/stool diary and diet diary  
 We will record your medical and medication history and smoking status (visit 1 
only) 
 We will check your weight  
 We will check your height (visit 1 only) 
 You will provide a fresh stool sample. You will need to provide the stool sample 
using a stool collection kit so that you can collect the whole stool. 
 You will be asked to complete an IBS symptom questionnaire,  two quality of life 
questionnaires and an acceptability questionnaire (these will take no more than 
35 minutes)  
 
Interventions 
At Visit 1 you will be randomly assigned one of the following four groups. You will not 
know which group you are in. 
 
Group 1: dietary intervention + probiotic food supplement 
Group 2: dietary intervention + placebo food supplement 
Group 3: sham diet + probiotic food supplement 
Group 4: sham diet + placebo food supplement 
 
The dietary intervention is the diet that might help people with IBS and the „sham‟ diet 
is the control diet. The control diet is used as a comparison and has been devised to 
appear like a diet to help with your IBS.  A specialised dietitian who is part of the 
research team will provide the dietary advice and give you detailed written information 





The probiotic food supplement is a tasteless commercially available powder 
supplement that you will add to your diet daily. A placebo is a dummy treatment, which 
looks like the real thing but is not. It contains no active ingredient.  The researcher who 
gives you the probiotic or placebo will also not know which one you are receiving. You 
will need to take the probiotic/placebo twice a day. It doesn‟t matter when you take the 
supplement as long as you take two a day. You will be given a compliance diary to 
complete to help us check how often you took the probiotic or placebo.  
 
A member of the research team will call you on a weekly basis during the 4 weeks to 
answer any questions and to remind you when to start your diaries. 
 
Throughout the study, we will ask that you do not consume any live (probiotic) yoghurts 
or prebiotic supplements (see pages 6,7). In addition, should it be medically necessary 
for you to take antibiotics, you will be withdrawn from the study. Should this occur 
please contact the research team as soon as possible.  
 
Alternative treatments 
Your doctor will discuss alternative treatments for your condition, which includes 
medications or other dietary treatments offered at Guy‟s and St Thomas‟ Hospital. 
 
Expenses  
Reimbursements for expenses (e.g. travel, meals, child-care, compensation for loss of 
earnings, etc.) will not be available for this study. No special arrangements will be 
made for compensation because this diet is routine treatment for people with IBS. 
 
What are the possible disadvantages and risks of taking part? 
An ethical review of this study has been carried out. The diet and probiotic food 
supplement have no known adverse effects and have been well tolerated in previous 
studies.  
 
Some people might find recording symptoms and/or collecting stool as part of the study 
embarrassing. You will be provided a toilet insert in which to collect your sample which 
will make this process easier. If you are concerned in any way please contact one of 
the researchers for advice. 
 
What are the possible benefits of taking part? 
The results of this study may help to answer scientific questions about what happens in 
your bowel when following the diet under investigation in conjunction with a probiotic 
food supplement, therefore helping other people in the future. In addition, it is possible 
that the study may result in improvements in your IBS symptoms. However, it is 
possible that no therapeutic or direct health benefits may result during or following your 
participation in this study.  
 
What if new information becomes available? 
If additional information becomes available during the course of the research regarding 
the diet or probiotic food supplement that is being studied, we will speak with you about 
it and whether you want to continue in the study. If you decide to withdraw we will make 
arrangements for your care to continue. If you decide to continue you may be asked to 
sign an updated consent form. Also, on receiving this new information the research 
team might consider it in your best interests to withdraw from the study. We will explain 





What happens at the end of the study? 
At the end of the 5-week study we will tell you whether you received the intervention or 
the sham diet. If you received the intervention diet we will provide you with advice 
regarding  the reintroduction of food items back into your diet just like we would in 
routine clinical care. If you received the sham diet and wish to receive advice regarding 
the dietary intervention we are investigating we can provide this at Visit 2 and then 
book you into a dietetic outpatient appointment for follow-up if you wish. You can also 
return to your usual diet if you would like. If you would like to know the probiotic food 
supplement that was being investigated we will tell you the product name at Visit 2 in 
order that you can purchase it if you wish. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should speak to Heidi 
Staudacher or one of the researchers who will do their best to answer your questions 
(0207 848 4447). We would not expect you to suffer any harm or injury because of your 
participation in this study. However, in the unlikely event of you suffering any adverse 
effects as a consequence of participating in this study you can contact King's College 
London using the details below for further advice and information and may be 
compensated through King‟s College London‟s „No Fault Compensation Scheme‟. Dr 
Kevin Whelan, Senior Lecturer in Nutritional Sciences, Tel: 020 78 48 38 58,  
Email: kevin.whelan@kcl.ac.uk 
 
Will my taking part in the study be kept confidential? 
We will contact your local doctor to inform them of your participation in the study. Any 
information/samples that leave King‟s College London will have your name, date of 
birth and hospital number removed so that you cannot be recognised from them. Data 
will be stored securely and only the research team will have access. Part of your 
medical records and information obtained during the study may be read by regulatory 
authorities to confirm the data collected. Your personal information will be strictly 
confidential and will not be made publicly available. If the results of the study are 
published, your identity will continue to remain confidential. Personal data and 
unidentifiable research data will be kept for 10 years. 
 
What will happen if I don’t want to carry on with the study? 
Taking part in this study is voluntary and your decision will in no way affect your current 
or future care within this trust. You will not lose any of your legal or ethical rights. You 
may withdraw from the study at any time without affecting your routine clinical care and 
you are not obliged to give reasons. However, if you withdraw because of a side effect 
please inform the research team. You may be withdrawn from the study, if it is 
considered in your best interests. If you withdraw from the study, we will destroy all 
your identifiable samples, but we will need to use the data collected up to your 
withdrawal. 
 
What will happen to any samples I give? 
During the study we will collect stool samples. The samples will have no personal 
details on them, so your identity will not be recognisable. Portions of the samples may 
be stored in a secure freezer for up to 10 years. Only members of the research team 









What will happen to the results of the research study? 
It is intended that the results of this study may be published in scientific or medical 
journals. You will not be identified in any report or publication. When the data from the 
study has been analysed you will receive a summary report of the results. 
 
Who has reviewed the study? 
This study has been checked by an independent group of people, called a Research 
Ethics Committee to protect your safety, rights, well-being and dignity. This study has 
been reviewed and given favourable opinion by the NRES Committee London - 
Fulham. 
 
Who is organising and funding the research? 
The study is organised and sponsored by King‟s College London and funded by 
internal funding (Diabetes and Nutritional Sciences Division, King‟s College London). 
The Principal Investigator is Heidi Staudacher. The Chief Investigator is Dr Kevin 
Whelan 
 
Further information and contact details 
If you would like further information about this research please contact Heidi 




Eating and drinking during the study 
 
Before the study it is important that you to continue to follow your usual diet, 
eating and drinking as you normally would.  
 
Before and during the study it is also important that you avoid foods, drinks and 
supplements that contain probiotics or prebiotics. This is because probiotics and 
prebiotics affect the bacteria in your gut – one of the things we are measuring.  
 
Probiotics and prebiotics are mostly found in yoghurts, yoghurt drinks and 
supplements. However, they can be found in other foods such as smoothies, 
cereals and cheese. You can usually tell from the label if there‟s a prebiotic or 






• Live culture 
• Lactic cultures 
• Yogurt cultures 
• Lactobacillus 
• Acidophilus 






Most yogurts contain probiotic, including many supermarket own brands. If you eat 
yogurt please check the label for the words listed above and select an alternative 
from the products listed below.  
 
Yogurts to avoid Suitable alternatives  











Weight Watchers  
 
Own brand, sheep or goat‟s milk 
yoghurt or other yogurts labeled with 
any of the words listed above.  
Müller corners (except Breakfast 
variety)  
Müller Light  
Müller Amoré  
Nom 
Yoplait Yop Drinking Yoghurt 
Yoplait Perle de Lait 
Frozen yoghurt e.g. Sainsbury‟s or 
Yeo Valley 
Fromage frais (e.g. Petit Filous) is 
usually not probiotic and can be 
used instead of yogurt 
 
Own brand or other yogurts where 
the words listed above do NOT 
appear on the label or in the 







Other foods, drinks and supplements  
Below is a list of other products that can be found in supermarkets and health food 
shops that report that they contain prebiotics or probiotics. (This list is not 
comprehensive – other products may contain prebiotics and/or probiotics).  
 
Please avoid the products listed below during the study. If you are unsure about a 
particular product please contact us to discuss it.  
 
 
• Alpen Light Cereal Bars  
• ASDA Cholesterol Lowering Yoghurt Drinks  
• ASDA Inner Defence Yoghurt Drinks 
• ASDA Vitality Cereal Bars  
• Bassetts Soft & Chewy Active Health Multivitamins With Minerals  
• Benecol Drinking Yoghurt 
• Biomuno products  
• Boots Probiotic Multivitamins  
• Boots Biobalance Support  
• Danone Actimel Yoghurt Drinks 
• Flora Pro Activ Cholesterol Lowering Health Drinks  
• Healthspan Probiotic Capsules  
• Healthspan Regulease  
• Healthspan Super20 Probiotic 
• Holland And Barrett Acidophilus Tablets  
• Kellogg‟s All Bran Breakfast Biscuits 
• Kellogg‟s Fibre Plus Cereal Bars  
• Moma Oat Breakfast Products 
• Muller Vitality Yoghurt Drinks  
• Multibionta Probiotic Multivitamins  
• Probio 7 Pre Or Probiotics  
• Quaker Morning Bars 
• Rice Krispies Multigrain  
• Sainsbury‟s Fruit Of The Forest Yoghurt Slices 
• Sainsbury's Probiotic Be Good To Yourself Yoghurt Drinks  
• Tesco Fruit And Fibre Cereal Bars 
• Tesco Light Choices Cereal Bars 
• Tesco Probiotic Yoghurt Drinks  
• VSL #3  
• Weetabix Oaty Bars 








9.3 Probiotic/placebo compliance diary  
COMPLIANCE DIARY:  WEEK 1 
          
Week commences date:       
 








































































9.4 Consent form  
 
Title of project: The impact of dietary interventions for irritable bowel 
syndrome on luminal microbiota, symptoms, nutrient intake and quality of 
life: a randomised controlled trial 
 
Participant ID: 
  Please 
initial  
1. 
I consent to the following: 
 Two visits at King‟s College London  
 Taking part in a four week dietary intervention 
 Take a probiotic food supplement or placebo supplement daily 
 Complete questionnaires and diaries as described in the 
participant information sheet 
 
2. 
I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical 
care or legal rights being affected. 
 
3. 
I agree that my stool samples can be used in the above study and I 
have been made aware of how any surplus material will be disposed of. 
 
4. 
I agree that any data, blood and stool samples that are surplus to this 
study, as well as any relevant information, can be used in future 
research that has been approved by a recognised Research Ethics 
Committee, but that my identity will be kept anonymous. 
 
5. 
I consent to the processing of my personal information for the purposes 
explained to me. I understand that such information will be handled in 
accordance with the terms of the Data Protection Act 1998. 
 
6. 
I understand that relevant sections of any of my medical notes and data 
collected during the study may be looked at by responsible individuals 
from regulatory authorities or from Guy‟s and St Thomas‟ NHS 
Foundation Trust, where it is relevant to my taking part in this research.  
I give permission for these individuals to have access to my records. 
 
7. I agree to my GP being informed of my participation in the study.  
8. I agree to take part in the above study.  
 
_________________________ _______________ _______________ 
Name of Participant Date Signature 
_________________________ _______________        _______________ 
Name of person taking consent Date Signature 
(if different from Investigator) 
 
_________________________ ________________             _______________         
Investigator Date Signature














Participant Diary  
























This is your Diary Booklet for Baseline Screening. Please try to remember to 
carry it with you at all times. If you forget to take the Diary Booklet with you, or 
are unable to carry it at all times, please make written notes on a pad and 
transfer them to the booklet as soon as possible. We have asked you to keep 
two diaries during this period: 
 
a) A 7-day Stool and Symptom Diary. Each diary day covers a 24 hour 
period. 
 Please record details of your stools as soon as possible after you 
have passed them.  
 Please complete the questions about IBS symptoms towards the 
end of each day, e.g. before you go to bed. 
 
b) A 7-day Food and Drink Diary. Please make entries in your booklet 
throughout the day, rather than from memory at the end of the day. 
During baseline screening for the study it is important that you to 
continue to follow your usual diet, eating and drinking as you normally 
would.  
This booklet is split into two sections.  
Section 1 contains the blank diaries for you to complete. We have organised 
the diaries in a day-by-day format to make it easier for you to record the right 
information on the right days. Each diary day covers a 24 hour period. 
Section 2 provides additional information on filling out your food diary and 
information on foods and medications that need to be avoided during the study 
Your next appointment 
Appointment Location Date Time 





How to contact us 
If you have any queries please contact  
Landline: 020 7848 4447  
Mobile: 07794690094 
Email: heidi.staudacher@kcl.ac.uk 




Day 7 of 7 
Day of week...............................                   
Date........................................... 
Every time you open your bowels today please complete the relevant box(es) 
below. Please refer to the Bristol Stool Chart on the back page.  
If you did not have a bowel action today please tick here:  
BOWEL MOVEMENT 1     
 Please indicate its consistency using the Bristol Stool 




BOWEL MOVEMENT 2     
 Please indicate its consistency using the Bristol Stool 




BOWEL MOVEMENT 3     
 Please indicate its consistency using the Bristol Stool 




BOWEL MOVEMENT 4     
 Please indicate its consistency using the Bristol Stool 




BOWEL MOVEMENT 5     
 Please indicate its consistency using the Bristol Stool 




BOWEL MOVEMENT 6     
 Please indicate its consistency using the Bristol Stool 











STOOL AND SYMPTOM DIARY 
At the end of each day, please rate your symptoms by placing a tick in 
the box that best describes them. If you do not have this symptom, 
tick ‘absent’ 




 Mild  
















Abdominal discomfort or pain  
(discomfort/ pain in your abdomen) 
 Absent  Mild  Moderate  Severe 
 
Heartburn (burning / discomfort behind 
your breastbone) 
 
Absent  Mild  Moderate  Severe 
 
Acid reflux / acid regurgitation 
(taste of sour fluid in your mouth) 
 
Absent  Mild  Moderate  Severe 
 
Nausea (feeling sick, but without 
vomiting) 
 
Absent  Mild  Moderate  Severe 
 
Abdominal gurgling / rumbling 
(vibration/ noise in your stomach or belly) 
 
Absent  Mild  Moderate  Severe 
 
Abdominal bloating / distension 
(swelling in your stomach or belly) 
 
Absent  Mild  Moderate  Severe 
 
Belching / burping (bringing up gas 
through your mouth) 
 
Absent  Mild  Moderate  Severe 
 
Flatulence / passing wind (release 
of gas from your bottom) 
 
Absent  Mild  Moderate  Severe 
 
Constipation  Absent  Mild  Moderate  Severe 
 
Diarrhoea  Absent  Mild  Moderate  Severe 
         
Loose stools  (mushy or watery 
stools) 
 
Absent  Mild  Moderate  Severe 
         
Hard stools(lumpy or dry stools)  
Absent  Mild  Moderate  Severe 
         
Urgency  (urgent need to open your 
bowels) 
 
Absent  Mild  Moderate  Severe 
         
Incomplete evacuation  (feeling of 
inability to pass all stool) 
 
Absent  Mild  Moderate  Severe 
         
Tiredness  Absent  Mild  Moderate  Severe 
  
       
Overall symptoms  Absent  Mild  Moderate  Severe 




FOOD AND DRINK DIARY Day of the week  Date  
 
Time Food/drink description and preparation Brand name 
Portion size or 
quantity eaten 









































Time Food/drink description and preparation Brand name 
Portion size or 
quantity eaten 





















































Time Food/drink description and preparation Brand name 
Portion size or 
quantity eaten 



























































Did you take any vitamins, minerals or other food supplements today?                                    Yes                     No   
If yes, please describe the supplements you took below 
 
Brand Name (in full) including strength Number of pills, capsules, teaspoons 
   
   
   
   
 
Please record details of any recipes or ingredients of made up dishes or take-away dishes (if not already described). 
NAME OF DISH:                                                                             SERVES:  
 
Ingredients Amount Ingredients Amount 
    
    
    
    
    
 





Did you have adequate relief of your IBS 
symptoms over the last 7 days? 
 
    Yes  No   
 






Instructions and guidance 
   
 
 
Food and Drink Diary 
example 
    
 Day of the 
week 
Thurs Date 31 March 
 
Time Food/drink description and preparation Brand name Portion size or quantity eaten 
6 am to 9am 
 











Filter coffee, decaffeinated 
Milk (fresh, semi-skimmed). 
Sugar (white)  
 
Filter coffee with milk and sugar  
Cornflakes  
Milk (fresh, semi-skimmed)  
Toast, granary medium sliced  
Light spread  
Marmalade 




As above  






A little  
1 level tsp  
 
As above  
Picture 1b  
Drowned  
1 slice  
Med spread  
1 heaped tsp 
9 am to 12 noon 





Instant coffee, not decaffeinated  
Milk (fresh, whole) Sugar brown  
 







A little, 1 level tsp  
 
2 




Pictures for food portion guidance 
 
Use the pictures to help you indicate the size of the portion you have 
eaten. Write on the food record the picture number and size A, B or C 
nearest to your own helping. 
Remember that the pictures are much smaller than life size. The actual 
size of the dinner plate is 10 inches (25cm), the side plate, 7 inches 
(18cm), and the bowl, 6.3 inches (16cm). 
The tables in your food diary guidance booklet also give examples of 




















Broccoli or cauliflower 
 
 






Quiche or pie 
 







Note: in each picture the slice, cube and pile of grated 
cheese represent the same weight of cheese. If you record 
the amount of cheese you’ve eaten as e.g. ‘Picture 9a’, your 
record will refer to just one of the three (slice, cube, grated) 



















150 200 300    
Wine 125 175 250    
Hot drinks    170 190 260 
 
Glasses come in different shapes and sizes.  On the next page is a life-
size glass showing approximate volumes. You can use this picture as a 
guide for estimating how much volume of drink the glass holds that you 
are drinking from. 
 





















   
 
 
Life size spoons 
 
Teaspoon  















Eating and drinking during baseline screening 
 
 
Before and during the study it is also important that you avoid foods, drinks and 
supplements that contain probiotics or prebiotics. You can usually tell from the 
label if there‟s a prebiotic or probiotic in a food or supplement. These labels will 





• Live culture 
• Lactic cultures 
• Yogurt cultures 
• Lactobacillus 
• Acidophilus 






If you eat yogurt please check the label for the words listed above and select an 
alternative from the products listed below.  
 
Yogurts to avoid Suitable alternatives  











Weight Watchers  
 
 
Müller corners (except Breakfast 
variety)  
Müller Light  
Müller Amoré  
Nom 
Yoplait Yop Drinking Yoghurt 
Yoplait Perle de Lait 
Frozen yoghurt e.g. Sainsbury‟s or  
Yeo Valley 
Fromage frais (e.g. petit filous)  
is usually not probiotic and can be  






Other foods, drinks and supplements  
Avoid the list of foods below as they contain probiotics or prebiotics. It is not 
comprehensive – other products may contain prebiotics and/or probiotics.  
 
• Alpen Light Cereal Bars  
• ASDA Cholesterol Lowering Yoghurt Drinks  
• ASDA Inner Defence Yoghurt Drinks 
• ASDA Vitality Cereal Bars  
• Bassetts Soft & Chewy Active Health Multivitamins With Minerals  
• Benecol Drinking Yoghurt 
• Bimuno products  
• Boots Probiotic Multivitamins  
• Boots Biobalance Support  
• Danone Actimel Yoghurt Drinks 
• Flora Pro Activ Cholesterol Lowering Health Drinks  
• Healthspan Probiotic Capsules  
• Healthspan Regulease  
• Healthspan Super20 Probiotic 
• Holland And Barrett Acidophilus Tablets  
• Kellogg‟s All Bran Breakfast Biscuits 
• Kellogg‟s Fibre Plus Cereal Bars  
• Moma Oat Breakfast Products 
• Muller Vitality Yoghurt Drinks  
• Multibionta Probiotic Multivitamins  
• Probio 7 Pre Or Probiotics  
• Quaker Morning Bars 
• Rice Krispies Multigrain  
• Sainsbury‟s Fruit Of The Forest Yoghurt Slices 
• Sainsbury's Probiotic Be Good To Yourself Yoghurt Drinks  
• Tesco Fruit And Fibre Cereal Bars 
• Tesco Light Choices Cereal Bars 
• Tesco Probiotic Yoghurt Drinks  
• VSL #3  
• Weetabix Oaty Bars 
• Weetabix Oatibix Sultana And Apple Bitesize Cereal  
• Yakult 
 
Medications and therapies during the study 
Please tell one of the researchers as soon as possible if you begin taking  
any of the following medications: 
 Antibiotics 
 Prebiotics or probiotics 
 Bowel preparation for an investigative procedure on your bowel 
 
If there is a change to the dose or type of your IBS medication 
If you start taking a new medicine and are unsure whether it is included  




Bristol Stool Chart 
 
Please refer to this chart each time you complete a Stool and 
Symptom Diary. 
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9.6 Instructions on stool collection 
Collecting your stool  
During the study we will ask you to collect your stool at Visit 1 and Visit 2. It is best that 
we collect your stool at the study centre as we need to start processing it within 1-2 
hours of being passed.  
We gather important information from these stool collections, including information 
about the bacteria in your gut and pH. 
 
Stool collection kit 
 
1. Disposable paper plate 
2. Tie-handle clear plastic bags  







How to collect your stool 
 
Most participants will collect stool at the study centre and therefore these instructions 
will be given to you at your visit.  
1. If you need to urinate, please do so before you collect your stool.  
YOU MUST ENSURE THAT YOU DO NOT URINATE AT THE SAME TIME AS 
COLLECTING YOUR STOOL SAMPLE - this would contaminate the sample.  
2. Put on the disposable gloves. 
3. Open up a tie-handle clear plastic bag, then 
flatten the bottom and shape the sides to form 
a container shape.  
1 
3 2 




4. Sit the opened plastic bag on top of the 
paper plate. Then put your hands inside 
the plastic bag, and tuck the base of the 
bag loosely over the rim of the plate. 
Please note: the plate should be sitting 
underneath the bag, not inside it. 
 
 
   
 
5. Starting with the handles, roll down the 
sides of the bag as shown in the next 
photo. Roll the bag down to leave about 5 
cm (2 inches) of the bag above the plate. 
 
6. Place the plate and bag into the toilet so 
that the bag remains on the top of the 
plate. The plate and bag should sit in the 
toilet bowl and prevent your stool from 
going into the water.  
Tip: Make sure the plate is stable in the toilet bowl – you may need to press on 
it a little to make sure it is wedged in place and won’t tip when you pass a stool 
into the plastic bag. 
7. Pass your stool. The stool should land inside the plastic bag. REMEMBER - YOU 
MUST ENSURE THAT YOU DO NOT URINATE AT THE SAME TIME as this would 
contaminate the sample. 
8. Double-bag the sample. 
9. Place the sample in the container provided with some ice cubes in the bottom 
of the container to keep the sample cold. 
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This form is designed to enable us to record and monitor the severity of your IBS. It is to be 
expected that your symptoms might vary over time, so please try and answer the questions 
based on how you currently feel (i.e. over the last 10 days).  
 
1. For questions where a number of different responses are possible, please circle the 
response appropriate to you 
 
2. Some questions will require you to write an appropriate response 
 
3. Some questions require you to put a cross on a line which enables us to judge the 
severity of a particular problem. 
 
For example: 
How severe was your pain? 
 
Please put a cross (X) anywhere on the line between 0-100% in order to indicate as 




















severe very  
severe 
0% 100% 
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1. a)  Did  you suffer from abdominal (tummy) pain in the last 10 days (please   


















 c)  Please enter the number of days that you had pain in the last 10 days. 
  
 




2. a)  Did you suffer from abdominal distension (bloated, swollen or tight  
 tummy) in the last 10 days (please circle)?   
   



















4. How satisfied were you with your bowel habit in the last 10 days? 
 
 











4.  Please indicate with a cross on the line below how much your Irritable Bowel 






Yes  No 
 
Yes  No 
 














                                                                                                                                          





SF-36 Your Health and Well being 
 
This survey asks for your views about your health. This information will help keep 
track of how you feel and how well you are able to do your usual activities. 
 






1.  In general, would you say your health is: 
 
 
     
Excellent Very Good Good         Fair          Poor 




























     
     
 





3. The following items are about activities you might do during a typical day.  
Does your health now limit you in these activities? If so, how much? 
 
 Yes, limited a lot 
 
Yes, limited a 
little 
 
No, not limited at 
all 
 
Vigorous activities, such as 
running, lifting heavy objects, 
participating in strenuous sports 
 
   
Moderate activities, such as 
moving a table, pushing a vacuum 
cleaner, bowling or playing golf 
 
   
 
Lifting or carrying groceries 
 
 
   
 
Climbing several flights of stairs     
 
 
   
 
Climbing one flight of stairs 
 
 
   
 
Bending, kneeling or stooping 
 
 
   
 
Walking more than a mile 
 
 
   
 
Walking several blocks 
 
 
   
 
Walking one block 
 
 
   
 













4. During the past 4 weeks, have you had any of the following problems with your 
work or other regular daily activities as a result of your physical health? 
 
 Yes No 
 
Cut down the amount of time you spent on 






















Had difficulty performing the work or other 












5. During the past 4 weeks, have you had any of the following problems with your 
work or other regular daily activities as a result of any emotional problems (such as 




 Yes No 
 
Cut down on the amount of time you spent 



























6. During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, 
neighbours or groups? 
 
 























Mild Moderate Severe Very severe 
 
 








8. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)? 
 
 
 Not at all 
 
A little bit 
 
Moderately Quite a bit Extremely 
 
 
     





      
9. These questions are about how you feel and how things have been with you during 
the past 4 weeks. For each question, please give one answer that comes closest to the 
way you have been feeling.  
 

























Did you feel full of pep? 
 
      
 
Have you been a very nervous 
person? 
      
 
Have you felt so down in the 
dumps that nothing could cheer 
you up? 
      
       
 
Have you felt calm and peaceful? 
      
       
 
Did you have a lot of energy? 
      
       
 
Have you felt downhearted and 
blue? 
      
       
 
Did you feel worn out? 
      
       
 
Have you been a happy person? 
      
       
 
Did you feel tired? 
      






10. During the past 4 weeks, how much of the time has your physical health or emotional 





All of the 
time 
 
Most of the 
time 
 




A little of the 
time 
None of the 
time 
    























I seem to get sick a little easier 
than other people  
     
 
 


















































PLEASE WRITE IN 
TODAY'S DATE: _____ ______  _____ 






PLEASE READ THIS CAREFULLY 
 
ON THE FOLLOWING PAGES YOU WILL FIND STATEMENTS CONCERNING BOWEL PROBLEMS 
(IRRITABLE BOWEL SYNDROME) AND HOW THEY AFFECT YOU. 
 
FOR EACH STATEMENT, PLEASE CHOOSE THE RESPONSE THAT BEST APPLIES TO YOU  
AND CIRCLE THE NUMBER OF YOUR RESPONSE. 
 
IF YOU ARE UNSURE ABOUT HOW TO RESPOND TO A STATEMENT, PLEASE GIVE THE BEST 
RESPONSE YOU CAN. THERE ARE NO RIGHT OR WRONG RESPONSES. 
 




IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT: 
 













The Irritable Bowel Syndrome - Quality of Life questionnaire (IBS-QOL) was developed by Donald L. Patrick, Ph.D. at 
The University of Washington, Douglas A. Drossman, MD at The University of North Carolina, Novartis Pharmaceuticals 
Corporation, and Novartis Pharma AG. Authors hold joint copyright over the IBS-QOL and all its translations. 
PARTICIPANT/PATIENT ID: 




About Your Feelings 
 
Please think about your life over the past month (last 30 days) and look at the statements 
below.  Each statement has five possible responses. For each statement, please circle the one 
response that best describes your feelings. 
 
 
1. I feel helpless because of my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
2. I am embarrassed by the smell caused by my bowel problems. (Please circle one 
number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
3. I am bothered by how much time I spend on the toilet. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
4. I feel vulnerable to other illnesses because of my bowel problems. (Please circle one 
number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
5. I feel fat or bloated because of my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL
 





6. I feel as though I am losing control of my life because of my bowel problems. (Please 
circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
7. I feel that my life is less enjoyable because of my bowel problems. (Please circle one 
number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
8. I feel uncomfortable when I talk about my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
9. I feel depressed about my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
10. I feel isolated from other people because of my bowel problems. (Please circle one 
number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 




11. I have to be careful about the amount of food I eat because of my bowel problems. 
(Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
12. Because of my bowel problems sexual activity is difficult for me. (Please circle one 
number) 
 (If not applicable, please circle “NOT AT ALL”) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
13. I feel angry that I have bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
14. I feel as though I irritate others because of my bowel problems. (Please circle one 
number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
15. I worry that my bowel problems will get worse. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 




16. I feel irritable because of my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
17. I worry that people think I exaggerate my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
18. I feel that I get less done because of my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
19. I have to avoid stressful situations because of my bowel problems. (Please circle one 
number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
20. My bowel problems reduce my sexual desire. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 




21. My bowel problems limit what I can wear. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
22. I have to avoid strenuous activity because of my bowel problems. (Please circle one 
number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
23. I have to be careful about the kind of food I eat because of my bowel problems. (Please 
circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
24. Because of my bowel problems I have difficulty being with unfamiliar people. (Please 
circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
25. I feel sluggish because of my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 




26. I feel “unclean” because of my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
27. Long trips are difficult for me because of my bowel problems. (Please circle one 
number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
28. I feel frustrated that I cannot eat when I want to because of my bowel problems. 
(Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
 
 
29. It is important to be near a toilet because of my bowel problems. (Please circle one 
number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 




30. My life revolves around my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 










31. I worry about losing control of my bowels. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
32. I am afraid that I won't be able to have a bowel movement. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
33. My bowel problems are affecting my closest relationships. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 A GREAT DEAL 
 
 
34. I feel that no one understands my bowel problems. (Please circle one number) 
 
  1 NOT AT ALL 
  2 SLIGHTLY 
  3 MODERATELY 
  4 QUITE A BIT 
  5 EXTREMELY 
        Pt Id Pt id 
 
 
9.10 Acceptability questionnaire 
Acceptability Questionnaire 

































































































































5. The money I spent on grocery shopping and eating out compared to my 


































10. Did any benefits of being involved in this study outweigh the burden of being  
on this diet? (Please circle) 
    Yes         No 
  
11. Overall did you have to make many changes to your diet? (Please circle)  
   
    Yes          No 
 
12. Was there a food or drink that you missed a lot? (Please circle)   
      
Yes         No 
 
13. If yes, what food or drink was it?             
 

























































































The following questions relate to the probiotic/placebo. Please circle the 















If so, please provide detail:  
 
               
            




















1.   Regarding taking the sachets daily for 4 weeks, was it  
Acceptable/easy  Difficult  
 
2. Did you get any side effects from taking the probiotic/placebo     
      sachets? 
 
Yes  No 
 







4. Would you classify a probiotic as a  
 




5.   Would you take a probiotic for your IBS symptoms in the future? 
























Instructions for completing your Food and Drink Diary 
 
PLEASE READ THROUGH THIS BOOKLET BEFORE STARTING  
YOUR FOOD AND DRINK DIARY 
 
This Food and Drink Diary Guidance Booklet provides additional information 
about recording what you eat and drink. 
Completing your diary: 
1. Day and date  
Please write down the day and date at the top of the page each time you 
start a new day of recording.  
2. Time slots  
Please note the time of each eating occasion into the space provided. 
For easy use each day is divided into sections, from the first thing in the 
morning to late evening and through the night.  
3. What do you eat? 
Please describe the food you eat in as much detail as possible. Be as 
specific as you can. Pages 7-14 of this booklet will help with the sort of 
detail we need, like cooking methods (fried, grilled, baked etc) and any 
additions (fats, sugar/sweeteners, sauces, pepper etc). 
4. Homemade dishes  
If you have eaten any homemade dishes e.g. chicken casserole, please 
record the name of the recipe, ingredients with amounts (including water 
or other fluids) for the whole recipe, the number of people the recipe 
serves, and the cooking method. Write this down in the recipe section at 
the end of the record day. Record how much of the whole recipe you 
have eaten in the portion size column. 
5. Takeaways and eating out  
If you have eaten takeaways or made up dishes not prepared at home 
such as at a restaurant or a friend‟s house, please record as much detail 
about the ingredients as you can e.g. vegetable curry containing 
chickpeas, aubergine, onion and tomato.  
6. Brand name  
Please note the brand name (if known). Most packed foods will list a 
brand name, e.g. Bird‟s eye, Hovis, or Supermarket own brands.   
7. Portion sizes 
Examples for how to describe the quantity or portion size you had of a 
particular food or drink are shown in this booklet.  
For foods, quantity can be described using:  
 304 
 
 Household measures, e.g. one teaspoon (tsp) of sugar, two thick 
slices of bread, 4 tablespoons (tbsp) of peas, ½ cup of gravy. Be 
careful when describing amounts in spoons that you are referring to 
the correct spoon size. Compare the spoons you use with the life size 
pictures in your participant diary.  
 Weights from labels, e.g. 4oz steak, 420g tin of baked beans, 125g 
pot of yogurt. 
 Number of items, e.g. 4 fish fingers, 2 pieces of chicken nuggets, 1 
regular size jam filled doughnut . 
 Picture examples for specific foods in your diary booklet.  
For drinks, quantity can be described using:  
 The size of glass, cup etc (e.g. large glass) or the volume (e.g. 
300ml). Examples of typical drinks containers are in your diary 
booklet.  
 Volumes from labels (e.g. 330ml can of fizzy drink).  
We would like to know the amount that was actually consumed which 
means taking leftovers into account. You can do this in two ways:  
 Record what was served and make notes of what was not eaten e.g. 
3 tbs of peas, only 2 tbs eaten; 1 large sausage roll, ate only ½ . 
 Only record the amount actually eaten i.e. 2 tbs of peas, ½ a large 
sausage roll. 
8. Supplements  
At the end of each recording day there is a section for providing 
information about any supplements you took. Brand name, full name of 
supplement, strength and the amount taken should be recorded.  
9. When to fill in the diary  
Please record your eating and drinking as you go, not from memory at 
the end of the day. Use written notes on a pad if you forget to take your 
diary with you. Each diary day covers a 24 hour period, so please include 
any food or drinks that you may have had during the night. Remember to 
include foods and drinks between meals (snacks) including water.  
10. Completed diary examples 
On pages 3-6 of this booklet you can see an example day that have been 
filled in. This shows you how we would like you to record your food and 
drink, for example a ready meal and a homemade dish.  
With thanks to the Medical Research Council for Human Nutrition Research for 
permission to use this Food and Drink Diary design. 
  
 
Food and Drink Diary example     
 Day of the week Thurs Date 31 March 
 
Time Food/drink description and preparation Brand name Portion size or quantity eaten 
6 am to 11am 
 











Filter coffee, decaffeinated 
Milk (fresh, semi-skimmed). 
Sugar (white)  
 
Filter coffee with milk and sugar  
Cornflakes  
Milk (fresh, semi-skimmed)  
Toast, granary medium sliced  
Light spread  
Marmalade 
 




As above  







A little  
1 level tsp  
 
As above  
Picture 1b  
Drowned  
1 slice  
Med spread  
1 heaped tsp 
10.15 am  
 
11 am 
Instant coffee, not decaffeinated  
Milk (fresh, whole) Sugar brown  






A little  




Did you take any vitamins, minerals or other food supplements today?                                    Yes                     No   
 
Brand Name (in full) including strength Number of pills, capsules, teaspoons 
Holland & Barrett Evening Primrose Oil – 1000 mg 1 capsule 
Holland & Barrett Vitamin E – 400 IU 1 capsule 
 
Please record details of any recipes or ingredients of made up dishes or take-away dishes (if not already described). 
 
NAME OF DISH:   Fairy cakes                                              SERVES: makes 20 cakes 
Ingredients Amount Ingredients Amount 
Tate & Lyle caster sugar 175g Silver Spoon icing sugar 140g 
Anchor butter, unsalted 175g Yellow food colouring 3 drops 
Eggs 3 Water 2 tablespoons 
Homepride self-raising flour 175g   
Baking powder 1 teaspoon   
 
Brief description of cooking method 
 
Mix together and bake for 15 min.  
 
Mix icing sugar with water and add colouring. Approx. 1 teaspoon of icing on each cake 
 




This table explains the detail we’d like you to provide in your Food and Drink Diary for the different foods and drinks listed. 
Food/drink Description and preparation Portion size or quantity 
Bacon  
Back, middle, streaky; smoked or un-smoked; fat eaten; 
dry-fried or fried in oil/fat (type used) or grilled rashers  
Number of rashers  
Baked beans  Standard, reduced salt or reduced sugar  
Tablespoons, weight of beans 
marked on tin label (e.g. 420g)  
Beefburger (hamburger)  
Home-made (ingredients), from a packet (brand name) or 
take-away; fried (type of oil/fat), microwaved or grilled; 
economy; with or without bread roll  
Number, large or small, ounces or in 
grams if info on package  
Beer  
What sort e.g. stout, bitter, lager; draught, canned, bottled; 
low-alcohol or home-made  
Number of pints or half pints, size of 
can or bottle  
Biscuits  
What sort and brand e.g. cheese, wafer, crispbread, sweet, 
chocolate, shortbread, home-made  
Number, size (standard or mini 
variety)  
Bread (see also sandwiches)  
Wholemeal, granary, white or brown; currant, fruit, malt; 
large or small loaf; sliced or unsliced loaf; give brand  
Number of slices; thick, medium or 
thin slices  
  
 
Food/drink Description and preparation Portion size or quantity 
Bread rolls  
Wholemeal, white or brown; alone or with filling; crusty or 
soft  
Size, number of rolls  
Breakfast cereal (see also 
porridge)  
What sort and brand e.g. Kellogg‟s cornflakes; any added 
fruit and/or nuts; Muesli – added sugar and/or fruit  
Tablespoons or picture 1  
Bun  Iced, currant or plain, homemade or bought (brand name)  Large or small, number  
Butter, margarine & fat 
spreads  
Give full product name  Thick/average/thin spread; spoons  
Cake  
Individual or piece of large; type and brand; fruit (rich), 
sponge, fresh cream, buttercream, iced; type of filling  
Number, slices, packet weight, see 
picture 10 for sponge cake  
Cheese  
Name, brand and type e.g. cheddar, cream, cottage, soft; 
low fat  
picture 9, or number of slices, thick 
or thin cut, number of spoons  
Chips  
Fresh, frozen, oven, microwave, take-away (where from); 
thick/straight/crinkle/fine cut; type of oil/fat used for cooking 
give brand name  
picture 4, as A, B, or C or 2 x B, etc  
Chocolate(s)  
What sort e.g. plain, milk, white, fancy, diabetic; type of 
filling; give brand name  
Number, weight/size of bar  
  
 
Food/drink Description and preparation Portion size or quantity 
Coffee  
With milk (see section on milk); half milk/half water; all milk; 
ground/filter, instant; decaffeinated; give brand name  
Cups or mugs  
Cream  
Single, whipped, double or clotted; dairy or non-dairy; low-
fat; fresh, UHT/Longlife; imitation cream e.g. Elmlea  
Tablespoons  
Crisps  
What sort e.g. potato, corn, wheat, maize, vegetable etc; 
give brand; flavour; low-fat or low-salt; premium variety e.g. 
Kettle chips, Walker‟s Sensations  
Packet weight  
Custard  
Pouring custard or egg custard; made with powder and 
milk/sugar, instant, ready to serve (tinned or carton); low 
fat, sugar free, brand  
Tablespoons  
Doughnut  
Plain, jam, cream or iced; round or ring, where 
bought/brand name  
Number, size e.g. mini, large  
Egg  
Boiled, fried (type of oil/fat), scrambled (type of fat used, 
with or without added milk), poached, omelette (with or 
without filling, type of oil/fat used), etc  
Number of eggs, large, medium or 
small eggs  
  
 
Food/drink Description and preparation Portion size or quantity 
Fish (including canned)  
What sort and brand e.g. cod, tuna; fried (type of oil/fat), 
grilled, poached (water or milk) or steamed; with batter or 
breadcrumbs; canned in oil, brine or tomato sauce  
Size of can or spoons (for canned 
fish) or picture 7 for battered fish  
Fish cakes & fish fingers  
Type of fish; plain or battered or in breadcrumbs; fried, 
grilled, baked or microwaved; economy  
Size, number, packet weight  
Fruit -fresh  What sort; eaten with or without skin  Size, number  
Fruit -stewed/canned  
What sort; sweetened or unsweetened; in fruit juice or 
syrup; juice or syrup eaten  
Tablespoons Size of can or weight 
on can  
Fruit – juice (pure)  
What sort and brand e.g. apple, orange; sweetened or 
unsweetened; pasteurised or UHT/Longlife; freshly 
squeezed; added vitamins/minerals, omega 3?  
Glass (size or volume) or carton size  
Ice cream  
Flavour; dairy or non-dairy; brand name; luxury/premium; 
added nuts, fruit  
Number of tablespoons/ scoops  
Jam, honey  
What sort; low-sugar/diabetic; shop bought/brand or 
homemade  
Teaspoons, heaped or level, or thin 
or thick spread  
Marmalade  
Type and brand; low-sugar; thick cut; shop bought/brand or 
homemade  
Teaspoons, heaped or level, or thin 
or thick spread  
  
 
Food/drink Description and preparation Portion size or quantity 
Meat (see also bacon, burgers 
& sausages)  
What sort; cut of meat e.g. chop, breast, minced; lean or 
fatty; fat removed or eaten; skin removed or eaten; how 
cooked; with or without gravy  
Large/small/medium, tablespoons, 
or picture 6 for stew portion  
Milk  
Brand and type (whole, semi-skimmed, skimmed); fresh, 
sterilized, UHT, dried; soya milk 
(sweetened/unsweetened), goats' milk, rice milk; flavoured; 
fortified with added vitamins and/or minerals  
Pints, glass (size or volume) or cup.  
For milk on cereal: 
damp/normal/drowned. For milk in 
tea/coffee: a little/some/a lot  
Nuts  
What sort and brand; dry roasted, ordinary salted, honey 
roasted; unsalted  
Packet weight, handful  
Pie (sweet or savoury)  
What sort and brand; individual or helping; one pastry crust 
or two; type of pastry  
Individual or slice, or picture 8  
Pizza  
Thin base or deep pan or French bread; topping; brand 
name and type  
Individual, slice, fraction of large 
pizza e.g. ¼  
Porridge  
Brand name; made with oats or cornmeal or instant oat 
cereal; made with milk and/or water; with sugar or honey; 




Food/drink Description and preparation Portion size or quantity 
Potatoes (see also chips)  
Old or new; baked, boiled, roast (type of oil/fat); skin eaten; 
mashed (with butter/spread and with or without milk); 
fried/chips (type of oil/fat); instant; any additions e.g. butter  
Mash – tablespoons, number of half 
or whole potatoes, small or large 
potatoes, or picture 4 for chips 
portion  
Pudding  
What sort; e.g. steamed sponge; with fruit; mousse; instant 
desserts; milk puddings  
Tablespoons, picture 10 for slice of 
sponge  
Rice  
What sort; e.g. basmati, easy cook, long or short grain; 
white or brown; boiled or fried (type of oil/fat); brand name  
Tablespoons or picture 2  
Salad  
Ingredients; if with dressing what sort (oil and vinegar, 
mayonnaise); brand name of dressing  
Amount of each component; e.g. 
number of tomatoes, slices of 
cucumber, leaves; tablespoons of 
dressing  
Sandwiches and rolls  
Type of bread/roll (see Bread & Rolls); butter or margarine; 
type of filling; including salad, mayonnaise, pickle etc. If 
shop-bought, where from?  
Number of rolls or slices of bread; 
amount of butter/margarine (on both 
slices?); amount of filling  
Sauce – cold (including 
mayonnaise)  
Tomato ketchup, brown sauce, soy sauce, salad cream, 
mayonnaise; low fat; brand name  
Teaspoons, tablespoons  
  
 
Food/drink Description and preparation Portion size or quantity 
Sausages  
What sort; e.g. beef, pork; fried (type of oil/fat) or grilled; 
low fat; economy; brand name  
Large or small, number  
Sausage rolls  Type of pastry; brand name  
Number, size e.g. jumbo, standard, 
mini  
Scone  
Fruit, sweet, plain, cheese; type of flour; bought/brand or 
homemade  
Number, small, medium or large  
Savoury snacks -in packet  
What sort: e.g. Cheddars, cheese straws, Twiglets, 
Pretzels; give brand name  
Size (standard or mini variety), 
packet weight, number  
Soft drinks – squash/ 
concentrate/cordial  
Give brand name & flavour; no added sugar/low 
calorie/sugar free; “high” juice; fortified with added vitamins 
and/or minerals  
Glass (size or volume)  
Soft drinks – carbonated/fizzy  
Give brand & flavour; diet/low-calorie; canned or bottled; 
cola – caffeine free  
Glass, can or bottle (size or volume)  
Soft drinks – ready to drink  
Give brand & flavour; no added sugar/low calorie/sugar 
free; does it contain real fruit juice, if so, how much?; 
fortified with added vitamins and/or minerals  




Food/drink Description and preparation Portion size or quantity 
Soup  
What sort; give brand name; cream or clear; canned, 
packet, instant or vending machine, home-made  
Tablespoons, bowl or mug  
Spaghetti, other pasta  
What sort; fresh/chilled or dried; white, wholemeal; canned 
in sauce; type of filling if ravioli, cannelloni etc  
Tablespoons (or how much dry 
pasta used per portion in 
grams/packet size) or picture 3  
Spirits  What sort: e.g. whisky, gin, vodka, rum  Measures as in pub  
Sugar  
Added to cereals, tea, coffee, fruit, etc; what sort; e.g. 
white, brown, demerara  
Heaped or level teaspoons  
Sweets  
What sort: e.g. toffees, boiled sweets, diabetic; give brand 
name  
Number, packet weight  
Tea  With/without milk (see section on milk); decaffeinated, herb  Mugs or cups  
Vegetables (not including 
potatoes)  
What sort; how cooked or raw; additions e.g. butter, other 
fat or sauce  
Tablespoons, number of florets or 
sprouts, weight from tins or packet 
as guidance  
Water  Tap, filtered, bottled: give brand name  Glass or bottle (size or volume)  
Wine, sherry, port  White, red; sweet, dry; low-alcohol; give brand name  Glass (size or volume)  
  
 
Food/drink Description and preparation Portion size or quantity 
Yoghurt, fromage frais  
What sort: e.g. natural/plain or flavoured; creamy, Greek, 
low-fat, very low fat/diet, soya; with fruit pieces or just fruit 
flavoured; twinpot with separate cereal/crumble; fortified 
with added vitamins and/or minerals; brand name  
Pot size or tablespoons  
Home-made dishes  
Please say what the dish is called (record recipe or details 
of dish if you can in the section provided) and how many 
persons it serves  
Tablespoons – heaped or level, 
number, size  
Ready-made meals  
Please give brand name and full description of product; did 
it contain any accompaniments e.g. rice, vegetables, 
sauces; was it chilled or frozen; microwaved, oven cooked, 
boil-in-the-bag; was it low fat, healthy eating range. 
Enclose label and ingredients list if possible in your plastic 
bag  
Packet weight, if not whole packet 
describe portion consumed  
Take-away food or food eaten 
out  
Please say what the dish is called and give main 
ingredients if you can. Give name of a chain restaurant e.g. 
McDonalds  
Tablespoons, portion size e.g. 
small/medium/large  




9.12 Demographic data and nutrient intake for the sham diet pilot study  
Demographic data and nutrient intake for the sham diet pilot study in healthy individuals 
(n=7) to be implemented in a 2x2 factorial design RCT of low FODMAP dietary advice and 
probiotic supplementation in patients with IBS 
 
 
Demographic data  
 
Variable Mean (SD) 
Age yrs 33 (7) 
Females n (%) 6 (86) 
Weight kg 71 (19) 
BMI kg/m
2
 26 (7) 





Mean (SD) for total energy, nutrient and FODMAP intake of habitual and sham diet  
 
Nutrient Habitual diet Sham diet p
#
 
Energy (kcal/d) 2108 (619)  2041 (779) 0.735 
Carbohydrate (g/d) 244 (47) 234 (99) 0.499 
Starch (g/d) 135 (41) 118 (32) 0.398 
Sugars (g/d) 89 (37) 99 (37) 0.499 
Protein (g/d) 78 (26) 86 (21) 0.735 
Fat (g/d) 80 (24) 80 (42) 0.866 
NSP (g/d) 13.4 (3.6) 17.3 (4.7) 0.043 
FODMAPs    
Total FODMAPs (g/d) 15.8 (5.1) 22.7 (8.5) 0.091 
     Fructans (g/d) 2.3 (0.9) 3.7 (2.4) 0.176 
     GOS (g/d) 0.7 (0.4) 0.9 (0.6) 0.310 
     Sorbitol (g/d) 0.4 (0.6) 1.3 (0.6) 0.091 
     Mannitol (g/d) 0.3 (0.4) 0.5 (0.3) 0.345 
     Excess fructose (g/d) 1.4 (0.9) 1.4 (0.7) 1.000 
     Lactose (g/d) 9.3 (5.1) 11.8 (7.7) 0.237 
Values are mean (SD). 
#
Wilcoxon signed rank test  
 




9.13 IBS-SSS total and subscores at baseline and follow up 
IBS-SSS scores for the  intention to treat population (n=104) of patients with IBS participating in a 2x2 factorial design RCT of low FODMAP dietary advice 
and probiotic supplementation  
 
 
Sham diet (n=53) Low FODMAP diet (n=51) Placebo (n=51) Probiotic (n=53) 
 Baseline Follow up Baseline Follow up Baseline Follow up Baseline Follow up 
IBS-SSS total (pts) 268 (72) 224 (89) 291 (76) 173 (95) 284 (75) 207 (98) 275 (75) 192 (93) 
     Pain severity 51 (25) 40 (23) 54 (21) 33 (24) 55 (25) 38 (24) 49 (21) 35 (24) 
     Days of pain (days) 54 (31) 44 (29) 59 (30) 30 (27) 58 (30) 39 (28) 55 (31) 35 (30) 
     Distension severity 46 (24) 40 (24) 51 (25) 29 (25) 48 (22) 34 (24) 48 (27) 35 (26) 
     Satisfaction with bowels 59 (18) 53 (17) 65 (19) 42 (23) 62 (18) 49 (22) 62 (19) 46 (20) 
     Affecting life 58 (17) 47 (21) 62 (19) 40 (20) 61 (20) 46 (21) 59 (17) 41 (20) 








9.14 IBS-SSS scores for intervention combinations  
IBS-SSS scores for the intervention combinations at follow up for the intention to treat 
population for the intention to treat population (n=104) of patients with IBS participating in 










diet + placebo 
(n=24) 
Low FODMAP 





IBS-SSS total (pts) 233 (93) 215 (86) 177 (97) 170 (95) 0.044* 
Pain severity  42 (25) 38 (22) 33 (23) 33 (26) 0.426 
Days of pain (days) 44 (28) 43 (31) 33 (26) 27 (27) 0.087 
Distension severity  41 (24) 39 (25) 26 (23) 31 (28) 0.103 
Satisfaction with bowels  54 (17) 53 (16) 45 (25) 39 (21) 0.024* 
Affecting life  51 (21) 42 (20) 40 (20) 41 (21) 0.141 
Change in IBS-SSS (pts) -39 (74) -49 (70) -121 (101) -114 (72) <0.001** 
Units are (mm) unless stated. Values are mean (SD). No differences at baseline. 
# One-way ANOVA with Tukey’s post hoc testing or Welch test with Games-Howell post hoc testing 
where homogeneity of variances was not met 
*no differences post hoc  
 
**Sham + placebo vs low FODMAP + placebo p=0.011 
    Sham + placebo vs low FODMAP + probiotic p=0.002 
    Sham + probiotic vs low FODMAP + placebo p =0.029 
    Sham + probiotic vs low FODMAP + probiotic p = 0.009 
 
 
Outcomes for those achieving the minimal clinically important difference in IBS-SSS score for 
intervention combinations at follow up for the intention to treat population (n=104) of 




Sham diet + 
placebo  
(n=27) 




diet + placebo 
(n=24) 
Low FODMAP 





Achieving MCID n (%) 10 (37) 12 (46) 17 (71) 20 (74) 0.013 
# Chi-squared test 
         
 
 
9.15 GSRS incidence and severity scores at baseline and follow up 
 
GSRS incidence scores for the intention to treat population (n=104) of patients with IBS participating in a 2x2 factorial design RCT of low FODMAP 
dietary advice and probiotic supplementation 
 
 
 Sham diet n=53 Low FODMAP diet n=51 Placebo n=51 Probiotic n=53 
 Baseline Follow up Baseline Follow up Baseline Follow up Baseline Follow up 
Abdominal pain 2.9 (2.2) 2.1 (2.0) 3.0  (2.4) 1.5 (1.9) 3.1 (2.3) 1.9 (2.1) 2.8 (2.3) 1.7 (2.0) 
Heartburn 07 (1.5) 0.2 (0.6) 0.8 (1.8) 0.4 (1.1) 0.8 (1.1) 0.2 (0.6) 0.7 (1.6) 0.4 (1.1) 
Acid reflux 0.5 (1.4) 0.3 (0.7) 0.6 (1.3) 0.4 (0.9) 0.6 (1.5) 0.3 (0.6) 0.5 (1.2) 0.4 (0.9) 
Nausea 0.6 (1.2) 0.6 (1.4) 0.6 (1.3) 0.3 (0.9) 0.7(1.5) 0.6 (1.6) 0.5 (1.0) 0.3 (0.6) 
Borborygmi 2.2 (2.0) 1.9 (2.2) 2.1 (2.4) 1.0 (1.9) 2.3 (2.3) 1.6 (2.2) 2.3 (2.3) 1.4 (2.1) 
Bloating 2.6 (2.5) 2.2 (2.3) 3.1 (2.6) 1.5 (2.0) 2.7 (2.4) 1.9 (2.2) 2.1 (2.1) 1.8 (2.2) 
Belching 1.1 (1.7) 1.9 (1.8) 1.1 (1.7) 0.6 (1.4) 1.1 (1.8) 0.9 (1.8) 1.4 (2.0) 0.8 (1.6) 
Flatulence 3.2 (2.6) 2.7 (2.4) 1.4 (2.1) 1.5 (2.0) 3.3 (2.6) 2.6 (2.4) 2.9 (2.5) 1.7  (2.0) 
Constipation 0.8 (1.7) 0.3 (0.7) 0.4 (1.0) 0.4 (1.2) 0.7 (1.6) 0.3 (1.0) 0.5 (1.2) 0.4 (0.9) 
Diarrhoea 0.6 (1.3) 0.5 (1.2) 0.8 (1.5) 0.5 (1.5) 0.9 (1.5) 0.7 (1.5) 0.5 (1.3) 0.4 (1.1) 
Loose stool 1.9 (2.0) 1.3 (1.8) 1.9 (2.0) 1.1 (1.9) 2.1 (2.3) 1.4 (2.1) 1.7 (1.7) 1.1 (1.6) 
Hard stool 0.4 (1.0) 0.2 (0.6) 0.3 (0.8) 0.3 (0.7) 0.3 (0.8) 0.1 (0.4) 0.4 (0.9) 0.4 (0.8) 
Urgency 1.7 (1.8) 1.6 (1.8) 2.7 (2.2) 1.2 (1.9) 2.5 (2.1) 1.5(2.0) 1.9 (2.0) 1.4 (1.8) 
Incomplete evacuation 1.7 (2.1) 1.7 (2.2) 1.9 (2.3) 0.7 (1.4) 1.8 (2.2) 1.3 (2.1) 1.8 (2.2) 1.2 (1.8) 
Tiredness 2.9 (2.6) 2.8 (2.4) 2.7 (2.8) 2.0 (2.5) 3.0 (2.7) 2.6 (2.6) 2.7 (2.7) 2.2 (2.3) 
Overall 2.8 (2.4) 2.3 (2.5) 3.1 (2.4) 1.6 (1.9) 2.8 (2.3) 2.3 (2.5) 3.1 (2.5) 1.7 (2.0) 
Values are mean (SD) of the number of days on which the symptoms were present in seven days 
         
 
 
GSRS severity scores for the intention to treat population (n=104) of patients with IBS participating in a 2x2 factorial design RCT of low FODMAP dietary 
advice and probiotic supplementation 
 
 Sham diet n=53 Low FODMAP diet n=51 Placebo n=51 Probiotic n=53 
 Baseline Follow up Baseline Follow up Baseline Follow up Baseline Follow up 
         
Abdominal pain 1.3 (0.6) 1.1 (0.6) 1.4 (0.7) 0.9 (0.7) 1.4 (0.6) 1.0 (0.7) 1.3 (0.6) 0.9 (0.6) 
Heartburn 0.3 (0.5) 0.2 (0.3) 0.4 (0.6) 0.2 (0.5) 0.4 (0.6) 0.2 (0.3) 0.3 (0.6) 0.2 (0.5) 
Acid reflux 0.3 (0.5) 0.2 (0.5) 0.3 (0.5) 0.2 (0.4) 0.3 (0.6) 0.2 (0.3) 0.3 (0.5) 0.2 (0.4) 
Nausea 0.4 (0.5) 0.3 (0.5) 0.4 (0.5) 0.3 (0.4) 0.4 (0.6) 0.3 (0.6) 0.4 (0.5) 0.2 (0.3) 
Borborygmi 1.1 (0.6) 1.0 (0.7) 1.1 (0.7) 0.7 (0.6) 1.2 (0.7) 0.9 (0.7) 1.1 (0.6) 0.8 (0.7) 
Bloating 1.2 (0.7) 1.1 (0.7) 1.3 (0.9) 0.8 (0.7) 1.3 (0.8) 1.0 (0.7) 1.3 (0.8) 1.0 (0.7) 
Belching 0.6 (0.7) 0.6 (0.7) 0.8 (0.7) 0.5 (0.6) 0.7 (0.7) 0.6 (0.7) 0.7 (0.7) 0.5 (0.6) 
Flatulence 1.5 (0.7) 1.3 (0.7) 1.4 (0.7) 0.9 (0.6) 1.5 (0.7) 1.2 (0.7) 1.4 (0.6) 1.0 (0.6) 
Constipation 0.4 (0.6) 0.3 (0.4) 0.2 (0.4) 0.2 (0.4) 0.3 (0.6) 0.2 (0.4) 0.3 (0.5) 0.3 (0.4) 
Diarrhoea 0.3 (0.5) 0.3 (0.5) 0.4 (0.5) 0.2 (0.5) 0.4 (0.5) 0.3 (0.5) 0.3 (0.5) 0.2 (0.4) 
Loose stool 0.8 (0.7) 0.7 (0.7) 0.9 (0.6) 0.5 (0.6) 0.9 (0.7) 0.7 (0.7) 0.8 (0.6) 0.5 (0.6) 
Hard stool 0.2 (0.4) 0.2 (0.2) 0.2 (0.4) 0.2 (0.3) 0.2 (0.4) 0.2 (0.2) 0.2 (0.4) 0.2 (0.3) 
Urgency 0.8 (0.7) 0.7 (0.6) 1.1 (0.7) 0.6 (0.7) 1.1 (0.7) 0.7 (0.7) 0.9 (0.7) 0.6 (0.6) 
Incomplete evacuation 0.8 (0.8) 0.7 (0.7) 0.9 (0.8) 0.5 (0.6) 0.8 (0.8) 0.7 (0.7) 0.8 (0.7) 0.6 (0.6) 
Tiredness 1.3 (0.8) 1.3 (0.7) 1.2 (0.8) 1.0 (0.8) 1.4 (0.8) 1.2 (0.8) 1.2 (0.8) 1.0 (0.8) 
Overall 1.4 (0.5) 1.2 (0.6) 1.4 (0.6) 1.0 (0.6) 1.4 (0.5) 1.2 (0.6) 1.4 (0.6) 1.0 (0.6) 
Values are mean (SD) severity rated daily over seven days on a scale of 0 (absent), 1 (mild), 2 (moderate), 3 (severe)




9.16 Stool output at baseline and follow up  
 
Stool output for the intention to treat population (n=104) of patients with IBS participating in a 2x2 factorial design RCT of low FODMAP dietary advice 
and probiotic supplementation 
 
 Sham diet (n=53) Low FODMAP diet (n=51) Placebo (n=51) Probiotic (n=53) 
 Baseline Follow up Baseline Follow up Baseline Follow up Baseline Follow up 
Stool consistency 4.4 (1.1) 4.3 (1.1) 4.6 (0.8) 3.9 (1.0) 4.6 (0.9) 4.2 (1.0) 4.4 (0.9) 4.0 (1.1) 
Stool frequency  14.0 (7.3) 12.9 (7.4) 15.7 (9.2) 14.0 (8.5) 14.4 (8.3) 13.8 (8.3) 15.3 (8.4) 13.1 (7.6) 
% Stools normal consistency 60 (25) 61 (30) 58 (27) 67 (26) 57 (27) 64 (30) 61 (25) 64 (26) 
Values are mean (SD). Stool consistency, the mean Bristol Stool Form Scale type over the 7-day period; Stool frequency, mean number of stools over the 7-day period; 
Stools normal consistency, proportion of stools of types 3-5 over the 7-day period 
 
         
 
 
9.17 Stool output for intervention combinations 
 
Stool output outcomes for the intervention combinations at follow up for the intention to treat population (n=104) of patients with IBS participating in a 
2x2 factorial design RCT of low FODMAP dietary advice and probiotic supplementation 
 
 Sham diet + placebo 
(n=27) 
Sham diet+ probiotic 
(n=26) 
Low FODMAP diet + placebo 
(n=24) 



















Stool consistency  0.137 
Stool frequency  0.600 
Stools normal consistency (%) 
 
0.788 
Values are mean (SD). No differences at baseline.
#
one-way ANOVA; Stool consistency, the mean Bristol Stool Form Scale type over the 7-day period;  
Stool frequency, mean number of stools over the 7-day period; Stools normal consistency, proportion of stools of types 3-5 over the 7-day period.  
         
 
 
9.18 HRQOL scores at baseline and follow up 
 
SF-36 and IBS-QOL score for the intention to treat population (n=104) of patients with IBS participating in a 2x2 factorial design RCT of low FODMAP 
dietary advice and probiotic supplementation 
 
 Sham (n=53) Low FODMAP (n=51) Placebo (n=51) Probiotic (n=53) 
 Baseline Follow up Baseline Follow up Baseline Follow up Baseline Follow up 
SF-36         
Physical functioning 87.6 (18.3) 87.3 (22.3) 83.6 (22.1) 86.3 (21.3) 86.5 (20.3) 88.9 (19.2) 84.9 (20.3) 84.7 (23.8) 
Role limitations due to physical health 57.1 (40.5) 55.2 (39.6) 61.3 (38.8) 70.6 (39.2) 54.9 (42.4) 62.8 (39.8) 63.2 (36.6) 62.7 (40.6) 
Role limitations due to emotional problems 52.8 (39.5) 65.4 (37.5) 56.9 (42.8) 64.0 (43.1) 60.1 (38.9) 71.2 (38.3) 49.7 (42.7) 58.5 (41.3) 
Energy/fatigue 38.5 (21.1) 42.6 (19.9) 41.1 (20.3) 52.1 (23.3) 37.2 (19.8) 43.9 (19.7) 42.3 (21.3) 50.4 (23.8) 
Emotional wellbeing 60.5 (18.8) 63.3 (17.3) 61.8 (18.0) 68.7 (17.8) 61.5 (17.2) 66.0 (17.8) 60.8 (19.5) 65.8  (17.7) 
Social functioning 67.0 (25.4) 77.8 (20.7) 64.7 (26.5) 73.3 (27.3) 65.2 (26.6) 76.0 (25.0) 66.5 (25.3) 75.2 (23.6) 
Pain 56.9 (21.8) 65.0 (20.4) 50.1 (22.6) 63.5 (27.0) 50.8 (20.8) 61.0 (23.7) 56.2 (23.6) 67.5 (23.6) 
General Health 53.6 (20.4) 56.2 (19.7) 51.3 (22.1) 57.5 (22.4) 52.8 (21.1) 55.8 (20.7) 52.1 (21.4) 57.8 (21.4) 
IBS-QOL         
Overall 61.6 (16.8) 70.6 (18.1) 57.7 (20.1) 72.4 (19.7) 56.2 (18.5) 68.6 (20.7) 63.1 (18.1) 74.3 (16.6) 
   Dysphoria 58.1 (23.7) 72.2 (20.5) 54.5 (25.9) 71.9 (24.7) 52.4 (25.3) 69.6 (24.7) 60.2 (23.9) 74.4 (20.3) 
   Interference with activity 61.5 (20.1) 71.2 (20.6) 57.3 (24.3) 72.9 (24.2) 56.4 (21.7) 68.9 (23.3)  62.4 (22.6) 75.0 (21.1) 
   Body Image 58.3 (23.1) 64.1 (22.7) 55.5 (25.1) 73.2 (22.7) 51.6 (24.2) 64.8 (24.2) 62.0 (22.9) 72.2 (21.5) 
   Healthy worry 60.5 (22.9) 71.1 (20.8) 59.5 (22.4) 73.0 (20.0) 58.5 (23.1) 69.6 (23.3) 61.5 (22.1) 74.4 (17.0) 
   Food avoidance 52.5 (27.7) 57.9 (29.2) 44.4 (29.3) 51.1 (26.7) 46.1 (27.8) 53.6 (28.8) 50.9 (29.5) 55.5 (27.5) 
   Social reaction 63.8 (17.8) 71.7 (22.2) 61.4 (25.6) 77.5 (22.4) 58.8 (21.5) 71.2 (23.3) 66.3 (21.9)  77.7 (21.1) 
   Sexual 71.9 (28.9) 76.2 (28.6) 69.9 (29.1) 79.7 (24.7) 68.1 (27.1) 73.3 (29.3) 73.6 (30.5) 82.3 (23.4) 
   Relationships 76.3 (22.1) 80.5 (19.9) 68.5 (22.8) 81.2 (18.8) 68.8 (23.5) 77.5 (20.1) 75.9 (21.5) 84.1 (18.1) 
Values are mean (SD)
         
 
 
9.19 HRQOL scores for intervention combinations 
 
SF-36 and IBS-QOL scores for the intervention combinations at follow up for the intention to treat population (n=104) of patients with IBS participating 
in a 2x2 factorial design RCT of low FODMAP dietary advice and probiotic supplementation 
 
 Sham diet +  
placebo (n=27) 
Sham diet +  
probiotic (n=26) 
Low FODMAP diet 
+ placebo (n=24) 
Low FODMAP diet + 




SF-36      
Physical functioning 90.2 (18.8) 84.2 (25.4) 87.5 (20.0) 85.2 (22.6) 0.759 
Role limitations due to physical health 52.8 (40.0) 57.7 (39.9) 74.0 (37.2) 67.6 (41.5) 0.226 
Role limitations due to emotional problems 70.4 (36.2) 60.3 (38.9) 72.2 (41.3) 56.8 (44.2) 0.438 
Energy/fatigue 38.9 (16.9) 46.4 (22.2) 49.6 (21.4) 54.3 (25.1) 0.054 
Emotional wellbeing 62.7 (17.7) 63.9 (17.1) 69.8 (17.5) 67.7 (18.4) 0.441 
Social functioning 78.7 (23.2) 76.9 (18.3) 72.9 (27.0) 73.6 (28.0) 0.805 
Pain 62.2 (22.3) 68.0 (18.2) 59.6 (25.6) 67.0 (28.2) 0.551 
General Health 52.8 (21.3) 59.8 (17.5) 59.2 (19.9) 55.9 (24.7) 0.604 
IBS-QOL      
Overall 65.6 (20.3) 75.8 (14.2) 72.0 (21.0) 72.8 (18.8) 0.240 
    Dysphoria 67.2 (23.1) 77.4 (16.3) 72.3 (26.6) 71.5 (23.4) 0.320 
    Interference with activity 65.5 (22.5) 77.1 (17.0) 72.8 (24.2) 73.0 (24.6) 0.296 
    Body Image 59.5 (23.9) 69.0 (20.8) 70.8 (23.6) 75.2 (22.2) 0.081 
    Healthy worry 67.0 (24.0) 75.3 (16.4) 72.6 (22.6) 73.5 (17.8) 0.481 
    Food avoidance 53.4 (30.4) 62.5 (27.7) 53.8 (27.6) 48.8 (26.1) 0.352 
    Social reaction 67.4 (24.7) 76.2 (18.6) 75.5 (21.4) 79.2 (23.4) 0.249 
    Sexual 70.4 (31.8) 82.2 (24.0) 76.6 (26.4) 82.4 (23.3) 0.305 
    Relationships 74.4 (22.0) 86.9 (15.5) 80.9 (17.5) 81.5 (20.3) 0.134 
Values are mean (SD). No differences at baseline. 
#
one-way ANOVA or Welch test if homogeneity of variance was not met 
 
 Sham diet +  
placebo (n=27) 
Sham diet +  
Probiotic (n=26) 
Low FODMAP diet + 
placebo (n=24) 





Achieving MCID n (%) 7 (26) 7 (27) 13 (54) 13 (48) 0.078 
#
 Chi-squared test




9.20 Acceptability outcomes  
 
Diet acceptability outcomes for patients with IBS (n=95) completing a 2x2 factorial design 
RCT of low FODMAP dietary advice and probiotic supplementation 




Foods most missed 
 









Sham (% of patients) 
Rice 46% 
Oats 19% 
Specific fruit 17% 
Specific vegetables 17% 
 
Product acceptability outcomes for patients with IBS (n=95) completing a 2x2 factorial design 












Meal preparation was more difficult  58% 91% <0.001 
Time spent shopping for food was longer 46% 85% <0.001 
Time spent preparing and cooking meals and snacks  was 
longer 
23% 72% <0.001 
Finding suitable food choices when eating out  was more 
difficult 
79% 96% 0.027 
The flavour of the meals and snacks was less appealing 17% 78% <0.001 
Grocery shopping and eating out compared to usual diet 
was more expensive 
8% 85% <0.001 
Difficulty with understanding written information  0% 2% 0.489 
Diet was less convenient 71% 89% 0.039 
Diet was more troublesome/difficult 71% 91% 0.017 
Made many changes to diet 58% 94% <0.001 
Missed a food or drink a lot 68% 85% 0.087 
Benefits of being involved in the study outweighed the 
burdens of being on this diet 







Taking the sachets daily for 4 weeks was easy 89% 77% 0.169 
I experienced a side effect from probiotic/placebo sachet 17% 19% 1.000 
I believe I understand definition of probiotic 67% 64% 0.828 
I would classify a probiotic as 
     Standard treatment 
     Complementary/alternative medicine 











I would take a probiotic in the future 92% 76% 0.076 




9.21 Bland Altman plots for inter rater agreement analysis 
Bland Altman plots for NSP intake from 21 diet records (7 baseline, 7 sham diet, 7 low 
FODMAP diet) to assess inter-agreement between three coders. Diet records were from 







Mean -1.96 SD 
Mean +1.96 SD 
Mean 
Mean -1.96 SD 
Mean +1.96 SD 
Mean 
Mean -1.96 SD 
Mean +1.96 SD 
         
 
 
9.22 Nutrient intakes from the RCT compared with NDNS and DRVs 
 
Energy, macronutrient and micronutrient intake for males at baseline (habitual diet) (n=34) and for males in the low FODMAP group at follow up 
(n=16) compared with UK population intakes and dietary reference values. Patients participated in a 2x2 factorial design RCT of the low FODMAP diet 
and probiotic supplementation in IBS 
 
Nutrient  Baseline Follow up NDNS
#
 DRV 
Energy  EAR (kcal/d) 2349 (547) 2207 (440) 2124 (584) 2581-2772 
Carbohydrate 
 
Population average (% total energy intake) 43 (10) 41 (8) 45 (7) 47 
Protein  RNI (g/d)  (19-49yr) 




102 (23) 85 (34) 
55.5 
53.3 
Fat  Population average (% total energy intake) 37 (10) 37 (10) 35 (6) 33 
NSP Individual minimum (g/d) 14 (5)
 
 13 (4) 15 (5) 12 
Potassium  RNI (mg/d) 3410 (933) 3291 (905) 2975 (932) 3500 
Calcium 
 
RNI (mg/d) 909 (289) 848 (411) 875 (343) 700 
Magnesium RNI (mg/d) 338 (110) 302 (93) 283 (95) 300 
Phosphorous RNI (mg/d) 1533 (360) 1444 (401) - 550 
Iron 
 
RNI (mg/d) 12.4 (3.1) 11.9 (2.1) 12.8 (8.2) 8.7 
Zinc RNI (mg/d) 10.6 (2.4) 9.8 (2.2) 9.7 (3.4) 9.5 
DRV, Dietary reference value; NDNS, National Diet and Nutrition Survey (combined 2008/9 and 2011/12);EAR, estimated average requirement,  
RNI, reference nutrient intake 
#
 Energy, macronutrient intakes taken from 25-49 yr cohort, micronutrient intakes from 19-65 yr cohort, all data from food sources only 
         
 
 
Energy, macronutrient and micronutrient intake for males at baseline (habitual diet) (n=34) and for males in the low FODMAP group at follow up 
(n=16) compared with UK population intakes and dietary reference values. Patients participated in a 2x2 factorial design RCT of the low FODMAP diet 
and probiotic supplementation in IBS 
 
Nutrient  Baseline Follow up NDNS
#
 DRV 
Thiamin  RNI (mg/d)  (19-49yr) 
RNI (mg/d)  (50+yr) 
1.6 (0.5)  




1.0   
0.9   
Riboflavin  RNI (mg/d) 1.9 (0.7)  1.8 (0.5) 1.7 (0.7) 1.3 
Niacin  RNI (mg/d) (19-49yr) 
RNI (mg/d) (50+yr) 
26 (8) 










Vitamin B6  RNI (mg/d) 2.3 (0.7) 2.5 (0.7) 2.5 (1.2) 1.4 
Vitamin B12   RNI (µg/d) 6.4 (3.5)  7.4 (3.1) 5.7 (3.9) 1.5 
Folate  RNI (µg/d) 264 (96)  273 (95) 287 (117) 200 
Pantothenic acid 
 
Safe intake (mg/d) 5.9 (1.8)  5.6 (2.2) - 3-7 
Biotin safe intake  
 
Safe intake (µg/d) 43 (19)  41 (21) - 10-200 
Vitamin C 
 
RNI (mg/d) 99 (59)  96 (57) 84 (67) 40 
DRV, Dietary reference value; NDNS, National Diet and Nutrition Survey (combined 2008/9 and 2011/12);EAR, estimated average requirement,  
RNI, reference nutrient intake 
#
 Energy, macronutrient intakes taken from 25-49 yr cohort, micronutrient intakes from 19-65 yr cohort, all data from food sources only 
 
         
 
 
Energy, macronutrient and micronutrient intake for females at baseline (habitual diet) (n=70) and for females in the low FODMAP group at follow up  
(n=35) compared with UK population intakes and dietary reference values. Patients participated in a 2x2 factorial design RCT of the low FODMAP diet 
and probiotic supplementation in IBS. 
 
Nutrient  Baseline Follow up NDNS
#
 DRV 
Energy  EAR (kcal/d) 1831 (401)  1728 (438) 1584(463) 2079-2175 
Carbohydrate 
 
Population average (% total energy intake) 45 (12)* 43 (7) 46 (8) 47 
Protein  RNI (g/d) (19-49yr) 








Fat  Population average (% total energy intake) 38 (9) 37 (5) 34 (7) 33 
NSP Individual minimum (g/d) 14 (5) 13 (5) 13 (5)
 
12 
Potassium  RNI (mg/d) 2759 (819) 2876 (631) 2457 (696) 3500 
Calcium 
 
RNI (mg/d) 790 (320) 739 (261) 715 (254) 700 
Magnesium RNI (mg/d) 262 (87) 250 (64) 226 (68) 270 
Phosphorous RNI (mg/d) 1152 (318) 1089 (244) - 550 
Iron 
 
RNI (mg/d) (19-49yr) 








Zinc RNI (mg/d) 7.8 (2.4) 7.5 (2.2) 7.6 (2.4) 7.0 
DRV, Dietary reference value; NDNS, National Diet and Nutrition Survey (combined 2008/9 and 2011/12); EAR, estimated average requirement 
RNI, reference nutrient intake 
#
 Energy, macronutrient intakes taken from 25-49 yr cohort, micronutrient intakes from 19-65 yr cohort, all data from food sources only 
 
         
 
 
Energy, macronutrient and micronutrient intake for females at baseline (habitual diet) (n=70) and for females in the low FODMAP group at follow up 
(n=35) compared with UK population intakes and dietary reference values. Patients participated in a 2x2 factorial design RCT of the low FODMAP diet 
and probiotic supplementation in IBS 
Nutrient  Baseline Follow up NDNS
#
 DRV 
Thiamin  RNI (mg/d) 1.4 (0.5) 1.2 (0.3)  1.3 (0.4) 0.8 
Riboflavin  RNI (mg/d) 1.4 (0.6) 1.3 (0.4)  1.4 (0.5) 1.1 
Niacin  RNI (mg/d) (19-49yr) 












Vitamin B6  RNI (mg/d) 1.8 (0.7) 1.8 (0.5)  1.9 (0.8) 1.2 
Vitamin B12   RNI (µg/d) 4.7 (2.8) 5.6 (2.2)  4.6 (3.2) 1.5 





Safe intake (mg/d) 4.3 (1.5) 4.4 (1.6)  - 3-7 
Biotin 
 
Safe intake (µg/d) 31 (15) 33 (15)  - 10-200 
Vitamin C 
 
RNI (mg/d) 92 (49) 115 (58)  82 (60)
 
40 
DRV, Dietary reference value; NDNS, National Diet and Nutrition Survey (combined 2008/9 and 2011/12);EAR, estimated average requirement,  
RNI, reference nutrient intake 
#
 Energy, macronutrient intakes taken from 25-49 yr cohort, micronutrient intakes from 19-65 yr cohort, all data from food sources only




9.23 Proportion of patients in the low FODMAP diet group meeting gender-specific DRVs  
 
Proportion of patients in the low FODMAP diet group meeting RNIs at baseline and follow 
up grouped by gender (females n=35, males n=16) Patients participated in a 2x2 factorial 
design RCT of the low FODMAP diet and probiotic supplementation in IBS  





         
 
 
9.24 Absolute and relative abundance of microbiota for the per protocol population  
 
Absolute abundance of microbiota (log10 cells/g faeces) at follow up for the per protocol population of patients with IBS participating in a 2x2 factorial 

















Universal 10.9 (0.4) 10.9 (0.3) -0.08 (-0.21, 0.06) 0.273 10.9 0.3) 10.9 (0.4) -0.05 (-0.18, 0.07) 0.421 
Bacteroides spp. 10.0 (0.7) 10.1 (0.8) 0.17 (-0.03, 0.37) 0.130 10.2 (0.5) 10.0 (0.9) -0.19 (-0.36, -0.01) 0.072 
Prevotella spp. 7.9 (1.9) 7.1 (1.8) -0.19 (-0.50, 0.11) 0.235 7.5 (1.9) 7.5 (1.9) -0.04 (-0.33, 0.23) 0.773 
Bifidobacteria 9.2 (0.9) 8.8 (0.6) -0.39 (-0.64, -0.13) 0.008 8.8 (1.0) 9.1 (0.6) 0.34 (0.05, 0.61) 0.019 
     B. longum 8.6 (0.8) 7.9 (0.8) -0.71 (-0.96, -0.47) 0.001 8.3 (0.9) 8.2 (0.8) -0.19 (-0.46, 0.07) 0.184 
     B. adolescentis 8.1 (1.1) 7.6 (1.1) -0.38 (-0.82, 0.11) 0.125 7.8 (1.1) 7.9 (1.1) -0.13 (-0.61, 0.33) 0.589 
Clostridium Cluster XIVa 10.2 (0.8) 10.2 (0.6) 0.02 (-0.23, 0.27) 0.895 10.2 (0.7) 10.2 (0.8) -0.01 (-0.26, 0.26) 0.985 
     Roseburia spp. & E. rectale 9.8 (0.5) 9.4 (0.9) -0.22 (-0.42, -0.02) 0.036 9.6 (0.9) 9.6 (0.6) 0.01 (0.20, 0.21) 0.995 
     F.prausnitzii 9.7 (0.6) 9.6 (0.7) -0.10 (-0.37, 0.17) 0.474 9.6 (0.8) 9.7 (0.6) 0.08 (-0.22, 0.38) 0.615 
R. Bromii 8.7 (0.7) 8.6 (0.8) -0.06 (-0.31, 0.19) 0.666 8.7 (0.7) 8.6 (0.8) -0.13 (-0.38, 0.12) 0.293 
A. muciniphila 8.0 (1.1) 7.9 (1.1) -0.49 (-1.00, -0.01) 0.067 8.0 (1.0) 7.9 (1.2) -0.22 (-0.70, 0.31) 0.367 
Lactobacilli 7.6 (0.9) 7.7 (0.8) -0.06 (-0.61, 0.51) 0.836 7.5 (0.9) 7.8 (0.8) 0.28 (-0.33, 0.90) 0.379 
Values are mean (SD), estimated mean difference and 95% confidence interval 
         
 
 
Relative abundance of microbiota (% of total) at follow up for the per protocol population of patients with IBS participating in a 2x2 factorial design RCT 
of low FODMAP dietary advice and probiotic supplementation (n=87) 
 


















Bacteroides spp.  18.8 (14.7) 27.5 (17.5) 8.07 (3.18, 12.99) 0.003 23.4 (15.7) 22.8 (17.7) -3.63 (-8.59, 1.14) 0.141 
Prevotella spp. 8.3 (16.4) 4.7 (12.2) -2.40 (-9.16, 4.80) 0.513 5.9 (12.8) 7.0 (15.8) 5.08 (-0.73, 11.13) 0.133 
Bifidobacteria  3.9 (4.9) 1.6 (1.7) -2.27 (-3.35, -1.13) 0.007 2.8 (5.0) 2.8 (2.6) 0.22 (-1.16, 1.56) 0.755 
      B. longum  1.4 (2.1) 0.4 (1.0) -1.06 (-1.78, -0.44) 0.018 1.2 (2.2) 0.7 (1.2) -0.29 (-1.00, 0.31) 0.390 
      B. adolescentis  0.7 (1.0) 0.4 (0.7) -0.49 (-0.87, -0.15) 0.039 0.4 (0.6) 0.7 (1.1) -0.01 (-0.30, 0.29) 0.958 
Clostridium Cluster XIVa  23.4 (15.1) 25.9 (13.6) 1.70 (-4.68, 7.50) 0.558 23.3 (14.0) 25.8 (14.8) 3.36 (-2.37, 8.92) 0.238 
      Roseburia spp. & E. rectale  8.3 (7.0) 7.8 (8.9) -0.42 (-3.34, 2.69) 0.783 7.3 (6.4) 8.7 (9.1) 1.22 (-1.67, 3.88) 0.409 
      F. prausnitzii  8.8 (9.1) 9.2 (10.0) 0.29 (-4.13, 4.51) 0.907 8.4 (9.4) 9.5 (9.6) 1.17 (-3.13, 5.41) 0.606 
R. Bromii 0.9 (0.8) 1.1 (1.1) 0.33 (-0.04, 0.674) 0.080 1.1 (1.2) 1.0 (0.8) -0.29 (-0.64, 0.12) 0.165 
A. muciniphila  0.4 (0.5) 0.4 (0.9) 0.09 (-0.34, 0.66) 0.780 0.5 (0.9) 0.3 (0.4) -0.49 (-1.13, 0.05) 0.305 
Lactobacilli  0.2 (0.6) 0.2 (0.2) -0.06 (-0.44, 0.19) 0.719 0.2 (0.7) 0.2 (0.2) -0.10 (-0.55, 0.18) 0.633 
Values are mean (SD), estimated mean difference and 95% confidence interval




9.25 Absolute and relative abundance of microbiota for intervention combinations 
 
Absolute abundance of microbiota (log10 cells/g faeces) at follow up for the combination interventions of patients with IBS participating in a 2x2 factorial 
design RCT of low FODMAP dietary advice and probiotic supplementation (n=104) 
 
 
Sham diet + 
placebo (n=27) 
Sham diet + 
probiotic (n=26) 
Low FODMAP diet 
+ placebo (n=24) 





Universal 10.9 (0.4) 10.9 (0.4) 10.9 (0.3) 10.9 (0.4) 0.886 - 
Bacteroides spp. 10.1 (0.5) 10.0 (0.7) 10.3 (0.4) 10.1 (0.9) 0.303 - 
Prevotella spp. 7.9 (1.9) 7.8 (1.9) 7.1 (1.7) 7.1 (1.8) 0.285 - 
Bifidobacteria 8.8 (1.3) 9.2 (0.8) 8.6 (0.7) 8.9 (0.6) 0.037* SH+Pro vs LFD+Pla* 0.020 
     B. longum 8.6 (1.0) 8.4 (0.9) 8.0 (0.9) 8.0 (0.8) 0.077 - 
     B. adolescentis 8.2 (1.0) 8.1 (1.1) 7.3 (0.9) 8.9 (1.1) 0.059 - 
Clostridium Cluster XIVa 10.1 (0.7) 10.1 (0.9) 10.0 (0.7) 10.3 (0.6) 0.731 - 
     Roseburia spp. & E. rectale 9.8 (0.5) 9.8 (0.5) 9.3 (1.0) 9.5 (.06) 0.049 >0.05 
     F. prausnitzii 9.7 (0.6) 9.7 (0.7) 9.4 (1.1) 9.7 (0.5) 0.453 - 
R. Bromii 8.7 (0.7) 8.7 (0.7) 8.5 (1.0) 8.6 (0.8) 0.639 - 
A. muciniphila 7.9 (1.1) 7.9 (1.1) 8.1 (0.9) 7.7 (1.1) 0.906 - 
Lactobacilli 7.4 (0.9) 7.6 (0.9) 7.6 (1.1) 7.6 (0.8) 0.894 - 
Values are mean (SD) 
#
ANOVA with Tukey post-hoc tests and Welch tests with Games-Howell post hoc where homogeneity of variances was violated.  
No differences at baseline.  
*Welch test with Games-Howell post-hoc test. SH, sham diet; LFD, low FODMAP diet; Pro, probiotic; Pla, placebo. 




Relative abundance of microbiota (% of total) at follow up for the combination interventions of patients with IBS participating in a 2x2 factorial design 
RCT of low FODMAP dietary advice and probiotic supplementation (n=104) 
 
 
Sham diet + 
placebo (n=27) 
Sham diet + 
probiotic (n=26) 
Low FODMAP diet 
+ placebo (n=24) 





Bacteroides spp. 18.9 (11.8) 20.1 (17.0) 33.5 (15.8) 26.0 (17.7) 0.006 
SH+Pla vs LFD+Pla 0.008 
SH+Pro vs LFD+Pla 0.019 
Prevotella spp. 8.0 (14.6) 8.5 (17.5) 3.3 (8.5) 6.0 (14.4) 0.613 - 
Bifidobacteria 3.8 (5.8) 3.8 (3.2) 1.3 (1.8) 1.7 (1.5) 0.005* 
Sh+Pro vs LFD+Pla 0.008* 
Sh+Pro vs LFD+Pro 0.022* 
     B. longum 1.5 (2.4) 1.1 (1.4) 0.7 (1.2) 0.3 (0.3) 0.009* >0.05* 
     B. adolescentis 0.6 (0.6) 0.8 (1.3) 0.1 (0.2) 0.5 (0.8) 0.002* SH+Pla vs LFD+Pla 0.012* 
Clostridium Cluster XIVa 22.7 (18.2) 24.6 (16.9) 22.1 (14.6) 27.6 (12.4) 0.591 - 
     Roseburia spp. & E. rectale 7.7 (5.1) 10.2 (9.6) 6.9 (7.3) 7.8 (9.4) 0.502 - 
     F. prausnitzii 8.0 (5.4) 10.7 (10.8) 10.3 (12.1) 8.6 (7.3) 0.682 - 
R. Bromii 0.9 (1.0) 1.0 (0.8) 1.3 (1.8) 1.0 (0.9) 0.543 - 
A. muciniphila 0.4 (0.5) 0.3 (0.4) 0.6 (1.4) 0.2 (0.4) 0.762* - 
Lactobacilli 0.3 (0.9) 0.1 (0.2) 0.2 (0.3) 0.2 (0.2) 0.882 - 
Values are mean (SD) 
#
ANOVA with Tukey post-hoc tests and Welch tests with Games-Howell post hoc where homogeneity of variances was violated.  
No differences at baseline 
*Welch test with Games-Howell post-hoc test. SH, sham diet; LFD, low FODMAP diet; Pro, probiotic; Pla, placebo.




9.26 Stool SCFA at baseline and follow up 
 
Stool SCFA concentration (µmol/g faeces) and stool pH for the intention to treat population of patients with IBS participating in a 2x2 factorial design 











 Baseline Follow up Baseline Follow up Baseline Follow up Baseline Follow up 
Total SCFA 119.9 (48.8) 124.0 (69.4) 115.1 (45.1) 98.6 (43.7) 122.6 (52.3) 108.6 (42.8) 112.7 (40.9) 113.1 (71.9) 
   Acetate 70.8 (30.4) 73.1 (37.1) 69.1 (30.8) 58.2 (25.9) 73.6 (35.0) 64.8 (27.4) 66.5 (25.1) 66.8 (43.6) 
   Butyrate 21.4 (10.4) 21.5 (15.8) 18.2 (8.6) 15.7 (9.5) 20.5 (10.6) 17.9 (10.1) 19.2 (8.7) 19.4 (15.9) 
   Propionate 20.9 (11.6) 20.9 (16.2) 20.5 (9.5) 18.0 (9.7) 21.5 (12. 6) 18.9 (8.3) 20.0 (8.3) 20.1 (17.0) 
   Valerate 2.5 (2.4) 2.4 (1.5) 2.4 (1.2) 2.0 (1.3) 2.5 (1.3) 2.2 (1.2) 2.5 (1.3) 2.2 (1.6) 
   Isobutyrate 2.3 (1.3) 2.7 (1.8) 2.7 (1.1) 2.6 (1.4) 2.5 (1.2) 2.7 (1.7) 2.5 (1.3) 2.6 (1.6) 
   Isovalerate 2.0 (1.0) 2.2 (1.4) 2.2 (0.9) 2.0 (1.1) 2.0 (0.9) 2.2 (1.2) 2.1 (1.0) 2.1 (1.4) 
pH 6.7 (0.5) 6.7 (0.5) 6.7 (0.4) 6.8 (0.5) 6.6 (0.5) 6.8 (0.5) 6.7 (0.5) 6.8 (0.5) 
Values are mean (SD)




9.27 Stool SCFA for intervention combinations 
 
Stool SCFA concentration (µmol/g faeces) and stool pH for the intervention combinations at follow up for the intention to treat population of patients 
with IBS participating in a 2x2 factorial design RCT of low FODMAP dietary advice and probiotic supplementation (n=104) 
 
 
Sham diet + placebo 
(n=27) 
Sham diet + probiotic 
(n=26) 
Low FODMAP diet + placebo 
(n=24) 
Low FODMAP diet + probiotic 
(n=27) 
p# 
Total SCFA  122.7 (42.8) 122.9 (89.9) 92.8 (37.6) 103.7 (48.7) 0.115 
   Acetate  74.7 (28.2) 71.4 (45.1) 53.7 (22.0) 62.3 (28.8) 0.052 
   Butyrate  20.6 (10.4) 22.4 (20.1) 14.8 (9.1) 16.5 (10.0) 0.075 
   Propionate  19.9 (8.0) 21.8 (21.8) 17.7 (8.7) 18.3 (10.7) 0.692 
   Valerate  2.3 (1.1) 2.5 (1.9) 2.0 (1.4) 1.9 (1.2) 0.337 
   Isobutyrate 2.3 (1.4) 2.1 (1.5) 2.0 (1.1) 2.1 (1.2) 0.906 
   Isovalerate  2.8 (1.8) 2.6 (1.7) 2.6 (1.5) 2.5 (1.4) 0.968 
pH 6.7 (0.6) 6.8 (0.5) 6.9 (0.5) 6.8 (0.6) 0.524 
Values are mean (SD) 
#  
Kruskal-Wallis Test for SCFA and one-way ANOVA for pH. No differences at baseline 
         
 
 
9.28 Proportion of patients with microbiota below the detection limit  
 
Proportion of patients (%) with IBS in the intention to treat population participating in a 2x2 factorial design RCT of low FODMAP dietary advice and 
probiotic supplementation with microbiota below the detection limit 
 
# 




Low FODMAP diet 




(n=53) p# p* 
 Baseline Follow up Baseline Follow up Baseline Follow up Baseline Follow up 
Universal 0 0 0 0 - - 0 0 0 0 - - 
Bacteroides spp. 2 2 2 0 1.000 1.000 2 2 2 0 1.000 0.490 
Prevotella spp. 28 11 29 8 1.000 0.742 29 12 28 8 1.000 0.522 
Bifidobacteria 6 4 0 2 0.243 1.000 4 6 2 0 0.614 0.114 
     B. longum 2 9 0 12 1.000 0.758 2 8 0 7 0.490 0.527 
     B. adolescentis 38 34 41 37 0.841 0.838 41 31 38 40 0.841 0.418 
Clostridium Cluster XIVa 0 0 0 0 - - 0 0 0 0 - - 
     Roseburia spp. & E. rectale 2 2 0 0 1.000 1.000 2 2 0 0 0.490 0.490 
     F. prausnitzii 0 0 0 0 - - 0 0 0 0 - - 
R. Bromii 2 2 0 0 1.000 1.000 2 2 0 0 0.490 0.490 
A. muciniphila 49 38 57 59 0.440 0.049 57 51 49 47 0.440 0.695 
Lactobacilli 43 30 53 31 0.433 1.000 44 53 51 9 0.563 <0.001 
         
 
 
9.29 Absolute and relative abundance of microbiota at baseline and follow up 
 
Absolute abundance of microbiota (log10 cells/g faeces) at baseline and follow up for the intention to treat population of patients with IBS participating 











 Baseline Follow up Baseline Follow up Baseline Follow up Baseline Follow up 
Universal 10.9 (0.4) 10.9 (0.4) 10.9 (0.3) 10.9 (0.3) 10.9 (0.4) 10.9 (0.3) 10.9 (0.3) 10.9 (0.4) 
Bacteroides spp.  10.2 (0.7) 10.0 (0.6) 10.2 (0.8) 10.1 (0.7) 10.2 (0.7) 10.2 (0.5) 10.2 (0.8) 10.1 (0.8) 
Prevotella spp. 8.4 (1.9) 7.8 (1.9) 7.7 (2.0) 7.1 (1.7) 8.1 (2.0) 7.5 (1.8) 8.0 (1.9) 7.4 (1.9) 
Bifidobacteria  8.7 (1.2) 9.0 (1.1) 8.8 (1.1) 8.8 (0.7) 8.7 (1.2) 8.7 (1.1) 8.8 (1.1) 9.1 (0.7) 
      B. longum  8.5 (1.1) 8.5 (0.9) 8.5 (1.2) 8.0 (0.8) 8.5 (1.1) 8.3 (1.0) 8.5 (1.2) 8.2 (0.9) 
      B. adolescentis 8.4 (0.9) 8.2 (1.1) 8.2 (1.1) 7.6 (1.0) 8.1 (1.0) 7.8 (1.1) 8.4 (1.1) 8.0 (1.1) 
Clostridium Cluster XIVa  9.9 (0.8) 10.1 (0.8) 9.9 (0.8) 10.2 (0.6) 9.9 (0.8) 10.1 (0.7) 9.9 (9.8) 10.2 (0.7) 
      Roseburia spp. & E. rectale  9.8 (0.5) 9.8 (0.5) 9.6 (0.8) 9.4 (0.8) 9.6 (0.8) 9.5 (0.8) 9.7 (0.5) 9.6 (0.6) 
      F. prausnitzii  9.9 (0.5) 9.7 (0.6) 9.7 (0.9) 9.5 (0.8) 9.7 (0.7) 9.6 (0.8) 9.8 (0.7) 9.7 (0.6) 
R. bromii  8.6 (0.7) 8.7 (0.7) 8.4 (1.0) 8.5 (0.9) 8.4 (0.9) 8.6 (0.8) 8.6 (0.9) 8.6 (0.8) 
A. muciniphila  7.9 (1.0) 7.9 (1.1) 8.0 (1.0) 7.9 (1.0) 7.6 (1.1) 7.9 (1.0) 8.2 (0.8) 7.8 (1.1) 
Lactobacilli  7.1 (0.9) 7.6 (0.9) 7.1 (0.9) 7.6 (0.9) 7.2 (0.9) 7.5 (1.0) 7.0 (0.9) 7.6 (0.9) 
Values are mean (SD)
         
 
 
Relative abundance of microbiota (% of total) at baseline and follow up for the intention to treat population of patients with IBS participating in a 2x2 











 Baseline Follow up Baseline Follow up Baseline Follow up Baseline Follow up 
Bacteroides spp.  31 (24) 20 (15) 34 (22) 30 (17) 31 (21) 26 (16) 34 (24) 23 (17) 
Prevotella spp. 16 (28) 8 (16) 12 (26) 5 (12) 17 (33) 6 (12) 11 (18) 7 (16) 
Bifidobacteria  3 (5) 4 (5) 3 (4) 2 (2)  3 (4) 3 (5) 3 (4) 3 (3) 
      B. longum  2 (3) 1 (2) 2 (3) <1 (1) 2 (4) 1 (2) 2 (3) 1 (1) 
      B. adolescentis 1 (1) 1 (1) 1 (2) <1 (1) 1 (1) <1 (1) 1 (2) 1 (1) 
Clostridium Cluster XIVa  17 (16) 24 (17) 18 (15) 25(13) 19 (17) 22 (16) 16 (12) 26 (15) 
      Roseburia spp. & E. rectale  10 (8) 9 (8) 8 (7) 7 (8) 9 (7) 7 (6) 9 (7) 9 (9) 
      F. Prausnitzii  11 (9) 9 (9) 11 (12) 9 (10) 11(13) 9 (9) 11 (13) 10 (9) 
R. bromii  1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 
A. muciniphila  <1 (<1) <1 (<1) <1 (<1) <1 (1) <1 (<1)  <1 (1) <1 (<1) <1 (<1) 
Lactobacilli  <1 (<1) <1 (1) <1 (<1) <1 (<1) <1 (<1) <1 (1) <1 (<1) <1 (<1) 
Values are mean (SD) 
  
 
 
